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Abstract 
{I) 5-HT receptor mediated responses were investigated in perinatal 
(foetal. 0-24 hours, 4 day and 7 day old), and adult rabbit isolated 
pulmonary conduit (PCAs) and reSistance (PRAs) arteries and in 
human PRAs. 
(2) In all rabbit vessels 5-HT and <x-methyl-5HT, which is selective for 
5-HT2A receptors, (lnM-100IlM) were eqUipotent in causing 
contractions at each age. In the perinatal PRAs, sumatriptan, a 
selective 5-HTIB/ID agoniSt, and 5-CT (5-HTl and 5-HT7 receptor 
agonist) produced negligible contractions, but in adult PRAs, 5-CT and 
sumatriptan were potent agonists with pECSOS of 6.05 ± 0.3 and 5.7 ± 
0.2 respectively. 
(3) The nitric oxide, synthase inhibitor NO> -nitro-L-arginine 
methylester (L-NAME: lOOIlM) markedly increased the maximum 
contraction to 5-HT in the 0-24h, 4 day and 7 day PRAs and in all 
pertnatal PCAs. L-NAME increased 5-HT potency in the 4-, 7-day old 
and adult rabbit PRA and the 0-24 hour PCAs. 
(4) In all perinatal vessels, contractions to 5-HT, with L-NAME 
present, were antagonized by ketansertn (30nM and O.lIlM), which is 
selective for 5-HT2A receptors, but not by GR55562 (lIlM; 5-HTIB/lD 
antagonist). A small ketanserin (30nM) resistant, GR55562-sensitive 
component was observed in 0-24 hour PRAs but not PCAs. 
(5) In adult PCAs, 5-HT-evoked contractions were competitively 
antagonized by low concentrations of ketanserin (lOnM and O.lIlM) 
giving a pA2 value of 8.9, but not by GR55562 (O.1-3J,.LM). 
(6) In adult PRAs, both ketanserin (30nM and O.lIlM) and GR55562 
(lIlM) inhibited 5-HT-evoked contractions. The selective 5-HTIB 
receptor antagonist SB-224289 (200nM) and 5-HTID antagonist BRL-
15572 (500nM) antagonized 5-CT-evoked contractions in these vessels. 
III 
These data suggest the presence of 5-HT2A, 5-HTIB and/or 5-HTID 
receptors in adult rabbit PRAs. 
(7) Vasodilator responses to 5-CT were observed in pre-contracted 
PRAs from 4-and 7-day old rabbits but not in the foetus. 0-24h old or 
rabbit vessels nor the PCAs at all perinatal ages. At 4 days the 
vasodilator response was inhibited both by L-NAME (1 OOJlM) and 
GR55562 (ljlM). At 7 days the response was only partly blocked by L-
NAME and resistant to GR55562. The L-NAME resistant component 
was antagonized by the 5-IIT7receptor antagonist spiperone (ljlM). 
(8) In precontracted adult PCAs. 5-HT and 5-CT induced relaxations 
which were inhibited by the 5-HT7 receptor antagonists spiperone 
(ljlM). pimozide (30nM) and risperidone (3nM) but not affected by 
endothelium removal. 
(9) Collectively the results suggest that 5-HT2A receptors 
predominantly mediate 5-IIT-induced contractions in perinatal rabbit 
PCAs and PRAs and adult rabbit PCAs. The 5-HTIB/ID receptor also 
contributes in adult rabbit PRAs. The 5-IITIB/ID receptor mediates 
NO-dependent vasodilation in PRAs from 4 day rabbits whilst 5-lIT7 
receptors mediate NO-independent vasodilation by 7 days. 
(10) In human PRAs. the contractile effects of 5-IIT (>O.ljlM) were 
partially antagonized by ketanserin (O.ljlM). whilst GR55562 (ljlM) 
inhibited 5-HT-induced contractions at all concentrations of 5-lIT 
(estimated pKB = 7.7 ± 0.2). 8umatriptan evoked contractions that 
were resistant to blockade by BRL-15572 (500nM) and ketanserfn 
(O.lIlM) but antagonized by 8B-224289 (200nM: estimated pKB = 8.4 ± 
0.1) and blocked by GR55562 (lIlM). These data suggest that 5-1IT-
induced contraction is mediated via the 5-IITIB and 5-HT2A receptors 
in human PRAs. 
IV 
(11) The influence of vascular tone induced by endothelin-l (ET-l). 
neuropeptide Y (NPy) , KCI 4-aminopyridine (in activator of Kv 
channels, 4-AP) or the calcium ionophore A23187 on contractile 
responses to 5-CT was studied in PRAs from control rats and those 
exposed to chronic hypoxia (CH rats). The influence of L-NAME was 
also studied. 
(12) In control rat smPAs, only high concentrations of 5-CT (> IIlM) 
induced vasoconstriction. Tone induced by NPY, 4-AP and A23187 had 
no effect on responses to 5-CT whilst responses to 5-CT were increased 
by ET-l- and KCI-induced tone. In the presence of ET-l- or KCI-
induced vascular tone, L-NAME enhanced 5-CT-induced contraction 
further, increasing responses 5- and 2-fold (ET-I) and 6- and 2-fold 
(KCI). 
(13) Responses to 5-CT were maximally enhanced in CH rat smPAs 
and increasing tone pharmacologically had no further effect on 
responses to 5-CT. 
(14) The results suggest that inhibition of NOS combined with KCL- or 
ET-l-induced vascular tone potentiates responses to 5-CT in rat PRAs 
in a synergistic fashion and mimics the effects of chronic hypoxic 
exposure. 
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cyclic 3'5' guanosine monophosphate 
chronic hypoxic pulmonaty hypertensive 
endothelium derived hyperpolarizing factor 
endothelial nitric oxide synthase 
hypoxic pulmonary vasoconstriction 
internal diameter 
inositol trisphosphate 
monoamine oxidase 
mitogen activated protein kinase 
myosin light chain 
myosin light chain kinase 
nitric oxide 
pulmonary arterial hypertenSion 
pulmonary conduit arteries 
phosphodiesterase 
prostacyclin 
pulmonaty hypertenSion 
protein kinase C 
phospholipase A2 
phospholipase C 
phospholipase D 
pulmonary neuroendOCrine cells 
perSistent pulmonary hypertenSion of the newborn 
pulmonaty reSistance arteries 
pertussis toxin 
pulmonary vascular resistance 
pulmonary vascular smooth muscle cell 
right ventricular hypertrophy 
small muscular pulmonary arteries 
smooth muscle myosin phosphatase 
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Glossary 11- I>r1lis used in this thesis 
I Drug Description/Use in this thesis-I 
NP-y Neuropeptide-Y: used to induce threshold contractions in smPAs 
4-AP 4-Aminopyridine; voltage operated K+ channel blocker used to induce threshold contractions in smPAs 
5-Cf 5-carboxamidotryptamine; 5-HTI and 5-fIT7 receptor agonist used to investigated 5-HT receptor 
mediated vasoconstriction (5-fITl) and vasorelaxation (5-JIT7) in pulmonary arteries 
5-1IT 5-hydro~tamine; used to investi~ate 5-1IT receptor mediated responses 
8-0HDPAT 8-hydroxy-2- (di-n-propylamino) tetralin; 5-HTIA agonist used to investigate 5-JIT receptor mediated 
contractions in pulmonary arteries. 
a-me-5-JIT a-methyl-5-hydroxytryptamine: 5-HT2 receptor agonist used to investigate 5-1IT receptor mediated I 
contractions in pulmoncu:y arteries. I 
ACh acetylcholine: used to investigate endothelium-dependent relaxation in precontracted pulmonary 
arteries 
BW723C86 1-[5-(2-thenyloxy)-lH-indol-3-yl]propan-2-amine: 5-HT2B receptor agonist used to investigate 5-fIT 
receptor mediated relaxation in precontracted pulmon~ arteries 
ET-I endothelin-I; potent vasoconstrictor peptide used to precontract pulmonary arteries for subsequent 
vasodilator studies 
L-NAME NOLnitro-L-arginine methylester: endothelial nitric oxide synthase blocker used to inhibit basal and 
stimulated NO release 
--- - --
NA noradrenaline; adrenoceptor agonist used to precontract pulmonary arteries for subsequent vasodilator 
studies J 
PE phenylephrine; a-adrenoceptor agonist used to precontract pulmonary arteries for subsequent I 
vasodilator studies 
SNP sodium nitroprusside; used to investigate endothelium-independent relaxation in precontracted 
Qulmonary arteries 
sumatriptan 5-HTIB/ID receptor agonist; used to investigate 5-HflB/lD receptor mediated responses in pulmonary 
arteries 
-
x 
~ 
Table of 5-HT receptor a,onists used in this thesis 
5-HT Receptor 
lA IB ID 2A 2B 7 
Agonists 
8-0H-DPAT * (Hoyer et al., 1994) 
Sumatrlptan * * (Humphrey et aL, 1994) 
5-cr * * * * (Hoyer et aL, 1994) 
BW723C86 * (Kennet et al., 1996) 
ex-me-5-HT * (Hoyer et al., 1994) 
Table 1 5-HT receptor-selective agonists used in this thesis. 
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GIQllary m-An:tdQnil:t affinitt valll~S at val~u1u D-HT r~~~RtQ[I 
Antagonist Reported antagonist affinity for vascular 5-HT 
receptor subtypes 
5-IITIB 5-IITID 5-IIT2A 5-IIT2B 5-IIT7 
fS-HTlB 
SB-224289 9.0a 6.2a 5.8b 
fS-HTm 
BRL-15572 6.1a 7.9a 
fS-HTlB/m 
GR55562 7.ge 8.3e 5.6 
fS-HT2A 
ketansertn 5.3f 7.1f 9.3 5.4 <6.0 
methiothepin 8.1 7.7 9.0 7.6C 9.7d 
fS-HT7 
7.3d spiperone 4.4 4.8 9.1 5.5c 
pimozide 8.2g 
rtsperidone 8.9g 
Affinity values for 5-HT receptor antagonists used in this thesis. 
Particular receptor subtype for which each antagonist was used in this 
thesis is emphasised in bold type. All data from Hoyer et al.. 1994 
unless otherwise stated. 
a Verheggen et al.. 1998: b Roberts et al.. 1997: C Hoyer et al .• 1989: d 
Leung et al.. 1996: e Conner et al., 1995: fBard et al., 1996: g Roth et 
al .• 1994 .. 
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Chapter 1 
Introduction and Literature Review 
1 
Introduction 
The pulmonary circulation can no longer be simply regarded as 
a passive conduit circuit, involved in gas exchange of the continual 
circulation of blood around the body. Extensive research 
investigating structural and functional aspects of this unique 
Circulation has highlighted complex systems involved in the 
regulation of blood flow in the lung as well being involved in several 
non-respiratory functions. In particular, a vast amount of evidence 
exists for the importance of the endothelium, with its ability to 
release vasoactive agents, in understanding the mechanisms for the 
local regulation of pulmonary (as well as systemic) vascular tone in 
health and disease states. 
The research presented in this thesis has focused on the 
vascular reactivity of pulmonary arteries, both conductance and 
resistance vessels, and in particular has focused on the role of 5-
hydroxytryptamine (5-HT, serotonin), a potent bioamine known to 
have complex vascular effects. Until recently, the majority of in vitro 
investigations on the pulmonary Circulation have focused on the 
large calibre conductance vessels. From indirect evidence, it is 
thought however, that the small pulmonary resistance arteries play 
an important role in controlling pulmonary vascular tone (Leach et 
al., 1989)) and are the major contributors to increased pulmonary 
vascular resistance in the pulmonary hypertensive state (Singhal, et 
al., 1973). Of the relatively few studies that have investigated these 
vessels, most have reported a number of important differences 
between the response of capacitance (1-2 mm internal diameter) and 
small muscular reSistance vessels (l00-300 Jlm internal diameter) 
(Leach, et al., 1992; McCulloch, et al., 1996). For example, previous 
studies recently demonstrated heterogeneity within the pulmonary 
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arterial circulation with regard to endothelin (ET) receptors (MacLean 
et al.. 1994b: McCulloch et al .• 1996). Coupled with the observation 
that the vascular smooth muscle cells of the pulmonary resistance 
arteries are phenotypically distinct from the larger vessels (Frid et al.. 
1997). it is important to make a separate characterisation of the 
vascular reactivity of pulmonary arteries of different sizes. 
The phySiology and pharmacology of 5-HT and its putative role 
in the hypertensive pulmonary circulation is reviewed in this 
introduction in sections 1.4 and 1.5 respectively. The responsiveness 
of the pulmonary vasculature was investigated mainly under two 
different states: a) during the transitional development from foetal to 
neonatal life and into adulthood and b) in the pulmonary 
hypertensive state due to chronic hypoxia. It is important to first 
gain an understanding of the normal pulmonary circulation. 
1,1 The Pulmonary Circulation 
The characteristics of the normal. adult pulmonary circulation 
are uniquely those of a low pressure. highly compliant, vascular bed 
which has low vascular resistance. This circuit can accommodate the 
total cardiac output from the right ventricle to the gas exchanging 
surface at less than 200/0 of systemic vascular pressure. The 
pulmonary circulation is thought to be under a state of very little or 
no resting vascular tone (Fishman. 1985) as vasodilators have little 
or no effect on pulmonary vascular pressures. The high compliability 
of this system, along with capillary recruitment, ensures low pressure 
maintenance even in situations of increased cardiac output and 
elevated flow rate during exercise. Lung perfusion pressure therefore 
remains constantly low. 
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A vast body of evidence from extensive studies of the 
pulmonary circulation of many species has revealed this special 
circulation as being more than simply a passive conduit for blood 
flow to and from the alveoli and has provided much information on 
its various aspects. 
1. 1. 1 Functions of the Pulmonruy Circulation 
As mentioned above, the entire cardiac output flows through 
the pulmonary circulation, essential for gas exchange to occur. A 
vast, 'sheet' network of pulmonary capillaries in the walls of the 
alveoli receives deoxygenated blood from the pulmonary arterial 
system, to allow gas exchange to occur. Once oxygenated, the blood 
returns to the left atrium of the heart via the pulmonary venous 
system. Apart from the primary role of the pulmonary circulation in 
gas exchange, the pulmonary vascular bed is also a major site of 
many non-respiratory functions including key metabolic processes. 
The large surface area of the pulmonary microvasculature is involved 
in the biological processing of several vasoactive substances (Vane, 
1969). Angiotensin converting enzyme is present on the luminal 
surface of the pulmonary capillary endothelial cells and catalyses the 
conversion of Angiotensin I to angiotensin II as well as inactivating 
bradykinin (Johnson & Erdos, 1977; Said, 1982). Several other 
mediators such as ET, noradrenaline (NA) and 5-HT are removed 
from the circulation on passing through the pulmonary vasculature 
(DeNucci, et al., 1988; Bakhle, 1970; Said, 1982). 
1. 1.2 Structure of the pulmonruy arteries 
Upon leaving the right ventricle, the main pulmonary artery 
trunk rapidly divides into two branches. the left branch extending to 
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the hilum of the left lung and dividing into a further two branches, 
one passing to each lobe. The right pulmonary artery divides Into two 
branches, the larger extending to the middle and lower lung lobes 
while the smaller branch extends to the upper lobe of the right lung. 
Upon entering the lung the pulmonary arteries form a rapidly 
branching structure, daughter branches generally form at the distal 
end of the parent vessel. Some side arteries. however. may have side 
branches coming off at right angles to the parent branch. The 
majority of pulmonary arteries follow the branching pattern of the 
airways. In man. 17 orders of pulmonary arterial vessels have been 
estimated (Singhal. et al.. 1973). From the main trunk down to an 
internal diameter of -1 mm. pulmonary arteries are defined as elastic 
pulmonary arteries and retain the structure of typical conducting 
arteries. They consist of a thin intima. thick adventitia and a media 
consisting of several elastic laminae interposed with a small amount 
of smooth muscle. The number of elastic fibrils gradually decreases 
with continued branching in the human pulmonary arterial tree. 
concomitant with an Increased proportion of medial smooth muscle 
as the arteries diminish in size. the thickness of this smooth muscle 
also increases relative to diameter (Daly & Hebb. 1966). The arteries 
accompanying the terminal bronchioles (IOOllm-1mm Internal 
diameter) are predominantly muscular and contain four to six 
smooth muscle cell layers. obliquely arranged and bound by distinct 
Internal and external elastic laminae (Brenner. et aL. 1935: Heath & 
Edwards. 1958). At respiratory bronchiole level. the smooth muscle 
cell layer reduces abruptly with more distal branches being only 
either partially muscular or non muscular (Meynlck & Reid. 1983). 
The pulmonary arterial vessels less than IOOllm internal diameter in 
the human lung consist of a single elastic lamina. with very sparse 
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smooth muscle (Heath & Edwards. 1958); this is the region of the 
pulmonary circulation most affected in pulmonary hypertension and 
is discussed further in section 1.3. of this introduction. 
Considerable variation exists both within and between species 
(Kay. 1983) in the structure of pulmonary vessels. The structure of 
the pulmonary arteries is generally Similar in man. monkey and 
ferret. whilst most other animals exhibit more muscular pulmonary 
arteries (Kay. 1983). In rabbit lungs. the pulmonary arteries have a 
conSistently thick muscle coat (Daly & Hebb. 1966). In some 
animals. muscular pulmonary arteries can extend to vessels with an 
internal diameter less than 100Jlm. while in man. vessels below 
100Jlm are normally non-muscular. 
1.1.3 Pulmonruy Pressures 
The pulmonary circulation is a low pressure system and In 
humans. the pulmonary systolic. diastolic and mean arterial 
pressures average approximately 23. 8 and 13 mmHg respectively. 
This low pressure state is associated with the structural features of 
the pulmonary arteries which have comparatively larger luminal 
diameters than systemic arteries of similar size. The pulmonary 
vascular reSistance (PVR) is approximately one-tenth of total 
(systemic) peripheral resistance (Fishman. 1985) as the mean 
pulmonary arterial-to-venous pressure difference is only about one-
tenth that in the systemic Circulation. In contrast to the systemic 
Circulation. where the arterioles represent -70% of resistance to 
blood flow. a more even distribution of PVR through the lung is 
indicated. Pressure declines gradually to -10mmHg in the pulmonary 
capillaries and to a mean of about 5mmHg in the venous bed. Some 
evidence from morphometric studies in human lung. however. 
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suggests that small muscular pulmonary arteries and arterioles are 
the major sites of PVR (Singhal, 1973), especially in PHT. 
1.1.4 Re~ulation of low pulmonruy vascular tone 
The systemic circulation is under the predominant control of 
neural and humoral mechanisms. Contrasting this, the pulmonary 
circulation is under the control of both active and passive factors 
(Daly & Hebb. 1966). Active factors. including humoral factors, 
autonomic nerves and respiratory gases. alter pulmonary vascular 
tone and resistance by either contracting or relaxing pulmonary 
arterial smooth muscle. Passive factors. such as changes in airway 
and interstitial pressure or changes in cardiac output and left atrial 
pressure. gravitational force and vascular recruitment or obstruction 
all influence pulmonary vascular pressure independently of changes 
in vascular tone. The investigations in this thesis concentrate on 
active factors. 
1.1.4.1 Neural Mechanisms 
The autonomic nervous system innervates the pulmonary 
vasculature primarily via the pulmonary plexus (Mitchell. 1956; 
Downing & Lee, 1980) and may modify the pulmonary circulation 
under physiological conditions. It may also be involved in the 
pathophysiology of pulmonary vascular diseases. Stimulation of 
sympathetic (adrenergic) nerve fibres in the pulmonary vasculature 
generally mediates a vasoconstrictor response. whereas stimulation 
of parasympathetic (cholinergic) nerve fibres mediates vasodilation 
(Downing & Lee, 1980; Barnes & Lui, 1995). 
The type and degree of innervation of the pulmonary 
vasculature varies markedly. dependent both on the species under 
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investigation and on the location and size of the pulmonary vessel 
(Downing & Lee, 1980; Barnes & Lui, 1995). Generally, extralobar 
and large muscular pulmonary arteries appear to be more densely 
innervated compared to smaller pulmonary arteries and arterioles 
which generally receive a very sparse innervation. Exceptions to these 
general observations include both the rabbit and man, which both 
display extensive, dense adrenergic innervation, extending to arteries 
<70J.1Il1 and 60 ~m outer diameter, respectively (eech & Dolezel, 1967; 
McLean, 1986). Adrenergic innervation in the intralobar pulmonary 
arteries of the rat, in contrast, are absent (McLean, et al., 1985). The 
pulmonary circulation in most species receives comparatively little 
cholinergic innervation when compared to adrenergic innervation, 
but notable exceptions include the rabbit pulmonary arteries, where 
extensive innervation with acetylcholine esterase-positive nerve 
fibres, extending down to vessels < 1 00 ~m is observed (Barnes & Lui, 
1995). Pulmonary arteries contain heterogeneous populations of both 
adrenergic and cholinergic receptors with variable regional 
distribution in terms of receptor subtype. The overall response, either 
vasoconstriction or vasodilation, in the pulmonary circulation will 
therefore be determined by this as well as the degree of pre-existing 
pulmonary vascular tone (Hyman & Kadowitz, 1988; 1989). The 
contribution of the autonomic nervous system to basal pulmonary 
vascular tone is uncertain, although some evidence suggests that 
sympathetic nerves may contribute, at least in some species, as a-
adrenergic antagonists reduce PVR in anaesthetised cats and 
conscious dogs (Barer, 1966; Murray, et al., 1986). 
1.1.4.2 Humoral factors 
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Several circulating mediators and hormones are known to 
affect pulmonary vascular tone either by causing vasoconstriction or 
vasodilation. The effects of these mediators are via stimulation of 
multiple receptor types and vary significantly with species. age and 
pre-existing tone (Barnes & Lui. 1995). In general. angiotensin II. 
thromboxane. neuropeptide Y and several prostaglandins (PGs) are 
pulmonary vasoconstrictors. whereas atrial natriuretic peptide and 
PGs El and 12 (prostacyclin) are pulmonary vasodilators. In man. for 
example. PGI2 causes a dose-dependent decrease in PVR when 
infused into healthy volunteers (Szczeklik .et al .• 1980) and it is now 
used in the treatment of PHT (Hoeper et al.. 2000). The effects of 
some mediators such as bradykinin. histamine. ETs and substance P 
are dependent on pre-existing vascular tone. generally causing 
contraction when pulmonary vascular tone is low. but relaxation 
ensues when vascular tone is high. One such mediator is 5-HT and 
its role in the pulmonary Circulation is introduced in sections 1.4 
and 1.5. 
1.1.4.3 Re~ulation by the Endothelium 
Despite the large volume of research conducted over many 
years. the factors involved in maintaining low pulmonary vascular 
tone still remain. to some extent. ambiguous. Increasingly. however. 
the endothelium derived factors are thought to play an important 
role in affecting the tone of vascular smooth muscle. 
Endothelial cells can influence vascular smooth muscle tone 
in several ways. The vascular endothelial cells of the lung play an 
important role in regulating levels of biologically active factors 
participating in their uptake and metabolism from the blood for 
example. 5-HT (Said. 1983). Endothelial cells can also synthesise 
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and release a variety of paracrine substances with vasoactive 
properties. Among these are the potent peptide vasoconstrictor ET-l 
(Yanagisawa. et al.. 1988) as well as endothelium derived relaxing 
factor-nitric oxide (NO). Prostacyclin (PGI2). produced from 
arachidonic acid by the cyclooxygenase pathway has been identified 
as a potent endothelium-derived vasodilator (Moncada and Vane .. 
1979). In the rat pulmonary artery. ACh-induced relaxation was 
reported to be partially inhibited by meclofenamate. a cyclooxygenase 
inhibitor. suggesting that cyclooxygenase products modulate ACh-
induced relaxation of these vessels (Yaghi. et al .• 1997). 
Endothelium derived hyperpolarizing factor (EDHF) is another 
relaxing factor derived from the endothelium (Nagao and Vanhoutte. 
1993) and is distinct from NO. EDHF causes the opening of K+ 
channels. without the involvement of cyclic 3'5' -adenosine 
monophosphate (cAMP) or cyclic 3'5' guanosine monophosphate 
cGMP. leading to smooth muscle hyperpolarization (Garland. et al.. 
1995) and has been reported in rat pulmonary arteries (Chen et al .• 
1988). Recently. in rat isolated pulmonary arteries. Karamsetty et al. 
(2000) demonstrated that NO-independent relaxation was completely 
abolished by charybdotoxtn plus apamin. suggesting that EDHF 
contributes to endothelium-dependent. NO-independent relaxation 
in these vessels. 
1.1 .4.4 Re~ulation by second messen~ers 
Cyclic nucleotides are important in the regulation of 
pulmonary vascular tone. A wide variety of vasoactive agents exert 
their effects by regulating the intracellular concentration of cyclic 
3'5' -adenosine monophosphate (cAMP) and cyclic 3'5' guanosine 
monophosphate cGMP (Bentley & Beavo. 1992) and these second 
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messengers can, in turn, regulate pulmonary vascular tone. 
Exogenous cGMP and cAMP are potent pulmonary vasodilators 
(Hayes, et al.. 1992; McMahon. et al.. 1992: 1993). NO-evoked 
pulmonary vasodilation involves cGMP as the key second messenger, 
and cAMP plays an important central role in mediating the 
pulmonary vasodilator response to several direct acting vasodilators 
including PGI2. ~-adrenoceptor and 5-HT7 receptor agonists. Cyclic 
nucleotide levels may also playa critical role in the responsiveness of 
pulmonary arteries to activation of G-protein coupled receptors as 
decreased cGMP levels potentiate Gi-coupled responses in human 
and bOvine pulmonary arteries (MacLean, et al.. 1993: 1994) and this 
phenomenon has been investigated in the studies of chapter 6 of this 
thesis. This may be pathophysiologically important in pulmonary 
hypertenSion where decreased levels of cGMP and cAMP are observed 
in pulmonary arteries from the chronic hypoxic pulmonary 
hypertensive rat which also exhibit enhanced vasoconstriction to 5-
lIT (MacLean. et al.. 1996). 
Cyclic nucleotide inactivation occurs via phosphodiesterase 
(POE) enzyme-mediated hydrolysis to the corresponding 5' nucleotide 
and POEs represent the only known means whereby cells can 
inactivate cyclic nucleotides. There are currently seven POE families 
which are derived from at least 15 genes in the mammalian genome 
(Conti et al. 1995). Four of the POE families (1, 3, 4 and 5) are 
known to playa significant role in the regulation of vascular tone 
and may be important in the regulation of vascular responses to 
injury (Beavo 1995: Conti. et al .. 1995: Polson & Strada, 1996). POEs 
1, 3. 4 and 5 have been identified in the pulmonary vasculature 
(Rabe et al.. 1994; Polson & Strada. 1996: Dent, et al., 1994) and 
inhibitors of PDEs 3. 4 and 5 relax preconstricted human pulmonary 
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arteries (Rabe, et al., 1994). Recent research has focused on the role 
that PDEs may play in regulating pulmonary vasoreactIvity in the 
hypertensive pulmonary vasculature (MacLean, et al., 1997; Wagner, 
et al., 1997) including persistent pulmonary hypertension of the 
newborn (Hanson, et aL, 1998). 
1.1.4.5 Re2ulation by respiratOlY 2ases 
Pulmonary vascular tone can be greatly influenced by the 
relative composition of the respiratory gas with both hypoxia and 
hypercapnia causing pulmonary vasoconstriction (Fishman, 1961). 
Uniquely, pulmonary arteries are known to contract in response to 
acute hypoxia and this phenomenon of hypoxic pulmonary 
vasoconstriction (HPV) was first described by Von Euler and 
LllJestrand (1947). HPV causes greatest constriction in small 
muscular pulmonary arteries (Fishman, 1976). In contrast, the 
systemic circulation exhibits a vasodilator response to hypoxia. This 
pulmonary vasoconstrictor reflex to acute hypoxia is of physiological 
importance in both foetal and adult life. In the foetus, HPV, as a 
result of the relatively hypoxic environs in utero, aids in diverting 
blood away from the foetus' non functioning lungs. (see section 
1.2.1). In the adult, HPV aids in ventilation perfusion matching, 
redirecting circulating blood towards better ventilated regions of the 
lung and away from less well vented alveoli, thus maximising arterial 
oxygenation. 
Despite many decades of investigation, the mechanism(s) 
responsible for HPV remain controversial although the mechanism is 
believed to reSide in the vascular smooth muscle cells as HPV can be 
demonstrated in pulmonary arterial rings devoid of endothelium as 
well as in single pulmonary arterial smooth muscle cells (Vaun, et 
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al., 1990; Madden, et al.. 1992). Recent evidence suggests one 
mechanism may be hypoxia-induced inhibition of potassium current 
in the smooth muscle cells of pulmonary resistance arteries. This 
would lead to membrane depolarisation and calCium entry through 
voltage gated calcium channels (Smirnov et al., 1994; Weir & Archer. 
1995). The channels initiating HPV are thought to be 4-
aminopyridine sensitive delayed rectifier channels. In CHPHT rat 
pulmonary artery smooth muscle cells. Osipenko (1998) recently 
demonstrated that increased 4-AP sensitivity reflects a switch in the 
major K+ current determining resting potential from the non-
inactivating K+ current to the delayed rectifier K+ current. Hypoxic 
inhibition of K+ current is speCific for pulmonary smooth muscle 
cells and may playa key intermediary step in HPV. 
Several studies have implicated an essential role for either 
Ca2+ influx (Cornfield et al.. 1994) or Ca2+ release from intracellular 
stores. In canine small pulmonary arteries. for example. ryanodine 
(inhibitor of intracellular Ca2+ release) plus caffeine can inhibit 
sustained hypoxia-mediated vasoconstriction by -80%, suggesting 
that HPV in this preparation is mainly mediated by Ca2+ release 
(Jabr, et al; 1997). It is apparent therefore that HPV is associated 
with a rise in intracellular Ca2+ concentration ([Ca2+ 11). 
HPV in pulmonary arteries typically consists of two 
superimposed phases (e.g. Robertson et al., 1995). the first being 
transient in nature. The second is a more slowly developing. but 
sustained, endothelium-dependent constriction. During phase 2 
[Ca2+ 11 does not rise in parallel with tension. It has been proposed 
that the rise in tension during phase 2 is produced via sensitization 
of the myofilaments to Ca2 + (Robertson et al.. 1995). Ca2+-
senSitization refers to the ability of agonists to enhance smooth 
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muscle force development at a given level of [Ca2+ h (see section 
l.l.4.7.2). Recently interest has focused upon the role of RhoA, and 
its effector Rho-associated kinase in agonist-induced Ca2 + 
sensitization. Robertson et al (2000) recently demonstrated that Rho-
associated kinase caused a concentration-dependent inhibition of 
acute sustained HPV in rat pulmonary arteries. This is consistent 
with the activation of RhoA-associated kinases, and presumably 
Ca2+ senSitization, being involved in the mechanism underlying the 
generation of sustained HPV. 
The presence of a functional vascular endothelium has been 
shown to enhance or facilitate HPV (Ward and Robertson, 1995; 
Karamsetty, et al., 1996) The influence of the vascular endothelium 
on HPV, however, has still to be satisfactorily explained. 
Acute hypoxic episodes produce an HPV which lasts for the 
duration of the stimulus. However, HPV appears to be malign 
following chronic hypoxic exposure and is sustained even upon 
return to normoxia (see 1.3). 
1.1.4.6 Re(lulation by ion channels 
A variety of ion channels have been characterized in the 
plasma membrane of VSMCs and their roles in controlling vascular 
tone have been extensively studied. 
1.1.4.6.1. Potassium (K±l channels 
In the pulmonary vasculature, K+ channels play a major role 
in the regulation of pulmonary vascular tone by governing membrane 
potential (Nelson et al., 1990). Closure of K+ channels results in a 
build up of positive charge on the inside of the membrane causing 
depolarisation of the pulmonary arterial (PA) smooth muscle cells 
(PASMC). Depolarisation results in opening of voltage-activated Ca2+ 
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channels and thus increases the cytoplasmic free Ca2+ concentration 
[Ca2+b (Nelson, et al.,1990, Yuan, 1995). In contrast, K+ channel 
activation hyperpolarises PASMCs and inhibits the evoked rise in 
[Ca2+b (Archer, et al., 1994, Yuan, et aI., 1996). The increase in 
[Ca2+b in PASMC is a major trigger for pulmonary vasoconstriction 
and an important stimulus for vascular smooth muscle cell 
proliferation, leading to pulmonary vascular remodelling (see section 
1.3.1). K+ channels in vascular smooth muscle cells are also 
potential targets of vasoactive neurotransmitters or therapeutic 
agents (e.g., nitric oxide) (Archer, et al., 1994; Yaun, et al., 1996). 
Altered K+-channel function/activity has been implicated in the 
pathogenesis of several cardiovascular diseases including primary 
pulmonary hypertension (Yuan, et al., 1996). Three types of K+ 
channel have been identified in PASMC: 
(1) Voltage-gated K+ (Kv) channels regulate resting membrane 
potential and hence pulmonary vascular tone, especially in the 
pulmonary resistance arteries (yuan, 1995; Archer, et al., 1996). In 
the rat isolated perfused lung, inhibition of Kv channels by 4-
aminopyrtdine results in depolarisatlon of the PVSMCs, increased 
[Ca2+Ji and increased pulmonary arterial pressure and PVR 
(Hasunuma, et al., 1991). Recently the molecular identity of the Kv 
channels regulating [Ca2+)i in rat PASMCs has also been elUCidated 
(yuan, et al., 1998). Evidence exists for a distinct, non-delayed 
rectifier, Kv channel active at resting membrane potential, and 
therefore important in the modulation of tone) in rabbIt pulmonary 
artery smooth muscle (Evans, et al., 1996). 
ii. Ca2+-dependent K+ (Kca) channels are a second major class of 
channels located in pulmonary vascular smooth muscle (Albarwani, 
et al., 1994; Archer, et al., 1994; Gelband & Hume, 1992; Peng, et al., 
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1996). Under resting conditions Kca channels are largely inactive and 
inhibition of these channels with charybdotoxtn has been reported to 
have negligible effect on resting membrane potential. [Ca2+h. or PA 
pressure (Peng. et al.. 1996). These channels are activated by 
membrane depolarisation and increases in [Ca2+h. During PASMC 
contraction. therefore. these channels tend to repolarise the 
membrane and limit vasoconstriction. In contrast to the Kv 
channels. the major determinants in controlling resting membrane 
potential. Rca channels are thought to comprise a negative feedback 
pathway in regulating active tension (Brayden. et al .• 1992. Pengo et 
al.. 1996) and are primarily located in large. conduit pulmonary 
arteries (Peng. et al.. 1996). 
iii. Voltage-independent ATP-sensitive K+ (KA1P) channels (Clapp & 
Gurney. 1992) are thought to play more of a modulatory role in 
regulating pulmonary vascular tone in times of metabolic stress. 
Under normal conditions the KA1P channel blocker glibenclamide has 
little effect on pulmonary vascular tone (Clapp & Gurney. 1992). 
1.1.4.6.2. CalCium (Ca2±) Channels 
The role of Ca2+ channels in the control of pulmonary vascular 
tone is a regulatory one as the activation threshold of the L-type 
Ca2+ channel is more depolarised than the resting membrane 
potential of the PVSMCs. L-type Ca2+ channel blockers such as 
nifedipine do not alter resting tone in isolated PA rings or lungs 
(Young. et al.. 1983) but do reduce artificially-induced pulmonary 
vasoconstriction (McMurtry et al.. 1976). There is some evidence for 
the presence of small conductance T-type Ca2+ channels in the 
chronic hypoxic pulmonary vasculature which are generally more 
active at more negative membrane potentials than L-type channels. 
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T-type channel blockers have been shown to partially dilate agonist-
constricted chronic hypoxiC rat lungs (Maramutsu. et aL. 1997). 
1.1.4.6.3. Chloride (CI-) channels 
Under physiological conditions. the most abundant intra- and 
extracellular anion is chloride. Activation of CI- channels results in 
a movement of negative CI- ions out of the cell translating into an 
inward current and producing membrane depolarization (Hllle. 1992). 
Modulation of CI- channels COUld. therefore. play an important role 
in the control of pulmonary vascular tone. The majority of reports 
concerning PVSMCs have identified the calcium-activated chloride 
channels (Clea) (Clapp. et aZ., 1996;. Salter, et az.. 1995. Wang & 
Large. 1993. Wang & Kotlikoff, 1996) which are activated by 
increases in [Ca2+Ji. These channels may therefore be important in 
maintaining agonist-induced responses (Yaun. 1997) rather than 
determining resting pulmonary vascular tone. Blockers of CICa 
channels have been reported to have no effect on basal pulmonary 
vascular tone (yaun, 1997). 
Agonist-induced pulmonary arterial constriction is frequently 
associated with an initial but transient increase in [Ca2+Ji via release 
from intracellular stores to trigger contraction (Somlyo & Somlyo, 
1994). This is accompanied by a sustained [Ca2+lt plateau due to 
influx of Ca2+ through sarcolemmal voltage-gated Ca2+ channels 
leading to sustained contraction (Nelson, et aZ., 1990). Elevated 
[Ca2+Ji activates Clea channels and elicits inward CI- current. The 
resulting CI- currents would cause membrane depolarisation and 
subsequent opening of voltage-activated Ca2+ channels. leading to an 
additional increase in [Ca2+h. Ca2 +-induced activation of CICa 
channels would therefore explain why vasoconstrictor agonists such 
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as ET-I, 5-HT and PE, in addition to increasing [Ca2+1t, also cause 
membrane depolarisation and sustained vasoconstriction in 
pulmonary arteries (yuan, 1997; Salter, et al., 1995). 
Many vasoconstrictors, are known to induce membrane 
depolarisation and Leblanc and Leung (1995) reported that Ca2+ 
activated CI- current is an important contributor to increase Ca2+ 
and vascular tone by inducing membrane depolarisatlon. Membrane 
depolarisation makes an important contribution to the triggering and 
maintenance of arterial contractions (Somlyo & Somlyo, 1994) and 
the activation of CICa channels (Salter, et al., 1995; Wang & 
Kotlikoff, 1996), as well as inhibition of delayed rectifier K+ 
channels, could play a crucial role in depolarising PVSMCs when 
[Ca2+1i is elevated by vasoconstrictor agonists. Agonist-induced 
release from inositol trisphosphate (IP3)-sensitive stores has been 
reported to activate Clea channels in PVSMCs (Salter et al., 1995; 
Yuan, 1997). 
1.1.4.7 Importance of [C~2±ll...and Ca2+ sensitivity 
It is communally agreed that an increase in intracellular 
Ca2+ concentration ([Ca2+]d is a determinant for vascular smooth 
muscle contraction in response to various contractile stimuli 
including agonists which bind to G-protein coupled receptors and 
mobilise Ca2+ (Somlyo and Somlyo, 1994). Recent studies have 
shown that most of these agonists are also able to modulate 
contraction by altering Ca2+ myofilament sensitivity or through 
Ca2 + -independent pathways (Horowitz, et al., 1996; Weber, et al., 
1999). 
1.1.4.7.1. Calcium mobilisation 
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Changes in intracellular Ca2 + concentration [Ca2 +Ji are 
important in vascular smooth muscle contraction and relaxation and 
the involvement and importance of ion channels in these changes 
have been highlighted in section 1.1.4.6. [Ca2+1t regulation involves a 
complex interplay between Ca2+ entry and extrusion across the 
plasma membrane, and Ca2+ release and re-uptake from 
intracellular stores. Ca2+ influx is an important pathway for 
increased [Ca2 +Ji and contractile stimuli often increase [Ca2+h via 
Ca 2+ entry from the extracellular milieu through voltage-gated or 
receptor-operated Ca2+ channels or Ca2+ release from the 
sarcoplasmic reticulum through Ca2+ release channels (inositol 
1,4,5-trtsphosphate receptors or ryanodine receptors). 
The major regulatory mechanism of vascular smooth muscle 
contraction and relaxation is phosphorylation/dephosphorylation of 
a 20k dalton protein myosin light chain (MLC) (Somlyo and Somlyo, 
1994). MLC is phosphorylated by myOSin light chain kinase (MLCK), 
an enzyme regulated by Ca2+ through calmodulin. A rise in [Ca2+lt, 
therefore, produces VSM contraction by activation of MLCK which 
phosphorylates one of the constituents of mYOSin, allowing myosin 
to interact with actin and subsequently initiating contraction. 
Conversely, relaxation of VSM results from a decrease In 
cytosolic Ca2+ concentration due to extrusion of Ca2+ from the cell 
by the sarcolemmal Ca2+-ATPase and the Na+-Ca2+ exchanger or 
uptake by the sarcoplasmic reticulum membrane Ca2+-ATPase. This 
results in dephosphorylation of MLC by a heterotrimeric smooth 
muscle myosin phosphatase (SMPP-1M) (Hartshore, et al .• 1998). 
1.1.4.7.2. Ca~ensitisation and Ca2+-independent contraction of 
vascular smooth muscle 
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It is now well established that MLC phosphorylation and 
contraction can be induced independently of change in [Ca2+h. 
Recent studies using permeabilized arteries have shown that Ca2+ 
mobilising agonists are able to modulate contraction by altering 
contractile myofilament Ca2+ sensitivity (Horowitz, et al., 1996). 
Endothelin receptor activation can induce constriction of arterial 
smooth muscle not only by raising the intracellular Ca2 + 
concentration (Highsmith et al., 1992; Pang et al., 1989; Enoki et al., 
1995). but by increasing the sensitivity of the contractile apparatus 
to Ca2+ (Nishimura et al., 1992; Ohanian et al., 1997). For example. 
in rat permeabilized pulmonary artery rings. ET-l was found to 
induce a sustained and reverSible constriction at a fixed [Ca2+h. 
Under these conditions. ET-l-induced constriction could only result 
from an increase in the sensitivity of the contractile apparatus to 
Ca2+ (Evans, et al., 1999). 
Agonist-induced Ca2+ sensitization of vascular smooth muscle 
contractile myofilaments to is thought to occur through inhibition of 
MLCP via different mechanisms involving the independent 
participation of several kinases: 
1) Phosphorylation of the 130 kDa subunit of SMPP-IM and 
inhibition of the phophatase may occur via activation of the small 
GTPase RhoA and subsequent Rho-associated kinase (Kimura, et al .• 
1996). RhoA dependent Ca2+ sensitization constitutes a major 
component of the sustained rise in tension induced by 
vasoconstrictors in various vascular beds including the pulmonary 
vasculature (Gong. et al., 1997). In human omental arteries, the Rho-
kinase inhibitor Y-27632 strongly inhibited agonist-induced 
contractions without affecting [Ca2+lt, suggesting the involvement of 
the Rho-kinase associated pathway in agonist-induced Ca2 + 
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sensitization of these vessels (Martinez. et al.. 2000). Recently. 
Hirata et al. (1992) reported that G protein-mediated Ca2 + 
sensitization in permeabilized vascular smooth muscle cells was 
inhibited by pretreatment with C3 exotoxin. a selective inhibitor of 
rho p21. a small G protein associated with Rho kinase. This 
phenomenon has now been confirmed in several other investigations. 
suggesting that activation of rho p21-Rho kinase is involved in Ca2+ 
sensitization presumably due to modification of the phosphorylation 
state of myosin light chain (Fujita. et al .• 1995: Noda. et al.. 1995). 
11) The involvement of tyrosine kinase in Ca2+ sensitization has also 
been reported in permeabilized arteries. Tyrosine kinases have been 
implicated in agonist induced Ca2+ sensitization in human small 
omental arteries (Martinez. et al .. 2000). Ohania et al. (1997) 
suggested that ET-1 may induce an increase in myofilament Ca2+ 
sensitivity in rat mesenter1c artery smooth muscle by activating a 
tyrosine kinase and subsequent protein tyrosine phosphorylation. In 
the rat pulmonary artery. however. the observed increase in Ca2+ 
sensitivity was mediated by a mechanism independent of the TK 
pathway (Evans. et al.. 1999). th1s may be of some importance. as the 
identification of a distinct Ca2+ sensitizing mechanism assoclated 
with the development of pulmonary hypertenSion (see section 1.3) 
may lead to the development of more selective and effective therapies 
for thls dlsorder. 
iii) Myofilament Ca2+ sensitization can occur through a protein 
kinase C-dependent pathway as PKC may also inhibit the 
dephosphorylation of myosin light chain by an inhibitory action on 
SMPP-1M (Akopov. et al.. 1998). In the rabbit mesenteric artery. 5-
HTIB/ID receptor-induced contraction occurs via myofilament Ca2+ 
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sensitization. which can be blocked by PKC inhibitors (Parsons. et 
al.. 1996). 
C a 2+ sensitization via the above pathways is therefore 
interpreted as SMPP-IM inhibition leading to an increase in the 
MLCK: SMPP-IM activity ratio. light chain phosphorylation and 
contraction without a change in [Ca2+h . 
Phosphorylation of other proteins. such as caldesmon by MAP-
kinase or calponin by PKC has also been suggested to play a role in 
Ca2+ sensitization (Horowitz. et al.. 1996). Recently. 5-HTIB/lD 
receptor mediated contraction in the rabbit renal artery was reported 
to be blocked by inhibitors of MAP-kinase (Hinton. et al.. 2000). 
Cross-talk between the different kinase pathways in the 
regulation of Ca2+ sensitization has been suggested as a key 
signalling event of Ca2+ sensitization of the contractile apparatus 
during agonist-induced contraction of vascular smooth muscle 
(Sasaki. et al.. 1998). 
Of relevance to the pulmonary circulation. calcium 
sensitization has also been implicated in the development of HPV 
(Robertson et al .• 1995: see section 1.1.4.5) 
1.2 The perinatal pulmonary circulation 
1.2. 1 The Foetal pulmonary circulation 
The foetal pulmonary circulation is characterised by high 
resistance and low blood flow. receiving only less than 10% of the 
foetal cardiac output. High PVR causes the majority of the foetal 
right ventricular output (-55-65% of total cardiac output) to be 
diverted through a patent ductus arteriosus to the descending 
thoracic aorta and enhances perfusion of the foetal organ of gas 
exchange. the placenta. thereby diverting the lungs (Rudolph 1979). 
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Pulmonary blood flow. although low in utero. remains essential for 
providing substrates. nutrients and hormones necessary for the 
normal growth and functional maturation of the lung before birth. 
Blood returning to the heart is shunted through the foramen ovale to 
the left atrium and ventricle. As the lung is in parallel with the 
placenta. the maintenance of high PVR results in this preferential 
distribution of blood flow to the comparatively low-resistance 
placenta. Much of the current understanding of the foetal pulmonary 
Circulation has arisen from investigation in the foetal lamb. PVR in 
this model was shown to be high at -6 mmHg ml-lmin- l at 0.4 
gestation with a progressive 20 fold fall by term (Rudolph. 1977). This 
fall in PVR is a result of increased cross sectional area of the 
pulmonary vascular bed. due to decreased resting vascular 
vasoconstriction. increased vessel diameter and formation of new 
vessels. When the lung is growing rapidly. during the latter half of 
gestation. the number of arterioles in the foetal lamb right lung 
increases nearly 50-fold from -100 thousand to 4.8 million (Levin. et 
al.. 1976). At term mean pulmonary arterial pressure is -50mmHg. 
Several mechanisms are thought to playa role in maintaining high 
foetal basal PVR. but are not understood completely. These include 
the low oxygen tension of the blood perfusing the lungs. Hypoxia is a 
potent pulmonary vasoconstrictor (see section l.l.4.5). so the 
perSistent hypoxaemia that exists produces perSistent active 
pulmonary vasoconstriction. The pulmonary vascular endothelium is 
known to release a number of vasoactive agents which cause either 
vasoconstriction or vasodilation (see section 1.1.4.3): the 
maintenance of high resting tone may therefore reflect a balance 
between these mediators. For example. low basal production of 
vasodilator products (such as Pgh and NO). combined with increased 
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production of vasoconstrictors including ET-l (Ivy et al., 1994) or 
leukotrienes (Soifer et al., 1985, Cassin et al., 1988). Recently, in 
vitro studies in ovine foetal pulmonary arteries have suggested that 
perinatal pulmonary arteries may exhibit a potent myogenic 
response, contributing to the high PVR in the foetal pulmonary 
circulation (Belik 1994: 1995). More recent, in vivo studies, have 
confirmed this (Storme et al., 1999). 
It is possible that locally released 5-HT from foetal pulmonary 
neuroendocrine cells (PNECs) may also contribute to the 
maintenance of high PVR. Human foetal PNECs have been shown to 
be immunoreactive for 5-HT from early in gestation (Cutz et al., 1995) 
and in rabbit cultured foetal PNECs, exposure of these cells to 
hypoxia resulted in decreased intracellular content of 5-HT 
accompanied by increased exocytosis of dense core veSicles. The 
amount of 5-HT release correlated with the degree of hypoxia (Cutz et 
al., 1993). Assuming this released 5-1IT is able to reach pulmonary 
arterial smooth muscle, contribution to vasoconstriction and hence 
high PVR is possible in the relatively hypoxic environment of the 
foetal pulmonary vasculature. 
1.2.2 Transition of the pulmonruy circulation at birth 
At birth, pulmonary arterial blood flow increases 8 to 10-fold 
(Cassin, et al., 1964: Dawes & Mott, 1962) and pulmonary arterial 
pressure rapidly declines by about 50% within the first 24 hours of 
extra-uterine life (Emmanouilides, et al., 1964). These key events are 
essential for the normal tranSition of gas exchange from placenta to 
the lungs to occur and are dependent on a dramatic decrease in the 
PVR within the first few hours of birth. The increased blood flow at 
birth raises left atrial pressure above right atrial pressure, forcing the 
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closure of the foramen ovale. As PVR falls below systemic resistance. 
flow through the ductus arteriosus reverses. Over the first few hours 
after birth. the ductus closes. 
The fall in PVR occurs as a result of a rapid sequence of 
integrated morphological (Haworth & Hislop. 1981; Hall & Haworth. 
1986) and functional (Zellers & Vanhoutte. 1991; Lui. et al.. 1992) 
changes. Within minutes of the initial vasodilator response. 
increased pulmonary blood flow distends the vasculature. resulting 
in a "structural reorganization" of the vascular wall that includes 
flattening of the endothelium and thinning of smooth muscle cells 
and matrix. 
In extensive studies. Haworth and colleagues have examined 
pulmonary arterial structural adaptation in the perinatal piglet 
observing immediate changes at birth. For example. at birth. in 
peripheral pulmonary arteries. thick interdigitating endothelial cells 
and brick-like Immature smooth muscle cells show an Immediate 
increase in surface/volume ratio and 'spread' within the wall to 
increase lumen diameter. lower resistance and halve right ventricular 
work by 2 weeks of age (Hall & Haworth. 1986a. b; Haworth. et al .• 
1987; Greenwald. et al .• 1985). There is no reduction in the amount 
of vascular smooth muscle. This rapid remodelling is probably 
facillitated by the relative lack of fixed collagen (Haworth. et al .• 
1987; Allen & Haworth. 1988). Changes in PVSMC shape are 
associated with a transient depolymerization of contractile and 
cytoskeletal filaments. The different SMC phenotypes identified in 
the vessel wall show rapid postnatal changes in the types of filament 
proteins and contractile-associated proteins (Haworth. 1995). 
Growth and development of the lung was observed to continue until 
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an adult pattern was reached by the age of 6 months (Haworth & 
Hislop, 1981). 
The mechanisms responsible in the normally successful 
cardiopulmonary transition from foetal to neonatal life are 
Incompletely understood and Involve multiple factors. Birth-related 
stimuli, such as ventilation, increased blood oxygen content, and 
endothelium-derived vasoactive substances such as prostacyclin 
(PGI21 (Leffler, et al., 1984) and endothelin-l (ET-l) (Ziegler, et al., 
1995) have all been implicated. In particular, growing evidence 
suggests that NO contributes to the tranSitional processes at birth. 
Physical stimuli, including, ventilation, Increased shear stress, and 
increased oxygen, cause pulmonary vasodilation in part by increasing 
production of NO (Abman, et al., 1992: Cornfield, et al., 1992: 
McQueston, et al., 1993; Moore et al., 1992). Pretreatment with the 
NOS inhibitor, Nw-nitro-L-arginine, attenuates pulmonary blood flow 
after delivery by 830/0 in near-term fetal lambs (Grtfiths, et al., 1987). 
These findings suggest that a significant part of the rise in 
pulmonary blood flow at birth may be related directly to the acute 
release of NO. Each of the birth-related stimuli can stimulate NO 
release independently, followed by vasodilation through cGMP 
kinase-mediated stimulation of Ca2+-activated K+ channels 
(Saqueston, et al., 1999). As endothelial NOS (eNOS) is present early 
in gestation, NO may also be involved in angiogeneSiS during lung 
development (Halbower, et al., 1994). This hypothesis was 
strengthened when Xue et al. (1996) detected increasing endothelial 
cells imunnopositive for eNOS progressing from 15 days of gestation 
to at least 7 days postnatally in pertnatal rat lung. 
The potent vasoconstrictor, ET-l has been implicated in 
playing an important role in the postnatal adaptation of the 
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pulmonary circulation (Zielger. et aZ .• 1995) as circulating levels are 
markedly high in the foetal and transitional pulmonary circulations 
(Endo, et aZ., 1996: Malamitsi Puchner, et aZ., 1993). Docherty & 
MacLean (1998) recently investigated contractile responses to ET-l in 
isolated, perinatal rabbit PRAs. They observed a rapid alteration in 
ET-receptor-mediated contraction in these vessels with a marked 
hypersensitivity to ETs receptor stimulation in newborn rabbits. 
Complex changes in the functional properties and interaction of both 
the endothelial and smooth muscle cells of pulmonary arteries are 
therefore thought to occur during postnatal development. Levy et al., 
(1995) for example, demonstrated that at birth a functional 
endothelium enhanced contractile responses to PGF2a and KCI in 
the newborn pig, but this was reversed at 10 days postnatal age. 
These changes may, therefore, also be reflected in perinatal 
pulmonary Circulatory responses to other known vasoactive 
substances such as 5-IIT. 
Other vasodilators, including adrenomedullin (Rudolph, 1998) 
and PGI2, may also modulate changes in pulmonary vascular tone at 
birth. PGI2 infusion in vivo into foetal lung produces a potent 
vasodilation (Cassin, et aZ., 1981), however, PGI2 production declines 
rapidly immediately after birth (Leffler, et al., 1984). Inhibition of 
prostaglandin synthesis only modestly attenuates the fall in PVR at 
birth in near term foetal lambs and does not alter postnatal 
adaptation. Collectively, the results suggest that PGI2 may 
contribute to pulmonary vascular changes during the transitional 
period at birth, but has minimal involvement In the postnatal 
adaptation. 
1.3 Pulmonary hypertension 
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Pulmonary hypertension (PHT) is defined as being present when 
mean pulmonary arterial pressure exceeds 25 mmHg (Fishman. 
1985). Regardless of aetiology. the clinical importance of PHT is 
related to high resistance to right ventricular outflow. low cardiac 
output. diminished arterial oxygenation and right ventricular 
pressure overload. right heart failure and death. 
PHT can arise as a primary phenomenon (idiopathic PHT) 
where the mechanism and cause are unknown. Primary PHT is a rare 
syndrome and is regarded as a disease of young adults, 
predominantly women aged between 30-40 years. with an average 
survival rate of 2-3 years (Rich, 1988). More commonly, PHT usually 
occurs secondary to other disease states and many mechanisms 
appear to either cause or contribute to the pathogenesis of PHT 
(Rich, et al., 1987). The principal causes of PHT fall into four main 
categories; (1) passive increases in pulmonary arterial pressure 
secondary to elevated left atrial pressure and left ventricular 
dysfunction. (2) veno-occlusive disorders. (3) conditions that cause 
an increased blood flow through the pulmonary vasculature beyond 
the ability of the pulmonary circulation to compensate; e.g. 
perSistent pulmonary hypertension of the newborn (PPHN) caused by 
patent ductus arteriosus (see section 1.3.2) and ventricular or atrial 
septal defects. (3) Vaso-occlusive type resulting in a diminished 
effective cross sectional area of the pulmonary vascular bed by 
obstructive e.g. thrombosis, chronic obstructive lung disease (COLD); 
obliterative, ego emphysema or advanced fibrosis; and 
vasoconstrictive means which is usually associated with hypoxia. 
Despite the different aetiologies of PHT, the condition is 
characterised by a relentless increase in PVR. 
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The high compliance of the major pulmonary blood vessels, 
and the tonic state of the peripheral precapillary resistance vessels 
both ensure the maintenance of low pulmonary arterial pressure in 
normal subjects, however, the structure of this highly compliant 
circuit may alter markedly with disease. The earliest changes include 
the muscularisation of the terminal part of the pulmonary arterial 
tree and narrowing of the peripheral vessels. Thickening of the major 
vessels also occurs (see section 1.3.1). Pulmonary arterial 
vasoconstriction elevates pulmonary arterial pressure, increasing the 
pressure on the right-hand side of the heart and causing right 
ventricular dysfunction. Pulmonary venous constriction can result in 
pulmonary oedema due to increased pulmonary capillary pressure. 
PHT, therefore, arises due to the combination of both 
vasoconstriction and anatomical restriction. 
The underlying mechanism(s) in the development of PHT have 
not been fully elucidated with multifactorial influences on both 
vascular remodelling (see section 1.3.1) and reactivity. Not 
surprisingly, altered endothelium function is thought to play an 
important role in altering pulmonary vascular tone in PHT. The 
pulmonary clearance of circulating catecholamines such as 
noradrenaline is abolished in patients with both primary and 
secondary PHT (Sole, et al., 1979). Impaired pulmonary vasodilation 
to stimulated NO release has been observed in vivo in patients with 
both primary (Conraads, et al., 1993) and secondary PIIT (Celermajer, 
et al., 1993). Recently, Giaid & Saleh (1995) observed a decreased 
expression in eNOS from the lungs of patients with severe PHT. 
Tuder and co-workers (1999) observed a marked reduction in PGI2 
synthase expression in lungs of severe PHT patients. Collectively, 
these results indicate an impairment of endothelium-dependent 
29 
vasodilator responses in PHT. In the normal pulmonary circulation. 
low pulmonary vascular tone is controlled by a balance between 
vasodilator agents such as NO and PGI2 and vasoconstrictors such 
as 5-HT and ET-l (Fishman. 1998: MacLean. 1999) (see section 
1.1.4.3). Alterations in this balance. in favour of the 
vasoconstrictors. through loss or reduction of protective NO and or 
PGI2 .. or indeed increased levels of endogenous vasoconstrictors such 
as ET-l (Stewart. et az.. 1991) will predispose a patient to pulmonary 
vasoconstriction. Elevated levels of the endogenous vasoconstrictors 
angiotensin II and thromboxane A2 may also be present in PHT. 
contributing to the increased vascular tone (Cargill & Lipworth. 
1995: Christman. 1998). Substantial evidence indicates that 5-HT 
(see section 1.4.5.4) and ET-l may also regulate growth and 
proliferation of vascular cell types. For example. ET-l stimulates 
DNA synthesis and cell proliferation of cultured pulmonary vascular 
smooth muscle cells (J anakidevt. et aZ.. 1992). Coupled with the loss 
of NO. known to inhibit vascular smooth muscle mitogenesis and 
proliferation (Garg & Hassid. 1989). altered pulmonary endothelial 
function could facilitate the process of pulmonary vascular 
remodelling and accelerate the development of PHT. 
Several other important factors could also be responsible for 
the increased vascular tone characteristic in PHT. These include 
depolarisation by inactivation of K+ channels. and decreased levels of 
cGMP and cAMP (due to increased phosphodiesterase activity): both 
have been observed in the chroniC hypoxic rat model of PHT 
(Osipenko. et aZ .. 1998: MacLean. et az.. 1996; 1997). Recently. 
Hanson and co-workers (1998) demonstrated a marked increase in 
PDE activity in the foetal lamb model of persIstent pulmonary 
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hypertension of the newborn, suggesting that decreased cGMP 
contributed to altered pulmonary vasoreactivity in perinatal PHT. 
Most standard vasodilators have been unsuccessful in the 
treatment of PHT due to lack of selectivity. Pulmonary vascular 
remodelling (see section 1.3.1) renders the pulmonary circulation 
relatively resistant to vasodilator therapy, and standard vasodilators 
exert a greater effect on the systemic circulation. This results in 
intolerable side-effects such as systemic hypotension. Inhaled NO, 
offers an attractive. pulmonary circulation selective. therapy in the 
treatment of PHT (Adnot. et al.. 1992). Recent studies have 
demonstrated that inhaled NO causes marked improvement in 
oxygenation in many newborn infants with PPHN (see section 1.3.2). 
Kinsella et al. (1992) reported rapid improvement in oxygenation in 
neonates with severe PPHN with the use of doses of 20 ppm NO for 4 
hours. after which the dose was decreased to 6 ppm for the duration 
of treatment: this strategy resulted in sustained improvement in 
oxygenation. Inhaled NO therapy may also be useful in other PHT 
states including acquired heart disease (Girard. et al .• 1992) and PHT 
secondary to congenital heart disease (Berner. et al., 1993). Oxygen is 
also an effective pulmonary vasodilator in several forms of PHT such 
as secondary to congenital heart disease (Bush. et al.. 1985) and 
bronchopulmonary dysplysia (Palmisano. et al.. 1990) and is the only 
selective vasodilator generally available. Increasing evidence suggests 
that 5-HT plays an important role in the aetiology of PHT (see 
section 1.5.3). The role of 5-HT in the pulmonary circulation and its 
putative involvement in PHT is introduced in section 1.5.2. 5-HT 
antagonists. therefore. present a possible therapeutic intervention. 
Recent studies. however have shown ketanserin. a 5-HT2A receptor 
antagonist (see section 1.4.3.2 ). to be ineffective or of limited use in 
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the treatment of PHT secondary to platelet storage pool disease 
(Herve, et al., 1995) or chronic obstructive pulmonary disease 
(Domenighettl, et al., 1997), due to systemic hypotenSion. Targeting 
of a more pulmonary vasculature-selective 5-lIT receptor subtype may 
be of more benefit. 
1.3.1 Pulmoncuy vascular remodell1n~ 
Figure 1.1 illustrates the progressive muscularisation of the 
pulmonary arteries in the pulmonary hypertensive lung. In PlIT of all 
aetiologies, the main changes involved in pulmonary vascular 
remodelling are smooth muscle hypertrophy, intimal proliferation 
and thickening of the adventitia of the pulmonary resistance vessels 
(Reid, 1990). As mentioned in section 1.3, the earliest changes that 
occur in the development of PlIT are a progressive musculartsatlon of 
the, originally non-muscular, terminal portion of the pulmonary 
arterial tree (Heath, et al., 1987) and is due to hyperplasia of the 
PVSMCs which extend distally in a layer to the original internal 
elastic lamina (Heath, et al, 1987), effectively forming an inner layer 
of longitudinal smooth muscle. Medial extension also occurs 
peripherally along the pulmonary arterial tree to the elastic arteries. 
Although both primary and secondary PHT share common 
pathobiologies, during the latter stages of pulmonary vascular 
remodelling, the patterns of smooth muscle cell proliferation and 
migration can be different. In primary PlIT, distinct plexiform lesions 
occur and occlude the pulmonary vascular lumen, smooth muscle 
cell migration is also widespread (Heath, 1992). In contrast migration 
is limited and plexiform lesions are rare in hypoxic PlIT. 
Although the study of vascular remodelling has focused 
extensively on the pulmonary arterial medial layer, all three vascular 
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layers of the pulmonary arteries. the intima. media and adventitia. 
all undergo varying patterns of thickening in PIiT dependent on the 
size of the pulmonary artery (Peacock, et al., 1993). 
The processes involved in remodelling are modification of cell 
growth, cell migration and extracellular matrix production and 
though not completely understood, several factors are thought to 
influence pulmonary vascular remodelling. Endothelial cells respond 
to shear stress arising from altered blood flow and as a result may 
secrete mediators, such as vascular endothelial growth factor, 
causing vascular SMC growth (Cool, et al., 1999). Altered endothelial 
cells may also lead to angiogenesis, resulting in hypertrophy and 
hyperplaSia (Lee, et al., 1998). Vascular injury may elicit vascular 
remodelling via inflammatory mediators. Wright et al. (1998) recently 
observed increased levels of transforming growth factor-~, and 
interleukins 1 and 6, resulting in production of inflammatory 
leukotrienes, in patients with primary PIiT. Increased production of 
endogenous vascular elastase in PVSMCs may result in cell migration 
from tunica media into the intima where they proliferate and secrete 
proteoglycans and matrixproteins (Rabinovitch, 1999). Once PIiT has 
developed, the associated vascular structural changes renders the 
pulmonary circulation relatively resistant to standard vasodilator 
therapy (section 1.3). 
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A 
Figure 1.1 
Terminal 
bronchiole 
B 
Terminal 
bronchiole 
Diagrammatic representation of the pulmonary arteries within the lung. (A) In 
the normal lung there is an uneven distribution of smooth muscle phenotypes 
and numerous non-muscular precapillary vessels. (8) In the pulmonary 
hypertensive lung there is progression of muscularization into the non-muscular 
terminal portion of the arterial tree. This is due to hyperplasia and redistribution 
of smooth muscle cell phenotypes (see text for details). 
From: MacLean et al., (2000) British Journal of Pharmacology 131, 161-168. 
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1.3.2 Persistent pulmonruy hypertension of the newborn (PPHNl 
The pulmonary circulation of some infants fails to adapt to life 
outside the uterus, which leads to severe respiratory distress and 
hypoxemia, referred to as persistent pulmonary hypertension of the 
newborn (PPHN). PPHN contributes significantly to morbidity and 
mortality in both term and preterm neonates (Hageman, 1984) and is 
characterised by a persistence of the foetal circulation with a high 
PVR leading to extrapulmonary right-to-Ieft shunting of blood flow 
across the ductus arteriosus and foramen ovale. PPHN is associated 
with diverse neonatal cardiopulmonary diseases, such as asphyxia, 
congenital diaphragmatic hernia, meconium aspiration, sepsis, 
pneumonia, acute respiratory distress syndrome, and lung hypoplasia 
(Gersony, et at, 1969; Levin, et al., 1970). PPHN Is occasionally found 
in term infants following a normal delivery. 
The vascular remodelling associated with PHT was Introduced 
In section 1.3. 1. In PPHN, the perSistence of foetal pulmonary 
vasculature morphology is often evident. 
Because PPHN represents the failure of postnatal adaptation of 
the lung circulation at birth, understanding basic mechanisms of 
normal functional and structural development of the pulmonary 
circulation in utero and mechanisms that contribute to pulmonary 
vasodilation at birth (see section 1.2.2) may provide insights into the 
syndrome of PPHN and its treatment. 
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1.4 5-HT (serotonin) 
l.4.1 Discovery 
In 1948. Rapport and colleagues isolated a substance released 
from platelets in clotting blood that was subsequently shown to be a 
powerful vasoconstrictor and was originally termed serotonin 
(Rapport. et al, 1948). Rapport quickly went on to identify the active 
component of this substance as 5-hydroxytryptamine (5-HT). a 
bioactive indole alkylamine . 
1.4.2 5-HT distribution, biosynthesis and de~radation 
5-HT occurs at its highest concentrations in three different 
locations throughout the body. In mammals. the main source of 5-
HT present in the body. apprOximately 900/0 of the overall total. is 
found in the enterochromaffin cells of the gastrointestinal tract; 
after being extracted from strips of gastrointestinal tract it was 
originally given the name enteramine (Erspamer & Asero. 1952; 
Stacey. 1962a). 5-HT is also present in high concentrations in blood 
platelets which possess mechanisms for its uptake. storage and 
release (see later in this subsection). 
5-HT also acts as a neurotransmitter in the central nervous 
system. is selectively contained in neurones with cell bodies mainly 
located in the midline area of the brainstem and terminals diffusely 
distributed throughout the central nervous system. 
Hamlin and co-workers (1951) originally described the 
synthesis of 5-HT and although conSiderable amounts of 5HT are 
found in normal diet. the high levels of 5HT in enterochromaffin cells 
does not arise as a consequence of 5-HT uptake from the intestine 
but by "in-situ" synthesis from the essential amino acid tryptophan 
(Douglas. 1980). 
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The amino-acid precursor for 5-fIT biosynthesis 1s tryptophan 
and is converted to 5-hydroxytryptophan in chromaffin cells (and 
neurones) through the action of the mixed functional oxidase 
enzyme. tryptophan hydroxylase requiring molecular oxygen and a 
reduced pteridine cofactor for activity. The resulting 5-
hydroxytryptophan then undergoes carboxylation by L-aromatic acid 
decarboxylase to 5-hydroxytryptamine. Platelets do not directly 
synthesise 5-HT. but possess a high affinity uptake system with 
relative specificity for 5-HT and avidly take up and store the 
bioamine as they pass through the intestinal Circulation (Coppen. et 
al.. 1978: Pletscher. 1978). Basal release of enteric 5-fIT can be 
augmented by mechanical stretching and vagal stimulation (Forsberg 
& Miller. 1982). Na+-dependent active transport of 5-HT across 
platelet surface membranes leads to uptake into very dense core. 
delta granules across a H+-translocating ATPase-dependent 
electrochemical gradient. It has been estimated that 1012 platelets 
circulating in a 70kg adult contain in total apprOximately 500llg 5-
HT (Fozard. 1981). Plasma also contains some free 5-HT. This 
fraction has been estimated to account for 15-120nM (Crawford. 
1965; Engback & Voldby. 1982). Low circulating free 5-HT levels are 
achieved by a combination of the avid uptake and storage by platelets 
and by the effective uptake and subsequent metabolism in the 
pulmonary vascular endothelium. 
Breakdown of 5-HT primarily occurs as a two-step process 
through oxidative deamination. resulting in the formation of an 
aldehyde via the action of monoamine oxidase (MAO). Two isoforms 
of this enzyme exist. MAO-A and MAO-B. and have been cloned 
(Shih. 1991). MAO-B is the predominant form in platelets. The 
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aldehyde produced is subsequently oxidised to 5-hydroxyindoleacetlc 
acid (5HIAA) which is excreted in the urine. 
1.4.3 5-lIT receptor classification 
The first studies on 5HT receptors concerned their 
pharmacological characteristics on guinea pig ileum and led Gaddum 
& Picarelli (1957) to propose the existence of 2 receptor types; 
originally described as the musculotrophic 'D' receptor and 
neurotrophic 'M'. These 'criteria' were based on theIr sensItivity to 
morphIne (M) and dibenzyline (phenoxybenzamine) (D). Subsequent 
studies by Peroutka & Snyder (l979) gave rise to the 5-HTl. 5-HT2 
classification of receptors based on radioligand bindIng studies on 
rat brain cortex. Bradley et al. (1986) in a pragmatic approach 
proposed the reconciliation of these two nomenclatures and 
suggested that 5-lIT receptors could be classified Into three groups 
designated '5-IITI-like'. 5-IIT2 and 5IIT3. 
For nearly ten years the classIfication of Bradley was widely 
accepted as it provided a logical framework in terms of operational 
characteristics for classifying 5-HT receptors. Recent advances in 
molecular biology have served to confirm. extend and establish the 
distinct identity of the 5-HT receptors. On this basis. the state of 
knowledge on 5-IIT receptors was re-addressed by Hoyer et al in 1994. 
The three criteria used to classify receptors are operational (Le. 
functional pharmacological and radio ligand binding data). 
transducttonal (receptor-effector coupling events) and structural 
(gene & receptor structural sequences for their nucleotide & amino 
acid components. respectively) (Hoyer and Martin, 1996); none of the 
three have precedence. The classification of 5-IIT receptors described 
in this chapter is based on an international view sanctioned by the 
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Receptor Nomenclature Committee of IUPHAR (see Hoyer et al, 1994) 
coupled with the alignment of the nomenclature with the human 
genome (Hoyer and Martin. 1996). 
Figure 1.2 shows the different classes of 5-HT receptor which 
are currently classified into at least seven classes of receptor. They 
comprise the 5HTI receptors. with subtypes 5-HTIA-F. 5-HT2 
receptors with subtypes 5-HT2A-C. 5-HT3 as well as the 5-HT4. 5-
HT5. 5-ht6 and 5-HT7 receptors. With the exception of the 5-HT3 
receptor, which comprises a ligand-gated ion channel. all other 5-HT 
receptors belong to a 'superfamily' that are coupled with guanine 
nucleotide binding (G)-proteins and contain seven transmembrane-
spanning hydrophobic regions. an extracellular N terminus and a 
cytosolic C terminus. 
It is beyond the scope of this chapter to fully review each 
subtype of 5-HT receptor belonging to the seven classes. This review 
will concentrate on the 5-HT receptors identified on vascular smooth 
muscle and endothelial cells. focusing on those receptors recently 
implicated in mediating vascular smooth muscle function. i.e. the 5-
HTlR 5-HTID. 5-HT2A, 5-HT2B and 5-Hf7 receptors. 
1.4.3.1 5-HTJR and 5-HTID receptors 
5-HTI receptors were first identified as a high-affinity site for 
5-HT in radioligand-binding studies on brain homogenates using 
[3H]-5-HT (Peroutka & Snyder. 1979). Later the subtypes 5-HTIA. 5-
HT1B. 5-HTIC. 5-HTID. 5-HTIE and 5-HTIF were identified. which 
can all be selectively labelled. All these receptors have also been 
cloned and shown to share a high degree of homology (>60% 
39 
~ 
Receotor: 5-HT 1 5-HT2 S-HT3 5-HT4 S-hts 5-HTS 5-HT7 
I I I I I I I 
Effector: .l. AC jpLC Ion Channel JAC -LAC? fAC JAC 
(Gj/GO) (Gq/11 ) Na+/K+/Ca+ 
I I 
(Gs) (Gs) (Gs) 
Subtvoes: 5-HT1A 5-HT1 B 5-HT2A 
5-HT 1 0 5-HT 1 E S-HT 1 F 5-HT2B S-HT2C S-hts A S-hts B 
Fi4ure 1.2 Current classification of 5-hydroxytryptamine receptors. 5-HT receptors currently divided into 
7 classes based upon operational, transductional and molecular data. Receptor subtypes mediating 
vascular responses shown in bold type. AC, adenylate cyclase; PLC,phospholipase C; Gs,stlmulatory G 
protein; Gi/Go, inhibitory G protein; Gq/ 11, Gq GTP binding protein. 
in transmembrane domains). They also have a high affinity for 5-fIT 
and share a common transduction system in being negatively coupled 
to adenylate cyclase via regulatory G-proteins (Hoyer, et at, 1994: see 
1.4.3.l.i). 
Selective receptor agonists are aVailable for 5-fITIA-D receptors 
and an agonist potency order of 5-CT > 5-HT> sumatriptan ~ (l-me-
5-HT > 8-0H-DPAT satisfies one of the criteria for identifying a 5-
HTI receptor mediated response (Hoyer, et at, 1994). The originally 
named the 5-HTIC receptor (Pazos et al., 1984) has now been 
renamed 5-HT2C (Humphrey et al., 1993) based on charactertsation 
criteria. It mediates activation of protein kinase C via increased 
phosphoinositide metabolism is entirely consistent with operational 
and structural data of the 5-HT2 receptor class. 
Two closely related human genes that encode for G protein-
coupled receptors have been cloned and share very Similar 
pharmacological profiles including high affinity for the 
vasoconstrictor compound sumatrtptan (Weinshank, et al., 1992). 
These receptors have been named the 5-HTlB and 5-HTID receptors. 
Until recently, with their very Similar pharmacology, these receptors 
were termed the 5-HTU)(x and 5-HT 10{3 receptors respectively but their 
nomenclature has recently been re-aligned (Hartig, et al., 1996) and 
compounds that are able to distinguish between them are beginning 
to be produced. Until recently, no truly selective antagonist existed 
which was able to distinguish between these two receptors and 
pharmacological claSSification relied upon agonist potency orders 
and resistance to antagonists with known selectivity at other 5-HT 
receptor subtypes. 
Involvement of either of these receptors, without clear 
distinction between the two, was often given the appellation 5-
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HTIB/ID receptor. Sumatriptan. used as a selective agonist for 5-
IITB/IO receptors. was initially identified by its ability to constrict 
dog isolated saphenous vein (Humphrey. et al.. 1988). It has 
subsequently been shown to produce potent contractile responses in 
several vascular preparations including cerebral (Janssen. et al .. 
1993). coronary (Kaumann. et al.. 1994) and pulmonary arteries 
(MacLean. et al .. 1996; Cortljo. et al .. 1997) in man. Used extenSively 
throughout this thesis as a 5-HTIB/ID receptor agonist. sumatriptan 
has an affinity value (pK~ at cloned rabbit 5-HTIB receptors of -6.8 
(Bard. et al.. 1996). The following antagonists were used in this 
thesis: (1) GR55562 is a selective antagonist at the 5-HTIB and 5-
IITID receptors and has a pA2 value of 7.9 against sumatriptan-
induced contractions of the canine and monkey isolated basilar 
artery (Conner. et al.. 1995) and has been shown to be a potent 
antagonist against the 5-HTIB/IO receptor in human isolated large 
pulmonary arteries (MacLean, et al., 1996). (ti) Recently. two 
compounds have been shown to be selective for the 5-IITIB and 5-
HTID receptors. SB-224289 a 5-HTIB receptor selective antagonist. 
has affinity values of 8.0 and 6.2 at 5-HTIB and 5-HTID receptors 
respectively (Roberts, et al.. 1997). BRL-15572. a 5-HTID receptor-
selective antagonist has antagonist affinity values of 6.1 and 7.9 at 
5-HI'IB and 5-HTIO receptors respectively (Price, et al.. 1997; 
Schlicker, et al.. 1997). These compounds were used in the studies in 
chapter 4 of this thesis. 
With regard to the possible pathophysiology associated 
with vascular 5-HTIB and 5-HTIO receptors. it is thought that the 
5-HI'IBreceptor mediates vasoconstriction in human cerebral vessels 
(Verheggen. et al.. 1998) which is part of the basiS of migraine 
treatment with sumatrlptan and other Similar trlptan derivatives. 
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Vascular 5-HTIB receptors may also be important in mediating 
pulmonary vasoconstriction both in the normal as well as the 
pulmonary hypertensive state (see section 1.5.3). 
1.4.3.1.1 5-HTIBIlD receptor si2nal transduction I effector 
mechanisms 
Activation of 5-HTIB and 5-HTID receptors results in 
inhibition of adenylate cyclase (Brancheck et al., 1991; Hartig et al., 
1996) and in a number of vascular preparations, activation of these 
receptors has been shown to be negatively coupled to the production 
of cAMP. In the canine saphenous vein for example, sumatriptan 
decreased the stimulated accumulation of cAMP (Sumner & 
Humphrey, 1990).Recently, the rabbit recombinant saphenous vein 
5-HTIB receptor stably transfected in C6-glial cells displayed 
significant reduction in cAMP when exposed to various 5-HTIB/ID 
receptor selective agonists including sumatriptan (Wurch, et al., 
1997). 
The 5-HTIB receptor is located on human chromosome 6q13. In 
cells stably expressing human 5-HTIB receptors, stimulation of these 
receptors blocks forskolin-stimulated adenylate cyclase and cAMP 
accumulation (Veldman & Bienkowki, 1992; Hamblin, et al., 1992) 
and these receptor mediated effects are blocked by pertussis toxin 
pretreatment, indicating the involvement of Gi/o proteins (Dickenson 
& Hill, 1995). The 5-HTID receptor has 63% structural homology with 
the 5-HTIB receptor, is located on human gene 1p36.3-p34.3 and has 
been shown to be negatively coupled to adenylate cyclase 
(Weinshank, et al., 1992). 
Although decreased cyclic AMP levels provide a useful indicator 
for 5-HTIB/ ID receptor function, it is unclear, however, if such a 
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reduction . following 5-HTIB/ ID receptor stimulation. is responsible 
per se for vascular smooth muscle contraction. 
In the bovine isolated pulmonary artery. contraction to the 5-
lITIB/lD receptor selective agonist sumatriptan correlated well with 
the concomitant decrease in basal cyclic AMP (Sweeney. et al.. 1995). 
Sumatriptan alone caused no significant contraction in those vessels 
and had no effect on intracellular cyclic AMP concentration. In the 
presence of agonist-induced tone. however. sumatriptan evoked a 
potent contraction in the bovine pulmonary arteries. concomitant 
with a decrease In basal cyclic AMP. Furthermore. administration of 
forskolin. a direct activator of adenylate cyclase (Koch. H.. 1982). 
potentiated the contractile response to sumatriptan and allowed 
sumatriptan to induce a further decrease in cyclic AMP. Collectively. 
the results suggest that the ability of sumatriptan to decrease cyclic 
AMP is positively correlated to its ability to induce vasoconstriction 
in bovine pulmonary arteries (Sweeney. et al.. 1995). 
In contrast. Sumner & Humphrey (1990) reported that 
decreased levels of cyclic AMP. in response to 5-HT1B/1D receptor 
activation. were only observed if adenylate cyclase was prestimulated 
with forskolin in canine saphenous vein. Furthermore. an 
involvement of extracellular Ca2+ in 5-HTIB/ID receptor-mediated 
vasoconstriction was carried out by Sumner et al. (1992). who found 
that sumatriptan-induced contraction in the dog saphenous vein. 
was blocked by removal of extracellular Ca2+ and markedly 
attenuated by the L-type Ca2+ channel antagonist verapamil. This 
suggests an important role for Ca2+ influx through voltage operated 
Ca2+ channels in 5-HTIB/ID receptor-mediated vasoconstriction. 
Sumatrtptan also inhibited agonist-stimulated cAMP in these vessels 
(Sumner et al.. 1992). Evidence exists against a causal relationship 
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between 5-HTIB/ID receptor-induced decrease in cyclic AMP and 
ensuing smooth muscle contraction (Movahedi & Purdy, 1997; 
Randall, et al., 1996). 5-lIT alone, through activation of 5-lITIB/lD 
receptors, was reported to significantly reduce basal levels of cyclic 
AMP without causing any significant contraction in the rabbit 
femoral artery (Randall, et al., 1996). In the same study, in pre-
contracted vessels, 5-HT also failed to reduce modest increases of 
cellular cyclic AMP but caused a potent contractile response. 
The rabbit ear artery possesses a significant population of 5-
lITIB/lD receptors which induce a potent vasoconstriction in the 
presence of agonist-induced tone and mediate inhibition of adenylate 
cyclase through a pertussis toxin (PTX)-sensitive G-protein 
(Movahedi & Purdy, 1997). In that study, PTX did not significantly 
alter the 5-HTIB/ID receptor-induced contraction but did mediate 
uncoupling of the receptor to adenylate cyclase and cyclic AMP 
formation. The authors concluded that the 5-HTIB/ID receptor-
mediated inhibition of adenylate cyclase, and therefore decreased 
cyclic AMP, was not per se responsible for the ensuing contraction. 
The contraction, however, was completely dependent on the 
availability of extracellular Ca2+ (Movahedi & Purdy, 1997), 
suggesting an alternative second messenger pathway associated with 
calCium influx. In a recent study using rabbit mesenteric arteries. 
Hinton and colleagues (1999) reported that 5-lIT decreased cyclic 
AMP following forskolin stimulation. and without the requirement to 
raise external potassium, a pre-requisite for 5-HTIB/ID receptor-
mediated contraction in this preparation. The observations argue 
against any major role for cyclic AMP in contraction (Hinton, et al., 
1999). Taken together, the findings suggest that contractile responses 
to 5-lIT are mediated via a cAMP-independent pathway and evidence 
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for the link between decreased cellular cAMP and smooth muscle 
contraction is. therefore. not substantive. Vascular smooth muscle 
contraction via 5-HT1B/lD receptor stimulation may. therefore. 
involve other signalling pathways operating either in addition to. or 
instead of decreased cyclic AMP. 
The precise role of Ca2+ in 5-HT1B/1D receptor-induced 
contractions may vary between different vessels. Vascular 5-HT1B/1D 
receptors have been shown to mediate extracellular Ca2 + 
mobilization in cultured bovine basilar artery VSMCs (Ebersole. et 
al.. 1993). In rabbit isolated ear artery. 5-HTIB/ID receptor-mediated 
contraction following precontraction with phenylephrine was 
attenuated by the voltage-operated Ca2+ channel blocker nifedipine 
and completely abolished by removal of extracellular Ca2+ (Movahedi 
& Purdy, 1997). In contrast, in rabbit saphenous vein. 5-HT1B/1D 
receptor-induced contractions were insensitive to nifediplne 
(Razzaque et al.. 1995). 
Agonist-induced elevation in intracellular Ca2+ may also result 
from release of Ca2+ from intracellular stores. 5-HT1B/1D receptor 
stimulation is known to induce transient increases in intracellular 
Ca2+ in the absence of extracellular Ca2+ in VSMCs from bOvine 
basilar artery (Ebersole. et al.. 1993). In contrast. in rabbit isolated 
mesenteric artery. the Ca2+ -ATPase inhibitor thapsigargin failed to 
inhibit 5-HT1B/ 1D receptor-induced contractions. providing evidence 
that Ca2+ release from intracellular stores did not contribute to the 
contractions (Hill. et al.. 2000). 
In addition to requiring extracellular Ca2+. several studies. 
mainly in the rabbit mesenteric artery. have demonstrated that 5-HT 
can stimulate contraction in permeabilized cells in the presence of a 
fixed concentration of Ca2+ (Parsons. et al.. 1996; Seager et al.. 1994; 
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Hinton, et al., 1999). This suggests that 5-HTIB/ID receptor-mediated 
contraction also involves senSitization of the contractile 
myofilaments to Ca2+. The myofilament sensitization evoked with 5-
lIT was reported to be blocked by inhibitors of either phosholipase A2 
(PLA21 (Parsons, et al., 1996) or proteIn kinase C (PKC) (Seager, et al., 
1994: Parsons, et al., 1996) and mimicked by arachidonic acid. In the 
same artery, 5-HTIB receptor-mediated activation is associated with 
the activation of the enzyme phospholipase D (PLD) (Hinton, et al., 
1999) which may be downstream of PKC activity and without the 
concurrent activation of phospholipase C (PLC) (Seager, et al., 1994). 
this provides evidence, albeit indirect, to suggest that PLD could 
represent a component of the link between 5-HTIB receptor-
activation and vascular smooth muscle contraction. 
Recently. Hinton et al (2000) reported that inhibitors of 
phosphaUdylinositol 3-kinase and activated mitogen-activated 
protein kinase (MAPK) significantly reduced the 5-HTIB/ID receptor 
mediated contractile response in the rabbit renal artery. This 
indicates that MAPK may also play an important role in the 
contractile pathway resulting from 5-lITIB/ID receptor activation. 
It is clear that the second messenger system linking 5-IITIB/ID 
receptor activation and vascular smooth muscle contraction is not 
clearly defined and that these receptors mediate the ensuing 
contraction in a complex way. This may involve the interaction of 
several intracellular signalling pathways. 
1.4.3.2 5-lIT2A receptors 
Peroutka & Snyder (1979) showed that 5-HT2 sites could be 
labelled with PH] LSD and PH] splperone but not [3H] 5-HT: this led 
to the proposed existence of 5-HTI and 5-HT2 sites. Three 5-HT2 
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receptor subtypes are currently recognised (5-HT2A. 5-HT2B & 5-
HT2C) and each has been cloned and shown to be a G-protein linked 
single protein molecule of similar size and close homology. All three 
subtypes mediate their effects through activation of phosphoinositide 
metabolism (see section 1.4.4.2). 
Originally deSCribed as the 5-HT2 receptor. the 5-HT2Areceptor 
is located on human chromosome 13q14-q21. Widely distributed in 
peripheral tissues. this receptor mediates contraction of many 
urinary. uterine. gastrointestinal and vascular smooth muscle 
tissues. (Hoyer. et al.. 1994). A number of compounds have high 
affinity for the 5-HT2A receptor but few are truely selective. especially 
with regard to the other members of the 5-HT2 receptor class. The 
agonist a-methyl-5-HT. often used as an agonist probe for the 5-
lIT2A receptor. is also a potent agonist at the 5-HT2B and 5-HT2C 
receptors. Nevertheless. an agonist potency order of 5-HT ~ a-me-5-
HT » 8-hydroxy-2-(di-n-propylamino)-tetralin (8-0H-DPAT) > 5-
carboxamidotryptamine (5-CT) st111 provides useful supporting 
evidence for mediation via the 5-HT2A receptor. One of the most 
useful antagonists is ketanserin. first described by Leysen and 
colleagues (1982) having a high binding affinity for 5-HT2 receptors 
(pKi = 8.9). this compound demonstrates -70 -100 fold selectivity over 
5-HT2B and 5-HT2C receptors and is used extensively in the studies 
of this thesis. The contractile response to 5-HT is mediated by the 5-
lIT2A receptor in a wide variety of arterial and venous preparations 
especially condUit vessels (Saxena & Villalon. 1990) and ketanserin 
has provided a strong basis in the identification of this receptor. In 
the rabbit isolated aorta. for example. Leff & Martin (1986) showed 
this compound to have a pA2 against 5-HT-induced contraction of 
8.6. This affinity value is typical for ketanserin showing a range of 
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8.1 - 10.4 in a variety of isolated conduit vascular preparations from 
different species including the rat basilar and rat caudal arteries 
(Chang & Owman, 1989; Leff & Martin, 1986) and the calf coronary 
artery, displaying subnanomolar antagonist affinity (pKB = 9.5) 
(Frenken & Kaumann, 1984). 
Several studies have shown that ketanserin is an antagonist at 
5-HTIB/ID receptors at ~M concentrations. In cloned rabbit and 
human 5-HTI Band 5-HTI D receptors, Bard, et al (1996) 
demonstrated that ketanserin was able to discriminate between these 
two 5-lIT receptor subtypes showing high affinity (pKi = 7.66) for the 
5-lITID subtype and a 20-fold selectivity over the 5-lITIB subtype. In 
rabbit isolated coronary arteries, high concentrations of ketanserin 
(l-10~M) were shown to antagonise sumatriptan-induced 
contractions (pA2 -6.5) (Ellwood and CurtiS. 1997). The POSSibility 
that ketanserin may antagonise 5-HTIB/ID receptor-mediated 
responses must therefore be taken into consideration when 
interpreting the results of pharmacological studies. EVidence 
indicates that the vasoconstrictor effect of 5-lIT in human systemiC 
arteries is normally mediated mainly through the 5-lIT2A receptor 
(Arneklo-Nobin, et at, 1985). 
1.4.3.3 5-IIT2B receptors 
The 5-lIT2B receptor is located on human chromosome 2q36.3-
2q37.1 . First cloned from rat and mouse stomach fundus (Foguet et 
at, 1992; Kursar, et al., 1992), it is the most recent member of the 5-
lIT2 receptor class, named because of its close structural homology 
with this family. Cloned human rat and mouse 5-HT2B receptors are 
coupled to Gq/ll G-proteins and signal transduction mechanisms 
include. primarily, an increased phosphoinositide hydrolysis (Kursar, 
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et al.. 1992). Cox and co-workers (1995) showed that stimulation of 
this receptor also results in the activation of protein kinase C in rat 
stomach fundus. 
5-HT2B receptors display a similar pharmacology to that of the 
5-HT2t\and 5-HT2C receptor in terms of the agonists 5-HT and (l-me-
5-HT having high affinity for this receptor (Wainscott. et al.. 1993). 
with the affinity for 5-HT at this receptor (-8.36) being higher than 
at any other functional 5-HT receptor described (Leff. et al.. 1987). 5-
CT displays a 7 -fold lower affinity than 5-HT at this receptor. 
Receptor binding affinities for ketanserin. however. at this receptor 
are comparatively poor (pKi = 5.4) compared to the 5-HT2A receptor 
(Wainscott. et al.. 1993). Recently. SB 204741 has been reported as a 
selective 5-HT2B receptor antagonist (pKi = 7.8) with -100-fold 
selectivity over the 5-HT2A and 5-HT2C sites. One of the most 
selective agonists. BW 723C86. has been reported to have 100 fold 
and 10 fold selectivity (pKi = 7.9) over the rat 5-HT2A and 5-HT2C 
receptors respectively (Kennet. et al.. 1996) and this compound has 
recently been shown to induce a potent. endothelium-dependent 
vasorelaxation in isolated porcine pulmonary arteries (Glusa.1992; 
2000). 5-HT2Breceptor mediated. endothelium-dependent. relaxation 
has also been reported in other isolated vascular preparations 
including the rat and rabbit Jugular vein (Ellis. et al .. 1995; LefT. et 
al.. 1987). In the rabbit Jugular vein. for example. BW 723C86 was 
shown to be a potent agonist (p E C 50 = 7.5) in mediating 
endothelium-dependent relaxation (Martin. et al.. 1993). The 
observed relaxation is thought to occur indirectly via endothelium-
dependent nitriC oxide release (Baxter. et al.. 1995; Ishida. et al.. 
1998). Ullmer and colleagues (1996) observed calCium release from 
ryanodine-sensitive intracellular stores in human pulmonary artery 
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endothelial cells upon activation of the 5-HT2B receptor. This is 
consistent with the NO-induced vessel relaxation. Strong evidence 
for an endothelial location for this receptor has also been provided 
using molecular studies as 5-HT2B receptor mRNA is present in 
cultured endothelial cells from human umbilical vein. coronary 
artery and aorta (Ullmer. et al.. 1995). 5-HT2B receptors are also 
present on smooth muscle and have been shown to mediate 
contraction of longitudinal muscle in human small intestine 
(Borman & Burleigh. 1995). The presence of 5-HT2B receptor mRNA 
in the cerebral vasculature (Ullmer. et al.. 1995) suggests that 
activation of this receptor may play a role in migraine headache. In 
many forms of hypertension the vasoconstrictor response to 5-HT is 
markedly increased (Collis & Vanhoutte. 1977; Thompson & Webb. 
1987; Turla & Webb. 1989) and in some forms of hypertension. 5-HT 
antagonists such as ketanserin are shown to be ineffective. Recently 
Watts and co-workers (1996) demonstrated a marked 5-HT2B 
receptor mediated vasoconstriction and increased mRNA for this 
receptor in mesenteric arteries from deoxycorticosterone acetate-salt 
hypertensive rats compared to controls (5-lIT2A receptor mediation). 
5-HT2B receptors may therefore be implicated in hypertension. 
1.4.3.3.1 5-HT2 receptor silj!nal transduction mechanisms- Activation 
of phospholipase C (PLC) Iprotein kinase C (PKC) 
The 5-HT2 class of receptor. including the 5-HT2A and 5-HT2B 
receptors are thought to be linked to the phosphinositol hydrolysis 
signal transduction system coupled to the (l subunit of the Gq GTP 
binding protein (Hoyer. et al.. 1994). PLC catalyses the formation of 
inositol phosphate (IP3) and diacylglycerol (DAG). This occurs 
through the hydrolysis of phosphotidyl 1 inositol (4.5) biphosphate 
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(PIP21. Doyle and co-workers (1986) demonstrated that 5-HT2A 
agonists activate PLC in rat culture aortic smooth muscle cells. IP3 
then acts via specific receptors to release intracellularly stored Ca2+. 
This increase results in activation of the enzyme myosin light-chain 
kinase (MLCK), which leads to the phosphorylation of myosin light-
chain protein, triggering contractile events. DAG may in turn 
activate PKC and ultimately cause the opening of voltage -dependent 
Ca2+ channels and the elevation of cytosolic Ca2+. Recently, in the 
isolated blood-perfused dog lung, Barman and co-workers (1997) 
demonstrated that PKC activation and subsequent activation of 
voltage-dependent Ca2+ channels was involved in 5-IIT2A receptor 
mediated pulmonary vasoconstriction. 
1.4.3.4 5-HT7Receptors 
The 5-HT7 receptor is the most recently identified member 
belonging to the family of G-protein coupled 5-HT receptors, has 
been cloned from several species including man and is located on the 
human chromosome 10q23.3-q24.4. Multiple splice variants of this 
receptor have been discovered (Heidmann, et al., 1997) but are not 
associated with markedly different functional capabilities. 
A rank order of agonist potency for this receptor has been suggested; 
5-CT > 5-HT > 8-0H-DPAT > sumatriptan, with affinities for 5-IIT 
and 5-CT being 8.1- 9.4 and 9.0 - 9.7 respectively in human 
recombinant receptors expressed in mammalian cells (Bard, et al., 
1993; Jasper, et al., 1996). Indeed, this receptor was originally classed 
as "5-HTI-like" due to high affinity for 5-CT. Several antipsychotic 
drugs and some 5-HT receptor antagonists have been found to bind 
to 5-HT7 receptors with high affinity. These include spiperone, 
risperidone and pimozide with affinity values (pKj) of 8, 8.86 and 
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respectively (Roth, et al., 1994). In chapter 3 of this thesis, 
risperidone, pimozide and spiperone were used as 5-lIT7 antagonists 
and in chapter 5, spiperone was used. The 5-lIT7 receptor has been 
identified in the vascular smooth muscle of several species using 
pharmacological and molecular analysis and this receptor subtype 
mediates 5-HT-induced vasorelaxation. The presence of 5-lIT7 
receptor mRNA has been demonstrated in canine and human 
coronary artery (Bard, et al., 1993) and in various rat and porcine 
blood vessels including the porcine pulmonary artery (Ullmer, et al., 
1995). Functional studies show that endothelium-independent, S-
lIT-induced vasorelaxation can be attributed to this receptor. In the 
endothelium-denuded. pre-constricted canine coronary artery. for 
example. 5-CT produced concentration-dependent relaxations with 
high potency which were significantly antagonised by risperidone, 
spiperone and pimozide with pKB values of 9.4, 7.14 and 8.27 
respectively. strongly indicative of a 5-HT7 receptor mediated 
response (Terron. et al.. 1996). Similar observations have also been 
made in monkey isolated jugular vein (Leung. et al.. 1996) and dog 
cerebral arteries (Terron, et al., 1999). In the rabbit, the 5-lIT7 
receptor is thought to mediate 5-HT-induced relaxation in the 
femoral and jugular veins (Martin & Wilson, 1995; Leff. et al.. 1987). 
Collectively. these data show that the 5-lIT7 receptor plays a 
role in mediating vascular smooth muscle relaxation. Interestingly. 
the predominant response to 5-HT in the cerebral arterial bed is 
vasoconstriction thought to result from stimulation of 
predominantly 5-lIT2A and 5-HTIB receptors (Deckert. et al.. 1994; 
Hamel. et al.. 1993). This is also true of the coronary artery (Ellwood 
& Curtis. 1997). A physiological role for the 5-HT7 receptor has been 
suggested in modulating the vasoconstrictor effects of 5-HT7A and 5-
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lITIB receptor activation (Eglen, et aL, 1997). Two important vascular 
beds where this receptor appears to be located are the cerebral 
(Terron, et al., 1999) and coronary (Terron, et al., 1996) vasculature. 
This may suggest a pathophysiological involvement in angina and 
migraine headache respectively. 
Schoeffter and co-workers (1996) demonstrated that 5-CT and 
5-HT enhanced forskolin-stimulated cAMP accumulation in human 
cultured uterine artery vascular smooth muscle cells and several 
studies have conclusively shown that the 5-lIT7 receptor is positively 
coupled to adenylate cyclase in various tissue preparations (Eglen, et 
al., 1997; Kitazawa, et al., 1998), a mechanism of action that is 
consistent with direct smooth muscle relaxation due to inhibition of 
myosin light chain kinase. For example, 5-HT7 receptor stimulation 
in the porcine myometrium results in inhibition of contractility of 
this tissue, coupled with increased cAMP synthesis (Kitazawa, et al., 
1998). No evidence exists for coupling of the receptor to other 
intracellular signalling pathways. 
1.4.5 5-lIT and the cardiovascular system 
The cardiovascular actions of 5-HT are complex due to the 
action of this bioamine at a multiplicity of 5-HT receptors. The end 
response depends on a number of factors including species, the target 
vascular bed and the concentration employed. 
1.4.5.1 Haemodynamic effects 
Intravenous infUSion of 5-HT into conscious, anaesthetised 
rats causes a triphasic effect on blood pressure, comprising a rapid 
and transient vasodilation, followed by a moderate increase in blood 
pressure and a long lasting decrease in blood pressure (Kalkman, et 
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al., 1984; Saxena, et al., 1985). The initial transient depressor 
response has since been demonstrated to be mediated via activation 
of the 5-HT3 receptor on afferent cardiac vagal nerve endings which 
produce a marked bradycardia and decreased cardiac output (see 
section 1.4.8.2). The magnitude of the pressor response is dependent 
upon species, being poor in rabbits (Wright, et al., 1989) and cats 
(Saxena, et al., 1985), whereas a prominent pressor response ensues 
in the dog (Scneider & Yonkman, 1954). This pressor response is 
thought to be mediated via vascular 5-HT2A receptor activation as 
ketanserin, the selective 5-HT receptor antagonist blocks the 
response (Kalkman, et al., 1984). The long lasting decrease in blood 
pressure is not altered by selective antagonists for 5-HT2 and 5-HT3 
receptors and was originally classed as "5-HTI-Uke" due to the high 
potency of 5-CT in mediating this response, coupled with blockade by 
methiothepin (Saxena, et al., 1985). Recent results from in vivo 
studies, however, suggest the hypotensive effects of 1.v. 5-HT in the 
rat involve activation of receptors closely Similar to the cloned 5-HT7 
subtype (DeVries, et al., 1997; Terron, 1997). 
1.4.5.2 Cardiac actions 
5-HT can elicit a variety of responses by the heart resulting 
from the activation of receptor subtypes, stimulation or inhibition of 
autonomic activity, or dominance of reflex responses to 5-HT. 5-HT 
action on the vagus nerve endings produces the Bezold-Jansh reflex 
mediated via the vagus nerve, resulting in extreme bradycardia, and 
involving 5-HT3 receptor activation (cardiac sensory receptors). This 
has been demonstrated in the rabbit (Wright, et al., 1989) as well as 
other species. 
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1.4.5.3 Vascular actions 
Due to the focus of this thesis being on the pulmonary 
circulation, the actions of 5-HT on the pulmonary vasculature in 
particular are discussed in section 1.5.2. 
It is clear that 5-HT mediates its vascular responses via action 
at a number of 5-HT receptor subtypes (see section 1.4.3). The 
response of a particular vessel to 5-HT will ultimately depend, 
therefore, on which 5-HT receptors are located on the particular 
vessel, and which subtype predominates. 5-HT, therefore, regulates 
vasoconstriction and vasorelaxation in a complex way and involving 
interaction of several 5-HT receptor subtypes. This is schematically 
summarised in figure 1.3. In systemic vascular tissue preparations, 
the vasoconstrictor actions of 5-HT have been attributed to 
mediation via either, predominantly, the 5-HT2A (see section 1.4.3.2) 
or, to a lesser extent, the 5-HTIB/ID (see section 1.4.3.1) receptors 
located on vascular smooth muscle. In contrast, endothelium-located 
5-HT2B (see section 1.4.3.3) and vascular smooth muscle 5-HT7 
receptors (see section 1.4.3.4) are thought to mediate the vasodilator 
responses to 5-HT and therefore may modulate the vasoconstrictor 
actions resulting from 5-HT2A or 5- lITIB/ ID receptor activation. 
As mRNA for the 5-HTIB receptor is expressed in abundance in 
several artery endothelial cells (Ullmer et al., 1995), a functional role 
In mediating NO-dependent vascular relaxation can not be ruled out. 
Several studies have reported that, at high concentrations 
(> IIlM), 5-HT can mediate an indirect vasoconstrictor effect via 
activation of a-adrenoceptors in some rabbit large blood vessels 
including the femoral artery (Grandaw & Purdy, 1996), ear artery 
(Black et al., 1981) and aorta (Purdy et al., 1987). In the rabbit 
isolated femoral artery, for example, 5-HT elicits a biphasic 
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concentration response curve. The first phase being sensitive to 
antagonism by ketanserin and the second phase blocked by the 
selective a 1-adrenoceptor antagonist benextramine (Grandaw & 
Purdy. 1996). The involvement of an a l-adrenoceptor in the 
contractile response to 5-HT in the rat pulmonary conduit artery has 
also been reported (Ogawa et al.. 1995). 
It has also been reported that high concentrations of 5-HT can 
have indirect sympathomimetic actions by releasing noradrenaline 
from perivascular sympathetic nerve endings (McGrath. 1977; Saxena 
& Villalon. 1990). 
With respect to the ability of 5-HT to interfere with 
sympathetic transmission. 5-HT inhibits. via pre-junctional 5-HTl 
receptors. the contractile responses to adrenergic nerve stimulation 
in several blood vessels including canine (Humphrey et al.. 1988) and 
human (Mol de rings et al.. 1990) saphenous veins and the rat vena 
cava (Molderings et al .• 1987). 
1.4.5.4 MOI:pholo~ical effects on the vasculature 
Substantial evidence indicates that 5-HT may regulate growth 
and proliferation of vascular cell types. 5-HT stimulates vascular 
smooth muscle cell proliferation cultured from porcine. rat and 
bovine aorta (Nemecek.et al..1986). Several groups have demonstrated 
that 5-HT increases DNA synthesis in cultured pulmonary vascular 
smooth muscle cells from different regions of the pulmonary vascular 
tree (Lee. et al.. 1991; Pitt. et al .• 1994). 
The mechanism responsible for the mitogenic effects of 5-HT 
varies with cell type and species. Several reports suggest mediation 
via the 5-HT2A receptor. as ketanserin (a selective 5-HT2A receptor 
antagonist) inhibits 5-HT mediated proliferation in rat cultured 
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pulmonary artery smooth muscle cells (Pitt, et al., 1994). Other 
reports suggest the mitogenic action is initiated by energy-dependent 
transport into the cell as known selective inhibitors of 5-HT 
transport inhibit 5-HT-induced proliferation of bovine and rat 
pulmonary artery SMCs (Lee, et al., 1991: Eddahibi, et al., 1999). The 
signal transduction mechanisms involved in the mitogenic effects of 
5-HT post-transport still remains uncertain. Recently, superoxide 
anion formation has been implicated in transport-associated 5-lIT-
induced mitogenesis (Lee, et al., 1998). The mitogenic effects 
mediated by cell surface 5-HT2A receptors have been shown to occur 
via the phosphatidylcholine-specific phospholipase C/mitogen 
activating protein kinase path in rat cultured mesangial cells 
(Goppelt-Struebe & Stroebel, 1998). The pathway in pulmonary 
vascular smooth muscle cells has yet to be confirmed. 
It has been proposed that growth and migration of endothelial 
cells are prerequisites for vascular remodelling. Pakala et al. (1994) 
demonstrated that 5-lIT dose-dependently causes a mitogenic effect 
on cultured vascular endothelial cells. Collectively these results 
suggest that 5-HT can contribute to remodelling of vascular tissues. 
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Figure 1.3 Schematic model of vascular 5-HT (serotonin) receptors. 
(see text for details). 
From: Ullmeret al. , (1995) FEBS Letters 370, 215-221 . 
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1.5 5-HT and the PulmODUY circulation 
1.5.1 Pulmonary actions of 5-lIT 
1.5.1.1 In vivo studies 
In the pulmonary circulation. varying responses in vivo to 5-lIT 
and its agonists have been described. Harris and co-workers (1960) 
observed that an intra-venous (Lv.) infusion of 5-lIT in man had no 
effect on pulmonary arterial pressure in vivo (HarriS. et al.. 1960). 
However. MacIntyre et all (1992) later observed that the selective 5-
HTIB/ID agonist sumatriptan caused a 58% increase in mean 
pulmonary arterial pressure (PAP) when infused Lv. into human 
subjects. These results suggest that for 5-lIT there is a balancing of 
its pulmonary vasoconstrictor and vasodilator effects but selective 5-
lITIB or 5-HTID receptor stimulation causes an overriding 
vasoconstrictor effect in the human pulmonary circulation. Recently. 
elevated PVR was observed following Lv. infusion of 5-HT in the 
anaesthetised dog and calf (Al-Tinawi. et al.. 1994; Linden. et al.. 
1996) In the anaesthetised rabbit. exogenous 5-HT produced a 
moderate. dose-dependent increase in PAP (Deuchar. et al.. 1997). 
In a study where pulmonary vascular tone was elevated 
experimentally by administration of U46619 in the cat in vivo. 5-lIT 
administration produced pulmonary vasodilation at low doses. 
biphasic vasoconstriction/vasodilation at mid-range doses and 
predominantly vasoconstriction at high doses of 5-lIT. suggesting the 
presence of more than one 5-lIT receptor subtype (Neely. et al.. 1993) 
1.5.1.2 In vitro studies 
5-HT is a potent vasoconstrictor of animal and human 
pulmonary arteries in vitro (Barnes & Lui. 1994). The use of selective 
5-lIT receptor agonists and antagonists has aided the progressive 
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identity of the 5-HT receptor subtypes that mediate vascular effects. 
In isolated rat pulmonary arteries. functional vasoconstrictor 
responses to 5-HT were inhibited by the selective 5-HT2A receptor 
antagonist ketanserin. thus indicating 5-HT2A receptor activation 
(MacLean. et al.. 1996a). Until recently. it was assumed that this 
receptor mediates pulmonary arterial contraction as this has also 
been shown in isolated canine and bovine pulmonary arteries (Chand 
& Altura. 1980; MacLean. et al .• 1994). However. evidence presented 
in this thesis indicates that the 5-HTIB receptor is predominant in 
mediating 5-HT-induced vasoconstriction in human pulmonary 
arteries. In isolated human large pulmonary arteries. 5-CT was 
shown to be more potent than 5-HT. which was eqUipotent to 
sumatrtptan. The selective 5-HTIB and 5-HTID antagonist GR55562 
inhibited responses to both 5-HT and sumatrtptan with a pKB value 
of 8.88 against sumatriptan (MacLean. et al .• 1996b). indicating 5-
HTIB (or 5-HTID) receptor activation. These results were later 
confirmed by Cortljo et al.. (1997) who observed effective antagonism 
of sumatriptan-induced contraction with GR127935. an antagonist 
at 5-HTIB and 5-HTID receptors (Conner. et al.. 1989). Collectively. 
these observations may explain why ketanserin has demonstrated a 
limited use in the treatment of PHT. The observations also 
collectively emphasise the importance of making comparative studies 
in human tissue where possible. 
Evidence for a role of vasodilator 5-HT receptors has also been 
reported in pulmonary vessels in vitro. For example. Glusa and co-
workers (1993) showed that 5-HT evoked endothelium-dependent 
relaxation of preconstricted porcine pulmonary arteries. Recently. 
further investigation by the same group. provided strong evidence 
that the 5-HT2B receptor mediates endothelium-dependent relaxation 
61 
in the same preparation (Glusa & Pertz. 2000). In ovlne 
preconstrtcted pulmonary vein. Zhang. et al. (1995) demonstrated an 
endothelium-independent relaxation to 5-HT which was positively 
coupled to adenylate cyclase and stimulated cyclic AMP formation. 
These observations are consistent with 5-HT mediating its action 
either via the recently desCribed 5-1IT7 receptor (see section 1.4.3.4) 
or via the 5-1IT4receptor. also positively coupled to adenylate cyclase 
(Hoyer. et al.. 1994). 
In contrast. in the isolated pulmonary arteries of some species. 
experimentally elevated vascular tone results in augmented 5-HT-
receptor-induced contractions. In bovine pulmonary arteries for 
example. pre contraction with U46619. uncovers a significant 
population of 5-1IT1 receptors that were previously silent (MacLean. 
et al .• 1994). 
Molecular analysis of 5-HT receptor mRNA expression has 
revealed the presence of mRNA for the 5-1IT1B. 5-HT2A 5-1IT2B and 
5-HT7 receptor in pig pulmonary arteries and in cultured human 
pulmonary artery smooth muscle cells (Ullmer. et aZ.. 1995). 
All the aforementioned studies indicate apparent species- and 
preparation- related differences in the functional effects of 5-HT-
receptor mediated responses on the pulmonary vasculature with a 
number of concomitant variables determining the overall response. 
as well as distinct differences compared to the systemic circulation. 
As previously mentioned in section 1.4.5.4. 5-1IT is also a 
potent mitogenic and proliferative agent. and has been shown to be a 
potent stimulus for DNA syntheSiS and proliferation of bovine. and 
rat pulmonary vascular smooth muscle cells in culture (Lee. et al.. 
1991: Pitt. et al.. 1994). 
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1 .5.2 Physiolo~ical role for 5-lIT in the pulmonru.y circulation 
The pulmonary vascular bed of the lungs under normal 
conditions. acting as a secondary filter downstream of the liver. does 
not encounter excessive levels of 5-lIT and a possible physiological 
role for 5-lIT in the pulmonary circulation is unclear. However. the 
noted pulmonary vascular effects of 5-lIT alluded to above (section 
1.5.1) suggest the influence of this bioamine in the physiological 
regulation of pulmonary vascular tone seems plausible. Due to the 
variation in S-HT mediated effects from various studies which have 
been reported. the definitive physiological role is difficult to 
determine. The vasodilator action of 5-JIT could be implicated in the 
maintenance of low pulmonary vascular tone through interaction 
with the vascular endothelium, or through direct action on vascular 
smooth muscle. The pulmonary circulation appears to be a primary 
site of 5-HT clearance and metabolism. probably limiting the 
vasopressor effects of circulating 5-JIT. 
1.5.3 Pulmonru.y hypertenSion 
Several studies. both in the clinical and experimental settings 
have suggested a role for S-lIT in the aetiology of PlIT and Figure 1.4 
schematically summarises this 64S-lIT Hypothesis of pulmonary 
hypertension". Due to the avid ability of the platelets to store large 
amounts of S-JIT (see section 1.4.2) and the fact that lungs are 
located downstream of the liver, and therefore act as a secondary 
filter, the pulmonary vasculature is not subject to excessive amounts 
of 5-HT under normal conditions. Changes in local, pUlmonary, 
availability of S-IIT may be associated with the development of PIIT 
although no link between plasma levels of free S-HT and PHT have 
been conclusively proven. Local to the pulmonary circulation, S-HT is 
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released from pulmonary neuroendocrine cells and neuroepithelial 
bodies distributed throughout the airways. Airway hypoxia and 
hypercapnia causes secretion of large amounts of 5-HT from these 
cells and may contribute to secondary PHT (Gosney. et al .. 1989; 
Johnson & Gieorgieff. 1989). 5-HT levels have been reported to be 
increased in several clinical settings. Herve et al. (1995) reported that 
plasma 5-HT levels are increased in primary PHT. even following 
normalisation of pulmonary arterial pressures post lung 
transplantation. ruling out PHT as the cause of the platelet 
dysfunction. PHT is often associated with diseases which exhibit 
elevated 5-HT levels due to altered platelet 5-HT storage including 
platelet storage pool disease (Herve. et al.. 1990) and systemic 
sclerosis (Kllmluk. et al.. 1989). McGoon and Vanhoutte (1984) 
demonstrated that aggregating platelets can release 5-HT. Inducing a 
vasoconstrictor response in canine Isolated pulmonary arteries and 
platelet aggregation often occurs in primary (Nakonechnicov. et al.. 
1996) and secondary pulmonary hypertenSion (Chouat. et at. 1996). 
For example. SIbbald and co-workers (1980) observed a correlation 
between elevated plasma 5-HT levels and pulmonary hypertenSion In 
patients with adult respiratory distress syndrome due to sepsis. A 
long association between anorexigenic drugs and PHT has been 
observed with the possibility that drugs such as fenfluramine trigger 
PHT by both Inducing or augmenting impaired platelet 5-HT storage 
(Eddahibi. et al.. 1998). The fawn hooded rat. as an experimental 
model of platelet storage pool disease. can develop very severe PHT 
after modest hypoxic exposure (Ashmore. et al .. 1991) and 
demonstrates increased vasoconstrictor responses to 5-HT (Ashmore. 
et at. 1991) along with reduced 5-IIT removal by lung tissue (Hilliker. 
et at. 1983). Pulmonary arteries from patients with primary PIIT who 
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The 5-HT Hypothesis of pulmonary arterial hypertension. (A) Platelet handling 
of 5-HT (see text for details). (8) 5-HT and human pulmonary vascular smooth 
muscle cells (see text for details). 
From: Maclean et a/_, (2000) British Journal of Pharmacology 131, 161-168. 
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have undergone lung transplantation exhibit an exaggerated 
vasoconstrictor response to 5-HT (Brink, et at, 1988). 
Experimentally, in anaesthetised rabbits exhibiting moderate 
PHT, with left ventricular dysfunction, 5-HT-induced pulmonary 
hypertenSion is enhanced (Deuchar, et al., 1997). Apart from diseases 
caused by parasites, hypoxia is thought to be the commonest of all 
causes of PHT due to the prevalence of chronic lung disease (Alpert, 
et al.. 1981). Several studies have investigated the association of 5-
lIT with PHT by various means using the chronic hypoxic rat model 
of PlIT. Recently, Jeffery and co-workers (2000) observed a 50% 
reduction in uptake of [3H15-HT in the lungs from hypoxic rats 
concluding that a decrease in 5-HT removal contributed to elevation 
in plasma levels of this bioamine in PHT. The structural and 
functional changes resulting in increased PVR are accelerated by 
continuous Lv. administration of 5-HT to rats exposed to chronic 
hypoxia (Eddahibi, et al., 1997). The 5-HT2A receptor solely mediates 
5-HT-induced pulmonary vasoconstriction in the rat. However, 
MacLean et al. (1996) observed that pulmonary arterial responses to 
5-lIT are elevated at all levels of the pulmonary arterial circulation in 
the chronic hypoxic rat model of PHT and the increased 
vasoconstriction to 5-HT was mediated by both the 5-HT2A and 5-
HTID or 5-HTIB receptor. Heeley et al. (1998) recently showed that 
the mRNA for the 5-HTIB receptor is increased in the pulmonary 
arteries from these rats. In human isolated large pulmonary arteries 
5-HT mediates its vasoconstrictor action via stimulation of the 5-
lITIB/ID receptor (MacLean, et al.. 1996b: Cortijo. et al.. 1997). The 
evidence accumulated from the human and rat studies. therefore. 
implicates the importance of the 5-HTIB receptor in mediating 
pulmonary vasoconstriction and may make a Significant contribution 
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to increased pulmonary arterial vasoconstriction in PHT. This is in 
contrast to the systemic circulation, at least in humans, where the 
5-fIT2A, receptor is thought to mediate the vasoconstrictor actions of 
5-fIT (Ameklo-Nobin, et al., 1985). 
Further observations also implicate the importance of the 5-
lITIB receptor in mediating increased pulmonary arterial 
vasoconstriction in PfIT. 5-lIT I receptor mediated vasoconstriction is 
often only observed in the presence of increased vascular tone 
(Movahedi et al., 1997), a phenomenon known as pharmacological 
synergism. This is thought to occur as a result of amplification of 
signal transduction mechanisms due to crosstalk between two G-
protein coupled receptors on the same cell, ultimately producing a 
greater than additive effect (Martin, et al., 1996). SystemiC arteries 
are under a degree of tonic sympathetic tone in vivo and such synergy 
may, therefore, normally operate in vivo. In contrast, pulmonary 
arteries are fully dilated in the normal lung and such synergy may 
operate only in conditions when pulmonary vessels are subjected to 
increased vascular tone. The observations that 5-fIT1B/ 10 receptor-
induced contractions are uncovered in bovine pulmonary arteries in 
the presence of agonist-induced tone (MacLean, et al., 1994), coupled 
with the fact that in the chroniC hypoxic rat model of PHT, 
pulmonary arteries exhibit elevated vascular tone, strongly suggest 
that these synergistic effects become pathophysiologic ally important 
in PHT. Pharmacological synergy may therefore contribute to the 
increased 5-lITIB receptor mediated vasoconstrictor response in PHT 
(MacLean, et al., 1999). 
The reported ability of 5-HT to stimulate hypertrophy and 
proliferation of pulmonary vascular smooth muscle cells suggests 
that it may also play a role in the concomitant vascular remodelling 
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in PHT. The mechanism responsible for this action of 5-HT is 
thought to be either via a cell surface 5-HT receptor (Pitt, et al., 1994) 
or via the active transporter (5-HIT) located on pulmonary vascular 
smooth muscle cells (Eddahibi, et al., 1999) or a combination of 
both. This has yet to be resolved. Several observations suggest, 
however, that 5-HT mediates the development of PHT through the 
activity of the 5-HTT. Pharmacological inhibition of 5-HT uptake 
results in the prevention of 5-HT-induced mitogenesis in cultured 
pulmonary artery SMCs suggesting the necessity of 5-HT 
internalisation by the 5-HTT. Recently, Eddahibi and co-workers 
(2000) observed a marked attenuation of chronic hypoxia-induced 
PHT development and vascular remodelling in mice that were 
defiCient in the 5-HTT gene compared to mice with the gene. Coupled 
with the observations that exposure of pulmonary artery SMCs to 
hypoxia increases the expression and activity of the 5-HIT (Eddahibi 
et al., 1999: Lee, et al., 1991). these results provide strong evidence 
for the importance of the 5-HTT in 5-HT-evoked vascular remodelling 
in hypoxia-induced pulmonary hypertenSion. 
Collectively, these findings and the marked effects of 5-HT on 
the pulmonary circulation (see section 1.5.1) suggests that 5-HT may 
contlibute to the elevated pulmonary vascular resistance and 
pulmonary vascular remodelling, charactelistic of all fonns of PHT. 
The potential effectiveness of various 5-HT receptor 
antagonists in the treatment of PHT in man depend not only on their 
efficacy in the pulmonary circulation, but also on having a desirable 
influence on the systemic circulation. ConSidering the collective 
evidence suggesting a role for the 5-HTIB receptor, antagonists at 
this receptor subtype may therefore be of therapeutic benefit it the 
treatment of PAR. 
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1.6 Project Aims 
The studies in this thesis focused primarily on the pulmonary 
vasculature of the perinatal rabbit. In the perinatal pulmonary 
circulation the pulmonary vasculature undergoes very marked 
changes in terms of structure and function in order to adapt to 
extrauterine life. In the normal lung, the pulmonary circulation is 
characterised by low pressure with low vascular resistance compared 
to the systemic circulation (see section l.l.3). In utero, the foetal 
pulmonary circulation is under high pressure and resistance (see 
section 1.2.1) both of which markedly fall when the lungs start their 
main functional role in life at birth (section 1.2.2). It is of interest to 
study the pulmonary vasculature at this important stage of life where 
the marked structural and functional changes are modulated by or 
indeed affect the response to known pulmonary vasoactive 
substances. The effect of this transition from foetal to early neonatal 
life was therefore studied in the perinatal rabbit allowing the 
investigation of the "active" regulation of the pulmonary Circulation 
due to changes in 02. Similar studies in the adult rabbit would 
provide a basis for comparison. 
The factor common to all the investigations in this 
thesis is 5-HT. The involvement of 5-HT has been implicated in 
pulmonary hypertension of various aetiologies (section 1.5.3). The 
effects of 5-HT on the pulmonary resistance vasculature in man is 
uncertain, therefore identification of the 5-HT receptors mediating 
these responses is of interest. 
With particular relevance to the perinatal pulmonary 
circulation, 5-HT has also been linked to PHT associated with 
hypoxia in the newborn infant and 5-HT turnover has also been 
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shown to be increased in children With PHT secondary to congenital 
heart disease (section 1.5.3). Little is currently known about the 
perinatal pulmonary vascular actions of 5-HT. Hence it is of interest 
to examine the 5-HT-receptor mediated responses of pulmonary 
arteries in the perinatal period as well as in adulthood. The chronic 
hypoxic rat is a well studied model of hypoxic PHT. Rats exposed to 
chroniC hypoxia display significant PHT, developing similar 
morphological alterations in the pulmonary vasculature that are 
exhibited in human PHT (Hislop & Reid, 1976; Rabonitch, et al., 
1979). In this model, important alterations in the responsiveness of 
the pulmonary arteries to 5-HT occur (section 1.5.3) in terms of 
magnitude and sensitivity of the contractile response as well as in 5-
HT receptor subtype(s) involved. These alterations occur in an 
environment of altered pulmonary vascular tone, cyclic nucleotide 
levels and 5-HT receptor expression. Thus, it is of interest to examine 
the 5-HT-receptor mediated responses in rat pulmonary vessels under 
conditions which mimic these altered factors. 
Chapters 3 and 5 show the results of the in vitro studies of 
pulmonary arteries in the adult and perinatal rabbit respectively. 
Chapter 4 focused on the in vitro examination of human small 
muscular pulmonary arteries, whilst the examination of pulmonary 
resistance vessels from chroniC hypoxic pulmonary hypertensive and 
control rats are presented in chapter 6. 
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Chapter 2 
Materials And Methods 
7 1 
2.1 Animal models used in the studies 
2. 1. 1 Adult rabbits 
Male New Zealand White rabbits weighing -2.5 kg were 
purchased from Harlan UK Ltd .. a credited commercial supplier of 
laboratory animals. These were held in the Central Research Facility. 
Biological Services. University of Glasgow. The rabbits were killed 
with an overdose of sodium pentobarbitone (200 mgkg- 1) through the 
left ear marginal vein. Lungs were rapidly removed into ice cold Krebs 
solution. The pulmonary arteries were dissected out as deSCribed in 
section 2.3.4.1 
2.1.2 Foetal and neonatal rabbits 
Pregnant female New Zealand White rabbits were obtained from 
Harlan UK Ltd. These rabbits were at 23 days gestation with their 
first Utter (normal gestation to Utter down date is 31 days) and were 
housed in the Central Research Facility. Biological Services. 
University of Glasgow. As previously described in this thesis (1.2.2). 
the pulmonary circulation undergoes rapid structural and functional 
changes at birth. The rabbit pups were studied either 2 day pre term 
foetal. 0-24 hours. 4 days or 7 days following birth. All pups were 
saCrificed with an overdose of sodium pentobarbitone (200 mgkg- 1). 
For foetal pups. the mother rabbit was overdosed and a caesarean 
section performed. The foetal rabbits were then rapidly overdosed and 
decapitated to ensure the foetus did not take a first breath. The 
lungs were rapidly removed to ice cold (40 C) Krebs solution for 
subsequent dissection of the pulmonary arteries. The dissection of 
these vessels is deSCribed in section 2.3.4.2. 
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2.1.3 Human pulmoncuy tissue 
Due to limited availability. only crucial. key experimental 
protocols were applied to human tissue. Macroscopically normal 
human lung tissue was obtained from patients (both male and 
female) undergoing surgery for bronchial carcinoma at the Western 
Infirmary. Glasgow and the Royal infirmary. Glasgow. Verbal 
information available from the medical staff indicated that these 
patients did not have any documented evidence of any other chronic 
pulmonary pathology. Information concerning individual patient age. 
clinical histories and variable treatments was not. however. made 
available. Acknowledgement must be made about the difficulties 
associated with using human tissue classified as 'normal'. Patient 
variables such as age and specific patient medication may affect 
vascular responses. In addition. bronchial carCinoma is known to 
induce chroniC inflammation. which may alter pulmonary vascular 
responses. These pOints must be taken into account when 
interpreting the data. The animal tissue studies in this thesis were 
performed with their relation to the situation in man in mind. Thus 
it is benefiCial to compare the responses in animal models with those 
in Similar preparations obtained from human tissue when available. 
Lung tissue specimens were placed in cooled (40 C), fresh Krebs 
solution on site and transferred rapidly to the laboratory and studied 
within 12 hours postoperatively. 
2.1.4 Chronic hypoxic rat model of pulmonary hypertension 
(CHRPIITl 
2.1.4.1 Introduction to the model 
Several experimental techniques can be employed to induce 
experimental pulmonary hypertension including the rabbit coronary 
ligated model of left ventricular dysfunction and monocrotaline 
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induced pulmonary hypertension. The chronic hypoxic rat model of 
PHT is a well studied model of hypoxia induced PHT (Hislop & Reid. 
1976; Rabonivitch. et al.. 1979). It is well established that rats 
exposed to a chronic. hypobaric hypoxic insult are known to exhibit 
well defined PHT with similar development of the morphological 
changes that are observed in the human pulmonary vascular bed in 
pulmonary hypertension (Hislop & Reid. 1976; Rabonitch. et al.. 
1979; MacLean et al.. 1996). This model therefore. provides highly 
reproducible means for examining the evolution of the structural and 
functional changes associated with PHT in the pulmonary vascular 
bed. 
Male Wi star rats 28 to 30 days old (at the start of the 
experiment) were placed in a specially designed perspex hypobaric 
chamber obtained from the Royal Hallamshire Hospital Sheffield. 
This chamber was depressurized very slowly at a rate of 30 mbar per 
hour. over 2 days. to 550 mbar. The oxygen concentration equivalent 
at this pressure is equivalent to about 10%. The temperature of the 
chamber was maintained at 21-220C. and the chamber was 
ventilated with room air at apprOximately 45 Imin- 1 to prevent 
accumulation of C02. NH3. and water vapour. Rats were maintained 
in these hypoxic/hypobaric conditions for 14 days. The chamber was 
recompressed briefly every 3 days to clean the cages and add fresh 
food and water. Age-matched norm oxic control animals were held in 
room air. 
All animals received humane care in compliance with the 
Home Office (UK) "Guidance on the operation of the Animals 
(SCientific Procedures) Act" published by Her Majesty's Stationery 
Office. 
2.1.4.2 Assessment of pulmonaty hypertenSion 
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2.1.4.2.1 Measurement of ri"ht ventricular hypertrophy (RVHl 
Right ventricular wall thickening occurs with the development 
of both clinical and experimentally-induced forms of PHT. The degree 
of right ventricular hypertrophy is a well established index of the 
degree and development of pulmonary hypertenSion (Hunter et al .• 
1974). CHRPHT rats from the hypobaric chamber and age-matched 
normox1c controls were overdosed with sodium pentobarbitone (100 
mgkg-l) intraperitonealy. The thoracic cage was carefully opened and 
the heart and lungs removed to ice-cold Krebs solution. Heart atria 
and associated large calibre blood vessels were dissected from the 
heart ventricular mass. The ventricular mass was then dissected very 
carefully in order to separate the free wall of the right ventricle from 
the left ventricle plus septum as fully described by Fulton et al. 
(1952). Once dissected, the ventricles were washed with fresh Krebs 
and blotted dry on tissue paper. The wet weights were then measured 
on a Mettler AT26l balance. The ratio of RV weight to left ventricular 
plus septum weight was used as an index of RVH. This index is a 
commonly used and reliable index of the degree of pulmonary 
hypertenSion present in experimental animals (Herget et al..l978: 
Wanstall et aL. 1991: Sheedy et al .• 1996). 
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2.2 Functional in vitro pharmacoloi1cal studies of isolated 
pulmonary arteries usini tissue baths. 
2.2.1 Tissue bath set up 
Ito isometric transducer 
glass rod 
tissue chamrer-+--i-I 
arterys~nt--+--;~~~~I 
ater jacket 
tungsten hook 
r=~;:::==+=- --gas mix inlet 
'Waste Kre1::6 solution 
Figure 2.1 Tissue bath arrangement for investigating in vitro 
pharmacological functional properties of large (conduit) pulmonary 
arteries. 
Figure 2.1 shows a typical tissue bath arrangement for the 
investigation of large pulmonary arteries. Extralobar and intralobar 
pulmonary arteries from adult and perinatal rabbits (internal 
diameters for each age group are described in the relevant results 
chapters of this thesis) were dissected free of surrounding 
parenchymal lung tissue (fully described in sections 2.3.4.1 and 
2.3.4.2: except for the size and location of the vessels used. the 
technique for dissection was identical) and prepared as rings -7 mm 
in length. The rings were placed over hooks made of tungsten wire 
and inserted over a second tungsten wire hook attached to a glass 
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holding rod and suspended in water-jacketed (370 C) tissue baths 
containing 5 ml of Krebs' solution. Preparations were gassed 
continuously with gas mixtures appropriate for adult and perinatal 
pulmonary arteries (see section 2.3.7.). Vessels were set up under 
tensions at which maximum, optimal contractile responses to 50mM 
KCI were obtained in previous experiments for the adult vessels 
(MacLean et al., 1993) or preliminary experiments in the perinatal 
vessels (see figure 2.5, page 97). These optimal tensions were 1.5g wt 
tension for adult pulmonary arteries and 0.8-1.0g for the perinatal 
arterial rings. Tension was recorded isometrically by means of a 
Grass FT03C force-displacement transducer and responses were 
displayed continuously on a multichannel pen recorder (Gould 
Instruments). 
2.2.2. General experimental procedure 
The precise detail of experimental procedures and protocols for 
each experiment are deSCribed in the methods section of each chapter 
of experimental results. Each vessel investigated however was 
subjected to a general, core experimental procedure listed below: 
(A) Each vessel, once mounted in the tissue bath and tensioned to 
an appropriate tenSion, was allowed to equilibrate for 45 - 60 
minutes in Krebs solution bubbled with an appropriate gas mixture 
(see section 2.3.7) and ma1nta1ned at 370 C. No drug was in contact 
with the vessel prior to the equilibration period. 
(B) KCI at 50mM final bath concentration was used to stimulate the 
vessels to assess their viability. This concentration of KCI was 
chosen as that which has previously been reported as giving 
maximum, optimal contractile responses to KCI in rabbit pulmonary 
arteries (MacLean et al., 1993). Once the contractile response 
attained a plateau, the vessels were washed 6-8 times with fresh 
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Krebs solution and left to return to baseline tenSion. This procedure 
with KCI was repeated in order to obtain a reference contractile 
response. 50mM KCI was used as a reference contraction in all adult 
and perinatal vessels examined in this thesis. 
(C) The vessels were allowed another 30 - 40 minutes equilibration 
before proceeding with the addition of any drugs. 
(D) The assessment of endothelial integrity is deSCribed in individual 
results chapters but invariably involved contraction with a 
submaximal concentration of a known vasoconstrictor followed by 
the addition of a known endothelium-dependent vasodilator such as 
acetylcholine once the contractile response had plateaued. Vessels 
were conSidered as having a functional endothelium if the 
endothelium-dependent vasodilator evoked a > 70% reversal of the 
precontractlon. No more than 10% of the vessels in any particular 
study had to be discarded when using this criteria. 
(E) Where cumulative concentration response curves (CCRCs) were 
constructed to required agonists. the concentration range was such 
that each agonist achieved a maximum contractile response. 
(F) For agonists which were known either to bind irreversibly to their 
receptor(s) or to produce marked desensitisation in certain tissues. 
only one CCRC could be constructed in each tissue. Separate vessels 
had to be used. therefore. to conduct experiments using inhibitors or 
antagonists. 
Inhibitor and antagonist incubation periods are clearly stated in 
each results chapter. 
2.3 Functional in vitro pharmacololical studies of isolated 
pulmonary arteries usinl wire myolrAphy. 
2.3.1 Back2found to wire my02raphy 
A technique initially deSCribed by Bevan and Osher (1972) for 
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the investigation of small blood vessels with internal diameters as 
small as 100~m was further developed in 1976 by Mulvany and 
Halpern who first described the use of the newly developed wire 
myograph. Until then, in vitro pharmacological examination of the 
functional properties of blood vessels was restricted to large diameter 
vessels. With the development of the new myographic technique, the 
in vitro pharmacology of blood vessels with internal diameters 
between 100-400 ~m, 1.e. those thought to make a major 
contribution to peripheral vascular resistance (Bohlen, 1986), could 
now be investigated. Initially wire myography naturally focused on 
the investigation of systemic resistance vessels, the technique can 
however, be applied to small veins (Jensen et al., 1987), bronchi 
(Chopra et al., 1994) and importantly in this thesis, pulmonary 
resistance vessels (Leach et al., 1992). 
2.3.2 Wire myo2faph eguipment 
Throughout the period of study, Mulvany/Halpern small vessel 
wire myographs (models 410 or 610M); Danish Myo-technology Ltd., 
Aarhus, Denmark) were used. These consist of 4 individual stainless 
steel organ chamber baths capable of having one vessel mounted in 
each bath. Vessels are mounted (see small vessel mounting procedure 
in section 2.3.5) by means of small, 40~m thick stainless steel wires 
which can be attached to metal vessel-supporting heads shown in 
figure 2.2. Each myograph chamber contains two vessel support 
heads, one is attached to a sensitive isometric force displacement 
transducer. The other support head is attached to an adjustable 
metal support arm which can be manipulated by a micrometer. This 
micrometer enables the sensitive adjustment of the distance between 
the two support heads to be carried out, allowing tension to be 
applied to the vessel located between the support heads. 
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Fine control of the myograph chamber temperature (to ± 0.1 oC) 
is achieved by electronically controlled. internal heating units. 
Digital readout of force and temperature is displayed on the separate 
myograph control base-unit. This base-unit allows for output 
connections to a 4-channeI. flatbed Linseis chart recorder (model no. 
6514LB). from which a hard copy of force measurement from each 
myograph transducer can be obtained. 
2.3.3 Myo~raph calibration 
The myography equipment was calibrated on a regular basis 
every 4 weeks using a force calibration device consisting of a 
calibration 'pan' balance and standard 2g weight. The calibration 
balance consists of a horizontal metal arm containing a holding pan 
at each end with a thin pivotal vertical transducer arm located 
central to the horizontal arm. A 40~m stainless steel wire is securely 
attached to the force transducer-connected mounting head of the 
myograph chamber. The transducer arm is positioned carefully just 
behind the wire. When a given load W (e.g 2g weight) is placed on the 
appropriate holding pan. the force transducer is subjected to a force 
(F) equivalent to: 
F = W x g x arm ratio 
where. g = 9.81 mNg-1 and arm ratio = 0.5 
Hence for calibration purposes using a 2g weight 
F = 2 x 9.81 x 0.5 = 9.81mN 
For calibration. the magnitude of deflection displayed on the pen 
recorder was equivalent to Ig weight or 9.B1mN. 
This provided a calibration factor (a). defined as the value of the force 
(mN) for a given deflection. and used both for calculating force as 
described in the normalisation procedure deSCribed in section 2.3.5. 
and for calculating the force as mg weight tension for a given 
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deflection. The absolute magnitude of functional responses in each 
experiment could then be calculated. 
Each calibration resulted in negligible variation being 
observed in the readings. 
i to transducer yessel support heads 
myograph chamber 
- .... (volume: 5 mls) 
-1::::b=i--..... ~~ Adjustable slide arm 
-----~~micrometer 
------- micrometer screw 
Figure 2.2 Illustration of Mulvany/Halpern wire myograph model 
610M. Isometric tension is measure by an integral force transducer. 
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2.3.4 Small muscular pulmoncuy artery dissection procedure 
2.3.4.1 Adult rabbit 
Adult rabbit lung was obtained as desCribed in section 2.1.1 
and the right lung cut free, pinned to a dissecting dish with the 
parietal surface lying in an inferior position. Periodically, the tissue 
was washed with fresh, ice-cold Krebs solution during the dissection 
to prevent tissue drying. An incision was made along the superficial 
section of the airway, cutting in the direction from the large proximal 
airway, along the bronchial tree and through to the distal 
bronchiole. Using a dissection microscope (Zeiss),the pulmonary 
artery which branched parallel to the bronchus was identified. 
Bronchiole tissue was carefully dissected free to expose the 
pulmonary artery beneath. After gentle dissection away of the lung 
tissue lying lateral to the pulmonary artery, the distal portion of the 
artery (intralobar pulmonary artery (B) in figure 2.3), of size -150-
200Jlm internal diameter, was removed. These isolated arteries were 
placed in a vial of ice-cold Krebs solUtion, ready for mounting on the 
myograph. 
2.3.4.2 Foetal and neonatal rabbit 
A Similar dissection technique employed for the dissection of 
adult small muscular pulmonary arteries was used to dissect out 
vessels from foetal and neonatal rabbit lungs. Slight modifications, 
however, were made as the lung lobe and assOCiated pulmonary 
vascular tree are smaller than in the adult, The right lung was 
processed as for the adult lobe and using a dissecting microscope, an 
incision made along the superficial aspect of the airway. The first 
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branch of the main intrapulmonary artery (illustrated in figure 2.3 as 
(A») was located beneath the bronchus parallel to it and lateral lung 
tissue associated with it was again carefully disssected free. Vessels 
smaller than this first branch pulmonary artery (-280-320~m 
internal diameter) could not be used due to their extreme fragility 
and subsequent significant damage upon dissection. Once dissected 
free. the isolated first branch intralobar pulmonary arteries were 
placed in ice cold Krebs in a glass vial in preparation for mounting. 
2.3.4.3 CHPHT and control rats 
A similar dissection technique employed for the dissection of 
adult rabbit small muscular pulmonary arteries was used to dissect 
out vessels from rat lungs. Slight modifications. however. were made 
as the lung lobe and associated pulmonary vascular tree are smaller 
than in the adult rabbit. The right lung was processed and vessels 
dissected out as for the adult rabbit lobe. Rat small intralobar 
pulmonary arteries (resistance arteries (PRAs) of internal diameter 
-150-250 ~ were used (vessels size (B) in figure 2.3. 
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Figure 2.3 Diagram of dissection of pulmonary arteries. See text for 
details. 
2.3.4.3 Human pulmonary arteries 
Human lung samples obtained during the course of the study 
varied greatly in sample size and also in location of where in the lung 
samples were removed from during surgery. This variation was 
unavoidable due to the surgical requirements of the individuals from 
whom the samples were obtained. Great care was exercised however 
during the postoperative dissection of these samples in order to 
obtain pulmonary arteries of an appropriately Similar size from each 
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individual lung sample. 
The tissue samples were pinned into a dissecting dish and 
periodically washed with Krebs during dissection. Segments of 
intralobar large pulmonary artery were located in the samples and 
progressively dissected along the branching pathway using a 
dissecting microscope. The subsequently smaller branches were 
followed by dissecting away lateral lung tissue until small muscular 
pulmonary resistance arteries of about 200 J,lm internal diameter 
were uncovered and dissected out. These were identifiable by the 
close proximity of accompanying bronchioles. Once dissected free and 
cleaned of adherent surrounding tissue, these vessels were removed 
into ice cold Krebs for subsequent wire myography. 
2.3.5 Vessel mountin/l procedure 
Irrespective of the source of small muscular pulmonary 
arteries, these vessels underwent an identical mounting procedure on 
the Mulvany/Halpern small vessel wire myograph: which is deSCribed 
in section 2.3.2. This mounting procedure was similar to that 
described previously by Mulvany & Halpern (1977). Slight 
modifications to the procedure were employed as Mulvany & Halpern 
used small systemiC arteries. 
The mounting procedure for the pulmonary arteries is shown in 
figure 2.4. Small muscular pulmonary arteries isolated previously 
were placed in a pert dish containing cold Krebs solution. Using a 
pair of very fine forceps, a 40J,lm stainless steel wire was slowly 
inserted into and passed through the lumen of the vessel whilst 
Simultaneously holding onto the end of the vessel with a second pair 
of fine forceps. 
A) This was transferred to the wire myograph chamber containing 
Krebs solution and carefully secured between the vessel mounting 
heads by advancing the head attached to the micrometer until the 
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two heads touched and held the wire such that the vessel was 
positioned in the space between the mounting head jaws. 
B) The wire was securely fIxed at each end to the left mounting head 
by wrapping the ends clockwise around the top and bottom screws 
which were then tightened. 
C) The mounting heads were then separated and any excess arterial 
segment located outside the jaw space was carefully cut away, this 
was necessary because any excess segment beyond the jaw would 
affect normalisation (described in section 2.3.6.). The distance 
between the jaws on each mounting head is 2mm, thus defIning the 
vessel length. 
D) Another 40~ wire was carefully inserted and passed through the 
vessel lumen. 
E) The movable mounting head was again advanced until it touched 
the other mounting head and the second wire fixed and secured 
around the mounting head screws on the right vessel mounting head. 
F) The mounting heads were separated slightly and the vessel allowed 
an appropriate equilibration period before an appropriate tension 
could be applied to the pulmonary artery. The Krebs was gassed with 
an appropriate mixture of gas (see section 2.3.7) once the vessels 
were mounted. The heating unit was engaged in order to heat to and 
maintain the Krebs solution at 370 C. 
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Figure 2.4 Procedure for mounting isolated pulmonary resistance 
arteries. Points (A) - (F) explained in body of preceding text. 
2.3.6 Vessel normalisation procedure 
In 1977, Mulvany & Halpern originally described a 
normalisation procedure for small systemic vessels. These vessels 
were stretched to a specified resting transmural pressure. Modifying 
the Laplace equation (equation 2.1), linking the wall tension in a 
cylinder with its radius and pressure Within it, the relationship 
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between these variables can be established for a vessel mounted on a 
wire myograph: 
Pi = Wall tension/ (internal circumference / 2n) (equation 2.1) 
Pi (effective pressure) is an estimate of the pressure that is necessary 
to extend a vessel to the measured internal diameter. 
Wall tension = Force (F)/(2 x vessel length (L)). (equation 2.2). 
The vessel effectively has an "upper" and "lower" wall thus giving 2 x 
L in the above equation 2.2. 
The vessel internal circumference (Ie) can be calculated for a given 
amount of stretch (i) applied to the vessel: 
ICi = (micrometer reading at i (Xd- micrometer reading at point 0 
(Xo)) x 2 + (lCo) 
Point 0 is the point at which the two 40J,1m wires are just touching. 
For two 40J,1m wires leo would be equal to 205.6 J,1m. The difference 
between the two micrometer readings at the two pOints Is equivalent 
to the distance between the two 40 J,1m wires (Xi - Xo). 
Equation 2.1 can be arranged to give: 
Pi = (21t) x wall tension/Ie 
Substituting the values for wall tension and internal circumference 
now gives: 
Pi = (21t) x F/ 2 x L (205.6 + (2 x (Xi - Xo)) 
This relationship can be used to stretch a particular vessel to mimic 
a required transmural pressure equivalent. 
2.3.6.1 Tension applied to pulmonruy arteries 
The majority of small systemic vessels are normalised to 
defined distending pressures (Mulvany & Halpern. 1977). This 
procedure sets the arteries at a passive tension equivalent to 90% of 
their internal Circumference (0.9 LIOO) if they had been relaxed and 
perfused with a pressure of 100mmHg. Under these conditions the 
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equivalent pressure of the systemic vessel is in the range 60 -
70mmHg. The pulmonary circulation is a low pressure and low 
resistance circulation and therefore more appropriate conditions 
need to be applied which are more suitable for these pulmonary 
arteries. In vivo, pulmonary arteries would normally experience an 
equivalent transmural pressure of -15 mmHg (Fishman, 1976). The 
isolated small muscular pulmonary arteries were therefore set at this 
equivalent transmural pressure of -15 mmHg. 
In the chronic hypoxic rat model of pulmonary hypertension, 
tension on the pulmonary vessels was set to an equivalent 
transmural pressure of around 33 mmHg again to mimic the in vivo 
transmural pressures that these pulmonary hypertensive arteries 
would experience and this setting was previously used in earlier 
studies (Maclean, et aI., 1996; Maclean and McCulloch, 1998). 
2.3.7 Gas mixtures 
The majority of in vitro pharmacological studies investigating 
isolated blood vessels use a "bubbling" gas mixture of 95% 02, which 
is equivalent to a P02 of > 500 mmHg. In these studies, a gas 
mixture mimicking physiological conditions was chosen as the 
pulmonary vasculature is markedly sensitive to both 02 and C02 
concentrations. The percentage gas mixtures used for bubbling the 
Krebs solution surrounding the isolated pulmonary arteries consisted 
of: 16% 02, 5% C02 and balance N2. Bubbling the Krebs solutions 
in this way gave final bath gas tensions of p02 100-120 mmHg and 
pC02 35 mmHg at pH 7.4 (measurements taken by oxygen electrode 
and blood gas analyser), which mimic in vivo p02 values. Moreover, 
large, conduit pulmonary arteries are well supplied by the vasa-
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vasorum despite receiving mixed arterio-venous blood. Hence the 
vessels are exposed to 02 tensions of -120mmHg. PRAs have walls < 
1.5 Ilm thick, and, hence, tissue diffusional problems are not 
encountered with active bubbling. This gas mixture was used when 
studying the majority of vessels from the adult and neonatal rabbits. 
the human lung tissue samples and from the lungs of the CHRPHT 
and normoxic control rats, thus minimising variables between the 
different groups. 
The gas mixtures used to bubble arteries isolated from the 2 
day preterm foetal rabbits were 3% 02. 5% C02. balance N2. The 
measured gas tensions surrounding these vessels were p02 -18-23 
mmHg, C02 -35-40 mmHg. This mimicked the hypoxic conditions 
experienced by the foetus in utero. This is a more appropriate 02 level 
than that used in the other vessels as a major factor initiating the 
structural and functional changes in the pulmonary Circulation at 
birth is the loss of the hypoxic pulmonary vasoconstrictor effect on 
first inhalation by the neonate from comparatively hyperoxic 
atmospheriC air. 
2.3.8 General emerimental procedure 
The precise detail of experimental procedures for each 
experiment are described in the methods section of each chapter of 
experimental results. 
Each vessel undergoing wire myography however was subjected 
to a general, core experimental procedure listed below. 
(A) Each vessel, once mounted in the myograph and tensioned to an 
appropriate equivalent transmural pressure was allowed to 
equilibrate for 45 - 60 minutes in Krebs solution bubbled with an 
appropriate gas mixture and maintained at 370 C. No drug was in 
contact with the vessel prior to the equilibration period. 
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(B) KCI at 50mM final bath concentration, giving optimum, maximal 
contractions to KCl, was used to stimulate the vessels to assess their 
viability. Once the contractile response attained a plateau, the 
vessels were washed 6-8 times with fresh Krebs solution and left to 
return to baseline tension. This procedure with KCI was repeated in 
order to obtain a reference contractile response. 
(C) The vessels were allowed another 30 - 40 minutes equilibration 
before proceeding with the addition of any drugs. 
(D) The assessment of endothelial integrity is described in individual 
results chapters but invariably involved contraction with a 
submaximal concentration of a known vasoconstrictor followed by 
the addition of a known endothelium-dependent vasodilator such as 
acetylcholine once the contractile response had plateaued. Vessels 
were conSidered as having a functional endothelium if the 
endothelium-dependent vasodilator evoked a > 70% reversal of the 
precontraction. No more than 10% of the vessels in any particular 
study had to be discarded when using this criteria. 
(E) Where cumulative concentration response curves (CCRCs) were 
constructed to required agonists, the concentration range was such 
that each agonist achieved a maximum contractile response. 
(F) For agonists which were known to either bind irreversibly to their 
receptor(s) or to produce desensitisation in certain tissues, only one 
CCRC could be constructed in each tissue. Separate vessels had to 
be used, therefore, to conduct experiments using inhibitors or 
antagonists. 
Inhibitor and antagonist incubation periods are clearly stated in 
each results chapter. 
2.4 Data Analysis 
2.4.1 Interpretation of results 
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For the in vitro pharmacological measurements of isometric 
tension using both the organ bath and the wire myograph, data for 
preparations subject to identical protocols were grouped and 
expressed as the mean value ± the standard error of the mean 
(s.e.m.) In contractile studies, functional data are expressed as a 
percentage of an agonists own maximum response in each 
preparation (% own maximum) for a particular agonist. This provides 
an indication of, as well as any changes in, the sensitivity to the 
agonist of a particular vessel. In order to standardise agonist 
responses, data are also expressed as a percentage of a reference 
contraction to a second exposure to 50mM RCI (% 50mM RCI). This 
also provides an indication of, as well as any changes in, the 
maximum contractile response of an agonist in a particular vessel. 
Some results are expressed as an absolute contractile response (mN 
tension or mg weight tension). For responses in relaxation studies, 
data are expressed as a percentage of the response relative to 
agonist-induced pre-contraction in each vessel. 
2.4.2 Aionist potency 
For contractile responses, as a measurement of agonist 
potency in pulmonary arterial preparations pEC50 values are given; 
pEC50 being the -log of the concentration of an agonist that evokes 
500/0 of the maximum possible contractile effect of that particular 
agonist. For the comparison of potency at low concentrations of 
agonlsts, values for the pEC 1 0 and pEC25 were also calculated being 
the -log of the concentration of an agonist that evokes 10 % or 25% 
respectively of the maximum possible effect of that particular 
agonist. For vasodilator responses, as a measurement of agonist 
potency In pulmonary arterial preparations pICSO values are given; 
pIC50 being the -log of the concentration of an agonist that evokes 
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50% of the maximum possible vasodilator effect of that particular 
agonist. These pEC and pIC values were calculated by computer 
interpolation from individual CCRCs (% agonists own maximum 
response) for each vessel. pEC and pIC values presented in the tables 
throughout this thesis are drawn from individual response curves 
expressed as % own maximum response for a particular agonist. 
2.4.3 Determination of anta~onist potency 
To appraise the effects of antagonists. pKB values were 
calculated according to the methods described by Arunlakshana and 
Schild (1959). giving an estimation of antagonist affinity. In 
preliminary experiments. 5-HT caused significant desensitization in 
the small pulmonary arteries investigated using wire myography in 
the studies. This effect violates classical Schild conditions. and in 
order to avoid this pKB values were determined by constructing 
CCRCs to agonists obtained in separate arterial segments either in 
the presence or absence of a particular antagonist. Owing to either 
the large number of study groups. large number of antagonist-agonist 
combinations employed or to limited availability of tissue and 
equipment. allocation of only one or two arterial segments from 
each tissue to the determination of each estimate of antagonist 
affinity. Therefore pKB values were determined instead of pA2 values. 
which requires analysis of the effects of at least three concentrations 
of antagonist using a Schild plot calculation. Where this was 
possible. this was clearly stated in the appropriate results chapter(s) 
in this thesis. 
For a particular antagonist. the pKB value is the - log of the 
dissociation equilibrium constant (KB) for that antagoniSt. This 
constant is the molar concentration of ligand needed to occupy 50% 
of the receptor pool. 
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For the experiments, an estimate of the pKB value was calculated 
using the following equation: 
pKB = log (DR-I)-log[B]; where DR is the ratio of the EC50 value in 
the presence of antagonist to the ECSO value in the absence of 
antagonist for a particular agonist (Choppin and O'Conner, 1995). 
Several important assumptions have to be made and taken 
into account when calculating pRa values using this direct equation. 
The equation assumes that the antagonist behaves in a competitive 
manner by interacting with the agonist for unoccupied receptors in a 
simple, reversible manner and a maximum response to the agonist is 
achieved in the concentration range studied. 
2.4.4 Statistical analysis methods 
Comparisons between two groups of data were made using 
Students t-test. Unless otherwise stated, the nature of the 
experiments were such that an un-paired t-test was used. For 
comparisons between three or more groups of data, one way analysis 
of variance (ANOVA) followed by an appropriate ad hoc post test was 
the statistical method used to analyse significant differences between 
groups. P< 0.05 was considered to be statistically significant. The 
statistical software package "InStat P203" for MacIntosh computers 
was used. 
2.5 Solutions 
All solutions, unless stated otherwise, were stored at 40 C and 
made up fresh each day. 
2.5.1 In vitro pharmacological studies 
Modified Krebs-Heinslet solution was composed of the 
following: NaCI 118.4mM, NaHC03 25 mM, KCI 4.7mM, KH2P04 
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1.2mM, MgS04 O.6mM, CaC12 2.5mM, glucose II.OmM. 
2.6 D1"11is and chemical reaeents 
The following is an alphabetical list of the drugs and chemical 
reagents used in the experiments presented in this thesis: 
Drug/Reagent SuppUer 
4-AminoPYtldine Si~ma 
5-Carboxamidotryptamine (5-CT) Semat 
5-Hydroxytryptamine creatine Sigma 
sulphate (5-lIT) 
8 OH-DPAT (8-hydroxy-2- (di-n- Semat 
I propylamino) tetralin) 
a-methyl-5-hydroxytryptamine Sigma 
A23I87 (calcimycin) Sigma 
Acetylcholine Si~ma -Aldrich 
BRL-15572 (1-(3-cholrophenyl)-4- Smith Kline-Beecham 
[3,3-dipheny1(2-(S,R) hydroxy-
propanyl) piperazine] hydrochlOride 
BW 723C86 (l-[5-(2-thenyloxy)- Sigma 
IH-indol-3-yl]propan-2-amine ) 
Endothelin-l (ET-I) Thistle Peptldes 
GR55562 (3-[3-(dimethylamino) 
propyl]-4-hydroxy-N-[4(4pyridinyl)-
phenyl] benzamide 
Ketanserin Tartrate Roche 
Methiothepin Semat 
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Neuropeptide Y (NP-Y) Tocrts-Cookson 
NOl.nitro-L-arginine methylester 
(L-NAME) Si,gma 
Phenylephrine Sigma 
Pimozide Semat 
Rispertdone Semat 
SB-224289 (2,3,6,7-tetrahydro-l'- Smith Kline-Beecham 
methyl-5-[2'methyl-4'(5-methyl-
1,2,4-oxadiazol-3-yl) (biphenyl-4-
carbonyllfuro [2,3,f] indol-3-spiro-
4' -piperidine hydrochloride 
Spiperone Semat 
Sumatrtptan (GR 43175) Glaxo-Wellcome 
Stock solutions of SB-224289 and BRL15572 were prepared in 
1.0% DMSO. All other drugs and all subsequent dilutions were 
prepared in distilled water. 
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Chapter 3 
5-hydroxytryptamine receptor subtypes in 
adult rabbit pulmonary arteries 
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3.1 Introduction 
The structural changes which take place in the pulmonary 
arteries due to pulmonary hypertension have been intensively studied 
and several factors have been implicated in this condition. such as 
the potent vasoconstrictor peptide endothelin-l (Kiowski. et al.. 
1995). Recently. several important clinical and experimental studies 
have suggested a role for 5-hydroxytryptamine (5-HT) in the aetiology 
of pulmonary hypertension. 5-HT is released by activated platelets 
and pulmonary neuroendocrine cells and has been implicated in PHT 
in the presence of pulmonary thromboemboli (Comroe. et al .• 1953). 
Elevated plasma levels of 5-HT due to platelet release have 
been reported in primary PHT (Herve et al; 1995) and platelet release 
of 5-Hf is thought to be involved in PHT secondary to cardiac surgery 
(Johnson & Giorgieff, 1989). Isolated pulmonary arteries from PHT 
patients undergoing transplantation exhibit exaggerated 
vasoconstrictor responses to 5-HT (Brink et at 1988). In the rat 
monocrotoline-induced PHT model. responses to 5-HT are 
significantly potentiated (Wanstall & O'Donnell. 1990). 
Pulmonary neuroendocrine cells have been implicated as the 
source of increased 5-HT production, resulting in acute PHT 
postoperatively in children with heart defects (Breuer et al.. 1996; 
Schindler et al., 1995). 5-Hf has also been linked to PHT associated 
with hypoxia in the newborn infant (Johnson & Georgieff; 1989). 
Hence, the 5-HT receptors mediating pulmonary vasoconstriction in 
the perinatal period are of interest and the studies in chapter 5, 
extensively examined and discussed the role of 5-HT receptor 
mediated responses in the pulmonary vasculature of the perinatal 
rabbit. 
5-HT interacts with a multiplicity of receptors causing either 
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vasoconstriction or vasodilation depending on receptor subtype. 
species, pulmonary vascular location and degree of underlying 
vascular tone (Hoyer et al .. 1994). For example. 5-HT causes 
vasoconstriction in isolated bovine intrapulmonary arteries via a 5-
HTID/IB receptor under conditions of raised vascular tone (Maclean 
et aI, 1994) but induces endothelium-dependent relaxation in 
isolated porcine pulmonary arteries via the '5-lITIC' receptor (Glusa 
& Richter, 1993). The 5-HTIC receptor has subsequently been 
renamed the 5-lIT2C receptor (Hoyer et al.. 1994). 
In human large pulmonary arteries, 5-HT-mediated 
vasoconstriction is via stimulation of 5-HTI D /1 B receptors 
(MacLean et al, 1996b) and in chapter 4 the importance of the 5-
HTIB receptor in mediating 5-lIT-receptor-induced vasoconstriction 
in the pulmonary small muscular reSistance arteries in man is 
discussed. In other vascular beds. 5-lIT can induce endothelium-
dependent vasodilation via the 5-lIT2C receptor (Bodelson et al.. 
1993). the 5-lIT2B receptor (Glusa & Roos, 1996: Ellis et al., 1995) 
and the 5-HTID/IB receptor (Gupta. 1992). There is also evidence 
that 5-lIT can mediate vasodilation directly through 5-HT 4 and 5-
HT7 receptors located on vascular smooth muscle (Cocks & Arnold. 
1992: Leung et al., 1996: Terron, 1996). Hence, in this study, 5-HT 
receptor mediated responses in isolated rabbit pulmonary arteries 
were studied. both in PCAs and PRAs in adult rabbits. This gives a 
more complete picture of 5-HT receptor mediated responses along the 
pulmonary vascular tree as the vascular smooth muscle cells from 
these two regions are phenotypically distinct (Frid et al., 1997). The 
investigations in the adult rabbit would also provide a basis for 
comparison with the studies in chapter 5 in the perinatal rabbit 
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isolated pulmonary arteries. The selective agonists and antagonists 
used in this study are deSCribed in chapter 1, section 1.4.3. 
3.2 Methods 
Rabbit lare;e pulmonary arteries 
New Zealand White adult rabbits were studied. They were killed 
by sodium pentobarbitone overdose (200mgkg-1) and the lungs 
removed and placed in cold Krebs. First pulmonary artery extralobar 
branches were carefully dissected out as described in section 2.3.4.1. 
Arterial rings were mounted between two stainless steel hooks for 
isometric tension recording in 5 ml tissue baths and bathed in 
Krebs-buffer solution (pH 7.4) (composition (mM): NaCI 118.4, 
NaHC03 25, KCI 4.7, KH2P04 1.2, MgS04 0.6, CaCl2 2.5, glucose 
11.0, and EDTA 23.0) at 370 C Vessels were bubbled with 
16%02/5%C02 balance N2 to give values similar to those found in 
vivo given that these vessels are well supplied by the vasa vasorum. 
Initial tension was set to 1.5g. being that which conSistently gives 
optimum contraction to a reference 50mM KCI challenge in these 
vessels (MacLean et al., 1993). The endothelium was removed from 
some PCAs by carefully, but thoroughly, rubbing a pair of blunt 
forceps around the luminal surface of the vessel whilst placed on 
tissue soaked in Krebs solution. 
Rabbit pulmonary reSistance arteries 
Adult male New Zealand White rabbits were overdosed with 
sodium pentobarbitone and the lungs removed and placed in ice-cold 
Krebs. Under a dissecting microscope, intralobar small pulmonary 
resistance arteries (-250 - 300~ internal diameter) from the right 
lung were carefully dissected out and mounted as ring preparations 
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in isometric wire myographs as described in section 2.3.5 and bathed 
in Krebs solution at 370 C. The vessels were bubbled with 
16%02/5%C02 balance N2 to give values similar to those found in 
vivo. Using the normalisation process explained in section 2.3.6., 
tension was then applied to all vessels to give a transmural pressure 
equivalent of apprOximately 15 mmHg, similar to in vivo pressures of 
pulmonary arterioles. 
Experimental protocol 
Lan~e pulmonruy arteries 
Vessels were allowed to equilibrate for 45-60 minutes prior to 
the addition of any drugs. The response to 50mM KCI was determined 
twice; once the contraction to KCI had reached a plateau, the vessels 
were washed out at least 8 times with fresh Krebs solution and 
allowed to equ1l1brate for a further 45 minutes. The presence of a 
functional endothelium was assessed with acetylcholine (ACh; I~M) 
in vessels precontracted with O.l~M phenylephrine. The vessels were 
then subjected to one of the following experiments: In order to 
evaluate the 5-HT receptor(s) involved in the pulmonary 
vasoconstrictor activity in the large pulmonary arteries, CCRCs were 
constructed to the 5-HT agonists 5-carboxamidotryptamine (5-CT, 
InM-O.lmM; 5-Hfl receptor agonist), a-methyl-5-HT (5-HT2-selective 
agonist, InM-O.lmM) 8-hydroxy-2-(di-n-propylamino) tetralin (8-0H-
DPAT, 5-HTIA agonist) and the 5-HTIB/ID receptor agonist, 
sumatriptan. The antagonists used were ketanserin (selective for 5-
HT2A receptors), methiothepin (non-selective antagonist at 5-HTI 
and 5-HT2A receptors and GR55562 (3-[3-(dimethylamino)propyl]-4-
hydroxy-N-[4(4pyridinyl)phenyl] benzamide) (selective 5-HTIB/lD 
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antagonist). In additional experiments, some antagonist studies were 
performed in the presence of O.lmM NCO-nitro-L-arginine methylester 
(L-NAME). This concentration of L-NAME was chosen to ensure 
complete inhibition of endothelial NOS activity. 100llM L-NAME 
completely inhibits endothelial cytosol cyclic GMP formation, a 
measure of NOS activity, in rat aorta (Rees et al., 1990). A 10-fold 
lower concentration of L-NAME completely abolished ACh-induced 
relaxation of rat isolated aorta in the same study (Rees et al., 1990). 
Moreover, Steeds et al (1997) recently reported that 100llM L-NAME 
abolished ACh-induced relaxation as well as basal-released NO in rat 
isolated PRAs. 
A second protocol examined the 5-HT receptor(s) mediating 
vasodilation in the adult rabbit large pulmonary arteries and these 
experiments were conducted in the presence of O.IIlM ketanserin to 
exclude any 5-HT2A -receptor mediated effects. Vessels were 
contracted with phenylephrine (PE; O.IIlM) as it reliably induces a 
maintained contraction in these arterial segments (MacLean et al., 
1993). Vessels were pre-contracted to give a contraction 
approximately half the maximal contractile response to this PE as 
preliminary studies indicated that contraction above this level 
actually decreased the sensitivity of vasodilators including 5-CT. I 
studied vasodilation in responses to 5-CT, 5-HT, sumatriptan and 
BW 723C86 (selective 5-HT2B agonist). For antagonist studies, 
CCRCs to 5-CT was constructed in each vessel either in the presence 
or absence of one of the following antagonists; GR55562 (lIlM), 
spiperone (lIlM,5-HT7 receptor antagonist), pimozlde (30nM, 5-lIT7 
receptor antagonist) or risperidone (3nM, 5-HT7 receptor antagonist). 
Antagonists were allowed a 45 minute eqUilibrium period prior to 
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constructing the CCRCs to 5-CT. All CCRCs were in the 
concentration range O.lnM-O.lmM. 
Pulmoncuy resistance arteries 
Following a 45 minute equilibration period. the response to 
50mM KCI was determined. followed by wash-out and further 
equilibration. 50mM is the concentration at which KCI produces an 
maximum contractile response in adult rabbit PRAs (Docherty. 
1997). This concentration was subsequently used to constrict vessels 
at the beginning of each protocol for all functional studies carried 
out in this thesis. The magnitude of the response to the second 
application of 50mM KCI was used as a reference contraction to 
compare subsequent vasoconstrictor responses to other agents. in 
the same preparation. In preliminary experiments. some PRAs were 
preconstricted with l~M 5-HT followed by CCRC to sodium 
nitroprusside (SNP; InM-O.lmM) in order to assess the ability of the 
adult PRAs to relax to endothelium-independent vasodilator agents. 
The vessels were subjected to one of the following experiments. 
Cumulative concentration-response curves (CCRCs) to 5-HT 
(lnM-O.lmM) were constructed either in the presence or absence of 
lOO~M L-NAME. 
In order to evaluate the 5-HT receptor(s) involved in the 
pulmonary vasoconstrictor activity in the PRAs. CCRCs were also 
constructed to the 5-HT agonists 5-carboxamidotryptamine (lnM-
O.lmM). a-methyl-5-HT (lnM-O.lmM) and sumatriptan (InM-
O.lmM). Previous experience dictates that attempts at mechanical 
removal of the vascular endothelium in these arteries damages the 
thin and fragile underlying smooth muscle. Antagonist experiments 
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were. therefore. also carried out in the presence of 1 OO~ L-NAME to 
prevent any inhibitory role of NO release on constrictor responses as 
the initial findings described in this study showed that NO from the 
endothelium markedly affected the sensitivity. as indicated by the 
pECSO value. to 5-HT-induced vasoconstriction in these PRAs. 
CCRCs to 5-lIT are not reproducible in each tissue as desensitisation 
often occurs with a second CCRC. therefore. only one CCRC to 5-lIT 
was constructed either in the absence or presence of an antagonist in 
each vessel. The antagonists used were ketanserin (selective for 5-
HT2A receptors) and GR55562 (3-[3-(dimethylamino)propylj-4-
hydroxy-N-[4-(4-pyridinyl)phenyl] benzamide) (selective 5-HTIB/ID 
antagonist). CCRCs to 5-CT were also constructed in the presence of 
8B224289 (selective 5-HTIB receptor antagonist; 200nM) and 
BRL15572 (selective 5-HTID antagonist; 500nM). All antagonists 
studies were also carried out in the presence of L-NAME (1 OOJlM). All 
antagonist concentrations which were studied. were chosen due to 
their affinity values in other in vitro vascular preparations. In all 
antagonist studies. antagonists were allowed a 45 minute 
equilibration period before the construction of any CCRCs. 
Data analysis 
Contractile responses are expressed as a percentage of the 
contraction to 50mM KCI determined at the start of the experiment 
in each preparation. The results are shown as the mean ± s.e.mean. 
Dilator responses are expressed as the % reduction of PE-induced 
tone. pEC50 and pICSO values were calculated according to methods 
stated in chapter 2. Statistical comparison of the means of groups of 
data were made by Student's unpaired t-test or one way analysis of 
variance where appropriate. P < 0.05 was considered statistically 
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significant. n = number of vessels/number of animals. In antagonist 
studies in the large pulmonary arteries, the antagonist potencies of 
ketansertn against 5-HT were calculated according to Arunlakshana 
and Schild (1959) using EC50 values obtained in the presence and 
absence of ketansertn to give pA2 values. The slope of the Schild 
regression was also determined. In the other antagonist studies, in 
particular for PRAs, estimated pKB values calculated assuming the 
antagonists behaves in a competitive manner and a maximum 
response to the agonist is achieved in the concentration range 
studied. Apparent pKB values were calculated for a single stated 
concentration of antagonist according to the methods described in 
chapter 2. 
3.3 Results 
Rabbit Lar~e (conduit) pulmonruy arteries (PCAs) 
The absolute magnitude of the contractile response to 50mM 
KCI in these vessels was 2275 ± 175 mg wt tension (n > 15). 
Assessment of endothelial inte~rttv with ACh 
ACh (111M) caused a relaxation of phenylephrine-pre contracted 
PCAs of 64 ± 5%(n = 24). In endothelium-denuded vessels, ACh either 
had no effect or caused a slight contraction. 
Response to 5-HT receptor a~onists 
Figure 3.1 demonstrates CCRCs to 5-HT, a-methyl 5-HT, 5-CT, 
8-0R-DPAT and sumatriptan in rabbit PCAs. All agonists caused 
concentration-dependent contractions in these vessels. The following 
rank order of potency was obtained, based on the pEC50 values for 
each agonist as summarised in table 3.1. 5-HT = amethy15-HT > 5-Cf 
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> 8-0H-DPAT > sumatriptan. The maximum contractile response to 
a-methyl-5-HT was significantly greater than 5-HT (P<0.05). 
Maximum contractile responses to 5-CT and 8-0H-DPAT were not 
significantly different to SlIT. The maximum contractile response to 
sumatriptan was not reached within the concentration range 
studied. The potency of the S-lIT2 receptor agonist a-methyl-5-HT 
strongly indicated the presence of vasoconstrictor 5-lIT2 receptors in 
this tissue. 
Agonist Maximum pEC50 n 
(% KCl) 
5-lIT 114±8 7.01 ± 0.07 36/36 
5-cr 112 ± 10 5.91 ± 0.08*** 12/12 
8-0H-DPAT 95± 14 5.32 ± 0.15*** 11/11 
a-me5-lIT 146 ± 10* 6.88± 0.08 12/12 
sumatriptan 71 ± 21a nc 12/12 
Table3.1 Characteristics of contractile response to 5-HT agonists in 
adult rabbit large pulmonary arteries. Statistical comparisons were 
made by ANOVA, agonist vs. 5-HT, *P<O.OS, ***P<O.OOl. Data are 
expressed as arithmetic mean ± s.e.mean. Maximum represents 
maximum contractile response expressed as percentage response to 
reference 50mM KCI contraction. n/n, number of ring 
preparations/number of animals. 
N2k a represents contractile response at maximum sumatriptan 
concentration; nc, not calculated. 
107 
A 
-
125 E 
:::s 
E 
>< 100 
co 
E 
r:: 75 
~ 
0 
~ 0 50 
-
Cl) 
tJ) 
25 r:: 
0 
c.. 
tJ) 
Cl) 0 a: 
-11 -10 -9 -8 -7 -6 -5 -4 -3 
Agonist (log M) 
200 B 
-() 
~ 
:E 150 
E 
0 
Lt') 
~ 0 100 
-
Cl) 
tJ) 
r:: 
0 50 
c.. 
tJ) 
Cl) 
a: 
0 
-11 -10 -9 -8 -7 -6 -5 -4 -3 
Agonist (log M) 
Fillure 3.1 Responses to 5-HT receptor agonists in peAs from adult 
rabbits. CCRCs to 5-HT (0. n/n = 12/12), a-methyl 5-HT (e. n/n = 
12/12), 5-CT (~. n/n = 12/12), 8-0H-DPAT (0. n/n = 11/11) and 
sumatriptan (0. n/n = 12/12). A. Data are expressed as a percentage 
of their own maximum. B Data are expressed as a percentage 
reference contraction to 50mM. Each point represents mean ± 
s.e.mean. 
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Effect of anta~onlsts on 5-HT -receptor mediated contraction of adult 
rabbit PCAs 
The effect of ketanserin and GR55562 on 5-HT-induced 
vasoconstriction in adult rabbit PCAs are shown in figures 3.2 and 
3.4 respectively. pEC10, pEC25 and pEC50 values are summarised in 
table 3.2. 
Figure 3.2 shows that ketansertn, even at nM concentrations, 
caused concentration-dependent, rightward shifts of the CCRCs to 5-
HT. There was no change in the maximum contractile response 
(figure 3.2 B) to 5-HT in the presence ofketanserin, being 116 ± 23%, 
126 ± 16% and 148 ± 31 % for 10nM, 0.1 J.1M and 1 J.1M ketanserin, 
respectively. The pKB values at each ketanserin concentration were 
8.95 ± 0.2, 8.79 ±0.2 and 8.6 ± 0.2 for 10nM, O.lJ.1M and IJ.1M 
ketanserin respectively. The relationship between log M ketanserin 
concentration and log 5-lIT (concentration ratio-I) fitted the Schild 
equation with a slope which was not significantly different from 
unity. The Schild plot (see figure 3.3) gives a pA2 value of 8.9. 
Figure 3.2 also shows that the a l-adrenoceptor antagonist 
prazosin (lJlM) had no effect on the sensitivity of these vessels to 5-
lIT (pEC50 value = 7.03 ± 0.2)). The maximum contractile response 
to 5-lIT in the presence of prazosin was 121 ± 20% of the reference 
contraction to 50mM KCl. This value was not significantly different 
to the control 5-lIT maximum contraction. 
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Fi2ure 3.2 Effect of ketanserin and prazosin on 5-HT-induced 
contraction in PCAs from adult rabbits. CeRCs to 5-HT (_, n = 
24/11), and in the presence of 10nM (0, n= 7/7), O.lIlM (e, n=11/11) 
and 1.0llM (.6., n= 6/6) ketanserin: in the presence of 1.0llM prazosin 
(., n = 5/5). A. Data are expressed as a percentage of their own 
maximum. B Data are expressed as a percentage of the reference 
contraction to 50mM KCl. Each point represents mean ± s.e.mean. 
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Fiflure 3.3 Schild plot for ketanserin (10nM-1IlM) versus 5-HT (n= 6-
11 for each antagonist concentration). CR = concentration ratio. 
Each point represents data obtained from a separate preparation. 
Gradient of best fit was determined by linear regression and the slope 
was l., r= 0.87. The pA2 value was 8.94. 
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GR55562 ys 5-lIT 
Figures 3.4 shows the effect of GR55562 on responses to 5-lIT 
in adult rabbit peAs. The pEe values are summarised in table 3.2. In 
these vessels, the CeRCs to 5-lITwere not affected by GR55562 (0.1-
1.0JlM). Figure 3.4 A and table 3.2 clearly shows that GR55562 had 
no effect on the sensitivity of these vessels to 5-HT. The maximum 
contractile responses to 5-HT were 127 ± 8%, III ± 21 % and 129 ± 
10% in the presence of O.lIlM, IJlM and 311M GR55562 respectively. 
These values were not different to the control 5-HT maximum 
contraction (155 ±12). 
Methiothepin vs. 5-lIT 
Figure 3.5 shows the effects of methiothepin against 5-HT-
induced contractions in adult rabbit peAs. The pEe values are 
summarised in table 3.2. Methiothepin (lnM-I0nM) produced a 
significant rightward shift of the concentration response curve. 
Methiothepin at 10nM did not significantly further decrease the 
sensitivity to 5-HT than 3nM methiothepin. A decrease in the 
maximum contractile effect of 5-HT was observed at methiothepln 
concentrations of 3nM (maximum contractile response = 77± 10%, n 
= 6/6: P<0.05 cf. control (maximum contractile response = 123 ± 8, n 
= 10/10); and 10nM (maximum contractile response = 37 ± 16, n = 
6/6; P<O.Ol cf. control). 
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Figure 3.4 Effect of GR55562 on 5-HT-induced contraction in PCAs 
from adult rabbits. ceRCs to 5-HT (_, n = 18/6), and in the 
presence of O.l~M (0, n= 6/6), l~M (e, n= 6/6) and 3~M (.6, n= 6/6) 
GR55562. A. Data are expressed as a percentage of their own 
maximum. B Data are expressed as a percentage of the reference 
contraction to 50mM. Each point represents mean ± s.e.mean. 
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Ketanserin 
5-HT control 
+10nM 
ketansertn 
+0.1 J.1M 
ketanserin 
+1.0 J.1M 
ketansertn 
GR55562 
pIC 10 pIC25 pIC SO n/n 
7.7±0.1 7.3±0.1 7.0tO.1 24/11 
6.6 ± 0.1 *** 6.3 ± 0.1 *** 6.0 ± 0.1 *** 7/7 
6.2tO.2"''''''' 5.6tO.2"''''''' 5.2tO.2"''' 11/11 
5.2 ±O.2"'*'" 4.9 ± 0.2"''''''' 4.4 ± 0.2*"'* 6/6 
5-HT control 7.9 t 0.2 7.3 t 0.1 
7.0 t 0.1 
6.8 t 0.1 
6.6 to.2 
18/6 
6/6 + 0.1 JlM 7.3 t 0.1 
GR55562 
+1.0 JlM 7.6 ± 0.2 
GR55562 
+3.0 J.1M 7.6 to. 1 
GR55562 
methiothepin 
7.1 ± 0.2 6.7 ±0.2 6/6 
7.2 t 0.1 6.8 t 0.1 6/6 
5-HT control 
+1.0 nM 
7.9 ± 0.1 7.6 ± 0.1 7.2 ± 0.1 18/6 
7.3 t 0.2"'''' 7.0 t 0.2"'''' 6.7 t 0.2"'''' 6/6 
methiothepin 
+3.0 nM 7.2 ± 0.1"''''''' 6.8 ± 0.1"''''· 6.4 ± 0.1··'" 6/6 
methiothepin 
+ 10 nM 7.0 ± 0.2**· 6.8 ± 0.1"'** 6.4 ± 0.2*** 6/6 
methiothepin 
Table 3.2 Effect of selective antagonists on the sensitivity to 5-HT in 
large pulmonary arteries from the adult rabbit. Statistical 
comparisons were made by Students' paired t-test: antagonist vs. 
control ··P<O.Ol, "'''P<O.OOI. Values are expressed as arithmetic 
mean t s.e.mean., 5-HT, 5-hydroxytryptamine: n/n, number of ring 
preparations/ number of animals. 
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Figure 3.5 Effect of methiothepin on 5-HT-induced contraction in 
PCAs from adult rabbits. CCRCs to 5-HT (_, n = 18/6), and in the 
presence of 1nM(D n= 6/6), 3nM (e,n= 6/6) and lOnM (ll, n= 6/6) 
methiothepin. A. Data are expressed as a percentage of their own 
maximum. B Data are expressed as a percentage of the reference 
contraction to 50mM KCl. Each point represents mean ± s.e.mean. 
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Effect of endothelial cell removal and nitric oxide synthase inhibition 
on contractile responses evoked by 5-HTI a20nists 
100J,LM L-NAME had no effect on the basel1ne tension in PCAs 
from adult rabbits. 
Figures 3.6 and 3.7 show the effect of L-NAME and endothelial 
cell removal on 5-HTI agonist-induced contractions in rabbit PCAs. 
Table 3.3 summarises the pEC values and shows that neitherl00J,LM 
L-NAME nor endothelium removal had any effect on the sensitivity of 
these vessels to 5-CT. 
pEC I0 pEC25 pEC50 maximum n 
(Ok KCl) 
5-CT 6.9±0.2 6.6 ± 0.2 6.2 ± 0.2 III ± 10 6/6 
+ L-NAME 6.8 ± 0.2 6.6 ± 0.2 6.3 ± 0.1 101 ±8 6/6 
-E 6.7 ± 0.1 6.3± 0.2 5.9 ± 0.1 102± 12 6/6 
Table 3.3 Contractile response to 5-CT in adult rabbit PCAs in the 
presence of L-NAME and the absence of a functional endothelium. 
Data are expressed as arithmetic mean ± s.e.mean. Maximum 
represents maximum contractile response expressed as percentage 
response to reference 50mM KCI contraction. n/n, number of ring 
preparations/number of animals. -E: no endothelium 
100J,LM L-NAME had no effect on the sumatriptan-induced 
contraction in these vessels (figure 3.7) 
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Figure 3.6 Influence of the endothelium and of nitric oxide synthase 
inhibition on 5-CT induced contractions in PCAs from adult rabbits. 
CCRCs to 5-CT (0. n = 6/6), and in the presence of O.lmM L-NAME 
(~. n = 6/6) and without endothelium present (e. n = 6/6). A Data 
are expressed as a percentage of their own maximum. B Data are 
expressed as a percentage of the reference contraction to 50mM KCl. 
Each point represents mean ± s.e.mean. 
117 
150 
-() 
125 ~ 
:E 
E 1 00 
0 
It) 
~ 0 75 
-
C1) 
(/) 50 c: 
0 
~ 
(/) 25 C1) 
a: 
0 
-11 -10 -9 -8 -7 -6 -5 -4 -3 
Sumatriptan (Jog M) 
Fi~ure 3.7 Influence of the endothelium and of nitric oxide synthase 
inhibition on sumatriptan-induced contractions in PCAs from adult 
rabbits. CCRCs to sumatriptan (e, n = 6/6), and in the presence of 
O.lmM L-NAME (0, n = 6/6) and after endothelium removal (6, n = 
6/6). Data are expressed as a percentage of the reference contraction 
to 50mM KCl. Each point represents mean ± s.e.mean. 
Effect of antagonists on 5-HT-receptor mediated contraction of adult 
rabbit PCAs in the presence of NOS inhibition 
Figure 3.B shows the effects of ketanserin and GR55562 on 5-
HT-induced contractions in adult rabbit PCAs in the presence of the 
eNOS inhibitor L-NAME. Ketanserin (0. 111M) caused a rightward 
displacement of the CCRC to 5-HT, reducing the pEC50 value from 
6.B ± 0.1 to 5.15 ± 0.17 (P<O.OO l,n= 6/6), without significantly 
affecting the maximum contractile response (126 ± 16%; cf control 
maximum contractile response = 105 ± 7). The estimated pKB for 
ketanserin was 8.64 ± 0.20. GR55562 (311M) did not significantly 
affect the sensitivity to 5-HT (pEC50 = 6.B ± 0.1; figure 3.BA) nor the 
maximum response (119 ± 9%; figure 3.BB). 
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Figure 3.8 Effect of selective antagonists on 5-HT-induced 
contraction in PCAs from adult rabbits. CCRCs to 5-HT (., n = 6/6), 
and in the presence of 1IlM(D, n= 6/6) ketanserin, and 11lM (.6, n= 
6/6) GR55562.A. Data are expressed as a percentage of their own 
maximum. B Data are expressed as a percentage of the reference 
contraction to 50mM KCl. Each point represents mean ± s.e.mean. 
All CCRCs in the presence of O.lmM L-NAME. 
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5-HT receptor mediated vasodilation in adult rabbit PeAs 
The contraction to phenylephrine in the adult rabbit PCAs was 
52 ± 6 % (n = 36/12) of the reference contraction to 50mM KCl. Both 
5-HT and 5-CT, but not sumatriptan or BW723C86 produced 
concentration dependent relaxations in pre-contracted adult rabbit 
PCAs, this can be clearly seen in figure 3.9B. The potency of 5-CT was 
significantly greater (pIC50 = 7.6 ± 0.2;P<0.001) compared to the 
potency of 5-HT (pICoo= 6.5 ± 0.2). There was no difference in the 
maximum relaxation response (5-CT = 64 ± 8 %; cf 5-lIT = 65 ± 4%). 
Removal of the endothelium did not significantly alter the potency 
(pIC50 = 7.6 ± 0.2) or maximum relaxation to 5-CT (68 ± lOOk; figure 
3.9A). 
Time control precontractlle data are also shown in figures 3.9A 
and illustrate the fall in vascular tone in parallel vessels during the 
time course of each experiment. This was significantly different (P < 
0.01) from the 5-CT response data at every time point of 5-CT 
administration where 5-CT induced a relaxation. 
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Figure 3.9 5-HT agonist-induced vasodilation of adult rabbit PCAs. A. 
CCRCs to 5-CT in the absence (0. n = 6/6) and presence 5-CT ( •. n 
= 12/12) of a functional endothelium. Time control pre-contractile 
data are also shown (A. n = 12/12). B. CCRCs to 5-HT (~. n = 6/6), 
5-CT ( •. n = 12/12), BW723C86 (D. n = 5/5) and sumatriptan (e. n 
= 5/5). CCRCs expressed as percentage of PE-induced tone. Each 
point represents arithmetic mean ± s.e.mean. All CCRCs are in the 
presence of O.1IlM ketanserin. 
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Effects of selective 5-HT receptor anta~onists on 5-CT-induced 
relaxation 
The effects of GR55562, spiperone, pimozide and risperidone on 
the relaxant responses induced by 5-CT in adult rabbit PCAs 
precontracted with phenylephrine (0.1-0.3IlM) and pre-incubated with 
ketanserin (O.lIlM) are depicted in figures 3.10A and 3.10B. The pIC50 
values and maximum relaxation responses are summarised in table 
3.4. Figure 3.10A shows that pimozide, an antagonist at the 5-HT7 
receptor, caused a significant rightward shift in the CCRC to 5-CT 
without changing the maximum relaxation, in contrast, pre-
incubation with risperidone resulted in a marked attenuation of the 
maximum relaxation response to 5-CT in these vessels. Figure 3.10B 
clearly shows that the 5-HT1B/ID antagonist, GR55562, did not 
significantly antagonise the 5-CT-induced relaxation in these pre-
contracted vessels. In contrast, splperone, an antagonist at the 5-
HT7 receptor, produced a rightward displacement of the CCRC to 5-
CT without significantly reducing the corresponding maximum 
relaxation. Estimated pKB values for spiperone and pimozide were 
6.84 ± 0.15 and 7.99 ± 0.20 respectively. All of the antagonists with 
affinity for the 5-HT7 receptor, namely. risperidone. pimozide and 
spiperone. therefore produced Significant antagonism of the 5-CT-
induced relaxation in PE-pre-contracted adult rabbit PCAs. 
Time control pre contractile data are also shown in figure 3.10 
and illustrate the fall in vascular tone in parallel vessels during the 
time course of each experiment. This was significantly different (P < 
0.01) from the 5-CT response data at every time point of 5-CT 
administration where 5-CT induced a relaxation. 
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pIC 50 
5-CT 7.6±0.2 
5-CT - endothelium 7.6±0.2 
5-CT + pimozide (30nM) 7.0 ± 0.2** 
5-CT + GR55562 (111M) 7.4 ± 0.2 
5-CT + risperidone (3nM) nc 
5-CT + spiperone (111M) 6.7 ± 0.2*** 
maximum 
relaxation 
(%) 
64±8 
68±10 
62±8 
69± 12 
13 ± 8*** 
66±7 
(n) 
12/12 
6/6 
6/6 
6/6 
6/6 
6/6 
Table 3.4 Effect of selective antagonists on the relaxation response to 
5-CT in adult rabbit PCAs in the presence of O.II1M ketanserin. Data 
are expressed as arithmetic mean ± s.e.mean. Statistical 
comparisons were made by ANOVA: antagonist vs. control **P<O.Ol, 
***P<O.OOI. Maximum represents maximum relaxation response 
expressed as percentage PE-induced contraction. nino number of ring 
preparations/number of animals. 
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Figure 3.10 Effect of selective 5-HT antagonists on 5-CT-induced 
vasodilation in adult rabbit PCAs precontracted with phenylephrine. 
5-CT CCRCs ( •. n = 7/7). and in the presence of A) 30nM pimozide 
(A. n = 6/6) or risperidone (D. n= 6/6). B) 1JlM GR55562 (.6.. n = 
5/5). or 1JlM spiperone (e. n = 6/6); All CCRCs are in the presence of 
O.lIlM ketanserin. Time control pre-contractile data are also shown 
(0. n = 12/12). Data are expressed as % reversal of PE 
preconstriction. Each point represents mean ± s.e.mean. 
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Adult rabbit pulmonary resistance vessels (PRAsl 
The effective pressure to which the adult rabbit PRAs were 
tensioned was 15.8 ± 1.2 mmHg (n = 28) and the resulting internal 
diameter of these vessels was calculated to be 162 ± 9.8 ~m. The 
absolute magnitude of the second contractile response to 50mM KCI 
was 2.3 ± O.17mN (n = 28). The second contractile response to 50mM 
KCI was used as a reference contraction for the comparison of 
contractile responses to other vasoconstrictors in these vessels. 
Assessment of endothelial inte~r1ty 
Adult rabbit PRAs are subject to marked desensitisatlon to any 
second challenge to the majority of vasoconstrictors including 5-HT. 
In order to assess the endothelial cell integrity in each vessel, IJlM 
ACh was added to the plateau contractile response to the second 
application of 50mM KCI in each vessel: ACh was unable to induce a 
significant vasodilator response in any vessel. 50mM KCI would block 
any hyperpolarisation due to ACh if ACh was acting via EDHF 
(Waldron & Garland, 1994). Separate preliminary studies were 
therefore performed using other agents known to induce 
endothelium-dependent vasodilation including substance P and 
A23187. These agents, including 1~ ACh, were added at I~M once a 
contractile response to a single challenge of I~M 5-HT had 
plateaued. None of the agents used caused any significant relaxation 
of the 5-HT pre-contracted vessels. The reason for this apparent 
general lack of relaxation to endothelium-dependent vasodilators in 
these vessels is unclear. However it is unlikely that damage to the 
endothelium accounted for this. Although the presence of an intact 
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endothelium was not confirmed histologically, similar sized PRAs, 
studied in this thesis, and mounted in the myograph exhibit 
endothelium-dependent relaxation (see chapters 4 and 5 of this 
thesis). It was concluded that adult rabbit PRAs were unresponsive to 
agents known to induce endothelium-dependent relaxation in 
agreement with previous studies in adult rabbit PRAs (Docherty & 
MacLean, 1997). 
Effect of NQS inhibition 
The effect of IOOIlM L-NAME alone on baseline tension of the 
PRAs was assessed. This nitric oxide synthase inhibitor evoked 
variable responses. Qf the vessels examined 40% showed an increase 
in baseline tone of 23 ± 11 % of the reference contraction to 50mM 
KeI. 
Effect of endothelium-independent vasodilator a~ent. sodium 
nitroprusside 
IIlM 5-HT induced a pre contraction of the magnitude 48 ± 6.3 % of 
response to 50mM KeI. Figure 3. 111 shows that SNP produced a 
concentration dependent relaxation in the pre contracted adult rabbit 
PRAs. The maximum relaxation response was 63.0 ± 7.0 % and the 
pIeSO was 7.2 ±0.2 (n/n = 6/6). 
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Fiwre 3.111 Effect of SNP on 5-HT-precontracted adult rabbit PRAs. 
Data are expressed as % I~M 5-HT-induced tone. CCRC to SNP ( •. n 
= 6/6). Each point represents mean ± s.e.mean. n/n, number 
vessels/number of animals. 
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Effect of 5-lIT receptor a~onists 
The effect of the 5-lIT receptor agonlsts 5-HT, 5-CT, a-methyl-
5-lIT and sumatriptan on PRAs from adult rabbits is shown in figure 
3.11 and the pEC50 values are summarised in table 3.5. 5-HT 
elicited concentration-dependent contractions in the adult rabbit 
PRAs. The selective 5-lIT2A receptor agonist a-methyl 5-HT elicited 
concentration-dependent contractions in these vessels with a 
significantly smaller maximum contractile response compared to 5-
HT. 5-CT evoked a concentration-dependent contractile response 
and the CCRC to 5-CT was biphasic in nature (see figure 3.11 B. The 
pEC50 value for 5-CT was significantly different from 5-HT. The 
maximum contractile response to 5-CT was also significantly smaller 
(P<O.05) than that of 5-HT (see table 3,5. Sumatrtptan also eliCited a 
concentration dependent contraction in the adult rabbit PRAs with a 
significantly lower potency compared to 5-HT (figure 3. 11 A: table 
3.5). The maximum contractile response was also significantly lower 
than that to 5-lIT. Both 5-CT and sumatriptan were eqUipotent in 
these vessels. 
Effect of L-NAME on 5-lIT a~onist-induced responses 
The response of adult rabbit PRAs to 5-lIT-receptor agonlsts In 
the presence and absence of O.lmM L-NAME are shown in figures 
3.11 and 3.15. pEC50 values and maximum contractile responses are 
shown in table 3.5. L-NAME significantly increased the sensitivity to 
5-HT and to 5-CT in the adult PRAs. In comparison, L-NAME did not 
sIgnificantly increase the sensitivity to a-methyl-5-HT or to 
sumatriptan in these vessels. The magnitude of the maximum 
contractile response to all the agonists was not significantly changed 
in the presence of L-NAME. 
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pEC50 Emax·(%) (n) 
5-Hf 6.08 ± 0.12 69±9 (8/8) 
+L-NAME 6.75 ± 0.13** 75±8 (8/8) 
a-methyl-5-Hf 6.51 ± 0.2 42±3t (6/6) 
+L-NAME 6.63 ± 0.22 43±2 (6/6) 
5-CT 5.32 ± 0.2tt 37±6t (6/6) 
+L-NAME 6.05 ± 0.3* 56±7 (6/6) 
sumatriptan 5.19 ± 0.15tt 37±8t (6/6) 
+L-NAME 5.7 ± 0.2 39±6 (6/6) 
Table 3.5 Characteristics of 5-Hf agonist-induced vasoconstriction in 
adult rabbit PRAs in the presence and absence of nitric oxide 
synthase inhibitor L-NAME (O.lmM).Statistical comparisons were 
made by Students unpaired t test. control agonist vs. control 5-HT. 
tP<0.05. ttP<O.OI; control vs L-NAME. *P<0.05. **P<O.Ol. Data are 
expressed as arithmetic mean ± s.e.mean. Emax. represents 
maximum contractile response expressed as percentage response to 
reference 50mM KCI contraction. n/n. number of ring 
preparations/number of animals. L-NAME, L-NOLnitro-L-arginine 
methylester. 
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Figure 3.11 Responses to 5-HT receptor agonists in adult rabbit 
PRAs. CCRCs to 5-HT (_. n = BIB), a-methyl 5-HT (b.. n = 616).L 5-CT 
(D. n= 616) and sumatriptan (e. n= 616). A. Data are expressed as a 
percentage of their own maximum. B Data are expressed as a 
percentage of the reference contraction to 50mM KCl. Each point 
represents mean ± s.e.mean. 
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Effect of selective 5-HT receptor anta20nists 
Figure 3.12 shows the effect of the selective 5-HTIB and 5-
HTlD antagonist GR55562 on 5-lIT-induced contractions in adult 
rabbit PRAs. 1~ GR55562 caused a slight but significant rightward 
displacement of the CCRC to 5-HT reducing the pEC50 value from 
6.08 ± 0.12 to 5.74 ± 0.08; P<0.05 cf. control. The maximum 
response in the presence of GR55562 (86 ± 11 %) was not significantly 
different from the control response to 5-HT (69 ±9°Al). 
Figure 3.13 shows the effect of the selective 5-HT2A antagonist 
ketansertn on 5-lIT-induced contractions in this preparation. O.I~M 
ketanserin caused a non-parallel rightward displacement of the 
CCRC to 5-HT. The pEC50 value in the presence of 5-lIT alone was 
6.08 ± 0.08. and in the presence of O.IJlM ketansertn was 5.21 ± 0.1. 
(P<0.05 vs. 5-lIT alone). The shift in response to 5-lIT in the presence 
of O. 1 ~M ketansertn in this preparation was not as great as that 
expected for 5-HT acting at a single receptor population. 
Furthermore. concentrations of 5-HT up to O.I~M were resistant to 
inhibition by ketansertn. There was no change in the size of the 
maximum contractile response to 5-HT in the presence of ketansertn 
(Figure 3.13B). 
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Fif.!ure 3.12 Effect of GR55562 (lIlM) on responses to 5-HT in adult 
rabbit PRAs. CCRCs to 5-HT ( •. n = 8/8). and in the presence of 
GR55562 (Ll. n= 6/6). A. Data are expressed as a percentage of their 
own maximum. B Data are expressed as a percentage of the reference 
contraction to 50mM KCl. Each point represents mean ± s.e.mean. 
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Figure 3.13 Effect of ketanserin (a. 111M) on responses to 5-HT in 
adult rabbit PRAs. CCRCs to 5-HT (., n = 8/8), and in the presence 
of ketanserin (0, n= 6/6). A. Data are expressed as a percentage of 
their own maximum. B Data are expressed as a percentage of the 
reference contraction to 50mM KCl. Each point represents mean ± 
s.e.mean. 
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Fi~ure 3 .14 Effect of eNOS inhibition on responses to 5-HT in adult 
rabbit PRAs. CCRCs to 5-HT (_, n = 8/8), and in the presence of 
O.lmM L-NAME (e, n= 8/8). A. Data are expressed as a percentage of 
their own maximum. B Data are expressed as a percentage of the 
reference contraction to 50mM KCl. Each point represents mean ± 
s.e.mean. 
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Fi2ure 3.15 Effect of eNOS inhibition on responses to 5-HT receptor 
agonists in adult rabbit PRAs. CCRCs to 5-HT (_, n = 8/8), a-methyl 
5-HT (~, n = 6/6L. 5-CT (0, n= 6/6) and sumatriptan (e, n= 6/6). A. 
Data are expressed as a percentage of their own maximum. B Data 
are expressed as a percentage of the reference contraction to 50mM 
KCl. Each point represents mean ± s.e.mean. All CCRCs in the 
presence of O.1mM L-NAME. 
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Effect of selective 5-HT receptor anta~onists 
L-NAME was shown to have a marked effect on the sensitivity 
to 5-HT (figure 3.14). the majority of antagonist studies were 
therefore performed in the presence of O.lmM L-NAME to prevent any 
InhIbitory effects of endothelium derived nitric oxide on 5-HT-
receptor mediated responses. 
The effect of ketanserin, GR55562, 5B224289 and BRL15572 
on 5-HT and 5-CT-induced vasoconstriction in PRAs from adult 
rabbits are shown in figures 3.16,3.17, and 3.18 respectively. pEC10, 
pEC25 and pEC50 values are summarised in table 3.6 
5-HT vs ketansertn 
Figure 3.16 shows the effect of the 5-HT2A antagonist 
ketanserin on 5-HT-lnduced contractions in adult rabbit PRAs. In 
adult PRAs ketanserin (30nM) significantly inhibited 5-HT-evoked 
vasoconstriction only at 5-HT concentrations ~ O.lJlM (see table 3.6). 
Responses to lower concentrations of 5-HT were resistant to 
ketanserin (Figure 3.16B). 0.1JlM ketanserin did not significantly 
inhibit the 5-IIT responses any further and the 'ketanserin-resistant' 
component observed at low concentrations of 5-HT was still present. 
In comparison, 1 JlM ketanserin did significantly inhibited the 5-HT 
CCRC at the level of the pEC 10 value (see table 3.6). All three 
concentrations of ketanserin did significantly decrease the pEC50 
value. The maximum contractile responses In the presence of 
ketanserin were 64 ±5%. 81 ±9% and 70 ± 80/0 (% response to 
reference 50mM KCI contractile response) for 30nM, O.lJlM and 1JlM. 
ketanserin respectively; ketanserin did not Significantly affect the 
maximum contractile response to 5-HT compared to the control 
response In the presence of 0.1mM L-NAME (Emax. = 75 ± 8%). The 
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estimated pKB value for lJ..l.M ketansertn was 6.98 ± 0.2. (% response 
to reference 50mM KCI contractile response). 
5-IITvs. GR55562 
The effect of the 5-HT1B/1D antagonist GR55562 on 5-HT-
evoked vasoconstrictions in adult rabbit PRAs is shown in figure 
3.17. pEC10, pEC25 and pEC50 values are summarised in table 3.6. 
GR55562 (lJ..l.M) significantly inhibited the 5-HT-induced contractions 
at the level of the pEC 10, pEC25, and pEC50 values, including the 
'ketanserin-resistant' component (see figure 3.17). Higher 
concentrations of GR55562 (1 OIlM) , further inhibited responses to 5-
HT but also significantly reduced the maximum response to 5-HT 
from 75 ± 8% to 41 ± 7% (% of response to 50mM KCI, P < 0.005). 
5-CTvs. BRL15572 and SB224289 
Figure 3.18 shows the effect of the selective 5-HT1B antagonist 
SB224289 and the selective 5-HT1D antagonist BRL15572 on 5-CT-
induced contractions in adult rabbit PRAs. Table 3,6 summarises the 
pECIQ. pEC25 and pEC50 values for BRL15572. SB224289 (0.2J..1.M) 
caused a marked inhibition of the CCRC to 5-CT, which did not 
achieve a maximum contractile response in the 5-CT concentration 
range studied. pEC values could not, therefore, be calculated. 
BRL15572 (O.5JlM) caused a significant, but non parallel, rightward 
shift of the CCRC to 5-CT, significantly inhibiting the 5-CT-induced 
contractions in these vessels at 5-CT concentrations > 1.OJlM, and 
resulted in a significant decrease in the sensitivity to 5-CT at the 
levels of the pEC25 and pEC50 values. The maximum contractile 
response to 5-CT in the presence of BRL15572 (47 ± 8% 50mM KCl) 
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was not significantly different from the control response to 5-CT (60 
± 6% 50mM KCl). 
pEC 10 pEC25 pEC50 n/n 
Ketanserin 
5-HT control 7.75 ± 0.2 7.21 ± 0.1 6.75 ± 0.1 8/8 
+30nM 
ketanserin 7.39 ± 0.3 6.70 ± 0.2* 5.95 ± 0.1 ** 7/7 
+0.1J,tM 
ketanserin 
+1.0 J,tM 
ketanserin 
GR55562 
7.63 ± 0.2 6.68 ± 0.3 6.04 ± 0.3* 7/7 
6.9 ± 0.2* 5.76 ±D.2*** 5.73 ± 0.2*** 6/6 
5-HT control 7.75 ± 0.2 7.21 ± 0.1 6.75 ± 0.1 8/8 
+ 1.0 J,tM 
GR55562 7.10 ± 0.2* 6.70 ± 0.1 * 6.05 ± 0.2** 6/6 
+10 J,tM 
GR55562 
5-CT control 
+0.2 J,tM 
SB224289 
+0.5 J.1M 
BRL15572 
7.25 ± 0.2 
7.3± 0.2 
nc 
7.2± 0.2 
6.20± 0.2*** 5.54 ± 0.2*** 6/6 
6.76 ± 0.2 5.85 ± 0.1 7/7 
nc nc 7/7 
6.08 ± 0.2* 4.82 ± 0.1 *** 7/7 
Table 3.6 Effect of selective antagonists on the sensitivity to 5-lIT in 
PRAs from the adult rabbit. Statistical comparisons were made by 
Students' unpaired t-test: antagonist vs. control *P<0.05. "P<O.Ol, 
***P<O.OO1. Values are expressed as arithmetic mean ± s.e.mean., 5-
HT. 5-hydroxytryptamine: nino number of ring preparations/ number 
of animals. All CCRCs constructed in the presence of O.lmM L-
NAME. 
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Figure 3.16 Effect of ketanserin on 5-HT-induced contraction in 
adult rabbit PRAs. CCRes to 5-HT (_, n = 8/8), and in the presence 
of 30nM (~,n= 7/7), O.lflM (e ,n= 7/7) and l.OflM (0, n= 6/6) 
ketanserin. A. Data are expressed as a percentage of their own 
maximum. B Data expressed as a percentage of the reference 
contraction to 50mM. Each point represents mean ± s.e.mean. All 
CCRCs in the presence of O.lmM L-NAME. 
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Figure 3.17 Effect of GR55562 on 5-HT-induced contraction in PRAs 
from adult rabbits. CCRCs to 5-HT (_, n = 8/8), and in the presence 
of O. lJ.l.M (0 , n= 6/6), and IJ.l.M (e, n= 6/6) GR55562. A. Data are 
expressed as a percentage of their own maximum. B Data are 
expressed as a percentage reference contraction to 50mM KCl. Each 
point represents mean ± s.e.mean. All CCRCs constructed in the 
presence of O.lmM L-NAME. 
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Fi~ure 3.18 Effect of selective antagonists on S-CT-induced 
contraction in adult rabbit PRAs. CCRCs to S-CT (_, n = 7/7), and 
in the presence of O.2J.lM SB224289 (e,n= 7/7), and O.SIlM BRL15572 
(~,n= 7/7). A. Data are expressed as a percentage of their own 
maximum. B Data are expressed as a percentage reference 
contraction to SOmM KCl. Each point represents m ean ± s.e .mean. 
All CCRCs in the presence of O.lmM L-NAME. 
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3.4 Discussion 
5-lIT receptor subtypes in adult rabbit PCAs 
5-lIT receptor mediated vasoconstriction 
The 5-HT receptor subtypes mediating vasoconstriction in the 
adult rabbit PCAs were examined using several selective agonists 
and antagonists. The potency order for the 5-HT agonists, using the 
pEC50 values as an index, was a-methyl 5-lIT = 5-lIT > 5-CT > 8-
OH-DPAT » sumatriptan. These data are consistent with the 
presence of a predominant population of 5-HT2 receptors, according 
to the criteria of Hoyer et al. (1994), which mediate 5-HT-induced 
vasoconstriction in these peAs. Although a-methyl-5-HT shows little 
selectivity between the 5-HT receptor subtypes in the 5-lIT2 class of 
receptors, the above agonist potency order provides some supporting 
evidence for the involvement of 5-HT2A receptors in mediating 5-lIT-
induced vasoconstriction in these vessels. In the rat, isolated extra-
lobar branch pulmonary artery, MacLean et al. (1996) reported an 
agonist potency order of 5-HT » 5-CT » sumatriptan and 
concluded, in conjunction with antagonist studies, that 5-HT was 
mediating its vasoconstrictor effect via the 5-HT2A receptor class in 
these vessels. The sensitivity to 5-lIT reported in this previous study 
was -5.3, which is markedly less than the sensitivity to 5-HT in the 
studies with the adult rabbit large isolated pulmonary artery, 
highlighting a significant species difference in the sensitivity of 
capacitance pulmonary arteries to the vasoconstrictor action of 5-
lIT. Ketanserin in these vessels behaved as a competitive 
antagonist. The sub-nM affinities observed for ketanserin against 5-
lIT in the rabbit PCAs, where the estimated pKB values ranged from 
B.6-8.95. strongly suggest that the 5-HT receptor mediating 5-HT-
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induced vasoconstriction in these vessels is the 5-HT2A receptor 
subtype (Hoyer et al., 1994). This range of apparent pKB values is 
consistent with the affinity of ketanserin for the 5-HT2A receptor in 
other rabbit vascular preparations including the rabbit aorta (pKB 
-8.6: Leff & Martin, 1986), and rabbit carotid artery (pKB -8.7: Black 
et al., 1981). It has been suggested that ketanserin at JlM 
concentrations has some affinity for the 5-HTID receptor (Kaumann 
et al., 1993; 1994). The pOSSibility that JlM concentrations of 
ketanserin may inhibit 5-HTIDreceptor-mediated contractions of 5-
HT in these adult rabbit PCAs is unlikely as the selective 5-HTIB/ID 
receptor antagonist GR55562 did not inhibit 5-HT-induced 
contractions in this study, suggesting an absence of 5-HTl D 
receptors in this preparation. 
MacLean et al. (1996), reported previously that the affinity for 
ketanserin against 5-HT in control rat extra-lobar pulmonary arteries 
was -7.8. The authors concluded that in those vessels, the 5-lIT2A 
receptor was predominantly present but could not exclude the 
possibility of the presence of another 5-lIT receptor subtype. In the 
left branch calf pulmonary artery, Frenken and Kaumann (1984) 
demonstrated that the high affinity of ketanserin (pKB -9.4) against 
5-HT indicated the presence of 5-HT2A receptors mediating 5-HT-
induced vasoconstriction in this preparation. In human large isolated 
pulmonary arteries, ketanserin had no significant effect on the 
sensitivity of the preparation to 5-HT at the pEC50 level but did 
reduce the maximum contractile response to 5-HT (MacLean et al., 
1996b), suggesting the involvement of a 5-HT receptor subtype other 
than 5-HT2A in mediating the vasoconstrictor actions of 5-HT in 
human pulmonary arteries and highlighting another species 
difference. GR55562 has previously been shown to be a selective 
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antagonist for the 5-fIT1B and 5-fIT1D receptor subtypes (Connor et 
al., 1995). giving an affinity value of -7.9 against sumatriptan-
induced contractions of the monkey and dog isolated basilar arteries. 
In the study on isolated human PCAs, MacLean et al.(I996b) provided 
conclusive evidence that the 5-HT1-like receptor mediating 
vasoconstriction in these vessels was either the 5-HTIB or 5-HTID 
receptor as GR55562 produced a truly competitive antagonism 
against 5-fIT with an affinity (pA2) value against the 5-fIT1D and 5-
fIT1B agonist sumatrtptan of -8.9. In the adult rabbit PCAs however, 
GR55562 had no effect on the 5-HT-induced vasoconstriction, 
shOwing that a 5-fIT1B or 5-HT1D receptor does not mediate the 
contractile response. 
Methiothepin has a pA2 value of -9 against 5-HT2A receptors 
and about a 10-fold less affinity for 5-HT1 receptors (Hoyer et al., 
1994). Here, methiothepin (I-10nM), significantly shifted the CCRC 
to 5-fIT to the right, suggesting further the presence of a population 
of 5-HT2A receptors, due to the non-competitive nature of 
methiothepin, a value for the affinity could not be calculated. 5-HT 
generally mediates its vasoconstrictor effect by activating 5-fIT2A or 
5-HTl receptors. There is some evidence to suggest that 5-fIT may 
mediate its vasoconstrictor actions indirectly in certain rabbit 
arteries (Black et al., 1981; Grandawand Purdy, 1996; Purdy et al., 
1987). Previous studies have shown that in rat pulmonary conduit 
arteries, 5-HT may activate <X1-adrenoceptors (Ogawa et al., 1995), 
mediating an indirect vasoconstrictor action of 5-HT. This was 
recently confirmed by Shaw et al (2000) who reported that the <X 1 -
receptor antagonist prazosin, at 10nM, produced a potent inhibition 
of 5-HT-induced contractions in the rat isolated extralobar 
pulmonary artery. In preliminary studies in the adult rabbit PCAs 
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investigated in this thesis, prazosin (If.lM) did not have any 
significant effect on responses to 5-HT in these vessels (n = 5/5). 
Hence (X1-adrenoceptors are unlikely to contribute to the observed 
responses to 5-HT in this study even though a previous study has 
shown that this preparation contains a significant population of (Xl 
and (X2 -adrenoceptors which mediate the vasoconstrictor actions of 
noradrenaline (MacLean et al., 1993). Taken together, the results of 
the current studies using isolated rabbit peAs strongly suggest that 
in the adult rabbit peA, vasoconstriction is mediated via the 5-HT2A 
receptor SUbtype. This is consistent with the observations that 5-
lIT2A receptors mediate the vasoconstrictor actions of 5-HT in a wide 
range of rabbit conduit arteries such as the carotid (Black et al., 
1981), aorta (Leff & Martin, 1986) and femoral (MacLennan & Martin, 
1992) arteries. This study demonstrated a conSiderable species 
difference compared to human conduit pulmonary arteries where 5-
HT mediates its potent vasoconstrictor action predominantly through 
5-HT1B or 5-HT1D receptors. Ullmer et al. in 1995 identified the 
mRNA for 5-HT1B receptors (as well as for 5-HT2A, 5-HT7 and 5-
HT2B receptors) using RT-PCR suggesting the importance of the 5-
HT1B receptor in the human peAs. In comparison, the studies in 
chapter 4 of this thesis also provide evidence that the 5-HT1B 
receptor mediates 5-HT -induced vasoconstriction in human PRAs, 
importantly, at physiological and pathophysiological concentrations 
of 5-HT. 
Several studies on other rabbit isolated vessels including the 
rabbit saphenous vein (Valentin et al., 1996) and rabbit basilar artery 
(Trezise, 1992) have demonstrated a profound inhibitory effect of the 
endothelium and endothelial-derived nitric oxide on contractions to 
5-HT and 5-HT1B/5-InlD agonists. More importantly for the 
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pulmonary circulation, in bovine isolated large pulmonary arteries, 
MacLean et al., (1994) demonstrated that either removal of the 
endothelium or inhibition of NOS with L-NAME significantly 
increased the sensitivity to sumatriptan. The presence of L-NAME 
also significantly increased the maximum contractile response to 
sumatriptan. Here, this pOSSibility was addressed by examining the 
effect of mechanical endothelial cell removal and eNOS inhibition 
using L-NAME on the vasoconstrictor responses to 5-HT, 5-CT and 
sumatriptan. Neither endothelial cell removal nor eNOS inhibition 
significantly affected the sensitivity to 5-HT, 5-CT or sumatriptan 
indicating that in contrast to bovine PCAs, NO or a functional 
endothelium did not mask any 5-HTl (specifically 5-HTIB or 5-HTID) 
receptor mediated vasoconstriction in this preparation. 
5-HT receptor mediated vasodilation 
Here, 5-HT receptor-mediated vasodilation in pre-contracted 
adult rabbit PCAs using selective 5-HT agonists and antagonists was 
also studied. In 1975, Eyre et al., first demonstrated that sub-JlM 
concentrations of 5-HT evoked a relaxation in isolated sheep 
pulmonary vein pre-contracted with histamine, Similarly this 
vasodilator effect of 5-HT was later confirmed in the goat pulmonary 
vein (Chand, 1981). More recently, 5-HT was shown to elicit an 
endothelium-dependent vasodilation in pig pulmonary arteries (Glusa 
& Richter et al., 1993). 5-HT receptors are therefore, known to 
mediate vasodilation in blood vessels either directly via 5-HT 
receptors located on the vascular smooth muscle (Cocks & Arnold, 
1992; Leung et al., 1996) or indirectly via endothelial released NO 
(Bodelson et al., 1993; Glusa & Roos, 1996: Glusa & Richter, 1993). 
In the studies where the 5-HT-induced vasoconstriction in rabbit 
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PCAs was investigated, the 5-HT2A receptor was shown to mediate a 
potent vasoconstrictor effect of 5-HT. For the vasorelaxant studies 
described here, all experiments were conducted in the presence of 
O.lJ.LM ketanserin in order to inhibit any vasoconstrictor responses to 
5-HT agonists. 5-CT and 5-HT both produced a significant 
concentration-dependent relaxation in the pre-contracted adult 
rabbit PCAs, suggesting an involvement of a 5-HTl-like receptor. 
However the lack of vasodilator effect of the 5-HTIB and 5-lITl D 
receptor agonist sumatriptan suggests that these receptors are not 
involved in mediating 5-HT-receptor-induced vasodilation in this 
preparation. This was confirmed using the selective antagonist 
GR55562 which did not significantly affect the 5-CT-induced 
vasodilation in this preparation. 
Glusa and Richter (1993) demonstrated endothelium-
dependent relaxation in porcine pulmonary arteries and concluded 
that this vasodilation was mediated via what was termed the '5-
HTlc-like' receptor. This 5-HT receptor subtype in the porcine 
pulmonary artery displays a markedly similar pharmacological profile 
to the 5-HT2B receptor. This was supported by the observations of 
Ullmer et al., (1995) who demonstrated the presence of mRNA for this 
receptor in porcine pulmonary arteries. BW 723C86 has recently been 
described as the most selective 5-HT2B receptor agonist to date 
(Kennet et al., 1996). This compound did not eliCit any significant 
vasorelaxation in the rabbit PCAs in these stUdies, suggesting a lack 
of this receptor in mediating vasodilation in this preparation, in 
direct contrast to the porcine pulmonary artery. The observation that 
endothelial cell removal did not affect 5-HT agonist-induced 
vasorelaxation in the rabbit PCAs in these studies also provides 
evidence against the involvement of any 5-HT receptor located on the 
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endothelium. 
Recently, the novel 5-HT7 receptor has been described and has 
been found on the vascular smooth muscle of several preparations 
including the canine coronary (Terron, 1996) and cerebral arteries 
(Terron, 1998) and Cynomolgus monkey jugular vein (Leung et al, 
1996). In the rabbit, this receptor is thought to mediate the direct 
relaxation of the femoral vein (Martin & Wilson, 1995). This receptor 
is thought to mediate smooth muscle relaxation directly being 
located on the vascular smooth muscle. Several binding studies have 
previously shown that 5-HT and 5-CT display nM affinities for rat 
and human cloned 5-HT7 receptors (Bard et al., 1993; Ruat et al.. 
1993). Their pIC50 values in the adult rabbit PCAs in the studies 
described here (-6.5 for 5-HT and -7.6 for 5-CT) are similar to those 
mediating vasodilation in the canine coronary artery (-6.7 and -7.6 
for 5-HT and 5-CT respectively: Terron. 1996). This may highlight 
important differences between functional and cloned 5-HT7 receptors. 
Several antipsychotic drugs have been shown to behave as 
antagonists at this receptor. Spiperone displays a high binding 
affinity for the cloned 5-HT7 receptor (Roth et al.. 1994) and 5-HT7 
receptors located on vascular smooth muscle which stimulate 
adenylate cyclase and mediate vascular relaxation directly (Hoyer et 
al.. 1994: Leung et al., 1996). There was good agreement between 
spiperones antagonist affinity against 5-CT (pKB -6.8) and the 
antagonist affinity of spiperone in both the primate jugular vein (pKB 
-7.3; Leung et al.. 1996) and the canine coronary artery (pKB -6.9; 
Terron, 1996), strongly indicating that 5-HT receptor-induced 
vasodilation in pre-contracted adult rabbit PCAs is mediated via the 
5-HT7 receptor. Spiperone also has a high affinity for 5-HT2A 
receptors (Leff & Martin, 1986) but the presence of ketanserin in 
148 
these studies rules out 5-HT2A receptor-mediated effects. Further 
evidence for the presence of the 5-HT7 receptor in this study was 
provided by the antagonism by pimozide and rtspertdone of the 5-CT-
induced relaxation. Rispertdone markedly attenuated the response to 
5-CT in these vessels and has been shown to exhibit a high 
selectivity for the cloned 5-HT7 receptor (Roth et al.. 1994). In 
addition. results from chapter 5 of this thesis demonstrate that PRAs 
from 7 day old rabbits exhibit direct relaxation of the pulmonary 
artery. possibly through the 5-HT7 receptor. In common with the 5-
HT7 receptor. 5-HT6 receptors have also been shown to activate 
adenylate cyclase (Ruat et al., 1993), this second messenger action is 
consistent with direct smooth muscle relaxation. The presence of this 
receptor cannot be definitely ruled out because selective antagonists 
for the 5-HT6 receptor are not currently available. 
5-HT receptor-mediated responses in adult rabbit PEAs 
Endothelial cell inte~rity 
In contrast to the results of the studies in the adult rabbit 
PCAs, ACh was unable to evoke a relaxation response in the pre-
contracted adult rabbit PRAs. In some vessels, ACh induced a small 
vasoconstrictor response. This is in agreement with Sada et al.. 
(1987) who reported ACh-induced contraction in rabbit small 
pulmonary vessels. One pOSSibility for this is either a lack of 
endothelial muscarinic receptors which mediate the release of NO, or 
a predominance of contractile muscarinic receptors located on the 
pulmonary arterial smooth muscle which override any vasodilator 
effects of ACh in this preparation. ConSistent with this. earlier 
studies, using in situ hybridisation and autoradiographic mapping. 
demonstrated a predominance of muscarinic M4 -receptors in 
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pulmonary vessels of rabbit lungs (Mak, et al., 1993). Other agents 
known to cause endothelium-dependent relaxation such as 
substance P and A23187 were also without effect in the rabbit PRAs. 
The PRAs were not insensitive to NO however as the endothelium-
independent, NO-donating, vasodilator SNP evoked a concentration-
dependent relaxation in these vessels. 
Vasoconstrictor response to 5-HT 
The identity of the 5-HT receptors mediating 5-HT-induced 
vasoconstriction in adult rabbit pulmonary resistance arteries was 
investigated. In the absence of eNOS inhIbItion. the rank order of 
agonist potency was a-methyl-5-HT = 5-HT> 5-CT = sumatrlptan 
which is indicative of the presence of 5-1IT2 receptors. The antagonist 
studies. however indIcate that 5-HT may mediate its vasoconstrictor 
activity in adult rabbit PRAs via either a different receptor, or via a 
heterogeneous population of 5-HT receptors. Ketanserin normally has 
a nM affinity for the 5-HT2A receptor, acting as a competitive 
antagonist. In this study, however, the inhibition in the presence of 
ketanserin (O.IJ.lM; -7-fold decrease In sensitivity) was not as marked 
as would be expected if 5-HT was interacting solely with the 5-HT2A 
receptor. This is in contrast with the studies in the adult rabbit PCAs 
where ketanserin antagonised 5-HT-evoked contractions with nM 
affinity, and 5-HT mediated its effects exclusively via the 5-HT2A 
receptor. This suggests that there is a transition in 5-HT receptor 
subtypes mediating pulmonary arterial vasoconstriction in the rabbit 
from a single population in the large conductance vessels to a mixed 
population in the smaller pulmonary resistance arteries. This is 
discussed further below. 
One other possibility is that 5-HT may partly mediate 
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contraction in these vessels indirectly via activation of a-adrenergic 
receptors and this has been reported in rat pulmonary arteries 
(Ogawa et al., 1995). Docherty and MacLean (1998) recently reported 
that in adult rabbit PRAs, of equivalent size to those in this present 
study, the endogenous a-adrenoceptor agonist noradrenaline does 
not cause vasoconstriction. This suggests a lack of functional a-
adrenoceptors in these vessels. The involvement of these receptors in 
mediating the vasoconstrictor actions of 5-HT directly in the adult 
rabbit PRAs is, therefore unlikely. 
Influence of endothelium derived nitric oxide on 5-HT-induced 
contractions 
In this study, the results demonstrated that the NOS inhibitor 
L-NAME, increases the sensitivity to 5-lIT and 5-CT in adult rabbit 
small muscular, pulmonary resistance arteries. 
In previous studies, several investigators have reported an 
inhibitory effect of the endothelium and NO on 5-HT receptor 
mediated responses in several vascular preparations from the rabbit. 
In the rabbit 1solated saphenous ve1n, for example, responses to 5-
RT, 5-CT and sumatriptan were potentiated in the presence of the 
NOS inhibitor L-NAME (V alen tin et al., 1996) and in the absence of a 
functional endothelium, suggesting the endothelial release of NO 
counteracted the constr1ctor responses of 5-lIT receptor agonists. A 
similar observation was evident in the rabbit basilar artery where the 
removal of the endothelium markedly increased the sensitivity and 
maximum contractile response to 5-HT (Trezise, et al., 1992). L-
NAME has been reported to elevate pulmonary artery pressure and 
pulmonary vascular resistance in rabbit lungs in vitro (Wiklund et al., 
1990) suggesting a role for basal release of NO in maintaining low 
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resting pulmonary vascular tone in the rabbit. This could explain 
why L-NAME potentiated the contractile response to the 5-HT 
agonists in this present study. In human pulmonary arteries, L-
NAME has been shown to potentiate the vasoconstrictor responses to 
sumatriptan (MacLean et al., 1993) and in bovine pulmonary arteries 
5-HT1B or 5-HT1D receptor -mediated contractions with sumatriptan 
are also potentiated in the presence of L-NAME (MacLean et al., 
1994). One interpretation of the current studies is that 5-HT may 
cause release of NO in the adult rabbit PRAs via an endothel1um-
located receptor, thus masking the true vasoconstrictor effects in this 
preparation and in chapter 5 of this thesis this is demonstrated in 4 
day and 7 day old neonatal rabbit PRAs. This interpretation, however, 
is unlikely as I was unable to demonstrate any vasodilator effects of 
5-HT or 5-CT in pre-contracted adult rabbit PRAs. 
The role of basal NO in the pulmonary circulation 
seems to be dependent on species. For example, in the dog, L-NAME 
does not have any effect on pulmonary vascular resistance (Nishiwaki 
et al., 1992) whereas in the rabbit NOS inhibition was shown to 
increase the baseline pulmonary arterial pressure (Wiklund et al., 
1990). Importantly in man, infusing the NOS inhibitor L-NMMA 
results in an increased pulmonary vascular resistance (Stamler et al., 
1994) as well as a decrease in pulmonary blood flow (Celermajer et 
al., 1994). This suggests that basal NO plays an important role in 
maintaining a low pulmonary vascular tone in man. NO mediates its 
effects predominantly via the generation of the cyclic nucleotide 
second messenger cyclic 3 '5 '-guanosine monophosphate (cGMP; 
Ignarro, 1989). It is possible that cGMP may playa crucial role in the 
responsiveness of pulmonary arteries to the activation of receptors 
coupled to Gi-proteins, for example NOS inhibition, resulting in 
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decreased generation of cGMP, causes an unmasking of CX2-
adrenoceptor (Gi-linked receptor)-mediated vasoconstriction of rabbit 
isolated pulmonary arteries (MacLean et al., 1993a,b). As described In 
chapter 1 of this thesis, 5-HT1 receptors also mediate their effects via 
a Gi-coupled second messenger system. In accordance with this, 
responses to sumatriptan, working through Gi-coupled receptors, 
have been shown to be potentiated in both bovine and human 
pulmonary arteries when levels of cGMP are decreased through NOS 
inhibition (MacLean, et al., 1994; MacLean et al., 1993c). The results 
of the current studies also suggest that decreased cGMP levels are 
required to 'uncover' responses to 5-HT1 receptor mediated 
vasoconstriction and produce a pharmacological 'synergism' 
increasing 5-HT -induced vasoconstriction (MacLean et al., 1999). The 
importance of this pathophysiologic ally in pulmonary hypertension is 
highlighted by the fact that in the CHPHT rat, decreased levels of 
cGMP (along with elevated tone) have been reported (MacLean et al., 
1996) along with an increased 5-HT1 B receptor-mediated 
vasoconstriction in isolated pulmonary arteries. In chapter 6 of this 
thesis this phenomenon was investigated more fully in the normal 
and CHPHT rat. 
In the presence of NOS inhibition, the agonist potency order in 
the adult rabbit PRAs was 5-HT = cx-methyl-5-HT ~ 5-CT > 
sumatriptan which is not typical for a single population of 5-HT 
receptor subtype (Hoyer et al., 1994). These findings are also in 
contrast to the 5-HT agonist potency order in the adult rabbit PCAs 
described earlier in this chapter, which, along with the antagonist 
studies, provided evidence for the presence of a single population of 
5-HT receptors mediating 5-HT-induced vasoconstriction, namely the 
5-HT2A receptor. Even in the presence of L-NAME, the results with 
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ketanserin and GR55562 in the adult rabbit PCAs strongly suggested 
a single population of 5-HT2A receptors exclusively mediated the 
vasoconstrictor action of 5-HT. The established criteria for 5-HTI-
receptor mediated responses. in terms of agonist potency order. is 5-
CT > 5-HT ~ sumatriptan ~ a-methyl-5-HT (Hoyer et al.. 1994). 
Clearly, in the rabbit PRAs. this was not the case. It is possible that 
the adult rabbit PRAs express a heterogeneous population of 5-HT 
receptors contributing to 5-HT-evoked vasoconstriction. Evidence for 
this co-existence of different vasoconstrictor 5-HT receptor subtypes 
exists in other rabbit vascular tissues including the cerebral arteries 
(Deckert et al., 1994; Ellwood & Curtis, 1997). It is shown here that 
in the adult rabbit PRAs, ketanserln inhibited responses to 
concentrations of 5-HT greater than 30nM. Responses elicited by 
lower concentrations of 5-HT were resistant to ketanserin (lOnM & 
0.1 J,lM). This does suggest the involvement of two 5-HT receptor 
populations evoking vasoconstriction in these arteries; non-5-HT2A 
receptors activated by low concentrations of 5-HT and 5-HT2A 
receptors activated by higher concentrations. Furthermore. GR55562 
antagonized responses to all concentrations of 5-HT, including those 
which were ketanserin resistant, suggesting that a significant 
population of 5-HT1B or 5-HflD receptors contributes towards 5-HT-
induced vasoconstriction. Hence, in the adult rabbit PRA, both the 5-
HT2A receptor and either the 5-HT1B receptor or the 5-HrlD receptor 
mediate vasoconstriction. Recently. in a study of cloned rabbit 5-
HT1B and 5-HT1D receptors Bard et al (1996). reported that 
ketanserin has an affinity for 5-HTIB/ID receptors at submicromolar 
concentrations. Ketanserin showed approximately 23-fold selectivity 
for 5-HTID receptors over 5-HTIB receptors. These findings indicate 
that, at the higher concentration of ketanserin used in the present 
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study (1jlM). 5-HTID receptors would have been greatly antagonised. 
The observation that IjlM ketansertn antagonized the response to 5-
HT in the PRAs suggests that a population of 5-HTID receptors may 
also be present in these vessels. The involvement of a population of 
5-HTID receptors in mediating 5-HT-induced vasoconstriction in 
adult rabbit PRAs is discussed further below. The study by Bard et al 
(1996) also reported that human and rabbit recombinant 5-lITIB and 
5-HTID receptors display a significant interspecies similarity in their 
ligand binding profiles. suggesting that responses in rabbit 
preparations mediated by these two receptors may provide 
information that is relevant to the pharmacology of the 5-HTIB or 5-
HTID receptor in man. In human large pulmonary arteries strong 
evidence exists that it is the 5-HTIB or the 5-IITlD receptor which 
mediates vasoconstriction. Templeton et al.. (1993; 1994) have shown 
previously that the 5-HTI receptor agonist 5-CT is more potent than 
5-HT and that sumatriptan is eqUipotent to 5-HT in these vessels. 
indicative of a 5-HTIB receptor mediated response. More recently. the 
5-HTID and 5-lITIB receptor antagonist GR55562 was shown to 
inhibit both 5-HT and sumatrtptan-induced contractions in a true 
competitive manner; whereas. the selective 5-HT2A receptor 
antagonist ketanserin and the non-selective antagonist methlothepln 
did not affect the sensitivity of these agonists (MacLean et al.. 
1996b). this was subsequently confirmed by Cortijo et al .• (1997). 
In chapter 4 of this thesis. the importance of the 5-HTIB 
receptor in mediating 5-HT-induced contractions in human small 
pulmonary arteries was demonstrated and recent RT-PCR analysis 
detected a strong signal of the mRNA transcript for the 5-HTIB. but 
not the 5-HTID receptor. in these vessels (Morecroft et al.. 1999). In 
the adult rat PRA. both the 5-HT2A receptor and the 5-HTIB or the 5-
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Hl)J) receptor mediate vasoconstriction but it is the 5-HT2A receptor 
which dominates (MacLean et al., 1996). Hence, there is species 
variation in the 5-HT receptor / s mediating vasoconstriction in small 
muscular pulmonary arteries. In chapter 5 of this thesis, the results 
demonstrated that 5-HT mediates its vasoconstrictor action in PRAs 
of perinatal rabbits, predominantly via the 5-HT2 A receptor type, 
thus providing evidence for a maturational change in receptors 
mediating 5-HT-induced pulmonary arterial vasoconstriction within 
the same species. 
Until recently, the pharmacological profile of the 5-HT1D and 
5-HT1B receptor was almost identical, both acting as Gi-protein 
coupled receptors with the majority of agonists and antagonists being 
non-selective for both receptor subtypes. SB224289 has recently been 
reported as a selective antagonist with high affinity for the 5-HT1B 
receptor (Roberts et al., 1997; Verheggen et al., 1998) and BRL 15572 
as a selective antagonist at the 5-HT1D receptor (Price et at, 1997; 
DeVries et al., 1999). In the results of the studies of this chapter, 
both compounds antagonised the 5-CT-induced contractions in the 
adult rabbit PRAs, SB224289 being more potent than BRL15572. It 
was difficult to obtain an accurate estimate of the affinity of either of 
these compounds from the experiments. Both displayed a non 
parallel rightward shift in the CeRC to 5-CT suggesting the presence 
of both the 5-HT1B and 5-HT1D receptors in this preparation. One 
interpretation of the data with SB224289 could be that this 
compound was inhibiting 5-HT2A receptor-mediated effects at the 
higher concentrations of 5-CT. This Is unlikely as this antagonist 
exhibits a low affinity for recombinant 5-HT2A receptors (Roberts et 
al.., 1997). 
The results in this chapter with BRL15572 are in contrast to 
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those described in chapter 4 in human PRAs where BRL15572 was 
without any significant effect. Some investigators have suggested 
that the predominant 5-HT1 receptor mediating vascular contraction 
is the 5-HT1B receptor subtype given that molecular studies display a 
predominance of expression of this subtype over that of the 5-HT1D 
subtype in vascular tissue (Hamel et al., 1993: Verheggen et al., 1998: 
Nilsson et al., 1999). Furthermore, DeVries et al (1998) have shown 
that SB224289 but not BRL15572 blocks 5-HT-induced decrease in 
canine external carotid blood flow in vivo. Coupled with evidence from 
in vitro pharmacology (Verheggen et al., 1998): these findings provide 
strong evidence for the importance of the 5-HT1B receptor over the 5-
HT 1 D receptor in mediating 5-HT1 receptor activated 
vasoconstriction. In the studies in the adult rabbit PRAs however, 
involvement of the 5-HTID receptor can not be completely ruled out. 
As mentioned earlier, the overall pulmonary arterial response 
to 5-HT will be dependent on the 5-HT receptor subtype, vascular 
location and underlying pulmonary vascular tone. As there was no 
evidence for 5-HT receptor mediated vasodilation in the adult rabbit 
PRAs, neither in the presence or absence of NOS inhibition, it is 
probable that the 5-HT-mediated contractile response would 
predominate over any vasodilator response in vivo in the rabbit 
pulmonary circulation. This has been confirmed by Deuchar et al 
(1998), who reported that 1.v. administration of 5-HT resulted In a 
Significant, concentration dependent increase in pulmonary artery 
pressure above baseline in the anaesthetised rabbit. 
One well characterised model of left ventricular dysfunction 
(LVD) is the rabbit coronary-ligation model (Pye et al., 1996: Denvlr, 
et al., 1996) which has recently been reported as a model for 
pulmonary hypertension secondary to LVD (Deuchar et al., 1998) 
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where the authors reported elevated baseline pulmonary arterial 
pressure and a supersensitivity to 5-HT administration compared to 
control, sham-operated rabbits. Given that the studies in this 
chapter have demonstrated the presence of 5-HTIB, also 5-HT2A and 
possibly 5-HTID receptors in mediating vasoconstriction in the 
pulmonary resistance arteries of the adult rabbit, further 
examination, using the selective agonlsts and antagonists, of the role 
of 5-HT and its receptor subtypes in this model of PHT is warranted. 
In conclusion, this study suggests that there is heterogeneity of 
5-HT receptor subtypes mediating vasoconstriction in the pulmonary 
arteries of the adult rabbit along the pulmonary arterial tree. The 
larger conduit pulmonary arteries contain a single population of the 
5-HT2A receptor subtype which mediate a potent vasoconstriction in 
this preparation. 5-HT receptor-mediated vasoconstriction in these 
PCAs is not affected by endothelium derived NO or endothelium 
removal. The PCAs also contain a functional population of 5-HT 
receptors which mediate vasodilation in these vessels when pre-
constricted and possibly mediate this action via the newly described 
5-HT7 receptor. In contrast, the results in the adult rabbit 
pulmonary resistance arteries are consistent with the mediation of 5-
HT-induced vasoconstriction through two receptor populations, 
namely the 5-HT2A receptor and 5-HTIB receptor. The 5-HTl 
mediated responses are markedly influenced by the presence of 
endothelium-derived NO. This study highlights the importance of 
heterogeneity within the pulmonary circulation with regard to 5-HT 
receptors and underlines the importance of determining 
independently the 5-HT pharmacology of the pulmonary arteries that 
determine pulmonary vascular resistance especially in PHT, namely 
the small muscular pulmonary resistance arteries. 
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Chapter 4 
5-Hydroxytryptamine (5-HT) receptors mediating 
contraction in human small muscular pulmonary 
arteries 
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4.1 Introduction 
Several studies have suggested a role for 5-lIT in the aetiology 
of pulmonary hypertension. As described in chapter 1 of this thesis. 
5-HT is released from pulmonary neuroendocrine cells and from 
neuroepithelial bodies distributed throughout the airways. Secretion 
of large amounts of 5-lIT from these cells has been shown to occur in 
response to airway hypoxia and therefore may contribute to 
secondary pulmonary hypertension (Johnson & Georgieff. 1989; 
Gould et al.. 1983). Elevated plasma levels of 5-lIT have been 
reported in primary PlIT (Herve et al .• 1990; 1995) and isolated 
pulmonary arteries from PHT patients undergoing lung 
transplantation exhibit augmented vasoconstrictor responses to 5-
lIT (Brink et at 1988). 5-lIT is also linked to hypoxia-induced PlIT in 
new-boms (Johnson & Georgieff. 1989) where a 34-fold increase in 5-
HT-immunoreactive cells has been demonstrated and recently. 
increased 5-HT turnover has been observed in children with PlIT 
secondary to congenital heart disease (Breuer et al.. 1996) as 
explained in chapter 1 of this thesis. 
5-HT may promote pulmonary vascular smooth muscle cell 
proliferation as well as pulmonary arterial vasoconstriction and local 
micro thrombosis (Fanburg & Lee. 1997). 
Ketanserin. the classic 5-lIT2A receptor antagonist. has had 
limited success in the treatment of pulmonary hypertension. for 
example in pulmonary hypertenSion secondary to platelet storage 
pool disease (Herve' et al.. 1990). Ketanserins' use. however. is based 
on the assumption that 5-HT2A receptors mediate vasoconstriction 
in the human pulmonary circulation. A considerable amount of 
evidence exists to suggest that other 5-HT receptors may play an 
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important role in mediating 5-HT-induced pulmonary arterial 
vasoconstriction. 
In 1992. McIntyre and colleagues studied the effect and 
duration of the 5-HTIB and 5-HTID agonist sumatriptan on central 
haemodynamics and the coronary circulation in patients undergoing 
diagnostic coronary angiography. Systemic and pulmonary pressures 
were also measured. Sumatriptan produced a more pronounced 
vasopressor effect on the pulmonary pressure when compared with 
overall systemic pressure. suggesting the preferential involvement of 
the 5-HTIB/ID receptor in vasoconstriction of human pulmonary 
arteries. This was subsequently supported by MacLean et al (1996b) 
who provided evidence that 5-HT is a potent human pulmonary 
artery vasoconstrictor and that 5-HT-induced vasoconstriction in 
isolated human large pulmonary arteries is mediated. in part. 
through a 5-HTI receptor thought to be either the 5-HTIB or the 5-
HTID receptor (MacLean et al.. 1996b). In these human large PAs, 
the 5-HTIB & ID-selective antagonist GR55562 was the only 
antagonist tested that produced a true competitive antagonism of 
responses to both 5-HT and sumatriptan. These results were later 
supported by Cortijo et al., (1997). Using RT-PCR, Ullmer et al., 
(1995) identified the mRNA for 5-HTIB. 5-HT2A. 5-HT7 and 5-HT2B 
receptors in cells isolated from human large pulmonary arteries. 
In the pulmonary hypertensive state, it is the small muscular 
pulmonary resistance arteries, however, which are the major 
contributors to increased pulmonary vascular resistance (Singhal et 
al.. 1973). Frid et al. (1997) demonstrated that the vascular smooth 
muscle cells of the human small muscular pulmonary resistance 
arteries are distinctly different phenotypically from those of the larger 
pulmonary arteries. In addition. McCulloch et al. (1996) and Maclean 
et al. (1994b) previously demonstrated a distinct heterogeneity 
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within the pulmonary circulation with regard to endothelin 
receptors, highlighting the observation that the pharmacology of 
small pulmonary arteries must be determined independently. Thus 
the aim of this chapter was to investigate the 5-HT receptor subtypes 
in human small muscular pulmonary arteries using several 5-lIT 
receptor antagonists. The functional responses to 5-HT-receptor-
evoked vasoconstriction in human small muscular pulmonary 
arteries (smPAs) were therefore examined using 5-HT, 5-CT (5-HTI 
non selective agonist) and sumatriptan. The 5-HT receptor 
antagonists used to characterise the 5-HT receptors mediating 5-lIT-
induced vasoconstriction were the 5-HT2A-selective antagonist 
ketanserin (Leysen, et at. 1982) the potent and selective 5-HTIB and 
5-HTID antagonist GR55562 (Connor et at, 1995), the novel 5-lITUr 
selective antagonist 8B224289 (Verheggen et at, 1998) and the 5-
HTID receptor selective antagonist BRL15572 (Price et al., 1997). 
Using RT-PCR to compliment these pharmacological studies, 
Morecroft et al., (1999) determined If the mRNA for the 5-IIT2A, 5-
HTIB and 5-HTID receptors was present in these vessels obtained 
from the same lung tissue samples. The results of that study are also 
presented here for direct comparison. 
4.2 Methods 
Human small muscular pulmonary arteries 
Human peripheral lung tissue was obtained postoperatively 
from patients undergoing surgery for bronchial carcinoma (described 
In section 2.1.3) at the Western Infirmary, Glasgow and the Royal 
Infirmary, Glasgow. Human small muscular, intralobar pulmonary 
arteries (- 250-300jlIll internal diameter) were promptly dissected out 
162 
from macroscopIcally normal samples of the lung tissue (see section 
2.1.3). The smPAs were mounted as ring preparations (2mm long) on 
an isometric wire myograph, bathed at 370 C with a constant supply 
of 16%02/5%C02 (balance N2). Using the procedures for 
normalisation explained in chapter 2, tension was applied to the 
vessels to gIve a transmural pressure equIvalent of apprOXimately 12-
16 mmHg. which is similar to in vivo pressures of pulmonary arteries. 
All vessels were studIed within a 12 hour postoperative time period. 
Experimental Protocols 
Following a 45-60 minute equilibration period under these 
condItions. the response of the smPAs to 50mM KCI was determIned 
twice. When the contractile response to KCI had plateaued. the 
vessels were washed out a minimum of 6 times with fresh Krebs 
solution and further equilibration for 45-60 minutes. The endothelial 
cell integrity of the vessels was assessed by contraction with a sub-
maximal concentration of phenylephrine (O.I~M) and subsequent 
addition of acetylcholine (ACh; 1 f.1M) once the contraction had 
plateaued. Only vessels displaying >70% relaxation were deemed as 
having an intact endothelium and used in the following studies. 
Upon washout (6 times with fresh Krebs) a further minimum 45 
minutes equilibration was allowed either in the absence or presence 
of a selected concentration of a 5-HT antagonist. Cumulative 
concentration response curves (CCRes) were then determined in the 
human smPAs for 5-HT. 5-carboxamidotryptamine. or sumatriptan. 
All CCRCs were performed in the ligand concentration range InM-
300~. 
CCRCs to 5-HT and sumatriptan were determined in the 
presence of the 5-HT2A receptor antagonist ketansertn (O.I~M), or 
the 5-HTIB/ID receptor antagonist GR55562 (l~M). CeRes to 
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sumatrtptan were determined in the presence of the 5-HTIB receptor-
selective antagonist SB224289 (O.2J,1M) or the 5-HTID receptor-
selective antagonist BRL15572 (O.5IlM). Concentrations of the 
various antagonists were selected from previous studies in other 
vascular preparations (see glossary III, p XXVII). 
Due to limitations of intermittent availability of tissue and in 
equipment and time it was not always possible to perform a control 
CCRC to a particular 5-HT agonist whilst stUdying the different 
antagonists. The data for the control curves have therefore been 
pooled over several protocols. No s1gn1ficant differences, however, 
were found in the control responses to the agonists when studied 
over the whole period of investigation. It was unfortunately not 
possible to study a range of antagonist concentrations in each tissue 
again due to the above mentioned constraints. 
Analysis of data. 
pEC50 values were calculated according to methods stated 1n 
chapter 2 and estimated pKB values calculated assuming the 
antagon1sts behaves 1n a competitive manner and a maximum 
response to the agon1st is ach1eved in the concentration range 
studied. Apparent pKB values were calculated for a s1ngle stated 
concentration of antagonist according to the methods desCribed in 
chapter 2. Result are expressed graphically as a percentage of their 
own maximum contraction, or as percentage of the reference 
contraction to the second application of 50mM KCl. Statistical 
analys1s for the means of groups of data were made by Student's 
unpaired t test or where appropriate, one-way analysis of variance 
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(ANOVA) followed by an ad hoc post test; a P<0.05 was considered to 
be statistically significant. Throughout the results. data are 
expressed as mean ± SEM. n/n = number of ring preparations/ 
number of lung samples. 
Results 
The effective pressure to which the human smPAs were tensioned. 
along with the resulting measurement of internal diameter are shown 
in table 4.1. 
en) Internal diameter Effective pressure 
(Jlm) (rnrnHM 
Human srnP As 15~ 243.9 ± 9.1 17.2±O.5 
Table 4.1 Internal diameter and effective pressure of human smPAs 
studied in this chapter. Values are mean ± s.e.mean. n = number of 
vessels. 
50 mM KCI induced a contraction of 202 ± 21 mg wt tension 
(l.98 ± 0.21 mN) in a representative 36 vessels from at least n = 6 
patients. 
Endothelium inte~r1ty 
IJlM ACh evoked a 74 ± 70/0 reversal of O.IJlM PE-induced 
contraction; which induced a contractile response of 28 ± 4% of the 
reference contraction to 50mM KCl. 
5-lIT a@nists 
Figure 4.1 shows that the agonists 5-HT. 5-CT and 
sumatriptan produced concentration-dependent contractions in 
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human small muscular pulmonary arteries with pEC50 values of 7.0 
± 0.2, 7.1 ± 0.3 and 6.7 ± 0.1 respectively. There was no significant 
difference in the potency of these agonists in the smPAs. The 
corresponding maximum contractile responses for these agonists 
were 112 ± 19%, 62 ± 11% and 106 ± 100/0 (of the maximum response 
to 50mM KCl) and were not significantly different. The potency of the 
5-lITl agonists strongly indicated the presence of vasoconstrictor 5-
fITl receptors in these vessels. 
Effect of 5-HT anta~onists on 5-HT-receptor-induced contraction of 
human small muscular pulmonruy arteries 
All pEC values for 5-lIT and sumatrtptan in the presence of 
specific antagonists are summarised in Table 4.2. 
Ketansertn (vs. 5-HTl 
Figure 4.2 shows that ketansertn caused significant inhibition 
of 5-HT-evoked vasoconstriction at 5-HT concentrations> O.IIlM but 
was without effect at lower concentrations of 5-lIT. This significant 
inhibition at 5-HT concentrations> O.IJ.lM can be clearly seen in 
Figure 4.2B (P<0.05 at 0.3, 1.0 and 10llM and P<O.OOI at 3J.1M) where 
the maximum contraction evoked by 5-lIT was reduced from 107 ± 
11 % (reference contraction to 50mM KCI (control)) to 49 ± 7% (in the 
presence of 0.11lM ketansertn); hence an estimate of the pKB value 
could not be made for ketanserin against 5-lIT-induced contraction 
in human smPAs. Ketanserin did not significantly affect the 
sensitivity to 5-IIT (figure 4.2A; table 4.2) where the pEC50 value for 
166 
A 
-
120 
E 
::::J 
E 100 
>< 
co 
E 80 
c: 
== 60 0 
~ 0 
-
40 
Q) 
C/) 
c: 20 0 
C. 
en 
Q) 0 a: 
-11 -10 -9 -8 -7 -6 -5 -4 -3 
Agonist (log M) 
B 
150 
-() 125 T ~ T 
== T E 100 
0 
It) 
~ 0 75 
-Q) 
C/) 50 t: 
0 
C. 
C/) 25 Q) 
a: 
0 
-11 -10 -9 -8 -7 -6 -5 -4 -3 
Agonist (log M) 
Figure 4.1 Vasoconstrictor responses to 5-HT receptor agonists in 
human smPAs. Responses to 5-HT (., n = 9). 5-CT (e, n = 5). and 
sumatriptan (0, n = 11) are shown. A Data are expressed as a 
percentage own maximum contraction B Data are expressed as a 
percentage of the reference contraction to 50mM KCl in each vessel 
and shown as mean ± s.e.mean. n = number of patients. 
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5-HT which was 7.0 ± 0.1 in the presence of ketanserin and 7.0 ± 0.2 
in its absence. The sensitivity of 5-HT at the level of pEC 10 and 
pEC25 was not significantly affected in the presence of ketanserin 
(Table 4.2). 
GR55562 vs. 5-HT 
The effect of GR55562 on 5-HT-induced vasoconstriction in 
human smPAs is shown in figure 4.3. pEC 10. pEC25 and pEC50 
values are summarised in Table 4.2. GR55562 (ljlM). In these vessels. 
GR55562 produced a concentration dependent inhibition of the 
responses to 5-HT (see figure 4.3C). including the 'ketanserin-
resistant' component. The estimated pKB value was 7.7 ± 0.2. The 
maximum response to 5-HT in the presence of 1.0j.1M GR55562 was 
72 ± 17 % which was not significantly different to the control 
maximum response to 5-HT (107 ± 11 % reference contraction to 
50mM KCI) In these human small muscular pulmonary arteries. 
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Figure 4.2 Effect of ketanserin on 5-HT-induced responses in human 
smPAs. CCRCs to 5-HT ( •. n = 7/7) and in the presence of l.OIlM (0. 
n = 6/6) ketanserin. Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage 
reference contraction to 50mM KCl. Each point represents mean ± 
s.e.mean. 
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Fi~ure 4.3 Effect of GR55562 on 5-HT-induced responses in human 
smPAs. CCRCs to 5-HT (0, n = 7/7) and in the presence of l.O/-lM (_, 
n = 6/6) GR55562. Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage 
reference contraction to 50mM KCl. Each point represents mean ± 
s.e.mean. 
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Ketansertn and GR55562 (vs. sumatriptan) 
Figure 4.4 shows that ketanserin did not significantly affect 
the sumatriptan-induced vasoconstriction in the human smPAs. 
Ketansertn had no significant effect on the sensitivity to sumatrtptan 
in these vessels (figure 4.4A; table 4.2) nor was there any Significant 
change in the magnitude of the maximum response to sumatriptan 
in the presence of O.l~M ketansertn (figure 4.4B). GR55562. however. 
almost totally abolished the responses to sumatriptan in these 
vessels (figure 4.4B). 
8B224289 and BRL15572 (vs. sumatrtptanl 
Figure 4.5 shows the effects of the 5-HTIB receptor selective 
antagonist 8B224289 and the 5-HTID receptor selective antagonist 
on sumatriptan-induced vasoconstriction in human smPAs. 
8B224289 acted as a potent antagonist against the sumatrtptan-
induced vasoconstriction. Assuming that sumatriptan reached a 
maximum contractile response in these vessels in the presence of 
8B224289 (82 ± 6% at 300~M sumatriptan). the estimated pKB value 
for this novel antagonist against sumatriptan was 8.4 ± 0.1. In 
contrast. BRL15572 did not significantly alter the sensitivity to 
sumatriptan (figure 4.5: table 4.2) but appeared to reduce the 
contractile response to sumatriptan at concentrations > l~M in 
these vessels although this was not shown to be statistically 
significant. The high blocking potency of 8B224289 against the 
vasoconstrictor effects of sumatriptan suggests that they are 
mediated via the 5-lITIB receptor and not the 5-lITID receptor. 
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Fi~ure 4.4 Effect of selective antagonists on sumatriptan-induced 
responses in human smPAs. CCRCs to sumatriptan (0. n = 11/11) 
and in the presence of O.lI1M ( •. n = 6/6) ketanserin and l.OI1M (e. 
n = 5/5) GR55562. Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage 
reference contraction to SOmM KCl. Each point represents mean ± 
s.e.mean. 
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Fillure 4.5 Effect of selective antagonists on sumatriptan-induced 
responses in human smPAs. CCRCs to sumatriptan (D. n = III II) 
and in the presence of O.2IlM ( •. n = 4/4) SB224289 and O.5IlM 
BRL15572 (e. n = 4/4). A Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage 
reference contraction to 50mM KCl. Each point represents mean ± 
s.e.mean. 
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n pEClO p EC25 pEC50 
5-HT 7 8.1 ± 0.1 7.6 ± 0.1 7.0 ± 0.2 
5-HT + 7 8.3 ± 0.1 7.7 ± 0.1 7.0 ± 0.1 
O.l~M ketanserin 
5-HT + 
1.0 ~M GR55562 6 6.3 ± 0.2*** 5.9 ± 0.2*** 5.4 ± 0.2*** 
Sumatriptan 11 7.8 ± 0.2 7.3 ± 0.2 6.7±0.1 
Sumatriptan + 0.1~M 6 7.8 ± 0.3 7.3 ± 0.2 6.8 ± 0.1 
ketanserin 
Sumatriptan + 4 6.7 ± 0.2*** 6.0 ± 0.2** 5.1 ± 0.3*** 
0.2~M SB224289 
Sumatriptan + 4 7.6 ± 0.3 7.2 ± 0.3 6.9 ± 0.3 
0.5~M BRL 15572 
Table 4.2 Effect of ketanserin, GR55562, SB224289, and BRL15572 
on sensitivity to 5-HT and sumatriptan in human smPAs. Statistical 
analysis made by Students un-paired t-test: antagonist vs. 
appropriate control **P<O.Ol, ***P<O.OOI. Values expressed as mean 
± s.e.mean. 5-HT, 5-hydroxytryptamine. n, number of vessels/lungs. 
175 
Discussion 
The present results presented in this chapter are consistent 
with the 5-HflB- and 5-Hf2A-receptors mediating vasoconstriction in 
isolated human smPAs via two different receptor populations. 5-Hf, 
5-CT and sumatriptan are eqUipotent, confirming, and satisfying one 
of the criteria for, the presence of 5-IITI-like receptors (Bradley et al., 
1986). This has also been shown by previous studies in human 
conduit pulmonary arteries (MacLean et al., 1996b). Responses to 5-
lIT at concentrations < O.IJ.lM and to sumatriptan (InM-300J.lM) were 
inhibited by GR55562 but resistant to ketanserin. responses to 5-lIT 
at concentrations> O.1J.lM were inhibited by ketanserin. Responses 
to sumatriptan were inhibited by the 5-HTIB receptor-selective 
antagonist 8B224289 but not by the 5-HTID receptor selective 
antagonist BRL15572. Substantial amounts of mRNA for 5-HTIB 
and 5-Hf2A receptors has been detected in human smPAs isolated 
from lung tissue of the same patients (Morecroft et a~ 1999). Figure 
4.6, from this complimentary study, shows that signals of mRNA 
transcripts for all of the vasoconstrictor 5-HT receptor subtypes 
investigated in pharmacology experiments; 5-HTID, 5-HTIB and 5-
fIT2A, were found in intact human smPAs. 5-HTIB and 5-HT2A mRNA 
transcripts were conSistently detected in all arteries studied. Figure 
4.6 shows typical RT-PCR signals of the expected size for each 
receptor, which was Similar in 6/6 patients. Compared to 5-HTIB and 
5-HT2A receptors, only weak signals corresponding to the mRNA 
transcript for the 5-HTID receptor was detected. 
In this chapter whole human small muscular pulmonary 
arteries comprised of a heterogeneous population of adventitial, 
smooth muscle and endothelial cells were studied. As 5-HTl 
receptors have previously been identified on vascular endothelium 
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M + + + (RT) 
Figure 4.6 RT-PCR detection of selected 5-HT receptors expressed 
in human small muscular pulmonary arteries. Lanes 2,4 and 6; 
5-HT1D (239 bpI, 5-HT1B (213 bpI and 5-HT2A (309 bpI receptor 
signals respectively. Lanes 3, 5 and 7, RT-negative controls: +, 
MMLV(+); -, MMLV (-). RT, reverse transcribed; MMLV, murine 
moloney leukaemia virus. 
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of other vascular preparations and can indirectly mediate 
vasodilation by a NO dependent process (Gupta, 1992; Ulmer et al., 
1995). it would have been advantageous to study endothelium-
denuded vessels. The vascular endothelium of these small. delicate 
arteries could not be removed as experience dictates that any attempt 
to remove the endothelium by mechanical disruption results in 
significant damage to, and reduction of, the smooth muscle layer. 
This is due to the relative sparsity and fragility of the vascular 
smooth muscle cells in the pulmonary arterial Circulation (Brenner 
1935; Frid et al., 1997). The lung tissue received for these studies was 
routinely taken from the lung periphery and therefore the arterial bed 
could not be perfused with detergents or other agents to successfully 
remove the endothelium. The RT-PCR experiments described in 
Morecroft et al., (1999) were, however, able to confirm that 5-HTIB 5-
HT2A and 5-HTID receptor mRNA was transcribed in the whole 
human small muscular pulmonary arteries. Only trace levels of the 
5-HTID receptor mRNA transcript appeared to be present compared to 
those of the 5-HTIB and 5-HT2A receptors. This is, therefore 
consistent with the pharmacological characterisation studies in this 
chapter and together provide strong evidence that both the 5-HTIB 
receptor and 5-HT2A receptor mediate vasoconstriction in these 
vessels. The receptor antagonist GR55562 is selective for both the 5-
HTIB and 5-HTID receptors. The PKB value of 7.7 for GR55562 
against 5-HT is consistent with previous observations in large 
human pulmonary arteries (MacLean et al., 1996b) where GR55562 
(at l.OIlM) was found to have a PKB value of -7.0, consistent with 
studies in other vascular preparations (Connor et al., 1995). Cloned 
and transfected 5-HTID receptors have been shown to have a higher 
affinity for ketanserin with a Kn value about 200nM compared to the 
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5-HTIB receptor with a KD value of about 10 JlM (Kaumann et al.. 
1994). In a study of rabbit cloned 5-HTIB/ID receptors, Bard et al. 
(1996) reported that ketanserin displayed -23-fold selectivity for 5-
HTID receptors over 5-HTIB receptors. In the studies described in this 
chapter, ketanserin did not, however inhibit the 5-HT-induced 
contraction at 5-HT concentrations < O.IJlM or the sumatriptan-
evoked contraction, suggesting that 5-HTID receptors do not 
significantly contribute to vasoconstriction in preparations of human 
small muscular pulmonary artery. This is confirmed by the 
observation that BRL15572, the 5-HTID receptor selective 
antagonist, at O.5JlM, did not inhibit contractions to the 5-HTIB and 
5-HTID receptor agonist sumatriptan at concentrations < IJlM. At 
sumatriptan concentrations> IJlM, BRL15572 (0.5JlM) appeared to 
cause a slight inhibition, the reason for this is uncertain. At high 
concentrations (> IJlM) sumatriptan may mediate vasoconstriction 
through the 5-HTID receptor and the presence of 5-HTID mRNA in 
these vessels, albeit in trace amounts, suggests this may be possible. 
However, as discussed below, it is the 5-HTIB receptor that is of 
physiological importance in mediating 5-HT -induced vasoconstriction 
in these vessels. This concentration of BRL15572 is selective for the 
5-HTID receptor with a 60 fold lower affinity for the 5-HTIB receptor 
(Price et at, 1997). 
In view of the fact that the contractile effects of high 
concentrations of 5-HT in some blood vessels may be mediated by a 
direct action on (l-adrenoceptors (Black, et al., 1981: Fenuik, 1984) 
including pulmonary arteries (Ogawa, et al., 1995), the possibility 
that 5-HT may mediate, at least partly, its contractile effects via (l-
adrenoceptors cannot be strictly ruled out in the human PRAs. 
However this is unlikely as sumatriptan and 5-CT, which are not 
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known to activate a-adrenoceptor. contracted the human PRAs in 
this present study with a similar potency and magnitude as 5-HT. 
It has also been reported that high concentrations of 5-HT can 
have indirect sympathomimetic actions by releasing noradrenaline 
(McGrath. 1977; Saxena & Villalon. 1990). The possibility that 5-HT 
and its agonlsts elicit contractions at high concentrations by 
releasing NA from sympathetic nerve endings cannot be ruled out. It 
is probable. however. that 5-HT is not involved in the modulation of 
sympathetic neurotransmission in the human pulmonary 
vasculature as no pre-junctional 5-HT receptors have been identified 
in the human pulmonary artery (Freeman. Rorie & Tyce. 1981). 
The estimated pKB of 8.4 for SB224289 against sumatriptan in 
human small muscular pulmonary arteries Is Similar to the affinity 
(pKi = 8.1) reported by Roberts et al.. (1997) for sumatriptan in 
binding to recombinant 5-HT1B receptors. This provides further 
evidence that 5-HTIB receptors playa significant role in mediating 5-
HT-induced vasoconstriction in human small muscular pulmonary 
arteries. Although sumatrtptan at very high concentrations. can 
mediate its vasoconstrictor effect through 5-HT2A receptors 
(Peroutka & McCarthy. 1989). SB224289 at 0.2jlM IS unlikely to 
interact significantly with 5-HT2A receptors in this study because 
SB-224289 has a low affinity (pKi -5.8) for recombinant human 5-
HT2A receptors (Roberts et at. 1997). 
The normal plasma concentration range for 5-HT in man has 
been reported as 1-2nM (Anderson et al.. 1987). Herve et al .. (1990; 
1995) recently reported that plasma concentrations of 5-HT can be 
significantly elevated to - 30nM In primary PHT. The results of this 
study show that 5-HT induced vasoconstriction in human small 
muscular pulmonary arteries only at concentrations greater than 
3nM and that responses to 5-HT up to -O.ljlM are ketanserin 
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resistant. It is reasonable, therefore, that the 5-HTIB receptor is 
likely to be responsible for mediating pulmonary arterial 
vasoconstriction in man at pathophySiological concentrations of 5-
HT. This probably explains why ketanserin has been shown to be of 
very limited use in the treatment of both primary and secondary 
pulmonary hypertenSion patients (Dominighetti et al., 1997: Herve" et 
al., 1990) where side effects such as marked systemic hypotenSion 
are common. The results presented in this chapter therefore highlight 
the possibility of a more 'pulmonary-selective' 5-IIT-receptor subtype. 
The 5-IITIB receptor may therefore provide an important therapeutic 
target in the treatment of PHT. From the results here, the 5-HT2A 
receptor would only mediate pulmonary arterial vasoconstriction if 
local concentrations of 5-HT in the pulmonary vascular bed were to 
exceed O.I~M in pulmonary disease. This possIbility, however, cannot 
be completely ruled out if there is concomitant local platelet and 
neuroendocrine body release of 5-HT in the lung (Johnson & 
Georgieff, 1989). 
MacLean et al (1996) demonstrated augmented responses to 5-
I-IT at all levels of the pulmonary arterial vasculature in the chroniC 
hypoxic rat model of pulmonary hypertenSion and, using various 5-
I-IT antagonists, concluded that this increased response was a result 
of enhanced 5-HT2A receptor stimulation in combination with an 
increased influence of r5-HTIB-like receptor stimulation. There is an 
abundant expression of 5-HTIB receptor mRNA in rat pulmonary 
arteries and that this expression is increased in the same chroniC 
hypoxic rat model of pulmonary hypertenSion (Heeley et al., 1998). 
Artificially induced tone 'uncovers' vasoconstrictor responses to 
sumatriptan in bovine pulmonary arteries (MacLean et al., 1994; 
Sweeney et al., 1995). Decreasing cyclic GMP levels by NOS inhibition 
also increases vasoconstrictor effect of sumatriptan in both bovine 
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and human large intralobar pulmonary arteries. (MacLean et aZ .• 
1993: 1994). These effects became pathophysiologically relevant 
recently when MacLean et aZ (1996) provided evidence that vascular 
tone is increased and cyclic GMP levels are decreased in pulmonary 
arteries from the CH rat. Collectively. these observations. taken with 
the results presented in this chapter. suggest that 5-HT1B receptor-
mediated pulmonary vasoconstriction is likely to be increased and 
play an important significant role in the increased pulmonary 
vascular tone observed in pulmonary hypertension. 
The studies in this chapter do not provide any indication of the 
second messenger system linking the pulmonary vascular smooth 
muscle contraction to 5-HTIB receptor stimulation. Although it is 
well known that the ketanserin-sensitive 5-HT2Areceptors are linked 
to a increase in the activity of phosphoinositide C. generating IP3 
and diacylglycerol (Martin. 1994). the contractile pathways. via 5-HTl 
receptor stimulation are less well defined. Although in a number of 
vascular preparations the 5-HTIB/I0 receptor is reported to be 
negatively coupled to the formation of cyclic AMP. contractions 
mediated via these receptors may well occur in a cyclic AMP-
independent manner (Movahedi & Purdy. 1997: Parsons. et az.. 1996: 
Randall, et az.. 1996). Recently. Hill et aZ. (2000) demonstrated that 
contractions linked to 5-HTIB/I0 receptor stimulation in the rabbit 
isolated renal artery can be explained by an influx of external Ca2+ 
through voltage-activated Ca2+ channels as well as Ca2+ 
sensitization of the contractile myofilaments (Hill et az.. 2000). In 
many vascular preparations. the contractile effect mediated through 
5-HTIB/ 10 receptor stimulation only becomes apparent when the 
vessels are prestimulated with another contractile agent. Clearly. the 
results of the studies in this chapter show that 5-HTIB receptor 
stimulation evokes contractions in the absence of a prestimulating 
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agonist. It would, therefore, be useful to investigate the contractile 
pathways involved in mediating 5-HTIB/ID receptor evoked 
contractions in human PRAs as this receptor subtype appears to 
mediate vasoconstriction in a complex way. which may involve the 
interaction of several intracellular signalling pathways. 
Myofilament Ca2+ senSitization is an important component of 
the smooth muscle contraction elicited by a number of G-protein 
linked receptors, occurring through different kinase pathways 
(Somlyo & Somlyo. 1998). Recently. Evans et al. (1999) reported that 
ET-l induced an increase in myofilament calcium sensitivity in rat 
pulmonary arteries via the activation of ETA receptors and by a 
mechanism(s) independent of tyrosine kinase. This pathway has 
been proposed to mediate ET-l induced Ca2+ sensitization in rat 
mesenteric arteries (Ohanian. et al .• 1997). From a clinical viewpoint. 
these observations may be of some importance, as the identification 
of a distinct signal transduction mechanism associated with the 
development of pulmonary hypertension could lead to the 
development of new more effective therapies for this disorder. Indeed, 
the possibility that physiologically relevant agonists such as ET-1 
and 5-HT (as well as NA) may act in the pulmonary vasculature 
primarily via a mechanism that does not involve mobilisation of Ca2+ 
may explain why only a small percentage of patients with PHT 
respond to Ca2+ channel blocker therapy (Palevsky and Fishman. 
1991). It would therefore, be useful to investigate possible 5-HTIB/lD 
receptor-induced Ca2+ sensitization of the contractile filaments to in 
the human PRAs. 
In conclusion. 5-HT-induced contractions of human small 
muscular pulmonary arteries are mediated through two receptor 
populations. The main important finding of this work is that one of 
these receptor populations is the 5-lIT1B subtype which mediates 5-
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HT-induced vasoconstriction in human smPAs at concentrations 
which are pathophysiologically relevant. The 5-HTIB receptor 
therefore provides a potentially important new therapeutic target for 
pulmonary hypertension. Further support for this hypothesis will 
require both molecular biological and further pharmacological 
evidence about the nature and location of 5-HT receptor subtypes in 
the human pulmonary vasculature from patients with pulmonary 
hypertension. 
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Chapter 5 
5-lIT receptors in the perinatal rabbit 
pulmonaty arteries. 
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6.1 Introduction 
As previously explained in chapter 1. at birth. the pulmonary 
circulation undergoes important structural and functional changes 
(Haworth & Hislop. 1981: Hall & Haworth. 1987: Dunn et al 
1989).The initiation of lung ventilation and concomitant Increase In 
pulmonary arterial P02 results in a rapid fall In pulmonary arterial 
pressure (PAP) and pulmonary vascular resistance (PVR) through 
vasodilation of the small pulmonary arteries. This fall in PVR 
continues postnatally over the first few hours after birth and Is 
essential to allow a ten-fold increase in pulmonary blood flow to 
occur in order to adapt to life outside the uterus and permit normal 
gas exchange. via the lungs. to begin (Heymann & SOifer 1989). In a 
significant number of neonates, PVR does not decrease at birth 
resulting in persistent pulmonary hypertension of the newborn 
(PPHN) (Gersony et al 1973: John et al 1988). This condition results 
in a considerably high mortality rate. 
5-hydroxytryptamine (5-HT) is a potent pulmonary 
vasoconstrictor in vitro in several species including man (Raffestln et 
al. 1985: MacLean et al: 1996b) and several studies have implicated a 
role for 5-HT in the aetiology of pulmonary hypertension (PHT). 
Elevated plasma levels of 5-HT have been reported in primary PHT 
(Herve et at 1995) and isolated pulmonary arteries from PHT patients 
undergoing transplantation exhibit exaggerated vasoconstrictor 
responses to 5-HT (Brink et al. 1988). With particular relevance to 
the perinatal pulmonary circulation. 5-HT has also been linked to 
PHT associated with hypoxia in the newborn Infant. Johnson & 
Georgleff (1989) suggested that secretion of excessive amounts of 
serotonin. as well as other vasoactive agents. from pulmonary 
neuroendocrine cells following airway hypOxia may be associated with 
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the development of PfIT in the newborn. Recently. 5-fIT turnover has 
been shown to be increased in children with PHT secondary to 
congenital heart disease (Breuer et al. 1996). Hence. the 5-HT 
receptors mediating pulmonary vasoconstriction in the perinatal 
period are of interest. 
5-fIT interacts with a multipliCity of receptors causing either 
vasoconstriction or vasodilation depending on receptor SUbtype, 
species, pulmonary vascular location and underlying vascular tone 
(Hoyer et al., 1994). The two variants of the 5-HTID receptor 
previously described as the 5-HTl Dn and 5-HTl D~ receptor 
(Weinshank et al., 1992) have recently been renamed the 5-fITID and 
5-HT1B receptor respectively (Hartig et al., 1996). Where it cannot be 
distinguished between the 5-fITID and 5-HTIB receptor. the receptor 
involved will subsequently be referred to as the 5-fITID/lB receptor. 
5-HT causes vasoconstriction in isolated bovine 
intrapulmonary arteries via a 5-HTID/IB receptor (MacLean et al, 
1994) but induces endothelium-dependent relaxation in isolated 
porcine pulmonary arteries via the '5-HTIC' receptor (Glusa & 
Richter, 1993). The 5-fITIC receptor has subsequently been renamed 
the 5-HT2C receptor (Hoyer et al.. 1994). 
In human large pulmonary arteries, 5-HT-mediated 
vasoconstriction is via stimulation of 5-HTID/IB receptors (MacLean 
et al, 1996b); and the studies in chapter 4 examined and discussed 
the importance of the 5-HTIB receptor in mediating 5-HT-receptor-
induced vasoconstriction in the pulmonary small muscular 
reSistance arteries in man. In other vascular beds, 5-HT can induce 
endothelium-dependent vasodilation via the 5-HT2C receptor 
(Bodelson et al .• 1993), the 5-HT2B receptor (Glusa & Roos, 1996; 
Ellis et aI .• 1995) and the 5-HTID/IB receptor (Gupta, 1992). There Is 
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also evidence that 5-HT can mediate vasodilation directly through 5-
HT4 and 5-lIT7 receptors located on vascular smooth muscle (Cocks 
& Arnold. 1992; Leung et ai. 1996; Terron. 1996). 
The receptors mediating vasoconstriction and vasodilation In 
perinatal pulmonary arteries have not previously been studied. The 
neonatal lung is still undergoing development and maturation at 
birth (Hislop & Reid. 1972: Meyrick & Reid. 1982). and very little is 
known at present about the actions of 5-lIT on perinatal pulmonary 
resistance vasculature. 
In order to understand more fully the possible role of 5-
hydroxytryptamine (5-HT) in both the ordinary adaptation of the 
perinatal pulmonary vasculature at birth and in the 
pathophysiological state of PPHN. it is important to eluCidate the 5-
HT receptor(s) present in the pulmonary vasculature at different 
developmental ages. The results from chapter 3 of this thesis suggest 
that in the adult rabbit pulmonary arteries. 5-HT-induced 
vasoconstriction is mediated solely via the 5-HT2A receptor in the 
large capacitance PAs. but by a heterogeneous population of both the 
5-HT2A and 5-HTIB or 5-HTID receptor in the pulmonary resistance 
arteries (PRAs). In adult human PRAs. 5-lIT-evoked vasoconstriction 
also appears to be mediated via stimulation of both 5-HT2A and 5-
HTIB receptors. with the 5-HTIB receptor being of more importance 
at physiological concentrations of 5-lIT (Chapter 5 of this thesis). 
Although. as previously mentioned. it is the PRAs which are the 
important determinants of pulmonary vascular resistance and 
pulmonary hypertenSion in vivo in the adult (Staub. 1985). it has 
been suggested that in the perinatal period. the pulmonary 
capacitance arteries (PCAs) may also playa significant role in the 
maintenance of PVR (Belik. 1994. 1995). Hence. The studies in this 
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chapter examined the functional responses to 5-HT. the influence of 
endothelium-derived NO and the 5-HT receptor subtype(s) involved in 
mediating 5-HT-induced vasoconstriction and vasodilation. in both 
PCAs and PRAs from near term (2 days pre-term) foetal and neonatal 
rabbits. 
5.2 Materials and methods 
Rabbit pulmonruy arteries 
New Zealand White rabbits were studied at the following ages: 
foetal (2 days pre-term). 0-24 hrs, 4 days. and 7 days after birth. They 
were killed by sodium pentobarbitone (200mgkg-1) and the lungs 
removed. The main pulmonary and 1st branch, extralobar. pulmonary 
conduit arteries (PCAs) were dissected out. The PCAs from the 2 day 
pre-term foetal (l-2mm 1.d.), 0-12 hour (l-2mm 1.d.). 4 day (l.5-
2.5mm 1.d.). and 7 (2-3.5 mm i.d.)) day old NZW rabbits were set up 
in 5 ml organ baths. Under a dissecting microscope, intralobar 
pulmonary resistance arteries ([PRAs], -250-300J.lm i.d.) were 
carefully dissected out and cleaned of surrounding parenchyma. Two 
mm long segments of the arteries were threaded onto 40J.lm stainless 
steel wires and mounted as ring preparations in isometric wire 
myographs. 
All vessels were bathed in Krebs-buffer solution (pH 7.4) 
(composition (mM): NaCI 11B.4. NaHC03 25. KCI 4.7. KH2P04 l.2. 
MgS04 0.6, CaCl2 2.5, glucose 11.0. and EDTA 23.0) at 370 C. Foetal 
vessels were bubbled with 30/002/50/0C02 balance N2 in order to 
mimiC in utero partial oxygen pressures (p02-1B-23mmHg. pC02-35-
40mmHg). and the neonatal vessels bubbled with 160/002/50/oC02 
balance N2 to give values Similar to those found in vivo 
(p02-120mmHg. pC0 2-35-40mmHg). 
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PCAs were set up under tensions at which maximum 
responses to 50mM KCI were obtained (0.8 -1.25 g). 
Tension was then applied to the PRAs to give a transmural 
pressure equivalent of approximately 12-16mmHg. similar to in vivo 
pressures of pulmonary arterioles after birth. Foetal PRAs were also 
tensioned to this pressure equivalent as this was the minimum 
tension at which reproducible. consistent contractile responses 
could be observed. 
ExPerimental protocol 
Following a 45 minute equilibration period. the response to 
50mM KCI was determined twice; once the contractile response had 
reached a plateau. the vessels were washed out 8 times with fresh 
Krebs solution. 
Pulmonary conduit arteries (PCAs) 
In any experiments involving the PCAs. no attempt was made 
to remove the endothelium as previous experience dictates that. with 
mechanical disruption. there is significant damage to the smooth 
muscle layer of these vessels. 
The vessels were pre constricted with IIlM NA and once the 
contraction had levelled off. Ij.1M ACh was added on top of the NA-
induced tone to assess endothelial integrity. 
(In separate experiments in the extralobar branch pulmonary 
arteries (bPAs) (see Morecroft & MacLean. 1998). the pulmonary 
arterial rings were pre-contracted with a concentration of 
phenylephrine which in a preliminary experiment produced 70% 
maximum contraction (O.I-0.3IlM). Once a stable, plateau had been 
reached, cumulative concentration-dependent-response curves 
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(CCRCs) to ACh (lnM-IOmM) were constructed in half log 
increments, each increment added when response to previous 
addition had plateaued (about 2 minutes)). 
Following washout and sufficient time for return to baseline 
tension the vessels were subject to one of the following protocols: 
In the PCAs, cumulative concentration-response curves 
(CCRCs) to 5-HT (lnM-O.lmM) were constructed, following washout 
with fresh Krebs and re-equilibratlon, the CCRCs to 5-HT were 
repeated in the presence of lOO~M L-NAME, a non-selective NO 
synthase inhibitor. Appropriate 'time control' CCRCs to 5-HT were 
also constructed in each age group which showed no change in 
sensitivity or magnitude of contractile response to 5-HT (not shown). 
In order to evaluate the 5-HT receptor(s) involved in the 
pulmonary vasoconstrictor activity in the extralobar branch PAs, 
CCRCs were also constructed to the 5-HT agonists 5-
carboxamidotryptamine (5-CT, InM-O.lmM: 5-HTI receptor agonist), 
a-methyl-5-HT (5-HT2-selective, InM-O.lmM) and the 5-HTIB/I0 
receptor agonist, sumatrtptan. 
For antagonist studies, CCRCs were constructed to 5-HT 
(lnM-O.lmM) and following washout and re-equiltbration, these were 
repeated in the presence of an appropriate antagonist which was 
allowed to equilibrate for 45 minutes before the commencement of 
the second CCRC to 5-HT. The antagonists used were ketanserin 
(selective for 5-lIT2A receptors) and GR55562 (3-[3- (dimethylamlno) 
propyl]-4-hydroxy-N- [4-(4pyrtdinyl)phenyl]benzamide) (selective 5-
lITIB/lD antagonist). Appropriate time controls for the second CCRC 
to 5-IIT were always performed. 
A second protocol examined the 5-lIT receptor(s) mediating 
vasodilation in the bPAs and these experiments were conducted in 
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the presence of O.l/lM ketansertn to exclude any 5-lIT2A -receptor 
mediated effects. Vessels were contracted with phenylephrine (PE 
-O.lIlM) as it reliably induces a maintained contraction in these 
artertal segments. Vessels were pre-contracted to give a contraction 
approximately 50-70% of the maximal contractile response to this PE 
as preliminary studies indicated that contraction above this level 
actually decreased the sensitivity of vasodilators including 5-CT. 
Vasodilator responses to 5-CT. 5-HT. sumatrtptan and BW 723C86 
(selective 5-HT2B agonist) were studied. 
Pulmonmy resistance artertes(PBAsl 
Cumulative concentration-response curves (CCRCs) to 5-HT 
(lnM-O.lmM) were constructed either in the presence or absence of 
100llM L-NAME. a non-selective NO synthase inhibitor. 
In order to evaluate the 5-HT receptor(s) involved in the 
pulmonary vasoconstrictor activity in the PRAs. CCRCs were also 
constructed to the 5-lIT agonists 5-carboxamidotryptamine (5-CT. 
InM-O.lmM: 5-HTl receptor agonist). a-methyl-5-HT (5-HT2-
selective. InM-O.lmM) and the 5-HTl B /1 D receptor agonist. 
sumatriptan. Previous experience dictates that attempts at 
mechanical removal of the vascular endothelium in these arteries 
damages the thin and fragile underlying smooth muscle. These 
experiments were therefore. carried out in the presence of 100llM L-
NAME to prevent any inhibitory role of NO release on constrtctor 
responses. CCRCs to 5-HT are not reproducible in each tissue as, 
unlike the conduit vessels, desensitization often occurs with a 
second CCRC, therefore, only one CCRC to 5-HT was constructed 
either in the absence or presence of antagonist in each vessel. The 
antagonists used were ketansertn (selective for 5-HT7A receptors) and 
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GR55562 (selective 5-lITIB/lD antagonist). All antagonists studies 
were also carried out in the presence of L-NAME (I OOIlM). 
The second protocol examined the 5-lIT receptor(s) mediating 
vasodilation in perinatal rabbit PRAs and these experiments were 
conducted in the presence of O.I~M ketanserin to exclude any 5-
HT2A-receptor mediated effects. Vessels were contracted with 
endothelin-I (ET-I) (O.I-IOnM) as it reliably induces a maintained 
contraction in these vessels (Docherty & MacLean, 1998). Vessels 
were pre-contracted to give a contraction approximately half the 
maximal contractile response to this ET-l as preliminary studies 
indicated that contraction above this level actually decreased the 
sensitivity of vasodilators including 5-CT. We studied vasodilation in 
responses to 5-CT as preliminary results showed that 5-lIT gave a 
variable vasodilator response with a tendency to cause contraction at 
higher concentrations in preconstricted PRAs. A CCRC to 5-CT was 
constructed in each vessel either in the presence or absence of one of 
the following: GR55562 (1 ~M), 1 OO~M L-NAME, I OO~M L-NAME + 
spiperone (l~M, 5-HT7 receptor antagonist). Antagonists were 
allowed a 45 minute equilibrium period prior to constructing the 
CCRCs to 5-CT. 
Data analysis 
Contractile responses are expressed as a percentage of the 
second reference contraction to 50mM KCI determined at the start of 
the experiment in each preparation. The results are shown as the 
mean ± s.e.mean. Dilator responses are expressed as the % reduction 
of ET-I-induced tone. pECSOs and pICsos were calculated by 
computer interpolation from individual CCRCs. Statistical 
comparison of the means of groups of data were made by Student's t-
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test or one way analysis of variance where appropriate. P < 0.05 was 
considered statistically significant. n = number of vessels/number of 
animals. In antagonist studies, estimated pKB values for antagonists 
were calculated whenever possible according to the methods described 
in chapter 2. 
5.3 Results 
5.3.1 Pulmonary conduit arteries 
Assessment of endothelial inte~rity 
Figure 5.1 shows the response to l~M ACh in 1 ~M NA-pre-
contracted foetal and perinatal rabbit A. main and B. first branch 
extralobar pulmonary arteries (PAs). Levels of preconstriction to 1J,lM 
NA were not significantly different between age groups being (% 
response to 50mM KCl): 97 ± 8% (foetal), 101 ± 11 % (0-24 hour), 106 
± 5.6% (4 day) and 92 ± 7% (7 day) for the main PA and 89 ± 11% 
(foetal), 103 ± 14% (0-24 hour) 92 ±8% (4 day) and III ± 9% for the 
branch PAs. No significant relaxation was observed in the 0-24 hr 
rabbit main PA. The greatest relaxation was observed in the 4 day 
main PAs. In the branch PAs, the greatest relaxation was observed in 
the 7 day old rabbits, where vessels relaxed slightly below the 
baseline tension. A substantial relaxation was also observed in the 
foetal and 4 day rabbit branch vessels but ACh-induced relaxation 
was virtually non-existent in the 0-24 hr rabbit vessels. The response 
at the foetal, 4 day and 7 days age pOints was significantly greater 
than that of the 0-24 hour rabbit PAs. 
Figure 5.1C illustrates the effect of ACh on pre-contracted 
branch PAs. Pulmonary arteries from the 0-24hr neonate did not 
relax to ACh. ACh caused vasodilation in all other vessels with the 
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following order of potency: adult> 4 day = 2 day pre-term as prCSO 
values for the ACh-induced vasodilation were 7.40 ± 0.1. 7.38 ± 0.20 
and 7.73 ± 0.04 for the foetal. 4 day old and adult rabbit bPAs 
respectively. Maximum vasodilation was in the following order (% 
preconstrictlon): 4 day (105.4 ± 3.0%) = 2 day pre-term (86.4 ± 4.2%) 
> adult (67.4 ± 6.6%. P < 0.01 cf. 4 day). 
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Fi~ure 5.1 ACh-induced vasorelaxation of perinatal rabbit PCAs. 
Response to l~M ACh in A main and B extralobar branch pulmonary 
artery expressed as percentage of NA (l~M)-induced tone. ***P<O.OOl 
foetal, 4 day and 7 day cf. 0-24 hr response. n > 10/10 for each age. 
Statistical comparisons were made using ANOVA. 
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Fillure 5.1.C ACh-induced vasodilation in endothelium-intact, 
pulmonary conduit artery rings pre-contracted with phenylephrine 
from 2 day pre-term foetal (0 n = 6) , 0-12 hour ( e, n = 12), 4 day (_, 
n = 7), and adult ( .... , n = 8) rabbits. Vasodilation is expressed as % 
reversal of pre-constriction. Each point represents mean ± s.e.m. 
Responses to 5-fIT 
Figure 5.2 shows cumulative responses to 5-fIT in perinatal 
rabbit extralobar branch pulmonary arteries (bPAs). pEC50 values are 
summarised in table 5.1. 5-fIT induced a concentration dependent 
contraction in the vessels at all age pOints studied. The sensitivity to 
5-HT was similar in the bPAs from the foetal, 4 day old and 7 day old 
rabbits, which, in turn were all significantly more sensitive than the 
vessels from the 0-24 hour rabbit. The maximum contractile 
responses to 5-HT were Similar at all age pOints studied being 115 ± 
10%, 127 ± 17%, 129 ± 13% and 131 ± 13% (% 50mM KCl response) 
for the foetal, 0-24 hour, 4 day and 7 day rabbit bPAs respectively. 
There was no significant difference between these responses. 
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Effect of L-NAME on 5-HT-induced responses 
The effect of lOOIlM L-NAME on baseline tenSion is shown in 
figure 5.3. 100llM L-NAME caused an increase in baseline tension in 
the majority of foetal, 4 day and 7 day old rabbit extralobar PAs. The 
magnitude of this response was quite variable. In contrast, L- NAME 
had no effect on the baseline tension in the 0-24 hour vessels 
studied. 
The response of foetal and neonatal main and first branch 
extralobar pulmonary arteries to 5-lIT in the presence and absence of 
100llM L-NAME are shown in figures 5.4-5.7. pEC50 values and 
maximum responses are shown in table 5.1. L-NAME had no effect 
on the sensitivity to 5-lIT in 0-24 hour (figure 5.5 A), 4 day old (figure 
5.6 A) or 7 day old (figure 5.7 A) rabbit main PAs (table 5.1). In 
comparison, a Significant increase in sensitivity was evident in 
vessels from foetal rabbit main PAs (figure 5.4 A, table 5.1). The 
magnitude of the maximum contractile response to 5-HT was 
increased by -180% in the foetal main PAs (figure 5.4 A, table 5.1) 
but there was no significant effect of L-NAME on the maximal 5-HT-
induced vasoconstriction in the other age groups. In the extralobar 
pulmonary arteries, a marked significant increase in sensitivity to 5-
lIT was evident in the 0-24 hour rabbit vessels in the presence of L-
NAME (figure 5.5 B, table 5.1), but not in the extralobar PAs from the 
foetal, 4 day old and 7 day old rabbits (figures 5.4 B, 5.6 B & 5.7 B, 
table 5.1). The magnitude of the maximal 5-HT-induced contraction 
was significantly increased in the presence of L-NAME in the foetal 
(figure 5.4 B), 0-24 hour (figure 5.5 B), 4 day old (figure 5.6 B) and 
the 7 day old (figure 5.7 B) rabbit extralobar PAs. The greatest 
increase was observed in 4 day rabbit vessels, where the maximum 
contractile response to 5-HT was augmented by -250% (figure 5.6 B, 
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table 5.1). In all experiments with L-NAME, 'time control' responses 
to a second CCRC to 5-HT in the same vessel did not significantly 
differ in sensitivity or maximal contractile response from the first 5-
lIT CCRC at all age pOints studied. 
Preparation pEC50 n/n Emax. 
(+ L-NAME) 
CQn:trQl + L-NAME 
Foetal 
-main 6.6 ± 0.1 7.0 ± 0.1* 6/6 280 ± 60*** 
-extra-lobe 6.9±0.ltt 7.1 ± 0.1 6/6 267 ± 32*** 
0-24 
hours 
-main 6.8 ± 0.1 6.8 ± 0.1 12/12 109±6 
-extra-lobe 6.5±0.05 7.2 + 0.02*** 12/12 142 ± 18·* 
4 day 
-main 6.8 ± 0.1 6.9 ± 0.1 8/8 104±7 
-extra-lobe 6.7 ± 0.07 6.8 + 0.1 8/8 349 ± 41·** 
7 day 
-main 7.2±0.2 7.2 ±0.2 6/6 115±6 
-extra-lobe 7.0 ± 0.1 tt 7.2 ± 0.1 6/6 135 ± 9*· 
Table 5.1 pEC50 values for 5-HT in the presence and absence of 
100J.1M L-NAME and maximum responses in the presence of L-NAME 
in perinatal rabbit pulmonary arteries. Emax. = maximum response 
expressed as % maximum control 5-HT response in the same 
preparation. n/n = number of preparations/number of animals. 
Statistical comparisons were made by ANOVA : 0-24 hour control vs. 
other age pOints ttp<O.Ol: tttp<O.OOl: and Students paired t-test 5-
lIT EC50 or maximum response vs. + L-NAME. 
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Figure 5.2 5-HT-induced contractions in perinatal rabbit extralobar 
branch pulmonary arteries. 5-HT CCRCs; foetal (.6.. n = 18/9). 0-24 
hour ( •. n = 18/9). 4 day (D. n = 18/9) and 7 day (e. n = 18/9) 
rabbits. A Data are expressed as percentage own maximum 
contraction. B Data are expressed as percentage reference 
contraction to 50 mM KCl. Each point represents mean ± s.e.mean. 
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Figure 5.3 Effect of L-NAME (lOOIlM) on basal tone in perinatal 
rabbit extra lobar branch pulmonary arteries. n ~ 8/8 for each age. 
Data are expressed as percentage reference contraction to 50mM KCl. 
Each response represents mean ± s.e.mean. 
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Figure 5.4 Effect of L-NAME (lOOIlM) on 5-HT responses in foetal 
rabbit pulmonary arteries. CCRCs; control (O,n = 6/6) and in the 
presence of L-NAME (.,n = 6/6) in A main and B extralobar branch 
pulmonary arteries. Data are expressed as percentage control 5-HT 
maximum contractile response. Each point represents mean ± 
s.e.mean. n = number of vessels/number of animals. 
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Figure 5.5 Effect of L-NAME (lOOIlM) on responses to 5-HT in 
pulmonary arteries from 0-24 hr rabbits. CeRCs; control (0, n = 
12/12) and in the presence of L-NAME (e, n = 12/12) in A Main and 
B extralobar branch pulmonary arteries. Data are expressed as 
percentage control 5-HT maximum contractile response. Each point 
represents mean ± s.e.mean. n = number of vessels/number of 
animals. 
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Figure 5.6 Effect of L- NAME (1 OOIlM) on responses to 5-HT in 
pulmonary arteries from 4 day rabbits . CCRCs; control (0, n = B/B) 
and in the presence of L-NAME (., n = B/B) in A Main and B 
extralobar branch pulmonary arteries. Data are expressed as 
percentage control 5-HT maximum contractile response. Each point 
represents mean ± s.e.mean. n = number of vessels/number of 
animals. 
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Firlure 5.7 Effect of L-NAME (lOOIlM) on responses to 5-HT in 
pulmonary arteries from 7 day rabbits. CeRCs: control (0. n = 6/6) 
and in the presence of L-NAME (e. n = 6/6) in A Main and B 
extralobar branch pulmonary arteries. Data are expressed as 
percentage control 5-HT maximum contractile response. Each point 
represents mean ± s.e.mean. 
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Responses to 5-lIT a~nists 
Figures 5.8-5.11 show the response to selective 5-HT agonists 
in perinatal rabbit extralobar PAs. The characteristics of the 
contractile responses to these agonists are shown in table 5.2. 5-lIT. 
ex.-methyl-5-HT and 5-CT all caused concentration-dependent 
contractions in perinatal rabbit extralobar pulmonary arteries at all 
age pOints studied. Within each age point studied. both 5-1-IT and ex.-
methyl-5-HT evoked equi-sensitive contractions (table 5.2). The 
sensitivity to 5-CT was significantly less than that of 5-HT or ex.-
methyl-5-HT within each age point (table 5.2). In the branch 
pulmonary arteries. all the agonists. except sumatrIptan. produced 
maximal contractions of Similar magnitude to that of 5-lIT (table 
5.2). Sumatrlptan produced no significant contractile response in the 
0-24 hour vessels (figure 5.9) and only evoked a comparatively small 
contractile response at concentrations greater than 10J,1M in the 
other age groups. Because of the poor contractile response elicited by 
sumatriptan. pECSO values for this agonist could not be determined 
at any of the age pOints studied. Although the maximum contractile 
response to ex.-methyl-5-lIT appeared larger than that to 5-HT in the 
4 day old vessels (figure 5.10). this was not statistically Significant. 
Effect of L-NAME and raised tone on sumatrlptan responses 
Figures 5.12 and 5.13 show the effect of the NO synthase 
inhibitor L-NAME and the effect of U46619-induced tone on 
sumatrtptan induced vasoconstriction in perinatal rabbit extralobar 
branch pulmonary arteries. In the foetal vessels (figure 5.12 A). 
neither 100J,1M L-NAME or U46619-induced tone had any significant 
effect on the poor contractile response to sumatriptan. In the 0-24 
hour vessels (figure 5.12 B). both 100J,1M L-NAME and U46619-
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induced tone 'uncovered' contractile responses to sumatriptan at 
concentrations greater than lO~Mt this response was very vartable. In 
the 4 day old vessels, both L-NAME and U146619-induced tone 
significantly increased the contractile response to sumatriptan at 
1~M-10~M and decreased the threshold for sumatriptan-induced 
contraction from 10~M to l~M (figure 5.13 A). the overall contractile 
response, however was still poor compared to that of 5-HT. 
2fJ7 
pECSO Emax (%) n 
Foetal 
S-lIT 6.92 ± 0.1 13S±S 6/6 
a-methyl-S-lIT 6.76 ± 0.19 lIS ± IS 6/6 
S-CI' 6.1S ± 0.2** 103± 13 6/6 
0-24 hour 
5-lIT 6.S1 ± 0.05 116 ±19 7/6 
a-methyl-5-lIT 6.56± 0.11 lOS ± 11 6/6 
5-CI' S.67 ± 0.21** 114± IS 6/6 
4 day 
5-lIT 6.71 ± 0.14 12S ± 19 7/7 
a-methyl-S-lIT 6.91 ± O.lS 163±27 6/6 
5-CI' S.61 ± 0.2*** 132± 13 6/6 
7 day 
5-IIT 7.19± 0.14 14S±21 6/6 
a-methyl-5-IIT 7.03 ± 0.11 152± 13 6/6 
5-CI' 6.13 ± O.lS*** 119± IS 6/6 
Table S.2 pEC50 values and maximum responses for S-IIT agonists in 
perinatal rabbit extralobar PAs. Emax. = maximum response 
expressed as Ok contraction to 50mM KCl. Statistical comparisons 
were made by Students unpaired t-test: pECSO for S-lIT vs agonist 
pECSO at each respective age point **P< 0.01, ***P<O.OOI. S-HT, 5-
hydroxytryptamine; S-CT, 5-carboxamidotryptamine. Data are 
expressed as mean ± s.e.mean. 
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Figure 5.8 Response to selective agonists in foetal rabbit extralobar 
branch pulmonary arteries. CCRCs; 5-HT (_,n = 6/6), a-methyl-5-HT 
(6.,n = 6/6), 5-CT (~,n = 6/6) and sumatriptan (e,n = 6/6). A Data 
are expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50 mM KCl. Each 
point represents mean ± s.e.mean. 
209 
E 125 A 
:J 
E 
>< 
cu 
E 
~ o 
-
CIJ 
C/) 
100 
75 
50 
c 25 
o 
Co 
C/) 
~ 04-~~~~~"~~~~~~~~--~~~~ 
175 
-() 150 ~ 
:E 125 
E 
o 
It) 100 
'#-
- 75 
CIJ 
C/) 
c 50 
o 
Co 
C/) 25 
CIJ 
a: 
-11 -10 -9 -8 -7 -6 
Agonist (log M) 
B 
o -+-~_I-tI~ __ 
-11 -10 -9 -8 -7 -6 
Agonist (log M) 
-5 -4 -3 
T T T T 
-5 -4 -3 
Fillure 5.9 Response to selective agonists in 0-24 hr rabbit extralobar 
branch pulmonary arteries. CCRCs; 5-HT (_,n = 7/6), a-methyl-5-HT 
(~,n = 6/6), 5-CT (. ,n = 6/6) and sumatriptan (e,n = 6/6). A Data 
are expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50 mM KCl. Each 
point represents mean ± s.e.mean. 
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Fi(i!ure 5.10 Response to selective agonists in 4 day rabbit extralobar 
branch pulmonary arteries. CCRCs; 5-HT (_,n = 7/7), a -methyl-5-HT 
(~,n = 6/6), 5-CT (A,n = 6/6) and sumatrlptan (e,n = 6/6). A Data 
are expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50 mM KCl. Each 
point represents mean ± s.e.mean. 
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Figure 5.11 Response to selective agonists in 7 day rabbit extralobar 
branch pulmonary arteries. CCRCs; 5-HT (.,n = 6/6), a-methyl-5-HT 
(~, n = 6/6), 5-CT (., n = 6/6) and sumatriptan (e, n = 6/6). A 
Data are expressed as percentage own maximum contraction. B Data 
are expressed as percentage reference contraction to 50 mM KCl. 
Each point represents mean ± s.e.mean. 
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Figure 5.12 Effect of L-NAME (lOOIlM) and raised tone on 
sumariptan-induced vasoconstriction in A foetal and B 0-24 hr 
rabbit extralobar pulmonary arteries. CCRCs to sumatriptan: control 
(e. n = 6/6). plus lOOIlM L-NAME (~. n = 6/6) and plus U46619 (1 -
3nM)-induced tone (0. n = 6/6). Data are expressed as percentage 
reference contraction to 50 mM KCl. Each point represents mean ± 
s.e.mean. n = number vessels/number animals. 
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Fiflure 5.13 Effect of L-NAME (100IlM) and raised tone on 
sumariptan-induced vasoconstriction in A 4 day and B 7 day rabbit 
extralobar pulmonary arteries. CCRCs to sumatriptan; control (e. n 
= 6/6). plus 100llM L-NAME (~. n = 6/6) and plus U46619 (l -3nM)-
induced tone (D. n = 6/6). Data are expressed as percentage reference 
contraction to 50 mM KCl. Each point represents mean ± s.e.mean. n 
= number vessels/number animals. 
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Anta~onist studies 
The effects of the selective antagonists ketanserin (5-HT2A receptor 
antagonist) GR55562 (selective 5-HT1B and 5-HT1D antagonist) were 
assessed against 5-HT-induced contractions of perinatal rabbit 
extralobar branch PAs. The effects of these antagonists are shown in 
figures 5.14-5.17. pEC50 values and maximum contractile responses 
are summarised in table 5.3. 
5-ill vs -GR55562 
The contractile response to 5-ill in these vessels was 
resistant to 1J.1M GR55562 at all age pOints studied. In the foetal 
bPAs, in the presence of 1J.1M GR55562, the sensitivity to 5-HT was 
6.98 ± 0.15 which was not significantly different from the control 
pEC50 value for 5-HT in these vessels (see table 5.3). There was no 
significant change in the maximum contractile response in the 
presence of GR55562 in these vessels compared to control (Emax. = 
169 ±140A>: n = 6/6) (% reference contraction to 50mM KCl). In 0-24 
hour, 4 day old and 7 day old rabbit bPAs, the pEC50 values in the 
presence of 1J.1M GR55562 were 6.3 ± 0.1,6.73 ± 0.16 and 7.1 ± 0.2 
respectively, none of which were significantly different from their 
respective control values (see table 5.3). The maximum contractile 
response to 5-HT in the presence of 1J.1M GR55562 was 115 ± 15%, 
138 ± 17016 and 185 ± 21% (% reference contraction to 50mM KCl) in 
the 0-24 hour, 4 day and 7 day old rabbit vessels respectively. None of 
these values was significantly different to their respective control 
values (see table 5.3). 
5-HI vs. ketansertn 
At all age pOints studied, 30nM ketansertn, a selective 5-Hf2A 
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receptor antagonist, behaved as a potent antagonist causing a 
concentration-dependent parallel rightward shift of the CCRC to 5-
HT with no significant reduction of the maximal contractile response 
(figures 5.14-5.17, table 5.3). In the foetal bPAs, the apparent pKB for 
30nM and O.lJlM ketanserin was 8.4 ± 0.2 and 9.3 ± 0.2 respectively. 
In the 0-24 hour rabbit bPAs, the apparent pKB for ketanserin at 
30nM was 8.7 ± 0.1. In the presence of O.lIJ.M ketanserin, in the 0-24 
hour vessels, the CCRC was shifted rightward but did not achieve a 
maximal contractile response within the concentration range studied 
(figure 5.15 B). In the 4 day old rabbit vessels, although the CCRC to . 
5-HT in the presence of 30nM ketansertn appeared to evoke a lower 
maximal contraction than in control CCRCs to 5-HT, this was not 
statistically significant (figure 5.16 B, table 2). The apparent pKB 
value in these vessels was 8.4 ± 0.2. In the presence of O.lIJ.M 
ketanserin, a maximal response to 5-1-IT was not achieved in these 
vessels. Concentration-dependent, rightward parallel shifts of the 5-
HT CCRC were also observed for ketanserin in the 7 day old rabbit 
bPAs. The apparent pKB values were 8.8 ± 0.2 and 9.2 ± 0.2 for 30nM 
and O.lIJ.M ketanserin respectively. 
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pECso E~. (%) n 
Foetal 
5-1IT control 6.96±0.15 153±4 18/9 
+ 30nM ketanserin 6.1 ± 0.1·· 152 ± 10 6/6 
+ 0.1J.1M ketanserin 5.12 ± 0.10··· 149 ± 14 6/6 
0-24 hours 
5-1IT control 6.51 ± 0.05 114 ± 17 18/9 
+ 30nM ketanserin 5.25 ± 0.1··· 128 ± 12 6/6 
+ O. 1 J.1M ketanserin nc nc 6/6 
4 day old 
5-1IT control 6.76 ± 0.16 157 ± 16 21/12 
+ 30nM ketanserin 5.85 ± 0.21·· 115 ± 21 7/7 
+ 0.1J.1M ketanserin nc 8/8 
7 day old 
5-1IT control 7.02 ± 0.1 161 ± 18 20/11 
+ 30nM ketanserin 5.7 ±0.2··· 174± 21 6/6 
+ 0.1J,l.M ketanserin 4.78 ± 0.15··· 198 ± 26 8/8 
Table 5.3 Effect of ketanserin on 5-hydroxytryptamine (5-1IT)-induced 
contraction of perinatal rabbit extralobar branch pulmonary arteries. 
Data are shown as mean ± s.e.mean. Emax. = maximum contractile 
response expressed as a percentage of the reference contraction to 
50mM KCI. Statistical comparisons were made by Students' paired t-
test ··P<O.Ol, ···P<O.OOl; compared with respective control 5-HT 
pEC50 data. n = number of vessels/number of animals. nc = not 
calculated. 
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Fi~ure 5.14 Effect of selective antagonists on 5-HT-induced responses 
in foetal rabbit extralobar pulmonary arteries. CCRCs to 5-HT (.,n = 
18/9) and in the presence of 30nM ketanserin (~,n = 6/6), O.I~M 
ketanserin (e,n = 6/6) and I~M GR55562 (~,n= 6/6).A Data are 
expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50 mM KCl. Each 
point represents mean ± s.e.mean. n = number vessels/number 
animals. 
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Figure 5.15 Effect of selective antagonists on 5-HT-induced responses 
in 0-24 hr rabbit extralobar pulmonary arteries. CCRCs to 5-HT (_,n 
= 18/9) and in the presence of 30nM ketanserin (~,n = 6/6), O.lJlM 
ketanserin (e,n = 6/6) and 1JlM GR55562 (6,n= 6/6}.A Data are 
expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50 mM KCl. Each 
point represents mean ± s.e.mean. n = number vessels/number 
animals. 
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Figure 5.16 Effect of selective antagonists on 5-HT-induced responses 
in 4 day rabbit extralobar pulmonary arteries. CCRCs to 5-HT (_,n = 
21/12) and in the presence of 30nM ketanserin (A,n = 7/7), O.lJlM 
ketanserin (e,n = B/B) and 1JlM GR55562 (.6,n= 6/6}.A Data are 
expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50 mM KCI. Each 
point represents mean ± s.e.mean. n = number vessels/number 
animals. 
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Figure 5.17 Effect of selective antagonists on 5-HT-induced responses 
in 7 day rabbit extralobar pulmonary arteries. CCRCs to 5-HT (.,n = 
20/ 11) and in the presence of 30nM ketanserin (., n = 6/6), O. IIlM 
ketanserin (.,n = 8/8) and IIlM GR55562 (~,n= 6/6).A Data are 
expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50 mM KCl. Each 
point represents mean ± s.e.mean. n = number vessels/number 
animals. 
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Anta~nist studies in the presence of L-NAME 
The effects of the selective antagonists ketanserin (5-HT2A 
receptor antagonist) and GR55562 (selective 5-HT1B and 5-HT1 D 
antagonist) were assessed against 5-HT-induced contractions of 
perinatal rabbit extralobar branch PAs in the presence of 100JlM L-
NAME as. previously shown already in this study. the responses to 5-
HT in these vessels are significantly affected by endothelial nitric 
oxide. The effects of these antagonists are shown in figures 5.18-5.21. 
pEC50 values and maximum contractile responses are summarised in 
table 5.4. 
5-IITvs -GR55562 + 100yM L-NAME 
In the presence of 100J.LM L-NAME, the contractile response to 
5-IIT in these vessels was resistant to 1JlM GR55562 at all age pOints 
studied. In the foetal bPAs. in the presence of 1JlM GR55562, the 
sensitivity to 5-HT was 6.85 ± 0.2 which was not significantly 
different from the control pEC50 value for 5-HT in these vessels (see 
table 5.4). There was no significant change in the maximum 
contractile response in the presence of GR55562 in these vessels 
compared to control (Emax. = 217 ± 25%; n = 6/6) (% reference 
contraction to 50mM KCl). In 0-24 hour, 4 day old and 7 day old 
rabbit bPAs, the pEC50 values in the presence of 1JlM GR55562 were 
7.1 ± 0.1,6.89 ± 0.15 and 7.01 ± 0.15 respectively, none of which 
were significantly different from their respective control values (see 
table 5.4). The maximum contractile response to 5-HT in the 
presence of 1JlM GR55562 was 129 ± 11%, 174 ± 18% and 1226 ± 
31 % (% reference contraction to 50mM KCI) in the 0-24 hour, 4 day 
and 7 day old rabbit vessels respectively. None of these values was 
significantly different to their respective control values (see table 5.4). 
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5-lIT vs ketansertn + 100uM L-NAME 
Ketanserin, in the presence of L-NAME, caused concentration-
dependent rightward shifts of the CCRC to 5-HT in perinatal rabbit 
bPAs at all age pOints studied (figures 5.18-5.21). In the foetal vessels 
(figure 5.18), the pKB value for ketansertn was 8.57 ± 0.2 and 9.00 ± 
0.21 for 30nM and O.l~M ketanserin respectively. There was no 
change in the maximum contractile response to 5-HT in the presence 
of ketanserln In these vessels (figure 5.18 B, table 5.4). In the 0-24 
hour rabbit vessels (figure 5.19), the pKB value for ketansertn was 8.8 
± 0.19 and 8.9 ± 0.2 for 30nM and O.l~M ketansertn respectively. The 
maximum contractile response to 5-lIT in the 4 day old rabbit bPAs 
appeared to be greater In the presence of 30nM ketanserln than in 
control response to 5-HT (figure 5.20 B), this was not statistically 
significant; ketanserin at this concentration had an apparent pRB of 
8.7 ± 0.18. At O.l~M ketansertn, the apparent pKB was 8.57 ± 0.2 in 
these vessels. In the 7 day old rabbit bPAs, ketanserin (30nM) 
significantly Inhibited 5-HT responses (figure 5.21), giving an 
apparent pRB value of 8.96 ± 0.19, this value and pEC50 value could 
not be calculated at O.l~M ketansertn since the responses to 5-HT in 
the presence of this concentration of antagonist did not reach a 
maximum (figure 5.21 B). 
5-HT receotor-mediated vasodilation 
At all the age pOints studied, 5-HT, 5-CT, sumatriptan and BW 
723C86, did not cause any significant relaxation in bPAs 
precontracted with phenylephrine (0.1-0.3~M). The level of 
precontraction was Similar at each age point being 78 ± 12%, 91 
±13%, 81 ± 6% and 102 ± 14% (% contraction to 50mM KeI) in the 
foetal, 0-24 hour, 4 day old and 7 day old rabbit bPAs respectively. 
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pEC50 Emax. (%) n 
Foetal 
5-HT + lOOJ.lM L-NAME 7.21 ± O.IS 207 ± 13 6/6 
+ 30nM ketanserin 6.1 ±0.2··· 22S±24 6/6 
+ O.ljlM ketanserin 5.20 ± 0.15··· 200 ± 17 6/6 
0-24 hours 
5-HT + lOOJ.lM L-NAME 7.10 ± 0.08 106 ± 13 6/6 
+ 30nM ketansertn 5.78 ± 0.1··· 119 ± 14 6/6 
+ 0.1 jlM ketanserin 5.21 ± 0.16··· 128 ± 14 6/6 
4 day old 
5-HT + lOOJ.lM L-NAME 6.92 ± 0.13 223±2S 6/6 
+ 30nM ketanserin 5.70 ± 0.15··· 297±32 6/6 
+ O.ljlM ketanserin 5.35 ± 0.15··· 189 ± 21 8/8 
7 day old 
5-HT + lOOJ.lM L-NAME 7.23 ± 0.2 275 ± 27 6/6 
+ 30nM ketanserin 5.75 ± 0.2··· 220 ± 28 6/6 
+ 0.1 J,J.M ketanserin nc nc 6/6 
Table 5.4 Effect of ketanserin on S-hydroxytryptamine (S-HT)-induced 
contraction of perinatal rabbit extralobar branch pulmonary arteries 
in the presence of 100JlM L-NAME. Data are shown as mean ± 
s.e.mean. Emax. = maximum contractile response expressed as a 
percentage of the reference contraction to 50mM KCl. Statistical 
comparisons were made by ANOVA ··P<O.Ol, ···P<O.OOI; compared 
with respective control 5-HT pEC 50 data. n = number of 
vessels/number of animals. nc = not calculated. 
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Figure 5.18 Effect of selective antagonists on 5-HT-induced responses 
in foetal rabbit extralobar pulmonary arteries in the presence of 
100llM L-NAME. CCRCs to 5-HT ( •. n = 6/6) and in the presence of 
30nM ketanserin (~.n = 6/6). O.ljlM ketanserin (e.n = 6/6) and lllM 
GR55562 (6.n= 5/5).A Data are expressed as percentage own 
maximum contraction. B Data are expressed as percentage reference 
contraction to 50 mM KCl. Each point represents mean ± s.e.mean. n 
= number vessels/number animals. 
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Figure 5.19 Effect of selective antagonists on 5-HT-induced responses 
in 0-24 hr rabbit extralobar pulmonary arteries in the presence of 
100llM L-NAME. CCRCs to 5-HT (.,n = 6/6) and in the presence of 
30nM ketanserin (A ,n = 6/6), 0.111M ketanserin (.,n = 6/6) and 111M 
GR55562 (~,n= 6/6).A Data are expressed as percentage own 
maximum contraction. B Data are expressed as percentage reference 
contraction to 50 mM KCl. Each point represents mean ± s.e.mean. n 
= number vessels/number animals. 
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Figure 5.20 Effect of selective antagonists on 5-HT-induced responses 
in 4 day rabbit extralobar pulmonary arteries in the presence of 
100llM L-NAME. CCRCs to 5-HT (.,n = 8/8) and in the presence of 
30nM ketanserin (~,n = 6/6), O.lIlM ketanserin (e,n = 6/6) and IIlM 
GR55562 (~,n= 6/6). A Data are expressed as percentage own 
maximum contraction. B Data are expressed as percentage reference 
contraction to 50 mM KCl. Each point represents mean ± s.e.mean. n 
= number vessels/number animals. 
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Figure 5.21 Effect of selective antagonists on 5-lIT-induced responses 
in 7 day rabbit extralobar pulmonary arteries in the presence of 
100llM L-NAME. CCRCs to 5-HT (.,n = 6/6) and in the presence of 
30nM ketanserin (. ,n = 6/6), 0.1/lM ketanserin (e,n = 6/6) and 11lM 
GR55562 (.6. ,n= 6/6). A Data are expressed as percentage own 
maximum contraction. B Data are expressed as percentage reference 
contraction to 50 mM KCl. Each point represents mean ± s.e.mean. n 
= number vessels/number animals. 
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5.3.2 Pulmonary resistance arteries PBAs 
Contractile responses to 50mM KCI are shown in figure 5.22. 
PRAs from 4 day old and 7 day old rabbits produced a significantly 
greater response than PRAs from the foetal and 0-24 hour rabbits. 
The mean internal diameters (J..Lm) for the perinatal rabbit PRAs were 
243 ± 16.261 ± 19. 291 ± 26 and 287 ± 21 for the foetal. 0-24 hour. 4 
day and 7 day rabbits respectively. The mean equivalent transmural 
pressures for these vessels were 12.9 ± 0.7 mmHg. 13.1 ± 0.3mmHg. 
12.5 ± 0.6mmHg and 13.3 ± 0.9 mmHg for the foetal. 0-24 hour. 4 
day and 7 day rabbits respectively. (n > 10 animals in each age 
group). The PRAs from each age point. therefore. exhibited Similar 
internal diameters when tensioned at Similar equivalent transmural 
pressures. 
Assessment of endothelial cell inteitlty 
These vessels are known to exhibit a marked diminution in 
vasoconstrictor responses if previously preconstrlcted to known 
vasoconstrictors such as endothelin-l (ET-l) and subsequently 
washed out. To prevent this in the main studies involving 5-HT-
receptor mediated responses. the integrity of the endothelium was 
assessed in a representative sample of vessels (n = 5/5) from each age 
point. IJ..LM ACh elicited a marked vasodilator response in ET-l 
(lOnM) precontracted vessels (> 80% reversal of ET -I-induced 
contraction) in all the representative vessels from each age point 
indicating the presence of a functional endothelium (see table 5.41). 
Addition of IJ..LM SNP to Similarly precontracted vessels resulted in 
relaxation of the vessels to baseline tension at all age pOints. 
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Figure 5.22 Contractile responses to 50mM KCI in PRAs from 
perinatal rabbits. n = > 10 lungs for each age. Data are expressed as 
absolute force contraction in mN. Each column represents the mean 
± s.e.mean. Statistical comparisons were made using ANOVA followed 
by Tukey's post test; ***P< 0.001 cf. 7 day response. 
AGE ET-l induced tone Relaxatory response (% SOmM KCl) to 111M ACh (% ET-l 
induced tone) 
Foetal 67.6 ± 3.6 97±6 
0-24 hour 62.5 ± 4.5 92±8 
4 days 61.3 ± 5.S 86±6 
7 days 71.6 ± 7.8 95±5 
Table 5.4i Relaxatory responses of perinatal rabbit PRAs to 111M ACh 
follOwing pre constriction with 10nM ET-l. 
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Responses to 5-HT and the influence of NO 
Figure 5.23 shows the response to 5-HT in perinatal rabbit 
pulmonary resistance arteries. pEC50 values and maximum 
contractile responses are summarized in Table 5.5. At all ages, 5-HT 
elicited concentration-dependent contractions in the PRAs (figure 
5.23). The maximum contractile responses to 5-HT were significantly 
smaller at 4 days and 7 days than at other ages (figure 5,23 B, table 
5.5). According to pEC50 values, potencies of 5-HT at the various 
ages were in the following order: 0-24 hr > foetus ~ 7 day old > 4 day 
old. 
The response of perinatal PRAs to 5-HT in the presence and 
absence of 100llM L-NAME are shown in figures 5.24-5.27. pEC50 
values and maximum contractile responses are summarised in table 
5.5. In the foetal PRAs, NOS inhibition with L-NAME did not 
significantly alter the contractile response to 5-HT either at the 
pEC50 level or the maximum contractile response (figure 5.24, table 
5.5). There was an increase in maximum contractile response to 5-HT 
in the presence of L-NAME in the 0-24 hour PRAs (figure 5.25 B, 
table 5.5) but there was no significant change in 5-HT potency (figure 
5.25 A, table 5.5). In both the 4 day old and 7 day PRAs, inhibition of 
NOS resulted in profound increases in the sensitivity and in the 
maximum contractile responses to 5-HT (figures 5.26 and 5.27, table 
5.5. 
The order of 5-HT potency was altered in the presence of L-
NAME: 7 day» 0-24 hour = fetus> 4 day. In the 0-24hr and 4 day 
vessels, in the presence of L-NAME, the maximum responses to 5-HT 
were significantly greater than at other age pOints (Table 5.5). 
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5-lIT receptor a2Qnist studies 
The selective 5-lIT2A receptor agonist cx-methyl-5-lIT (in the 
presence of L-NAME) elicited concentration-dependent contractions 
in rabbit PRAs at all ages (Table 5.5). There was no significant 
difference in sensitivity or maximum response to a-methyl-5-HT 
when compared to 5-lIT at any other age. However, at 0-24hrs and 4 
days (as with 5-HT in the presence of L-NAME) the maximum 
responses to a-methyl-5-HT was significantly greater than at other 
age pOints (Table 5.5). 
5-CT only caused contractions at very high (> 10mM) 
concentrations, in the foetal to 7 day pertod, and the size of these 
contractions were extremely variable and never greater than -15% of 
the response to 50mM KCl. Sumatriptan did not contract vessels 
from the foetal-7 day pertod. 
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5-HT Control 5-HT+ O.lmM L-NAME a.-methyl-5-HT (+O.lmM L-NAME) 
Age pEe 50 EmaH pEe 50 EmaH pEe 50 E maH· 
Poe tUB 6.47 ± 0.11 42 ± 8 6.79 ± 0.17 66 ± 91 6.80 ± 0.19 65 ± 71 
(n = 6/6) 
0-24h 6.93 ± 0.08t 63 ± 15 6.98 ± 0.15 102 ± 8t 6.79 ± 0.16 100 ± 9 
(n = 7/7) 
4 days 5.99 ± 0.03t 15 ± 1 6.38 ± 0.12· 95 ± 20u 6.48 ± 0.19 95 ± 9 
(n = 6/6) 
7 days 6.32 ± 0.04 7 ± III 7.73 ± 0.07Ut 64 ± 2tuIII 7.57 ± 0.05 66 ± 411 
(n = 6/6) 
FjgYre 5.5 pECso and Errmc wlues for 5-hydroxytryptamine (5-HT) and oc.-methyl-5-HT in perinatal rabbit 
pulmonary resistance arteries in the presence and at5ence of 10QuM L-NAME. Emax. maximum contractile 
resJDnse (% ofresp:lnse to 50mM KCI); L-NAME: N(I)-nitro-L-azginine methylester. Statistical comp:trison using 
ANOVA:. com}El"ed with 5-HTcontrols ·P<0.05. uP<O.Ol; ,uP<O.OOl; cOmp1red with foetal resIDnse. tP <0.05; 
compared with 0-24 h data. 1p<O.05. IIp<O.Ol. §§Ip<O.OOI (ANOVA). n = number of~sels/number of rabbits. 
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Fi~ure 5.23 Contractile responses to 5-HT in perinatal rabbit 
PRAs.CCRCs to 5-HT in foetal (O,n = 6/6). 0-24 hour (.,n = 6/6), 4 
day (A ,n = 6/6) and 7 day old (O,n = 6/6) rabbit PRAs. A Data are 
expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50 mM KCl. Each 
point represents mean ± s.e.mean. n = number vessels/number 
animals. 
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Figure 5.24 Effect of L-NAME (lOO~M) on responses to 5-HT in foetal 
rabbit PRAs. 5-HT CCRCs; control (0, n= 6/6) and in the presence of 
L-NAME (e, n= 6/6). A Data are expressed as percentage own 
maximum contraction. B Data are expressed as percentage reference 
contraction to 50 mM KCI. Each point represents mean ± s.e.mean. n 
= number vessels/number animals. 
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Fi~ure 5.25 Effect of L-NAME (lOOIlM) on responses to 5-HT inO-24 
hrs rabbit PRAs. 5-HT CCRCs; control (0, n= 6/6) and in the 
presence of L-NAME (e, n= 7/7). A Data are expressed as percentage 
own maximum contraction. B Data are expressed as percentage 
reference contraction to 50 mM KCl. Each point represents mean ± 
s.e.mean. n = number vessels/number animals. 
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Figure 5.26 Effect of L-NAME (lOO~M) on responses to 5-HT in 4 day 
old rabbit PRAs. 5-HT CCRCs; control (0 , n= 6/6) and in the 
presence of L-NAME (e, n= 6/6) . A Data are expressed as percentage 
own maximum contraction. B Data are expressed as percentage 
reference contraction to 50 mM KCl. Each point represents mean ± 
s.e.mean. n = number vessels/number animals. 
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Figure 5.27 Effect of L-NAME (lOO)lM) on responses to 5-HT in 7 day 
old rabbit PRAs. 5-HT CCRCs: control (0, n= 6/6) and in the 
presence of L-NAME (e, n= 6/6). A Data are expressed as percentage 
own maximum contraction. B Data are expressed as percentage 
reference contraction to 50 mM KCl. Each point represents mean ± 
s.e.mean. n = number vessels/number animals. 
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5-lIT receptor anta~onist studies 
Figures 5.28 -5.31 show the effect of the selective antagonists 
GR55562 (lIlM) and ketanserin (30nM-0.1IlM) on 5-HT-induced 
vasoconstriction. in the presence of lOOIlM L-NAME. of perinatal 
rabbit pulmonary resistance arteries. pEC50 values and maximum 
contractile responses are summarised in table 5.6. 
5-lITys. GR55562 
The 5-lIT 1B/ 1D receptor antagonist GR55562 did not inhibit 
the 5-HT-evoked vasoconstriction in PRAs from foetal. 4 day old and 
7 day old rabbits (Figures 5.28-5.31. Table 5.6). The exception to this 
lack of antagonist effect was in the 0-24 hour PRAs (Figure 5.29). In 
these vessels. GR55562 (11lM) significantly inhibited the 5-lIT-evoked 
contraction at the level of the pEC 10 value (pEC 10 = 7.26 ± 0.03 in 
the presence of GR55562. compared to pEC 10 = 7.52 ± 0.10 without 
GR55562: P<0.05) and at the pEC20 level (pEC20 = 7.07 ± 0.05 and 
7.33 ± 0.10. with and without IIlM GR55562 respectively; P<0.05). 
In the foetal 4 day and 7 day old rabbit vessels. ketanserin 
(30nM) behaved as a potent antagonist causing concentration 
dependent parallel rightward shifts of the CCRC to 5-HT (figures 
5.28, 5.31 and 5.31, table 5.6). This inhibition of the 5-HT-induced 
response (figures 5.28 and 5.30). resulted in estimated pKB values of 
9.06 ± 0.2 and 8.5 ± 0.2 for foetal and 4 day old vessels respectively. 
where maximum responses to 5-HT were achieved in the presence of 
this antagonist. In contrast. in the 0-24 hour rabbit PRAs (Figure 
5.29), ketanserin caused a non-parallel rightward shift of the CCRC 
for 5-HT and only inhibited the contractile response to 5-HT at 
concentrations ~O.lIlM although this ketanserln resistant 
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Fi~ure 5.28 Effect of selective antagonists on 5-HT-induced responses 
in foetal rabbit PRAs. CCRCs to 5-HT (e,n = 6/6) and in the presence 
of 30nM ketanserin (O,n = 6/6), O.1IlM ketanserin (_,n = 6/6) and 
111M GR55562 (b. ,n= 6/6). A Data are expressed as percentage own 
maximum contraction. B Data are expressed as percentage reference 
contraction to 50 mM KCl. All CCRCs in the presence of 100llM L-
NAME. Each point represents mean ± s.e.mean. n = number 
vessels/number animals. 
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Fillure 5.29 Effect of selective antagonists on 5-HT-induced responses 
in 0-24 hr rabbit PRAs. CCRCs to 5-HT (e,n = 7/7) and in the 
presence of 30nM ketanserin (O,n = 6/6), 0.111M ketanserin ( •. n = 
6/6) and 11lM GR55562 (6,n= 6/6). A Data are expressed as 
percentage own maximum contraction. B Data are expressed as 
percentage reference contraction to 50 mM RCI. All CCRCs in the 
presence of 100llM L-NAME. Each point represents mean ± s.e.mean. 
n = number vessels/number animals. 
241 
I\) 
~ 
I\) 
2.5 
-l 
C') 
::l 
en 
. . .. ~~~-~r~~ t 
A 
o· 
::l 
,-... 
~ 
0 
log [5-HT] (M) 
-8 -7 . 
-6 -9 
-5 B 
--- . 
~ . - .. .. .• 1~ '~-1~~~~·-~ ~: --. 
,k- _ -';\IM - .' -- --, .-i 
j + _-C: t ..... -.'. --. t - t : 
t 
50 mM KCl log [5-HT] (M) -8 -7 -6 -5 
Figure 5.29C Representative trace showing the effect of ketanserin (30nM) on 5-HT-evoked 
contractions in 0-24 hour old rabbit isolated PRAs. A. In the presence and B. in the absence 
of ketanserin. Responses are compared with response to 50mM KCl. Vessels were incubated 
with 190J.lM L-NAME prior to and throughout the cumulative addition of 5-HT. Responses 
are compared with response to SOmM KCl. 
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Figure 5.30 Effect of selective antagonists on 5-HT-lnduced responses 
in 4 day old rabbit PRAs. CCRCs to 5-HT (.,n = 6/6) and in the 
presence of 30nM ketanserin (O,n = 6/6), O.l~M ketansertn (_, n = 
6/6) and l~M GR55562 (~, n= 6/6). A Data are expressed as 
percentage own maximum contraction. B Data are expressed as 
percentage reference contraction to 50 mM KCl. All CCRCs in the 
presence of 100)lM L-NAME. Each point represents mean ± s.e.mean. 
n = number vessels/number animals. 
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Figure 5.31 Effect of selective antagonists on 5-HT-induced responses 
in 7 day old rabbit PRAs. CCRCs to 5-HT (e, n = 6/6) and in the 
presence of 30nM ketanserin (O,n = 6/6), O.1IlM ketanserln (_, n = 
6/6) and 111M GR55562 (~,n= 6/6). A Data are expressed as 
percentage own maximum contraction. B Data are expressed as 
percentage reference contraction to 50 mM KCl. All CCRCs in the 
presence of 100llM L-NAME. Each point represents mean ± s.e.mean. 
n = number vessels/number animals. 
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tv 
~ 
CJ1 
5-HT Control + 1.0~ GR55562 + 300M ketanserln + 0.1J,lM ketanserln 
Age pEC50 n pEC50 n pEC50 n pEC50 n 
Fetus 6.79 ± 0.17 6/6 6.71 ±0.10 6/6 5.22 ± 0.14** 6/6 <4 6/6 
0-24 hour 6.9B±0.15 7/7 6.64 ± 0.06 6/6 6.56±0.13 6/6 5.07 ± 0.02* 6/6 
4 day 6.3B±0.12 6/6 6.40±0.IB 6/6 5.34 ± 0.10** 6/6 <4 6/6 
7 day 7.73±0.07 6/6 7.62 ±0.06 6/6 5.63 ± 0.22** 6/6 <4 6/6 
Table 5.6 pEC50 values for 5-hydroxytryptamine (5-Hf, in the presence of l00flM L-NAME) in perinatal rabbit 
pulmonary resistance arteries: effects ofketanserin and GR55562.Statistical comparisons were made by ANOVA: 
5-Hf pEC50 vs 5-Hf + ketanserin at same age point; * P<0.05, ** P<O.Ol.Values are shown as mean ± s.e.mean.n = 
number of vessels/number of animals. 
component fonned only - 20-30% of the total contractile response to 
5-HT. Although this concentration of ketanserin did not significantly 
affect the pEC50 in these vessels (Table 5.6). the pEC75 and pEC80 
values (5.64 ± 0.2 & 5.45 ± 0.21 respectively) were significantly less 
(P< 0.01) than their respective control values of 6.76 ± 0.12 & 6.72 ± 
0.12). In these 0-24 hr vessels. 100nM ketanserln did Inhibit 
responses to 5-HT in a competitive fashion with a parallel rightward 
shift in the CCRC giving an estimated pKB of 8.91 ± 0.2. At 7 days 
(Figure 5.31). 30nM ketanserin inhibited responses to 5-HT with an 
estimated pKB = 9.6 ± 0.2. The CCRC to 5-HT in the presence of 
0.1JlM ketanserln. failed to reach a maximum within the 
concentration range examined in vessels from foetal (figure 5.28 B). 4 
day old (figure 5.30 B) and 7 day old (figure 5.31 B) animals. pKB and 
pEC50 values could therefore not be calculated at this antagonist 
concentration. 
5-CT-mediated vasodilation 
The contractile response to ET-1 (0.1-10nM) in the perinatal 
rabbit PRAs was similar in each age group being 47 ± 12%. 51 ± 15%. 
44 ± 9% and 53 ±13% (% contraction to 50mM KCl) In the foetal. 0-
24 hour. 4 day old and 7 day old rabbit PRAs respectively. 
Figure 5.32 shows the vasodilator effect of 5-CT in perinatal 
rabbit PRAs precontracted with ET-l. 5-CT evoked concentration-
dependent vasodilation in the vessels of both the 4 day and 7 day old 
animals (figure 5.32). The pIC50 values were 7.1 ± 0.2 and 7.5 ± 0.2 
for the 4 day old rabbit (n = 7/7) and 7 day old rabbit (n = 6/6) 
respectively. The respective maximal relaxations were 91 ± 5% and 91 
± 2 % (0/0 relaxation of ET-1-induced tone). 5-CT failed to elicit 
relaxation of any significance in the foetal and 0-24 hour rabbit 
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vessels (figure 5.32). In the 4 day old rabbit PRAs, L-NAME virtually 
abolished vasodilation induced by 5-CT, significantly reducing the 
maximal vasodilator response to 21 ± 6 (P<O. 01; cf. con troll, 
suggesting an indirect, NO-dependent dilation at this age (figure 
5.33). In these 4 day vessels, GR55562 (l~M) inhibited 5-CT-induced 
vasodilation (see figure 5.33C) significantly increasing the pIC50 
value to 5.7 ± 0.2 (P <0.001 cf. control 5-CT response) without 
affecting the maximal vasodilator response (98 ± 5%). This gave an 
apparent pKB value of 7.36 ± 0.3 (figure 6.33) in these vessels. 
Figure 5.34 shows the effect of NO synthase inhibition and 
GR55562 on 5-CT-induced vasodilation in ET-1 precontracted PRAs 
from the 7 day rabbits. 100~M L-NAME significantly reduced the 
maximum dilation to 5-CT (43 ± 5%; P<O.O 1) compared to control 
responses to 5-CT but there was no significant change in sensitivity 
in terms of the pIC50 value (7.3 ± 0.3, figure 6.34 A). This suggests 
that L-NAME only partly blocked the 5-CT-induced dilation at this 
age (figure 6.34). In these 7 day vessels, GR55562 (l~M) only 
inhibited the dilation evoked by high concentrations of 5-CT (figure 
6.34 B). In the presence of 100~ L-NAME and 0.1~M ketanserin, 
the 5-lIT'7 receptor antagonist spiperone (l~M) was a potent inhibitor 
of the vasodilator responses to 5-CT causing a concentration-
dependent. parallel rightward shift in the CCRC to 5-CT in the 7 day 
vessels (figure 7.35). The pIC50 value was significantly reduced to 5.6 
± 0.3 (P<0.001; cf. 5-CT pIC50in the presence of 100~M L-NAME) and 
the estimated pKB for spiperone was 7.64 ± 0.3. 
Time control data are also shown (figures 5.33-5.35) and 
illustrate the falloff in vascular tone during the time course of each 
experiment. This was significantly different from the control 5-CT 
response data at every time point of 5-CT administration where 5-CT 
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induced a relaxation. 
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Figure 5.32 Relaxation by 5-carboxamidotryptamine, of ET-l pre-
contracted foetal (O,n = 6/6), 0-24 hr (_, n = 6/6). 4 day (~, n = 7/7) 
and 7 day (e, n = 6/6) rabbit PRAs in the presence of O.I~M 
ketanserin. Data are expressed as % relaxation of the ET-I-induced 
pre-contraction. Each point represents mean ± s.e.mean. n = number 
vessels/number of animals. 
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Figure 5.33 Effect of L-NAME (lOO)lM) and GR55562 (lIJ.M) on 5-CT-
induced relaxation in ET-l pre-contracted 4 day old rabbit PRAs in 
the presence of O.lIJ.M ketanserin. CCRCs to 5-CT; control (e. n = 
6/6) and in the presence of L-NAME (O.n = 6/5 ) and GR55562 ( • . n 
= 6/5). Time control pre-contractile data are also shown ( 6. n = 
6/6). A Data are expressed as percentage own maximum relaxation. 
B Data are expressed as percentage relaxation of the ET- l 
precontraction. Each point represents mean ± s.e.mean. n = number 
vessels/number animals. 
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Figure S.33C Representative trace showing the effect of GR55562 (111M) on 5-CT evoked 
relaxations in 4 day old rabbit isolated PRAs. A. In the presence and B. in the absence of 
GR55S62 . Vessels were pre-contracted with ET-l (l n M) prior to the cumulative addition of 5 -
CT. 
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Figure 5.34 Effect of L-NAME (lOOIlM) and GR55562 (lIlM) on 5-CT-
induced relaxation in ET-l pre-contracted 7 day old rabbit PRAs in 
the presence of O.lJ1.M ketanserin. CCRCs to 5-CT: control (e, n = 
6/6) and in the presence of L-NAME (.,n = 6/5 ) and GR55562 (D.n 
= 6/5). Time control pre-contractile data are also shown ( 6, n = 
6/6). A Data are expressed as percentage own maximum relaxation. 
B Data are expressed as percentage relaxation of the ET- 1 
precontraction. Each point represents mean ± s.e.mean. n = number 
vessels/number animals. 
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Figure 5.35 Effect of spiperone (l~M) on 5-CT-induced relaxation in 
ET-l pre contracted 7 day rabbit PRAs. in the presence of lOO~M L-
NAME and O.lJ.1M ketanserin. CCRCs to 5-CT; control (e.n = 6/5) 
and in the presence of spiperone (D.n = 6/5). Time control pre-
contractile data are also shown ( £. n = 6/6).A Data are expressed as 
percentage own maximum relaxation. B Data are expressed as 
percentage relaxation of the ET-l precontraction. Each point 
represents mean ± s.e.mean. n = number vessels/number animals. 
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5.4 Discussion 
The results of this chapter demonstrate that. in rabbit 
perinatal pulmonary arteries. both the contractile and vasodilator 
responses to 5-HT-receptor activation alter significantly with 
developmental age and that endothelium-derived NO plays a 
significant role in modulating these responses following birth and 
during the first week of life outside the uterus. Very marked 
functional changes are thus seen during the transitional stage of the 
pulmonary c1rculation as it adapts to fulfilling its vital normal 
function of in vivo gas exchange (Inselman & Mellins. 1976). 
The response to KCI in the pulmonary arteries provides an 
indication of the integrity and mass of smooth muscle in the 
preparations as KCI med1ates contraction through its effect on 
membrane potential (Burnstock et al, 1963) and is therefore receptor 
independent. The contractile response to KCI at the three levels of 
the pulmonary vascular tree in this study. significantly Increased 
from birth to the first seven days of life. suggesting a continued 
smooth muscle extension or maturation in the pulmonary arteries 
within the first 7 days of life outside the uterus. Similar results for 
small intrapulmonary arteries from foetal and neonatal lambs have 
been previously reported (Dunn et al, 1989). although in that study. 
vessels with a larger internal diameter (530-1000Jlm) demonstrated 
no Significant change in KCI-induced contraction. This may reflect a 
species difference in the maturation of the pulmonary arteries. 
Pulmonary conduit arteries 
Endothelium -dependent vasodilation 
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In assessing the integrity of the endothelium in the PCAs. a 
marked alteration in the response to ACh in NA pre-constricted 
vessels was noted indicating developmental changes in the ACh-
induced vasodilation of rabbit conduit pulmonary arteries during the 
perinatal period into the fIrst week of extra-uterine life. ACh-induced 
vasodilation was substantial in the 2 day preterm foetal vessels. 
absent in the 0-24 hour vessels and restored by 4 days. The loss of 
ACh-induced vasodilation in pulmonary arteries immediately after 
birth suggests NO activity is transiently compromised immediately 
after birth and is in agreement with previous reports in newborn 
isolated pulmonary arteries from other species ( Lui et al.. 1992: 
Steinhorn et al.. 1993). This could reflect changes in expression of 
eNOS. ACh-induced prostaglandin release. changes in muscarinic 
receptor number or decreased sensitivity of the tissue to NO at birth ( 
Lui et al.. 1992: Steinhorn et al.. 1993). The 'transient loss' in these 
vessels was extensively investigated further in a separate study not 
presented in this thesis (see Morecroft & MacLean. 1998) where the 
findings are discussed more extensively. Those findings suggested 
that ACh-induced NO activity may be compromised by endogenous 
superoxide anion production and deficiencies in endogenous 
superoxide dismutase (SOD) activity at birth as pre-incubation with 
SOD uncovered ACh-induced vasodilation in the 0-24 hour vessels 
(Morecroft & MacLean. 1998). 
Besides the release of NO. ACh can induce pulmonary 
vasodilation via the production and release of prostacyclin and 
EDHF from endothelial cells (Chand & Altura. 1981. Nagao & 
Vanhoutte. 1993). The NOS- and prostacyclin-independent 
component of the relaxation response to ACh Is accompanied by an 
endothelium-dependent hyperpolarization of vascular smooth 
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muscle. criteria which define EDHF (Chen. et al.. 1988: Zygmunt, et 
al.. 1997). In rat pulmonary arteries. for example. EDHF is thought 
to mediate about 20-25% of the relaxation induced by ACh (Chen. et 
aL. 1988). EDHF has been reported to contribute to the variabil1ty in 
ACh-induced relaxation of rabbit isolated arteries from different 
vascular beds (Trtggle. et al .• 1999). It is unlikely. however. that 
EDHF (or prostacyclin) plays any major role In mediating the 
vasodilator response to ACh in the perinatal rabbit PCAs. L-NAME 
abolishes ACh-induced vasodilation in these vessels suggesting that 
NO is the main endothelium-derived factor responsible for ACh-
induced relaxation (Morecroft & MacLean. 1998). 
Vasoconstrictor response to 5-J-IT and the influence of NO 
5-HT was a potent vasoconstrictor of perinatal rabbit 
pulmonary conduit arteries at all age pOints studied with a potency 
order of 7 day = foetus = 4 days> 0-24 hours. Dunn and co-workers 
(1989) also observed a similar fall in sensitivity to 5-HT-evoked 
contractions in 1 day old lambs compared to older neonates and 
suggested that this may be an important. selective mechanism in the 
newborn in adjusting to the stress of birth. allowing the maintenance 
of the marked drop in PVR vital at birth. and in spite of the presence 
of high circulating levels of vasoconstrictor agents. 
Several studies have suggested that spontaneously released 
NO plays an active role in aiding the maintenance of the pulmonary 
vasculature at a low state of tone in adult pulmonary arteries 
(Cremona et a~ 1994: Steeds et a~ 1997) including man (Cremona et 
al: 1994); and in the adaptation of the perinatal pulmonary 
circulation to extra-uterine life (Davidson & Eldermerdash. 1991). An 
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increase in pulmonary vascular NOS enzyme activity is thought to 
occur after birth. For example Hislop et al (1993) have shown an 
abundance of endothelial NOS at birth in the Intra-pulmonary 
arteries of neonatal piglets, using immunocytochemistry, which 
reaches a peak by 2-3 days old and then decreases to adult levels by 
the second week of extra-uterine life. Similarly, In the newborn rat, 
the highest levels of constitutive endothelial NOS (eNOS) mRNA were 
detected by 24 hours after birth (Kawai et at 1995). In human 
neonates, an increase in serum NO metabolites was observed between 
birth and 5 days of age (Endo et al., 1996). The possibility that NO 
was having an inhibitory effect on the 5-HT-evoked contractile 
responses in the perinatal rabbit pulmonary arteries was Investigated 
using the eNOS enzyme Inhibitor L-NAME (Rees, et at 1990) as this 
was demonstrated in adult rabbit PRAs (see chapter 3). Studies using 
isolated vessels from other vascular beds in the rabbit have also 
demonstrated a marked inhibitory effect of NO on the contractile 
responses to 5-HT (Valentin et al., 1996). 
L-NAME alone produced an increase in baseline tension in the 
foetal, 4 day and 7 day old rabbit vessels highlighting a significant 
contribution of endogenous NO to basal tone in these vessels. In the 
foetal vessels, the response to L-NAME appeared to be smaller than 
in the 4 and 7 day old bPAs. The lack of contraction to L-NAME in 
the 0-24 hour vessels suggests that basal NO was compromised at 
this age: subsequent studies were carried out and showed this may be 
due to an excess of superoxide anion production at birth (More croft 
& MacLean, 1998). In contrast, from the results of chapter 3, in adult 
rabbit extralobar arteries, L-NAME did not cause a Significant, 
sustained contraction highlighting a maturational change in these 
vessels to a non-existent basal NO release in the adult bPAs. 
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Inhibition of NO synthesis with L-NAME significantly potentiated the 
magnitude of the maximal response to 5-HT in the extralobar branch 
pulmonary arteries at all age pOints studied suggesting a marked 
depressant effect of NO on contractions to 5-HT in these vessels. 
The most pronounced effects in terms of maximal response 
were shown in the bPAs from the 4 day old rabbit. In contrast. the 
presence of L-NAME had no effect on maximal contractile response to 
5-HT in the main pulmonary artery from birth onwards. In the foetal 
main pulmonary artery however. NO synthase inhibition did result in 
a marked augmentation of the contractile response to 5-HT as well as 
an increased sensitivity to 5-HT. These findings indicate functional 
differences between vessels of different sizes in the tranSitional 
pulmonary Circulation. In the absence of endogenous NO. in the 
presence of L-NAME. the potency of 5-HT in the bPAs at the various 
ages was 0-24 hour = foetus = 7 day >4 day old rabbits. 
Interestingly. in the 0-24 hour rabbit bPAs. NOS inhibition 
resulted in a marked increase in sensitivity to 5-HT which was not 
observed at any other developmental age up to the first week of extra-
uterine life. These observations suggest that the sensitivity to 5-HT is 
normally attenuated by NO in 0-24 hour vessels. It is unclear. 
however. why this marked increase is observed in these vessels in the 
presence of L-NAME despite the observations that L-NAME produced 
no observed increase in the baseline tension of the 0-24 hour rabbit 
bPAs. indicating a lack of basal NO release. One possible explanation 
could be that in these vessels. a population of 5-HT receptors may 
exist on the endothelium which mediate release of NO as this has 
been shown recently in the porcine pulmonary artery (Glusa. et al, 
1993: Glusa & Pertz. 2000) where activation of endothelial 5-HT2B 
receptors is thought to stimulate NO release. leading to vascular 
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relaxation. This has also been demonstrated in the rat jugular vein 
(Ellis. et al. 1995). A greater contractile response to 5-HT would 
therefore be expected in these 0-24 hour vessels in the presence of L-
NAME if these receptors were present. This explanation. however 
seems unlikely as no evidence was found for 5-HT agonist-mediated 
relaxation of pre-contracted bPAs from the 0-24 hour rabbit. Indeed. 
no evidence for 5-HT receptor mediated vasodilation could be found 
at any of the developmental ages studied. The results in chapter 3 of 
this thesis. show that the adult rabbit extralobar pulmonary arteries 
contain a population of 5-HT receptors (probably the 5-HT7 type) 
which directly mediates vasorelaxation in these pre contracted 
vessels. The results in this chapter. therefore. highlight a 
maturational change in vasodilator 5-HT receptors which appear 
after the first week of life and by adulthood in the rabbit extralobar 
branch pulmonary arteries. 
Another potential explanation exists. Plasma ET-l 
levels in the newborn piglet have been shown to be greater at birth 
than at 3 days old or later (Levy. et a~ 1995) and a Similar occurrence 
has been shown in the human infant (Malamitsi et a~ 1993; Endo. et 
a~ 1996). Threshold concentrations of ET -1 are known to potentiate 
the contractile response to 5-HT in rat mesenteric arteries 
(Hempelmann. et a~ 1999) and contractions to other vasoconstrictors 
such as noradrenaline (Tabuchi. et al.. 1989). The results in chapter 6 
of this thesiS also indicate that this 'synergism' occurs in rat PRAs 
where low concentrations of ET-l produced a significant potentiation 
of 5-HT receptor mediated contraction and this is fully discussed in 
that chapter. A synergistic potentiation of the sensitivity to 5-lIT in 
the 0-24 hour rabbit vessels. in the presence of L-NAME. may 
therefore occur at a time when plasma ET-l levels are known to be 
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elevated. No evidence. however. of potentiated 5-HT1 receptor-
mediated contractions could be found either in the presence of raised 
tone or L-NAME in these vessels. making this explanation unlikely. 
It could be concluded that at this age point there are changes 
in the coupling of the second messenger system with the contractile 
apparatus in the presence of NOS inhibition. a possibility that would 
require further investigation. 
Several studies have reported that. at high concentrations 
(> Ij.1M). 5-HT can mediate an indirect vasoconstrictor effect via 
activation of (l-adrenoceptors in some rabbit large blood vessels 
including the femoral artery (Grandaw & Purdy. 1996). ear artery 
(Black et al .• 1981) and aorta (Purdy et al.. 1987). In the rabbit 
isolated femoral artery. for example. 5-HT elicits a blphaslc 
concentration response curve. The first phase being sensitive to 
antagonism by ketanserin and the second phase blocked by the 
selective (l1-adrenoceptor antagonist benextramine (Grandaw & 
Purdy. 1996). The involvement of an (l1-adrenoceptor in the 
contractile response to 5-HT in the rat pulmonary conduit artery has 
also been reported (Ogawa et aL. 1995). Noradrenaline has previously 
been shown to be a very poor vasoconstrictor of perinatal rabbit PRAs 
and actually fails to contract PRAs from adult rabbits (Docherty & 
MacLean. 1998). In addition. the preliminary experiments in adult 
rabbit conduit pulmonary arteries in chapter 3 of this thesis failed to 
demonstrate any effect of the (l1-adrenoceptor antagonist prazosin on 
contractile responses to 5-HT. Hence a contribution of (ll-
adrenoceptors to 5-HT-induced responses in these perinatal vessels Is 
unlikely although cannot be strictly ruled out without the use of 
selective (l}-adrenoceptor antagonists. 
It has also been reported that high concentrations of 5-HT 
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can have indirect sympathomimetic actions by releasing 
noradrenaline from perivascular sympathetic nerve endings 
(McGrath. 1977; Saxena & Villalon. 1990). Further studies would 
need to be performed to clarify if this occurs in perinatal rabbit 
pulmonary arteries. 
One of the most important determinants of vascular reactivity 
to a particular agonist is the receptor subtype to which the agonist 
binds. It is therefore possible that any changes In the sensitivity and 
reactivity to 5-HT related to perinatal development in the pulmonary 
arteries may be associated with changes in 5-HT receptor type. This 
possibility was investigated in the perinatal rabbit bPAs (and later 
the pulmonary resistance arteries) using selective 5-HT receptor 
agonists and antagonists. 
5-lIT receptor a~onist and anta~onist studies 
As L-NAME did not significantly affect the contractile 
response to 5-HT in the main pulmonary artery of the perinatal 
rabbits (the foetal vessels being the exception) compared to its effect 
on the bPAs. the agonist and antagonist studies in the pulmonary 
arteries focused on the bPAs. 
In the bPAs from all age pOints studied. 5-HT was more potent 
in inducing contraction than either 5-CT or sumatriptan and was 
equipotent to the 5-HT2 receptor agonist a-methyl-5-HT. These data. 
with an agonist potency order of 5-HT= a-methyl-5-HT > 5-CT » 
sumatrtptan are consistent with the mediation of 5-HT-lnduced 
contraction via a 5-HT2 receptor type according to the criteria 
established by Hoyer et al. (1994). 5-CT displayed a low potency 
(pECsos -5.6-6.2) in bPAs at all age pOints studied. suggesting that 
these contractile responses to 5-CT were mediated via 5-HT2 receptor 
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stimulation as 5-CT has previously been shown to typically display 
pEC50 values of -7.9-8.6 at most 5-HTl receptors (Hoyer, et al. 1994). 
The virtual absence of any contractile response to sumatriptan, 
known to be a selective agonist at 5-HTIB and 5-HTID receptors 
(Peroutka & McCarthy, et al. 1989), also strongly suggests that these 
receptor subtypes are absent in perinatal rabbit extralobar branch 
pulmonary arteries. 
Several studies on isolated pulmonary arteries have shown 
that contractile responses to sumatriptan can be augmented or 
'uncovered' by the eNOS inhibitor L-NAME and by raised tone. For 
example, in isolated bOvine pulmonary artertes, MacLean et al. (1994) 
demonstrated that in the presence of L- NAME, which effectively 
decreases cGMP levels, or in the presence of raised tone, the 
senSitivity to sumatriptan were significantly increased -3 fold and 
-15 fold respectively. A marked increase in the maximum 
contraction to sumatriptan was also observed. The same authors 
have also observed a Significant increase in the sensitivity of this 
agonist in isolated human pulmonary arteries in the presence of L-
NAME (MacLean, et al. 1993). This may be pathophysiologically 
important in pulmonary hypertenSion where both a decrease in cGMP 
levels and increase in vascular tone, alongside potentiated responses 
to 5-HTIB receptor-induced contraction, have been observed in 
pulmonary arteries from the chronic hypoxiC rat model of pulmonary 
hypertenSion (Maclean, et al, 1996). This phenomenon may also be 
of pathophysiological importance in PPHN when considering the 
observation that in the prenatal model of PPH in the lamb, impaired 
production of cGMP is evident (Steinhorn et al, 1995) as well as 
decreased endothelial NO synthase gene expression. The possibility of 
augmented responses to sumatriptan under conditions of raised 
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pulmonary vascular tone and decreased cGMP levels through NOS 
inhibition was investigated in the bPAs from perinatal rabbits. 
In the foetal, 0-24 hour and 7 day vessels, there was no 
significant effect of either raised tone or eNOS inhibition with L-
NAME, suggesting an absence of 5-HTIB/ID receptors in these 
vessels. In contrast, in the 4 day old vessels, a small but significant 
reduction in the threshold concentration for contraction to 
sumatriptan was evident in the presence of L-NAME and in the 
presence of raised pulmonary arterial tone suggesting an 'uncovering' 
of a small population of 5-HTl receptors, this however requires 
further pharmacological investigation with appropriate antagonists. 
Studies with the selective antagonists provide further evidence 
that in the perinatal extralobar branch pulmonary arteries, the 
predominant 5-HT receptor type mediating 5-HT-induced 
vasoconstriction is the 5-HT2A receptor. The near nM affinities 
observed for ketanserin against 5-HT in these vessels (pKB -8.6-9) is 
consistent with 5-HT mediating its vasoconstrictor effects via the 5-
1IT7A receptor (Van Neuten, et al, 1981; Leff & Martin, 1986). 
Ketanserin has also been shown to display 5-HTID receptor 
antagonist activity, but only in the micromolar range (Kaumann et 
al, 1993). The marked inhibition of 5-HT-induced contractions by 
concentrations of ketanserin below this micromolar range, impUes 
that ketanserin is mediating its antagonist effect at the 5-HT2A 
receptor rather than the 5-lITID receptor in perinatal rabbit peAs. 
In chapter 3 of this thesis, in the adult rabbit extralobar 
branch pulmonary artery, the affinity for ketanserin was -9, Similar 
to that observed in these perinatal vessels and suggesting that there 
is no significant maturational change in the 5-lIT receptor subtype 
mediating 5-HT-induced vasoconstriction in rabbit conduit 
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pulmonary arteries. The lack of any antagonist effect of GR55562. the 
selective antagonist at 5-HTIB and 5-HTID receptors. again provides 
further strong evidence against the presence of either of these 
receptors in these vessels. In the presence of L-NAME, there was no 
alteration in the affect of the selective antagonists ketanserin or 
GR55562 on the 5-HT-induced contractions in the perinatal rabbit 
vessels, underlining the proposition that perinatal rabbit pulmonary 
conduit arteries contain a single population of 5-HT receptors, 
namely the 5-lIT2Areceptor, which mediate the contractile effects of 
5-HT and that there is no significant shift in receptor subtype 
mediating these effects with developmental age. 
Together, these findings suggest that the changes in the 
branch pulmonary arteries reactivity to 5-lIT during the first week of 
extra-uterine life in the rabbit probably do not involve changes in 5-
HT receptor subtype. but rather alterations in the coupling of the 
receptor to the contractile apparatus. 
Pulmonary resistance arteries 
Vasoconstrictor response to 5-HT and the influence of NO 
The results of this chapter demonstrate a marked alteration in 
5-HT-induced vasoconstriction in perinatal rabbit PRAs between near 
term foetal life. birth and during the first 7 days of extra-uterine life. 
with the 0-24 hour vessels displaying the greatest sensitivity to 5-HT. 
Several studies have suggested that NO is released under 
basal conditions to maintain the pulmonary vasculature under a low 
state of tone in both adults (Wiklund et at, 1990: Steeds et al., 1997) 
and in neonatal guinea pigs (Davidson et al., 1991). The posSib1l1ty 
that NO was having an inhibitory effect on the 5-HT-induced 
contractile response was investigated as this has been demonstrated 
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in the perinatal rabbit conduit pulmonary arteries (described earlier 
in this chapter) and in other rabbit vascular preparations such as the 
isolated basilar artery and saphenous vein (Trezise. et al. 1992: 
Valentin et al. 1996). Inhibition of NO synthesis with L-NAME 
significantly potentiated the maximum contractile response to 5-HT 
at all ages. except the foetus. In the foetal PRAs the presence of L-
NAME had no effect on senSitivity or magnitude of the maximal 
response of 5-lIT. At this age. the sensitivity of the PRAs to 5-HT is 
-2.5 fold greater than in adult rabbit PRAs (see chapter 3 of this 
thesis). One of the bioactive secretory products of pulmonary 
neuroendocrine cells (PNECs) in the lung is 5-HT. In the developing 
human lung. these PNECs have been shown to be immunoreactive for 
5-lIT as early as 8 weeks gestation (Cutz. et al. 1985). to increase in 
number towards term and they are greatest in number in the foetus 
and newborn (Johnson & Georgieff. 1989). These observations. 
coupled with the results in this chapter. which show 5-lIT to be a 
potent vasoconstrictor of foetal PRAs. suggest the possibility that 
this bioamine could contribute directly to the elevated pulmonary 
vascular tone of the foetus. Vessels of similar order of magnitude 
examined in this study make a significant contribution to in vivo PVR 
(Staub. 1985). 
PRAs from the 0-24 hour rabbits also demonstrated no 
alteration in sensitivity to 5-lIT. whilst a marked augmentation of 
the contractile response was observed. In the absence of endogenous 
NO. in the presence of L-NAME. the potency of 5-lIT at the various 
ages was: 7 day»0-24 hr = foetus> 4 day. This suggests variable 
developmental changes in 5-HT receptor sensitivity or changes in the 
coupling of the second messenger system with the contractlle 
apparatus. 
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One possibility could be developmental changes in Ca2+ 
sensitivity of the contractile myofilaments of the PRAs as recent 
studies clearly establish Ca2+ sensitivity as a variable determinant of 
vascular reactivity in many vascular beds (Nishimura. et al.. 1989: 
Somlyo and Somlyo, 1994). It is now well established that receptor-
mediated activation of vascular smooth muscle elicits a 
proportionally smaller change in cytosolic Ca2+ for a given 
production of force than does depolarization with K+ (Rembold & 
Murphy, 1988). suggesting that modulation of the Ca2+ sensitivity of 
the contractile apparatus is a key mechanism governing overall 
reactivity (Somlyo & Somlyo. 1994). Moreover. agonist-induced Ca2+ 
sensitization is responsible for a significant portion of the increase in 
contractile tone resulting from activation of 5-HT receptors (Parsons, 
et aL. 1996). 
Ca2+ sensitivity and/or its alteration by G protein-dependent 
mechanisms may determine variations in pulmonary vascular 
reactivity associated with differences developmental age. 
Developmental changes in baseline Ca2+ sensitivity have recently 
been demonstrated in rabbit common carotid. basilar and femoral 
arteries (Akopov, et al .• 1998). In the same study, 5-lIT demonstrated 
an increase in Ca2+ sensitivity via a G-protein coupled mechanism 
which was more effective in neonatal than adult arteries. It would 
therefore be useful to investigate contractile myofilament sensitivity 
during perinatal development. 
Frid et al (1994) indentified phenotypiC alterations of distinct 
smooth muscle cell populations with development. It would also be 
useful to investigate contractile protein regulation during perinatal 
development in these vessels. Docherty & Maclean. (1998) recently 
reported a Similar phenomenon for ET-l induced contraction in the 
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same preparations. 
The effect of NOS inhibition was most pronounced in the 
vessels removed from the 4 and 7 day old rabbits where the 
contractile response to 5-HT. in the absence of L-NAME. was 
extremely small. This suggests that significant responses to 5-HT in 
these vessels are normally masked by endogenous NO production in 
these vessels at this age and that sensitivity to 5-HT Is normally 
attenuated by NO in the 4 day and especially in the 7 day rabbit 
vessels. These results suggest that there Is an increase in NO 
production associated with birth in these vessels. One interpretation 
of this data is that 5-lIT can cause release of NO in 4 and 7 day old 
vessels but is less able. or unable. to do this in the vessels from the 
foetus and 0-24 hr old rabbits. This is confirmed by the studies 
discussed later in this chapter on 5-HT receptor-induced. NO-
dependent vasodilation. which was only present in the vessels from 
the 4 and 7 day old rabbits. In the 7 day old vessels. in the presence 
of L-NAME. a fall in tension at the higher concentrations of 5-HT 
was observed. One explanation is that. in these vessels. 5-HT may 
activate a 5-HT receptor subtype which causes direct pulmonary 
arterial smooth muscle relaxation. This receptor has been shown to 
directly mediate smooth muscle relaxation in a variety of isolated 
vascular tissues such as the neonatal pig vena cava rrrevethick. et at 
1986) and the canine coronary artery (Terron. 1996) and has been 
claSSified as the 5-HT7 receptor which is positively cou pled to 
adenylate cyclase. The results deSCribed later in this chapter provide 
evidence that this may be so. via a 5-HT7 receptor population. Other 
possibilities. however cannot be ruled out including the actions of 
mediators such as PGI2 or EDHF. or that the fall in tension may be 
due to desensltlsatlon of the 5-HT-induced response. 
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The response of the fetal PRAs to NO synthase inhibition 
differs from that of the rabbit foetal pulmonary conduit arteries 
where L-NAME markedly potentiated the size of the 5-HT 
vasoconstrictor response, this is discussed earlier in this chapter. 
This comparison suggests heterogeneity of NO activity throughout 
the pulmonary arterial bed in the foetal rabbit, with 5-HT-sensitive, 
endogenous NO activity being present in the large conduit arteries 
but not in the small muscular pulmonary arteries. Such 
heterogeneity has been observed in the adult rat where eNOS can be 
detected in large conduit arteries but not small muscular vessels (Le 
Cras et at, 1996). 
In comparison to neonatal PRAs, the lack of effect of eNOS 
inhibition on 5-Hf-induced responses of foetal vessels suggests there 
are diminished NO levels in the pulmonary resistance vasculature in 
near term foetal compared with extra-uterine life in the first week. 
These results are Similar to previous studies in pigs and sheep, 
showing a diminution of basal and stimulated NO release from 
isolated pulmonary arteries of the near term foetus compared to 
neonatal animals (Abman, et al, 1991; Zellers & Vanhoutte, 1991; 
Lui, et al, 1992; Steinhorn, et al, 1993). In the previous study on 
foetal rabbit conduit pulmonary arteries, these were exposed to 
relatively low oxygen tensions, hence this excludes the possibility 
that these low oxygen tensions had inhibited NO production in the 
present study. The foetal PRAs were therefore maintained at the 
oxygen tension expected in utero. As Docherty and MacLean (1998) 
have shown that these foetal PRAs demonstrate a marked relaxation 
response to ACh, this suggests that there are differential effects on 
the control of agonist-induced NO release (by ACh) and basal release 
of NO in these pre-term vessels. This has also been suggested by 
267 
Cremona et al (1994) who investigated the inhibition of NO release in 
isolated human, ovine, porcine and canine lungs. 
5-lIT receptor a20nist studies 
Due to the inhibitory role of NO on constrictor responses to 5-
HT at some age pOints, the response to the selective 5-HT agonists 
(and antagonists) were investigated in the presence of L-NAME. 
5-HT and a-methyl-5-HT were eqUipotent in their ability to 
induce vasoconstrictor responses in the PRAs from the perinatal 
rabbits at all age pOints studied. As previously described, an agonist 
potency order of 5-HT = a-me-5-HT > 5-CT satisfies one of the 
criteria for classifying 5-HT2 receptors (Hoyer et al., 1994). In this 
study, the rank order of agonist potency in the PRAs from foetal 
rabbits to 7 days of age was 5-lIT = a-me-5-HT » 5-CT. 
Sumatriptan did not induce contraction in these vessels. In the 
absence of any contractile response to sumatrtptan, and only weak 
and variable contractions to 5-CT, suggests that the 5-HTIB and 5-
HTID receptors are unlikely to be present in the perinatal rabbit 
PRAs. This suggests that the predominant receptor mediating 5-lIT-
induced vasoconstriction in these vessels, at the perinatal ages 
studied, is of the 5-lIT2 class. The maximum responses to both 5-HT 
and a-me-5-HT were significantly higher in the 0-24 hr and 4 day 
rabbit vessels. This may be due to a comparatively greater number of 
5-HT receptors present in the newly born compared to the foetal and 
older neonatal lung. Indeed the results from chapter 3 in the adult 
rabbit PRAs also show a decreased maximal contraction to these two 
agonists compared to the newborn PRAs, suggesting there are 
developmental differences in 5-HT2 receptor density. Similarly, 
evidence for developmental changes in ET-1 receptor density also 
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exists in the same preparation (Docherty & MacLean. 1998). 
Ketanserin. at submicromolar concentrations. shows selectivity 
for 5-HT2A receptors (Hoyer et al., 1994). 30nM Ketanserin inhibited 
responses to 5-HT in a competitlve manner in the fetal, 4 day and 
seven day old rabbit vessels confirming that 5-IIT2A receptors mediate 
the contractile response to 5-IIT in these vessels. The results in 
chapter 3 of this thesis showed that In the rabbit PRAs, 30nM 
ketanserin only antagonised 5-HT-induced vasoconstriction at the 
higher concentration range of 5-HT, This further indicates an 
alteration in the distribution of 5-HT receptor subtypes with 
developmental age. 
The estimated pKB values for ketanserin in the present study 
were 8.6-9.6 and are Similar to the affinity values obtained for 
ketanserin in other systems where a 5-HT2A subtype is desCribed 
(Hoyer et al., 1994). From the results in chapter 4 of this thesis, in 
human PRAs, both the 5-IIT2Areceptor and 5-IITIB receptor mediate 
vasoconstriction, but it is the 5-HTIB receptor which appears to be 
physiologically important. Whether this simply reflects a species 
difference or is also due to a maturational change in the 5-HT 
receptors mediating vasoconstriction from perinatal human 
pulmonary arteries to those in adulthood remains unclear. 
In the vessels from the 0-24 hr old rabbits, 30nM ketanserln 
caused a non-parallel rightward shift of the 5-HT CCRC revealing 
small, ketanserin-resistant contractions to low concentrations of 5-
HT. These were Inhibited by the 5-HTID/IB receptor antagonist 
GR55562 and by higher concentrations of ketanserln. This suggests 
that, immediately after birth, there is transitory expression of a small 
population of contractile 5-HTID/IB receptors. One possible 
explanation for this could be the pharmacological synergism 
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described earlier in this chapter. where threshold concentrations of 
ET -lor decreased NO may augment 5-HT -induced vasoconstriction 
in these vessels and uncover. if only to a small degree. a 5-HTl 
receptor-mediated response. This explanation takes on more 
importance given that several reports indicate the highest levels of 
plasma ET-1 are found in the neonate at birth in humans (Malamitsi 
Puchner. et al. 1993; Endo et al. 1996) and the pig (Levy et al.. 1995) 
and that decreased endothelium-derived NO has been observed in 
these neonatal rabbit vessels at birth (Docherty & Maclean. 1998). In 
the newborn rabbit. therefore. both an increase in the sensitivity of 
5-HT and an uncovering of 5-HTIB/ID receptor mediated responses 
were observed at a time when high tissue and plasma levels of ET-1 
may occur. Noguchi et al. (1994) have reported a transient appearance 
of the ETa receptor on the endothelium in 2-3 day old piglet 
peripheral pulmonary arteries. 
GR55562 has recently been shown to be selective for the 5-
HflB and 5-HflD receptors (Connor et al.. 1995). In recent studies 
this compound was used to identify a functional population of 5-
HT1B/lD receptors in human pulmonary conduit arteries (Maclean et 
al..1996b) and. from the results of the studies in chapter 4. in human 
pulmonary resistance arteries. However. in the rabbit. GR55562 did 
not inhibit the 5-HT-mediated vasoconstriction at the foetal. 4 day 
and 7 day age pOints and only inhibited responses to 5-HT in the 0-
24 hour vessels at the pEC10 and pEC20 levels. Any major 
involvement of 5-HT1B/lD receptor subtype in mediating 5-HT-
induced vasoconstriction in the rabbit perinatal small pulmonary 
artery can therefore be ruled out. Thus the combined agonist and 
antagonist data are consistent with the interpretation that the 
dominant receptor in mediating vasoconstriction in these vessels is 
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the 5-HT2A receptor. In contrast. the results from chapter 3, provide 
evidence that the adult rabbit PRAs, contain a heterogeneous 
population of 5-HT receptors contributing to 5-HT-evoked 
vasoconstriction. The agonist and antagonist studies in the adult 
provide strong evidence that this vasoconstriction is mediated by the 
5-HT2A receptor and 5-HTIB receptor. Taken together, the results 
from both the adult and perinatal studies highlight a maturational 
change in 5-HT receptor type mediating 5-HT-induced 
vasoconstriction in rabbit PRAs. 
Interestingly, pulmonary resistance arteries in the rabbit have 
been shown to rely more on extracellular calCium for activation 
compared to larger arteries which rely more on intracellular calcium 
release through inositol trisphosphate (IP3) (Franco-Obergon & 
L6pez-Bameo, 1996). ThIs is in accordance with reports using other 
vascular preparations (Cauvin, et aL 1984, 1985). Thus, from the 
studies in chapter 3, the 5-HT receptor type mediating 
vasoconstriction in the adult rabbit pulmonary arteries is closely 
related to the relative dependence on a particular arteries source of 
activator calcium. Hence, in the large, conduit, PAs 5-HT mediates 
Its vasoconstrictor action predominantly through the 5-IIT2Areceptor 
which is known to be coupled to the formation of IP3 and ultimate 
release of intracellular calcium (Roth, et at, 1986). In contrast, the 
PRAs contain a 5-HTIB/ID receptor. In the perinatal PRAs, however, 
5-HT still mediates its vasoconstrictor action solely (the 0-24 hour 
vessels not withstanding) via a 5-HT2Areceptor. Theoretically, several 
possibilities could explain this. It is possible that the perinatal PRAs 
contain greater intracellular stores of calCium compared to adult 
PRAs. Alternatively, as diacylglycerol is concomitantly released with 
IP3 during 5-IIT2A receptor stimulation (Berridge, 1983; Martin, 
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1994), it may cause increased calcium sensitivity in perinatal vessels 
compared to adults, as shown in ovine cerebral vessels (Akopov, et al, 
1997). Das et al (1995), recently provided evidence for increased 
protein kinase C activity, which is dependent on diacylglycerol, in 
foetal compared to adult pulmonary arteries. It is therefore possible, 
that in the perinatal rabbit PRAs, diacylglycerol release, through 5-
Hf:1A receptor stimulation, plays a greater role in increaSing 
extracellular calCium entry than in the adult vessels. Experiments 
investigating signal transduction mechanisms of 5-HT receptor 
stimulation during the perinatal period in the first week of life and 
into adulthood would help clarify this. 
5-Hf receptor-induced vasodilation 
5-HT has previously been shown to elicit endothelium-
dependent relaxation in porcine pulmonary arteries (Glusa & Richter, 
1993) as well as other, systemic preparations (Bodelson et al., 1993). 
Using 5-CT, it was established that there is 5-HT-receptor-induced 
vasodilation present in the vessels from the 4 and 7 day old rabbits. 
Other studies have previously shown that pre-constriction of bOvine 
pulmonary arteries can 'uncover' 5-HTI -receptor-mediated 
vasoconstriction (MacLean et al., 1994; Sweeney et al .• 1995). It is of 
interest, therefore, that no contractile responses to 5-CT were 
observed in the present study. indicating that under the conditions 
used. there was no uncovering of 5-HTI-receptor-mediated 
vasoconstriction these perinatal rabbit pre-constricted vessels. 
Vasodilations to 5-CT were not observed in the fetal, 0-24 
hour (or from the results in chapter 3, adult) rabbit PRAs again 
demonstrating rapid developmental changes in the rabbit pulmonary 
circulation. It is possible that there is a maturational alteration in 
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the ability of the pulmonary vascular smooth muscle to relax to NO 
as shown in porcine perinatal pulmonary arteries (Wilson et al., 
1993). This explanation is. however. unlikely in this rabbit 
preparation as ACh-induced relaxation has been demonstrated in the 
foetal and 0-24 hour rabbit PRAs (Docherty & MacLean. 1998). 5-HT 
receptors are known to mediate vasodilation in blood vessels either 
directly via 5-lIT receptors located on the vascular smooth muscle 
(Cocks & Arnold. 1992: Leung et al., 1996) or indirectly via 
endothelium released NO (Bodelson et al, 1993: Glusa & Roos. 1996: 
Glusa & Richter. 1993). The results in this study show that. in 4 and 
7 day rabbit small pulmonary arteries. 5-CT-evoked vasodilation is 
inhibited by the NO synthase inhibitor L-NAME. This suggests that 
5-lIT-induced vasodilation in these vessels involves release of the 
endothelium-derived relaxing factor NO. The endothelial cell location 
of the receptor could not be confirmed by experiments in which the 
endothelium is removed as previous experience dictates that any 
attempt to remove the endothelium greatly damages the thin and 
fragile underlying smooth muscle in this preparation. Endothelial 
cell. vasodilator 5-HT receptors have previously been identified in 
arteries and veins as being similar to either the 5-HT2B subtype or 
the 5-HTID/IB subtype (Glusa et aL. 1996: Gupta, 1992). In the 
present study, in the 4 day old rabbit vessels, GR55562 inhibited 5-
CT-Induced vasodilation suggesting that the 5-HTIB/ID subtype 
mediated NO-dependent vasodilation in these vessels. In contrast. in 
the 7 day old rabbit vessels, GR55562 only caused a smallinhibitlon 
of 5-Cf induced vasodilation at high concentrations of 5-CT. In these 
vessels L-NAME slgntficantly reduced the maximum 5-CT-eUcited 
relaxation and so NO does contribute to 5-CT-induced vasodilation 
in these vessels. Spiperone, however, potently inhibited 5-CT-induced 
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vasodilation in these vessels. Recently. the novel 5-HT7 receptor has 
been described and has been found on the vascular smooth muscle of 
several preparations including the dog coronary artery rrerron. 1996) 
and Cynomolgus monkey jugular vein (Leung et at 1996). This 
receptor Is thought to mediate smooth muscle relaxation directly. 5-
CT Is known to be a potent agonist at this receptor (Raut. et al. 
1993; Schoeffter et at 1996). Several antipsychotic drugs. Including 
splperone have been shown to behave as antagonists at this receptor. 
Splperone displays a high binding affinity for the cloned 5-HT7 
receptor (Roth et al., 1994) and 5-HT7 receptors located on vascular 
smooth muscle stimulate adenylate cyclase and mediate vascular 
relaxation directly (Hoyer et al .. 1994; Leung et al., 1996). The pKB of 
splperone against 5-CT mediated vasodilation was 7.6 which Is 
comparable with its pKB of 7.1-7.8 at 5-HT7 receptors in the monkey 
jugular vein. rabbit femoral vein and dog coronary artery (Leung et 
aL, 1996; Martin. 1994; Terron, 1996). Splperone has a high affinity 
for 5-Hr2A receptors (Leff & Martin. 1986) but the presence of 
ketansertn in these studies rules out 5-HT2A receptor effects and 5-
Hf2A receptors are highly unlikely to mediate any 5-Hr-Induced 
vasodilator effects. Hence it Is likely that. in the vessels from the 7 
day old rabbits, 5-HT mediates NO-independent vasodilation through 
the 5-Hr7 receptor located on the vascular smooth muscle as well as 
NO-dependent vasodilation through the 5-HTID/IB receptor. 
Involvement of other 5-JIT receptors cannot be completely ruled out. 
for example the 5-hts receptor Is known to stimulate adenylate 
cyclase (Hoyer, et at 1994). a signal transdUction mechanism 
identical to that of the 5-HT7 receptor and one which favours direct 
smooth muscle relaxation. 5-CT. however has low affinity for 5-h ts 
receptors (Sebben, et at 1994). and given the potency of 5-CT in the 4 
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and 7 day old vessels. it is unlikely that the 5-hts receptor is 
mediating 5-CT-induced relaxation in these vessels. 
Endothelium involvement in the L-NAME resistant 
component of 5-CT-induced relaxation in the 7 days vessels could 
not be ruled out however. One possible explanation could be that 5-
CT mediates relaxation. in part. in these 7 day resistance vessels via 
EDHF. In addition to NO (and prostacyclin). EDHF appears to be an 
important mediator of vasodilation in various vascular beds by 
hyperpolarizing the vascular smooth muscle through K+ channel 
activation (Garland et aL. 1995) including pulmonary arteries (Chen. 
et aL. 1988). EDHF is now thought to assume a greater importance 
in vascular reSistance beds. Sh1mokawa et aL (1996) reported that the 
contribution of EDHF to endothelium-dependent relaxation in rat 
mesenteric arteries is greater in the smaller diameter vessels. The 
contribution of the EDHF response in human arteries is also 
slgnUlcantly greater in small blood vessels compared to large arteries 
(Urakami-Harasawa. et aL. 1997). Involvement of EDHF in 5-CT-
Induced relaxation in the 7 day rabbit vessels is unclear. however. as 
no documented evidence for 5-HT agonist-evoked EDHF production is 
currently available. One other possibiltty is that 5-CT may induce 
PGI2 release in these vessels. causing relaxation. The ability of 5-HT 
to stimulate vascular synthesis and release of prostacyclin was first 
reported by Coughlin et aL (1981) in bovine aorta. Moreover. Demolle 
et aL (1989) demonstrated that 5-HT-induced release of was mimicked 
with greater potency by 5-CT in aorta. 
The presence of 5-lIT receptor-induced vasodilation 
between 4 and 7 days is consistent with previous studies in the pig 
where endotheUum-dependent vasodUation is most marked 3-10 days 
after birth. declining with increasing age (Uu et aL. 1992). After hirth. 
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there is a reduction in muscularisatlon of the pulmonary circulation 
between 24 hrs and two weeks (Haworth & Hislop., 1981). The 
presence of pulmonary 5-HT vasodilator mechanisms at this age may, 
therefore, facilitate such changes. The current advancement in 
molecular techniques, particularly in the development of specific 
monoclonal antibodies for the different 5-Hr receptor subtypes (eg 
Wu. et al. 1998) will aid the future study of these receptors in terms 
of their expression and distribution in newborn pulmonary resistance 
arteries. 
The role of 5-HT in PPHN is uncertain but given the fact that 
this bloamine is a potent pulmonary vascular smooth muscle cell 
mitogen (Lee. et al .. 1991: Pitt. et al., 1994), it may contribute to 
increased pulmonary vascular remodelling associated with smooth 
muscle migration and proliferation. It is also likely that the balance 
of 5-HT receptor subtypes in the perinatal pulmonary vasculature 
would determine the end functional response to 5-HT, thus affecting 
pulmonary vascular reSistance. A reduction of 5-HT receptors 
medlatlng 5-HT-induced relaxation, such as the endothelium-located 
5-HrlB/lD receptor which mediates indirect vasodilation via NO 
release or the 5-HT7 receptor, which mediates direct relaxation of the 
vascular smooth muscle would presumably augment responses to 
endogenous 5-HT. The results of this chapter provides strong 
evidence for the existence of both these receptors in the 4 and 7 day 
old rabbit PRASe If these receptors exist in human neonatal 
pulmonary arteries, one could speculate that in the instance of the 
endothelial 5-HTIB/ID receptor for example, a reduction of this 
receptor type may impair vasodilation by decreased release of 
endothelium-derived NO. In PPHN, a reduction, or absence of these 
receptors in the pulmonary vasculature may contribute to the 
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maintenance of abnormally high pulmonary arterial pressure after 
birth. characteristic of this disease. Concerning functional 
vasoconstrictor 5-HT receptors. a similar effect would probably be 
observed if there was an elevation in the number of these receptors in 
PPHN. In the chronic hypoxic rat model of PHT. for example. elevated 
vasoconstrictor responses to 5-HT are observed. thought to be partly 
due to increased expression of contractile 5-HT2A and 5-HTIB 
receptors (Maclean. et aL 1996). 
In conclusion. these studies have demonstrated marked 
developmental changes in the 5-HI' receptors involved in mediating 
vasoconstriction and vasodilation in rabbit small pulmonary arteries. 
The predominant receptor mediating vasoconstriction Is the 5-HT2A. 
receptor In fetal to 7 day old rabbits. In contrast. In adult vessels 
both 5-HT2A. arx:l 5-HTID/IB receptors contribute towards 5-HT-
induced vasoconstriction. 5-HT receptor-mediated vasodilation is 
absent in the fetus. 0-24 hour and adult rabbits. In the 4 day old 
rabbit vessels 5-HI' -mediated vasodilation is mediated indirectly via 
NO release following 5-HI'ID/IB receptor activation. In 7 day rabbit 
vessels. however. vasodilation Is also mediated directly by a 5-HT7 
receptor. 
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Chapter 6 
Effect of increased tone and cGMP reduction on 5-
HTI-receptor-induced vasoconstriction in rat small 
muscular pulmonary arteries; evidence for 
pharmacological synergism 
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8.1 Introduction 
Pharmacological synergism occurs when a greater than additive 
effect ensues as a result of two agonists acting at different receptors 
on the same cell. This phenomenon has been observed in several 
systemic blood vessels including the rabbit femoral artery and rabbit 
ear artery (Movahedi & Purdy, 1997; MacLennan & Martln, 1992) as 
well as in the guinea-pig iliac (Sahin-Erdemli et a~ 1991) and human 
coronary (Cocks et al., 1993) arteries. This involves Gi-coupled 5-IIT1-
receptor induced vasoconstriction being 'uncovered' or greatly 
potentiated by increasing vascular tone through a Gq-coupled 
receptor pathway or by elevations in extracellular K+. 
The members of the 5-lITl receptor family are coupled to the 
Inhibition of adenylate cyclase through pertussis toxin-sensitive 
GIlo proteins (Dickenson and Hill; 1995; Sumner and Humphries, 
1990). However reductions in the cytoplaSmic concentration of cyclic 
AMP may not per se be responsible for ensuing smooth muscle 
contraction (Randall et al., 1996). There is substantial evidence that 
5-HTIB receptors play an important role in mediating 5-HT-induced 
vasoconstriction in human large pulmonary arteries (MacLean et al 
1999., 1996a; Cortijo et al., 1997). More recently, this has been 
demonstrated in human small muscular pulmonary arteries (see 
chapter 4 of this thesiS and Morecroft et al., 1999). In rat pulmonary 
arteries, 5-HT-induced vasoconstriction is mediated entirely by the 
Gql II-coupled 5-HT2A receptor (MacLean, et al., 1996). However, 
pulmonary arterial responses to 5-hydroxytryptamine (5-HT) are 
augmented in the chroniC hypoxic rat model of pulmonary 
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hypertension where the increased vasoconstriction to 5-HT 1s 
mediated by both the Gq-coupled 5-1IT2A and the Gi-linked 5-HTIB 
receptors (MacLean et at. 1996). It has also been demonstrated in the 
chronic hypoxic pulmonary hypertensive rat. that at all levels of the 
pulmonary vascular bed. increased endogenous vascular tone is 
evident (MacLean et al .• 1996). This may be mediated by an elevation 
of vasoconstrictors such as ET-l (MacLean et al.. 1999). 
depolarisatlon via inactivation of K+ channels (Osipenko et al .• 1998) 
or decreased levels of cyclic nucleotides (MacLean et al.. 1996). Given 
these findings and that 5-HT has recently been implicated in the 
aetiology of pulmonary hypertenSion (Herve et al .• 1995). any evidence 
for pharmacological synergism and the effect of increased vascular 
tone on 5-HT receptor induced vasoconstriction in the pulmonary 
arteries that are the major determinants of pulmonary vascular 
resistance is of interest. 
Here the effect of Increasing vascular tone via different second 
messenger signalling pathways on 5-carboxamidotryptamine (5-CT. 
5-HTl agonist)-induced vasoconstriction was examined on small 
muscular pulmonary arteries (smPAs) from normoxtc (control) rats. 
The effect of decreasing cGMP levels on these responses was also 
examined. Any key observations were further investigated in age-
matched chroniC hypoxic pulmonary hypertensive rats. 
flea Methods 
~hronic hypoxic rats 
The chroniC hypoxic rat model of pulmonary hypertension is 
fully deSCribed in chapter 2. section 2.1.3 of this thesis. Briefly. male 
Wlstar rats aged 28 days were placed in a speCially deSigned perspex 
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hypobariC chamber. This was depressurised, over 2 days, to 550 mbar 
(oxygen concentration equivalent to 1 001O). The temperature of the 
chamber was maintained at 21-220C, and the chamber was 
ventilated with air at approximately 45 lmln- l . Rats were maintained 
in these hypobaric/hypoxic conditions for 2 weeks in order to develop 
pulmonary hypertenSion (PHT). Age-matched norm oxic animals were 
held in room air. The right ventricle (RV) was carefully dissected free 
from the septum and left ventricle (LV), and both were blotted lightly 
and weighed. PHT was assessed by measuring the ratio of RV weight 
to total ventricular (TV) weight (see section 2.1.4.2). RV lTV ratio is 
an established and reliable index for PlIT in this model (Herget et 
aL,1978; Wanstall et at, 1991; Sheedy et at, 1996). 
Intrapulmonruy arteries 
Rats from both experimental groups were killed by an overdose 
of sodium pentobarbitone (60 mgkg-l) and the lungs promptly 
removed. Small, intralobar pulmonary arteries (smPAs) with an 
internal diameter of between 150-250J.1.m were dissected out according 
to the same methods stated in section 2.3.4.1 for the adult rabbit 
vessels, These were mounted on a wire myograph, bathed In Krebs 
solution (pH 7.4) at 37°C and bubbled with 16% 02/6%C02 balance 
N2. The gas mixtures were chosen as they are Similar to those which 
the control rat vessels would be exposed to in vivo. The smPAs from 
the CH rats were also bubbled with the same gas mixture for direct 
comparison, thus minimising variables between the two groups. 
Some difficulty Is encountered when trying to control the p02 of the 
myograph baths at values equivalent to the CH rats breathing 10016 
02. In preliminary studies, bubbling CH vessels with a 10% 
02/6%C02 balance N2 gas mixture still produced p02 values of 
-100mmHg, probably due to the influence of atmospheriC 02. USing 
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the normalisation process explained in section 2.3.6, smPAs from 
control rats were tensioned to an equivalent transmural pressure of 
-15mmHg in order to mimic in vivo pulmonary arterial transmural 
pressure in the rat. Vessels from the chroniC hypoxic rats were 
tensioned to a transmural pressure equivalent of -34mmHg to mimic 
pulmonary artery and arteriolar pressure of chroniC hypoxic animals 
in vivo. No attempt was made to remove the endothelium In any 
vessel. 
Experimental protocol 
The smPAs were allowed to equilibrate for 1 hour prior to the 
addition of any drugs. The response of the vessels to 50mM KCt was 
determined twice; once the contractile response had plateaued, the 
vessels were washed out a minimum of 6 times with fresh Krebs 
solution. Vessels were then preconstricted with a threshold 
concentration of either endothel1n-l (ET-I, Gq-l1nked receptor 
activation) (O.I-l.OnM),10mM RCI (opening of calCium channels and 
subsequent raising of intracellular calcium concentration). 
NeuropepUde Y (NPY, Gi-linked receptor activation), A23187 
(calcium tonophore) or 4-aminopyridine (4-AP, Rv channel blocker). 
Once a stable plateau had been reached, cumulative concentration 
response curves (CCRCs) to 5-CT (lnM-O.lmM) were obtained either 
in the presence or absence of NW-nitro-L-arglnlne methyl ester (1..-
NAME) (lOOjlM) to decrease levels of cGMP. In some vessels, the 
CCRCs to 5-CT, both in the presence or absence of lOOjlM L-NAME, 
were constructed without prior addition of threshold concentrations 
of contractile agent. 
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Data analysis 
Contractile responses are expressed as a percentage of the 
reference contraction to the second application of SOmM KCI. 
pEC 10, pEC2S, and pECSO values for the hypoxic groups were 
calculated, according to the methods described in section 2.S.2, from 
individual CCRCs. Statistical analysis of the means of groups of data 
were made by Student's unpaired t-test when two groups of data were 
compared. one-way analysis of variance (ANOVA) followed by Tukeys 
post test when three groups or more were compared. P < O.OS was 
considered to be statistically Significant. Throughout. data are 
expressed as mean ± s.e.mean and nln = number of vessels In umber 
of animals. 
6.3 Results 
Assessment of PIIT 
The RV lTV ratio of the control rats was 0.2S1 ± 0.009 and of 
the chroniC hypoxic rats was 0.387 ± 0.008 (P<O.OO 1; unpaired 
Student's t test. n = 6-12); this is indicative of severe pulmonary 
hypertenSion and in agreement with previous findings of others 
(Maclean et aL. 1996). 
Wire myo~rapby 
The effective pressure to which the vessels from normoxic rats 
were tensioned was 14.6 ± 0.3 mmHg and the resulting estimate of 
internal diameter for these vessels was 169.7 ± 9.8Jlm. These two 
measurements for the CH vessels were 34.S ± O.S mmHg and 172 ± 
11.1Jlm respectively. For both groups n > 20/10. There was no 
significant difference between the internal diameters from the two 
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groups. 
Response to KCI 
50mM KCI-induced contractions were of the same magnitude 
In both the normoxic (control) and chronic hypoxia-treated groups. 
These were 2.53 ± 0.28 mN and 2.75 ± 0.37 mN respectively. 
Responses to 5-CT and 5-HT 
Figure 6.1 demonstrates CCRCs to 5-1IT and 5-CT in normoxic 
and chronic hypoxic rat smPAs. In normoxic rat smPAs, 5-CT evoked 
a small, concentration-dependent vasoconstriction only at 5-CT 
concentrations> 111M, and did not produce a maximum response in 
the concentration range stUdied, thus a pEC50 value could not be 
accurately determined. The response at the maximum concentration 
of 5-CT used ([5-CTJmax.) was 33.3 ± 5.3 % 50mM KCI reference 
contraction. Exposure to chronic hypoxia markedly increased (pEC50 
= 5.6 ± 0.2) the response to 5-CT in the smPAs. 5-HT evoked a 
potent, concentration dependent contraction in both the normoxic 
and CH rat vessels. Figure 6.1 shows that exposure to chronic 
hypoxia markedly increased (P<O.Ol; Student's unpaired t-test) the 
maximum contractile response to 5-HT (Emax. = 35 ± 6% and 118 ± 
26 % for normoxic and chronic hypoxic vessels respectively). There 
was no significant difference between the 5-1IT pEC50 values for the 
normoxic (pEC50 = 5.8 ± 0.2) and CH rat smPAs (pEC50 = 6.4 ± 0.2). 
The maximum contractile responses to 5-CT and 5-1IT in the CH rat 
vessels were similar (figure 6.1). 
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Fi~ure 6.1 Effect of 2 weeks chronic hypoxia on contractile respons s 
to 5-HT and 5-CT in rat smPRAs. CCRCs to 5-CT in control (0. n = 
12/12) and in chronic hypoxic (e. n = 8/8) rats. CCRCs to 5-HT in 
control (,6,. n = 6/6) and in chronic hypoxic (A. n = 6/6) rats. Data 
are expressed as a percentage of reference contraction to SOmM KCl. 
Each point represents mean ± s.e.m. 
Normoxic rat sPAs 
Figures 6.2 and 6.3 and Table 6.1 demonstrate the effects of 
elevated tone on the CCRCs to 5-CT in smPAs from normoxic rats. 
ET-l (1-3nM) and KCI (IOmM) induced threshold contractions (12.S 
± 1.2 %; 12.6 ± 1.4% respectively, % 50mM KCI reference contraction) 
of the smPAs. Prior exposure to these threshold concentrations of 
either ET-1 or KCI significantly augmented the 5 -CT-induc d 
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contraction {Figure 6.2 and Table 6.1} by decreasing the threshold 
concentration for 5-CT 10-100 fold. KCI pre-contraction significantly 
potentiated the response to 5-CT at all concentrations (response at 
[5-CT1max. = 49 ± 3%; P <0.05). Figure 6.3 shows the CCRCs to 5-CT 
in the presence of threshold concentrations of the contractile agents 
4-AP, neuropeptide-Y and A23187. Prior exposure to 4-AP (l-3mM), 
neuropeptide Y (l-10/lM),or A23187 (l-10/lM) which induced 
threshold contractions in the sPAs of 12.7 ± 1.2%,10.7 ± 0.5% 
and11.3 ± 1.4% respectively; % 50 mM KCI) did not significantly alter 
the response to 5-CT (response at [5-CT1max. = 32.7 ± 3.3%. 30.8 ± 
2.80/0 and 30 ± 5.50/0 respectively). 
Effect of cGMP reduction on 5-CT-lnduced contraction of rat smPAs 
The effect of L-NAME on 5-CT-induced vasoconstriction both 
in the absence and presence of threshold concentrations of ET -1 and 
KCI are shown in figure 6.4 and table 6.1. Inhibition of nitriC oxide 
synthase with 1001lM L-NAME, in order to reduce cGMP levels. did 
not significantly alter the response to 5-CT (figure 6.4A and table 
6.1). In the presence of lOOIlM L-NAME. the 5-CT-lnduced 
contraction was further significantly augmented by threshold 
concentrations of ET-1 or KCI (Figure 6.4B and table 6.1). 
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Group 
5-CT 
+ET-1 tone 
+ KCI tone 
+ 4-AP tone 
+ NPYtone 
+ A23187 tone 
-L-NAME 
Et 
0.4± 0.3 
6.8 ± 1.1* 
7.4 ± 3.4** 
0.2 ± 0.2 
0.7±0.S 
O.S ± 0.3 
Table 6. 1 Effect of elevated 
n 
12/12 
8/8 
9/9 
6/6 
6/6 
6/6 
tone and 
+L-NAME 
Et 
3.2 ± 1.3 
14.4 ± 2.0**tt 
33.0 ± 6.0*t 
n 
7/7 
6/6 
8/8 
L-NAME on S-CT -induced 
contractions in normoxic rat smPAs. Statistical comparisons were 
made by ANOVA followed by Tukey's post test: 1) control vs. presence 
of threshold concentration of contractile agent ·P<O.OS. "P<O.Ol. 2) 
response in absence of L-NAME vs. respective response in presence of 
100llM L-NAME tp<O.OS. ttp<O.Ol. Data shown as % response to 
50mM KCI reference contraction. Values are mean ± s.e.m. Et. 
Response at control S-CT threshold concentration (lIlM). n. number 
of vessels/number of animals. 
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Figure 6.2 Effect of threshold concentrations of ET-l and KCl on 5-
CT-induced vasoconstriction in normoxic rat smPRAs. CCRCs to 5-
CT (0. n = 12/12) and in the presence of ET-l(O. n = 8 / 8) and KCI 
(~. n = 9/9). Data are expressed as a percentage of reference 
contraction to 50mM KCl. Each point represents mean ± s .e .m. 
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Fi~ure 6.3 Effect of threshold concentrations of n europeptide Y 
(NPY). 4-aminopyridine (4-AP) and A23187 on 5 -CT -induced 
vasoconstriction in normoxic rat smPRAs. CCRCs to 5-CT (0, n = 
12/12) and in the presence of NPY (., n = 6/6). 4-AP ( .. , n = 6/6) 
and A23187 (e. n = 6/6). Data are expressed as a percentage of 
reference contraction to 50mM KCl. Each point represents In a n ± 
s.e.m. 
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Figure 6 .4 Effect of lOO~M L-NAME (to reduce cGMP levels) on 5-CT-
induced vasoconstriction in norm oxic rat smPRAs. A CCRCs to 5-CT 
(a, n = 12/12) and in the presence of 100llM L-NAME (e , n = 7/7). B 
CCRCs to 5 -CT (e, n = 7/7) and in the presence of threshold 
concentrations of ET -1 (0, n = 6/6) and KCl (~ , n = 8/8): all in the 
presence of lOO~M L-NAME. All data are expressed as a percentage of 
reference contraction to 50mM KCl. Each point represents mean ± 
s.e.m. 
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Chronic hypoxic rat smPAs 
The effect of threshold concentrations of KCI and ET -1 on 5-
CT-induced contractions in smPAs from chronic hypoxic rats are 
shown in figures 6.5. pEC 10. pEC25 and pEC 50 values are 
summarised in table 6.2. In quiescent vessels (in the absence of 
precontraction with ET-1 or KCl), 5-CT induced a concentration 
dependent vasoconstriction (figure 6.5 and table 6.2). Pre-contracting 
the smPAs from chroniC hypoxic rats with ET-1 did not significantly 
alter the sensitivity (figure 6.5A; table 6.2) or maximum contractile 
response to 5-CT (figure 6.5B) in these vessels. The effect of reducing 
cGMP levels with L-NAME on 5-CT-induced contractions in the 
absence and presence of threshold contractions of ET -1 and KCI are 
shown in figures 6.6 and 6.7. pEC10. pEC25 and pECSO values are 
summarised in table 6.2. In the presence of 100~M L-NAME to 
decrease levels of cGMP, there was no significant alteration in the 5-
CT induced vasoconstriction, neither did L-NAME Significantly alter 
the response to 5-CT after prior exposure to threshold levels of ET -1 
or KCI (figure 6.7 and table 2). 
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Figure 6.5 Effect of threshold concentrations of ET- I and KCl on 5-
CT-induced vasoconstriction in chronic hypoxic rat smPRAs. CCRCs 
to 5-CT (0. n = 6/6) and in the presence of ET-I (D. n = 6 / 6) and 
KCl (.6. . n = 6/6) . A Data are expressed as a percentag own 
maximum contraction. B Data are expressed as a percenta of 
reference contraction to 50mM KCl. Each point represents ill n ± 
s.e.m. 
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Fi~ure 6.6 Effect of lOO~M L-NAME (to reduce cGMP lev Is) on 5-CT-
induced vasoconstriction in chronic hypoxic rat smPRAs. CCRC to 
5-CT (0, n = 6/6) and in the presence of lOO~M L-NAME (e, n = 6/6). 
A Data are expressed as a percentage own maximum contraction. B 
Data are expressed as a percentage of reference contraction to 50mM 
KCl. Each point represents mean ± s.e.m. 
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Fiflure 6.7 Effect of threshold concentrations of ET-l and KCl on 5-
CT-induced vasoconstriction in chronic hypoxic rat smPRA in th 
presence of lOOIlM L-NAME. CCRCs to 5-CT (e. n = 6/6) nd in th 
presence of ET-l (D. n = 6/6) and KCl (~ . n = 6/6). A D ta r 
expressed as a percentage own maxinlU111 contraction. B Data r 
expressed as a percentage of reference contraction to 50mM K 1. 
Each point represents mean ± s.e.m. 
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tv 
co 
Q1 
Group pEC10 pEC25 pEC50 Emax. n 
5-CT control 6.4±0.3 5.9±O.2 5.6±0.2 121 ± 11 6/6 
+ 10{}JJM L-NAME 6.9±0.3 6.7±0.3 6.0±0.1 103± 10 6/6 
+ ET-1 tone 6.1 ± 0.2 5.7±0.2 5.5±0.1 120±7 6/6 
+ KCI tone 7.1 ± 0.3 6.7±O.2 6.1 ±0.2 l05± 12 6/6 
+ ET tone + 100~ L-NAME 7.0±O.4 6.3±0.3 5.8±0.1 106±20 6/6 
+ KCI tone + 100~ L-NAME 6.5±0.3 6.2±0.2 6.0±0.1 107±9 6/6 
Table 6.2 Effect of elevated tone and L-NAME on 5-CT-induced vasoconstriction in chronic 
hypoxic rat smPAs. Statistical comparisons (ANOV A) indicated no significant differences between 
relevant groups. Tone raised using threshold concentrations of endothelin (ET-1) and KCI. Values 
are mean ± s.e.mean.n = number of vessels/number of animals. 
6.4 Discussion 
The very marked augmentation of vasoconstrictor responses to 
5-CT and to 5-lIT in the pulmonary hypertensive chronic hypoxic rat 
intralobar small pulmonary arteries is in agreement with previous 
observations (MacLean et al.. 1996b) where an 'uncovering' of GI-
linked 5-HTIB receptor-mediated vasoconstriction was observed 
(along with an enhanced 5-HT2A receptor mediated contraction). 
Although the intracellular Signalling pathways mediating pulmonary 
arterial responses to ETs are still to be fully elUCidated. several 
studies in vitro have shown ET -1 to mediate its effects through 
Gq/ 11 -protein coupled receptors and subsequent activation of 
phospholipase C (Reslnk et al. 1988; Ohlsteln et al.. 1995). The 
augmented response to 5-CT in normoxic rat smPAs observed in this 
study. in the presence of ET-l is consistent with several reports 
showing that pre-contraction with agonists that act via Gq/ll-
coupled receptors causes an augmentation or uncovering of Gi-
coupled receptor responses such as 5-HTI receptor mediated 
vasoconstriction (Selbie & Hill. 1998). In the rat tail artery. for 
example. responses to the <X2-adrenoceptor agonist UK14304. which 
mediates its effects via a Gi-coupled receptor. are uncovered by 
threshold Gq-receptor-induced vasoconstriction (MacLean. et 
al..1990). MacLennan and Martin in 1992 reported that threshold 
contractions to the thromboxane A2-mlmetlc. U46619 (acting via a 
Gq-coupled receptor), Increased the sensitivity of the rabbit femoral 
artery to 5-lIT and uncovered a 5-HTI receptor-mediated contractile 
response in those vessels. This synergistic interaction has ma1nly 
been demonstrated in large systemic arteries as well as in isolated 
bovine large pulmonary arteries (MacLean. et al .• 1994;1999). The 
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results presented in this chapter are the first to demonstrate this 
phenomenon in the small muscular pulmonary arteries. which are 
the major contributors to increased pulmonary vascular resistance in 
the pulmonary hypertensive state (Singhal et al .• 1973). This suggests 
that crosstalk between two G-protein coupled receptors may result in 
the amplification of signals and lead to an uncovering of otherwise 
silent contractile receptors in these pulmonary resistance vessels as 
well as in larger systemic vessels (Martin et al.. 1996). Systemic 
arteries in vivo are under a certain amount of tonic sympathetic tone 
and therefore. the synergistic interactions between receptors in these 
vessels may be normally operative in vivo. In contrast. pulmonary 
arteries in the normal lung are fully dilated and therefore synergistic 
effects may only operate when the pulmonary arteries are under the 
influence of increased vascular tone as in pulmonary hypertension. 
Importantly. in pulmonary hypertenSion. there is evidence for an 
increased production of endothelin-1 (MacLean et al.. 1999) as well 
as thromboxane (Christman. 1998) and angiotensin-II (Cargill and 
Lipworth. 1995). These all are agonists acting via Gq-coupled 
receptors and collectively. supports the possibility that increased Gq-
coupled-receptor activation may synergise With Gi-coupled responses 
in pulmonary hypertenSion. 
The potentiation of 5-CT-induced vasoconstriction in the 
normoxic sPAs by threshold concentrations of KCl suggests that 
direct elevation of intracellular Ca2+ augments responses to Gt-
coupled agontsts. Several studies have demonstrated a crucial role 
for Ca2+ influx through voltage-operated Ca2+ channels in the 
mediation of 5-HTl receptor-mediated contraction ( Hill et al.. 2000; 
Movahedi & Purdy. 1997; Sumner et al .• 1992). Although 5-HT18/lD 
receptor activation may not activate voltage-operated Ca2+ channels 
in quiescent vessels. in depolarised arteries when the channel open 
297 
probability has been increased, such activation of these receptors 
may occur, leading to contraction. In fact, the 5-HT1-receptor 
mediated vasoconstriction was augmented at all concentrations of 5-
CT and the potentiation was greater than that of ET -1. In addition to 
membrane depolarisation, KCl has been shown to stimulate 
phospholipase C (PLC) (Phillipe & Chien, 1995) and may, therefore, 
facilitate entry to 5-HT1 receptor stimulation by activation of the 
PLC signalling pathway. Jin et al., 1993 have shown that KCI can 
also increase the formation of inositol (1,4,5) triphosphate (IP3) in 
rat pulmonary arteries, this may explain the strong synergistic 
interaction observed here. Decreased levels of cGMP have previously 
been shown to potentiate Cl2-adrenoceptor (Gt/o-coupled receptor) 
induced vasoconstriction in rabbit large pulmonary arteries (MacLean 
et al., 1993) and, in bOvine pulmonary arteries, responses to the 5-
HflB/lD -Gi-linked receptor agonist sumatriptan are potentiated by 
decreased cGMP (MacLean et al., 1994). The results of this present 
study, show that a decrease in cGMP levels via the inhibition of NOS 
with L-NAME further potentiates the augmented responses to 5-CT 
but only in the presence of ET-l- and KCI-induced tone. This 
suggests that levels of the cyclic nucleotide cGMP may also play an 
important synergistic role in the response of pulmonary resistance 
arteries to Gi-coupled receptor-induced vasoconstriction. In 
pulmonary arteries removed from chroniC hypoxic, pulmonary 
hypertensive rats, decreased levels of cGMP, as well as decreased 
cAMP. along with increased vascular tone have been observed 
(MacLean et al.. 1996). The observed decrease in the cyclic 
nucleotides is thought to be caused by increased phosphodiesterase 
activity (MacLean, et al .• 1997). The observation here that Gq and Gt-
coupled interactions can be further modulated by cyclic nucleotide 
levels may therefore be of pathophYSiological Importance tn 
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pulmonary hypertension. 
Pulmonary arterial cell membrane depolarisation is known to 
occur in the CH rat model of pulmonary hypertension (Osipenko et 
al.. 1998) and this is possibly due to a down regulation of K channels 
in these cells. Based on these results. the observed augmented 
response to 5-HT receptor-induced vasoconstriction in pulmonary 
hypertension would be expected to be mimicked by blocking Kv 
channels with 4-aminopyridine. Surprisingly. the findings in this did 
not support this hypothesis. suggesting that down regulation of Kv 
channels may not be involved in the observed augmentation of 5-lITl 
receptor-mediated vasoconstriction in small muscular pulmonary 
arteries from the chroniC hypoxic rat model of pulmonary 
hypertension. Similarly. Doggrell et al.. 1999 observed that 4-AP did 
not augment responses to 5-HT in the rat intralobar small 
pulmonary artery. but did in the main pulmonary artery. suggesting 
membrane depolarisation plays a more important role in 5-HT-
induced vasoconstriction in large. conduit pulmonary arteries. 
Neuropeptide Y (NPy) mediates its vasoconstrictor effects. like 
5-HT1 receptor mediated stimulation. via activation of a Oi-coupled 
receptor (Lundberg et al.. 1988). Not surprisingly. prior exposure to 
threshold concentrations of NPY did not significantly alter the 
response to 5-CT in the rat sPAs. The majority of blood vessels In 
which 5-HTl mediated smooth muscle contraction has been 
described require prestimulation. either with another agonist or with 
a slight increase in the extracellular [K+]. before 5-HTI receptor 
stimulation can elicit a contraction (Movahedi et a1.. 1997: Randall. 
et al.. 1996). The suggestion has been that prestimulation somehow 
increase [Ca2+h to a 'threshold' value such that contraction to 5-HTl 
receptor activation is facilitated. A23187 mediates its vasoconstrictor 
effects as a calcium ionophore (Yamashtta et al.. 1994), however it 
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was also unable to significantly alter the response to 5-CT. This 
suggests that simply elevating [Ca2+Ji does not produce synergistic 
amplification of vasoconstriction, at least in rat PRAs. Although we 
have demonstrated here that increasing vascular tone and decreasing 
cGMP levels significantly potentiate the response to 5-CT in rat sPAs. 
none of these were able to augment the response to the same degree 
as that observed in sPAs from the chronic hypoxic rat. Other 
amplification factors such increased expression of 5-HTIB receptors. 
are likely to be present which can influence the magnitude of the 
response. Increased mRNA for the 5-HTIB receptor has been recently 
demonstrated in pulmonary arteries from this rat model of PHT 
(Heeley, et al., 1998). 
The fact that increasing vascular tone and/or decreasing levels 
of cGMP in the sPAs from chronic hypoxic pulmonary hypertensive 
rats did not significantly change the sensitivity or maximum 
contraction to 5-CT provides further evidence that the amplification 
factors necessary for pharmacological synergism already exist in 
these vessels and collectively provide an 'optimum' environment for 
5-HTI-Gi-protein coupled receptor mediated vasoconstriction. This 
synergism may play an important role in pulmonary vasoconstriction 
assOCiated with pulmonary hypertenSion. 
In conclusion, these results show that in rat smPAs. increased 
vascular tone via either Gq-coupled receptor activation or increased 
KCI can potentiate Gi-coupled 5-HTl receptor-induced 
vasoconstriction. Pulmonary arteries in vivo are normally fully 
dilated. This synergism may. therefore, become pathophYSiologically 
important in pulmonary hypertenSion which is characterised by 
elevated pulmonary vascular tone. The observation that decreaSing 
cGMP (via NOS inhibition) can further augment the Gq-Gi 
interactions in these smPAs strengthens the suggestion that 
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pharmacological synergism is pathophysiologlcally important in 
pulmonary hypertenSion. A greater understanding of the key 
signalling events occurring in pulmonary hypertension should 
provide new therapeutic strategies in treating this disease. 
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Chapter 7 
General Discussion 
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The results from all the studies have been extensively 
discussed in the relevant chapters of this thesis. This final chapter 
will focus on drawing on the findings from the preceding chapters, in 
order to speculate on the significance of the results and suggest 
future studies. 
The vascular reactivity of rabbit pulmonary arteries (both 
conduit and resistance vessels) were examined particularly under the 
important transitional state from foetal to neonatal life and in 
adulthood. These studies focused on 5-HT receptor mediated 
responses and the influence of developmental age and endothelial NO 
on these responses. 
Primarily, the results from the studies in chapter 3 and 5 
demonstrate that in rabbit pulmonary arteries, especially resistance 
arteries, both the contractile and vasodilator responses to 5-IIT alter 
significantly with developmental age and that endothelial NO plays a 
significant role in modulating these responses. 
The predominant 5-IIT receptor mediating vasoconstriction in 
the foetal to 7 day old rabbit pulmonary arteries (both conduit and 
resistance vessels) was the 5-HT2A receptor characterised by the 
nanomolar affinity of ketanserin against 5-HT. An exception to this 
was the tranSitory expression of a small population of contractile 5-
HTIB/ID receptors occurring immediately after birth in the neonatal 
reSistance vessels. The reason for this may reflect a pharmacological 
synergism as the 'uncovered' 5-IITIB/ID receptor mediated response 
seems to exist at a time when plasma levels of the potent pulmonary 
vasoconstrictor ET-l have been shown to be elevated in both human 
and animal neonates (Endo et al., 1994; Noguchi et al., 1997). As 
discussed in chapter 6, a pharmacological synergistic action was 
demonstrated between ET-l and 5-HT receptor mediated responses In 
the rat smPRAs. It would be useful in further studies at this age 
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point to focus on mimicking intracellular changes thought to occur 
in the neonatal pulmonary vasculature in PPHN with the hypothesis 
that this may amplify the 5-HTI B / 1 D receptor mediated 
vasoconstriction. Earlier studies have reported the transient 
appearance of the ETs receptor in neonatal piglet per1pheral 
pulmonary arteries. 
Other studies in chapter 5 demonstrated rapid developmental 
changes in 5-lIT receptor mediated relaxation in rabbit PRAs. There 
was a lack of 5-CT-induced vasodilation in the foetal and 0-24 hour 
rabbits. however 5-CT-induced vasodilation was present by 4 days old 
being mediated by an endothelium-dependent 5-HTI8/1D receptor. 
By 7 days old however this vasodilation was also mediated by the 5-
HT7 receptor. The presence of pulmonary vasodilator mechanisms at 
these neonatal age pOints is consistent with previous studies in the 
piglet where endothelium-dependent vasodilation is most marked 3-
10 days after birth (Liu et al.. 1992). The presence of pulmonary 
vasodilator mechanisms at this time may therefore facilitate such 
changes. 5-lIT receptor localisation studies using receptor subtype 
speCific monoclonal antibodies would aid in clarifying the identity 
and location of these receptors on the pulmonary vasculature. The 
findings of the studies in chapter 5 are of great importance in gaining 
an understanding of the effects of 5-lIT in the normal adaptation of 
the pulmonary Circulation to extra uterine life and is essential before 
examining any alterations in pathologic conditions. In speculating 
the possible influence of 5-lIT in PPHN. the potent effects of 5-HT 
observed in the perinatal pulmonary vasculature suggests that the 
balance of 5-HT receptor subtypes would determine the overall 
functional response. To speculate. a lack or significant reduction of 
endothelial 5-HT vasodilator receptors such as the 5-HTIB/I0 
receptor and/or Similar decrease in arterial smooth muscle 
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vasodilator 5-HT7 receptors would presumably enhance the 
vasoconstrictor actions of 5-HT. Similarly. any increase in functional 
contractility mediated by contractile 5-HTIB. 5-HTID or 5-HT2A 
receptors. would contribute to the maintenance of abnormally high 
pulmonary arterial pressure after birth which occurs in the 
pathological state. 
Endothelium-derived NO was observed to playa significant role 
in modulating the 5-HT receptor mediated responses in the perinatal 
and adult PRAs (chapters 3 & 5). The comparatively greater role of 
NO on functional responses in the neonatal vessels is consistent 
with its putative role in the rapid and progressive reduction of PVR 
following birth as the system takes on its normal role characterised 
by low pressure and low resistance. 
In contrast to the perinatal PRAs. in adult vessels both 5-HT2A 
and 54-HTIB/ID receptors contribute towards the observed 5-HT-
induced vasoconstrictor response as discussed in chapter 3. A useful 
study in the future would be to examine the effect of PHr on 5-Hr 
receptor mediated responses in rabbit pulmonary arteries. A previous. 
in vivo. study using the well established rabbit coronary Ugatton 
model of PHT secondary to left ventricular dysfunction. demonstrated 
a marked increase in pulmonary pressor response to i.v. administered 
5-HT in 8 week ligated rabbits when compared to control, sham 
operated animals (Deuchar. et aI.. 1997). 
A further aim of this project was to investigate the pOSSibility 
that pharmacological synergism could be observed in the smPRAs in 
the rat given that th1s phenomenon may contribute to the increased 
5-HTIB receptor mediated vasoconstriction observed in the CH rat 
model of PHT (MacLean et al .• 1996; 1999). The results from chapter 6 
demonstrated that agon1st-induced tone. potentiated vasoconstrictor 
responses to 5-HTI receptor stimulation in rat smPRAs and that 
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altering cyclic nucleotide levels. by decreasing cGMP content led to a 
further augmentation of the 5-HT} receptor mediated response in 
these vessels. The results from this study strengthen the suggestion 
that pharmacological synergism is pathophysiologically important in 
PlIT where increased endogenous tone and decreased cGMP levels are 
known to prevail (MacLean et al .. 1996: Sweeney et al.. 1995). 
Immediate future functional studies would be the use of selective 5-
HT receptor antagonists. including SB224289. to conclusively 
identify the 5-HTl receptor subtype responsible for the observed 
augmentation of the 5-CT-induced response in these vessels. 
Investigation of the key intracellular signalling events occurring 
during pharmacological synergy in these vessels would be of great 
importance in helping to provide new therapeutic strategies in 
treating PHT. An initial investigation could involve the use of routine 
signalling assays for cyclic nucleotide and phospholipase C slgnalltng 
in pulmonary arterial homogenates from snap frozen vessels to 
determine the signalling elements implicated in Gi/Go synergy. This 
technique has been successfully used in examining intracellular 
messenger changes in these vessels (MacLean et al.. 1996: Mullaney 
et al.. 2000). 
It is important to compare the responses obtained in animal 
vessels with those in similar preparations obtained from human 
tissue. As discussed in chapter 4. investigation of human smPAs 
demonstrated a similar sensitivity to 5-HT and 5-CT as observed In 
adult rabbit pulmonary arteries of similar internal diameter. Due to 
the infrequency of human tissue available. only key studies with 5-
HT receptor antagonists could be carried out. again fOCUSing on 
those compounds examined in the animal vessels. Primarily. the 
results of this study suggest that 5-HT-induced vasoconstriction is 
mediated through both 5-HT2A receptors and 5-HTIB receptors and 
306 
significantly highlight the importance of the 5-HTIB subtype in 
mediating this vasoconstriction. These conclusions were Indicated by 
the following observations: 1) equipotency of 5-HT. 5-CT and 
sumatrtptan, confirming the presence of 5-HTI-like receptors. 2) 
responses to lower 5-HT concentrations «O.I~M) and to sumatriptan 
(lnM-300~M) being resistant to ketanserin inhibition but be1ng 
significantly inhibited by GR55562. the 5-HTIB and 5-HTID receptor 
antagonist. 3) Responses to sumatriptan were inhibited by the 
selective 5-lITIB receptor antagonist SB224289 but not BRL15572 (5-
mID receptor antagonist). The results of these functional studies 
were confirmed by RT -PCR, showing the presence of 5-lIT2A and 5-
HTIB receptor mRNA transcripts in human pulmonary arteries of 
similar size (More croft et al., 1999). Given that the normal plasma 
concentrations of 5-lIT are between 1-2 nM and can rise to 30nM in 
PHT (Herve, et al.. 1990: 1995: Anderson et aI .• 1987), the results of 
these functional studies provide evidence that the 5-lITIB receptor 
plays a significant role in mediating 5-lIT -induced vasoconstriction 
in human small PAs. Essential future studies in the human smPAs 
would have to include an investigation of the possible existence of 5-
HT-receptor mediated vasorelaxations. Although these appear to be 
absent in human larger. capacitance PAs (Cortijo et aZ.. 1997), the 
pharmacology of the small pulmonary arteries must be determined 
separately as explained in chapter 4. Secondly the results from 
chapter 4 suggests that this receptor may provide an important new 
therapeutic target in PHT. 
The profile of 5-lIT receptor mediated responses in human PHT 
is unknown. Although isolated pulmonary artertes from PlIT patients 
undergoing lung transplantation demonstrate augmented 
vasoconstrictor responses to 5-HT (Brink et aZ .• 1988). It is not yet 
clear how significant a role the 5-HTIB receptor may play in human 
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pulmonary hypertensive states. Of immense interest for future 
studies. would be to examine 5-HT receptor mediated responses in 
pulmonary resistance arteries obtained from patients with PHT. 
These studies would assess any changes in the pulmonary arterial 
vascular reactivity to 5-HT. and would also characterise the 5-1-IT 
receptor populations involved in these responses as well as highlight 
any possible changes in the 5-HT receptor subtypes present which 
may occur. 
Finally. these studies have demonstrated marked 
developmental changes in the 5-1-IT receptors involved in mediating 
vasoconstriction and vasodilation in rabbit pulmonary arteries. 
These studies have also highlighted the importance. in particular of 
the 5-HTIB receptor in the control of pulmonary vascular tone and 
suggest this receptor may be a pulmonary-selective target for PI-IT 
both in the adult and newborn. 
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Research Summary and Conclusions 
Responses to 5-HT, and the receptor subtypes involved were 
studied in foetal, 0 - 24 h, 4 day, 7 day and adult rabbit pulmonary 
conduit arteries (PCAs). 5-HT was a potent vasoconstrictor of 
pennatal and adult rabbit peAs with a potency order of adult = 7 
days = foetus = 4 days> 0-24 hours and investigation of 5-HT-
receptor mediated responses showed an agonist potency profile of 5-
HT = a-methyl-5-HT > 5-carboxamidotryptamine (5-CT) » 
sumatriptan at all ages. This indicates a predominant role of 
contractile 5-HT2A receptors in these vessels. 
In PCAs at all age pOints, ketanserin (5-HT2A receptor 
antagonist) displayed near nanomolar affinities against 5-HT in 
these vessels. GR55562 (5-HTIB/ID receptor antagonist) lacked any 
inhibitory effect. These findings are consistent with 5-HT 
contractions mediated via 5-HT2A receptors and suggest no 
significant maturational alteration in the 5-HT receptor subtype 
mediating 5-HT-induced vasoconstriction in rabbit PCAs. 
The influence of nitric oxide (NO) on 5-HT-receptor mediated 
contractile responses was examined in peAs from adult and perinatal 
rabbit. The NO synthase inhibitor L-NAME potentiated 5-HT 
responses in vessels from all perinatal rabbits but not in adult 
vessels. The most pronounced effect was observed in the 4 and 7 day 
rabbit vessels suggesting 5-HT-induced vasoconstriction is normally 
attenuated by NO in perinatal rabbit vessels, accompanied by 
maturational changes in the magnitude of this attenuation. 
5-HT-receptor mediated relaxation was examined in pre-
contracted peAs from perinatal and adult rabbits. 5-CT and 5-1-IT 
both induced relaxation of adult vessels (pECSO s -7.6 and -6.5 
respectively). Spiperone, pimozide and risperidone inhibited the S-CT-
induced responses in the adult vessels. These findings indicate that 
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5-fIT receptor induced vasodilation is mediated via 5-HT7 receptors 
in adult rabbit PCAs. No evidence for 5-HT-receptor induced 
vasodilation was observed in the perinatal vessels. 
5-fIT agonist responses were studied in the perinatal and adult 
rabbit isolated pulmonary resistance arteries (PRAs). alone and in 
the presence of L-NAME. The effect of the selective 5-HT receptor 
antagonists ketanserin and GR55562 on vasoconstrictor responses 
to 5-fIT were studied in the presence of L-NAME. Vasodilator 
responses to 5-CT were studied in pre-contracted PRAs. 5-HT and a-
methyl-5-fIT were equipotent in the PRAs at each age. In the 
perinatal PRAs. sumatriptan and 5-CT produced negligible 
contractions. but in adult PRAs. 5-CT and sumatriptan were potent 
agonists with pEC50s of 6.05 ± 0.3 and 5.70 ± 0.20 respectively. 
These findings indicate maturational changes in the 5-HT receptor 
mediating contractions in these vessels. 
L-NAME markedly increased the maximum response to 5-HT in 
the 0 -24 h. 4 day and 7 day vessels and increased 5-HT potency In 
the 4-7 day-old and adult rabbit vessels. These findings indicate that 
endothelial NO markedly attenuates 5-HT-induced responses and 
provide evidence for diminished NO levels in the pulmonary 
vasculature in foetal compared to neonatal life where increased NO 
associated with early neonatal life aids the continued fall in PVR 
observed following birth. 
In perinatal vessels. responses to 5-HT. with L-NAME present. 
were antagonised by ketanserin (30 nM and 0.1 ~) but not GR55562 
(1 JlM). A small ketansertn-resistant. GR55562-sensitlve component 
was observed at 0-24 h. In adult vessels. both ketanserin and 
GR55562 inhibited 5-HT-induced responses. The predominant 
receptor mediating vasoconstriction is the 5-HT2A receptor in foetal 
to 7-day old rabbits. In the adult rabbit PRA. both the 5-HT2A 
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receptor and the 5-lITIB/lD receptor mediate vasoconstriction. 
Vasodilator responses to 5-CT were observed in pre-contracted 
PRAs from 4- and 7 -day-old rabbits but not in the foetus. 0-24 hold 
or adult rabbit vessels. At 4 days the vasodilator response was 
inhibited both by L-NAME and GR55562. At 7 days the response was 
only partly blocked by L-NAME and resistant to GR55562. The L-
NAME resistant component was antagonised by the 5-lIT7 receptor 
antagonist spiperone (1 JlM). The 5-lITID or 5-lITIB receptor mediates 
NO-dependent vasodilation in vessels from rabbits at 4 days of age 
whilst 5-HT7 receptors mediate NO-independent vasodilation by 7 
days. 
Collectively. the results demonstrate marked developmental 
changes in the 5-lIT receptors involved in mediating vasoconstriction 
and vasodilation in rabbit pulmonary arteries and that endothel1um-
derived NO plays a significant role in modulating these responses. 
The 5-HT receptors mediating vasoconstriction in isolated 
human small muscular pulmonary arteries (smPAs) was determined. 
The agonists 5-HT. 5-CT, and sumatriptan all caused contraction 
and were eqUipotent (pECso; were 7.0 ± 0.2, 7.1 ± 0.3 & 6.7 ± 0.1. 
respectively). suggesting the presence of a 5-lITi receptor. 
Ketanserin (O.IJl.M) inhibited 5-HT contractions only at non-
physiological/pathological concentrations of 5-HT (>O.IJl.M) whilst 
GR55562 (lJl.M) inhibited 5-HT contractions at all concentrations of 
5-HT (estimated pKB = 7.7 ± 0.2). 5B224289 (5-HTIB-selective 
antagonist, 0.2Jl.M) inhibited sumatriptan-induced contractions 
(estimated pKB = 8.4 ± 0.1). Whilst these were unaffected by the 5-
HTID-selective antagonist BRL15572 (0.5Jl.M) suggesting that the 5-
HfiB receptor mediates vasoconstriction in these vessels. 
These findings suggest that a heterogeneous population of 5-
Hf2A and 5-HTIB receptors co-exist in human small muscular 
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pulmonary arteries but the 5-fITIB receptor normally mediates the 
5-HT induced vasoconstriction at physiological and 
pathophYSiological concentrations of 5-HT. These results have 
important implications for the treatment of pulmonary hypertension 
in which the 5-HTIB receptor may provide a novel and potentially 
important therapeutic target. 
The effect of raised tone and reduced cGMP levels on 5-HTl 
receptor mediated vasoconstriction was studied in isolated PRAs from 
control and chroniC hypoxic pulmonary hypertensive (CH) rats. 
The CH rats displayed right ventricular hypertrophy. consistent 
with the development of severe PfIT. Responses to 5-CT and 5-HT 
were augmented in the isolated PRAs compared to control animals. 
Threshold concentrations of endothelin-l (ET-l) and KCI 
significantly augmented 5-CT-induced contractions in the PRAs from 
normal but not from CH an1mals. L-NAME further augmented the 
contractile response to 5-CT but only in the presence of ET-l or KCI-
increased tone. 
These results suggest that inhibition of NOS comb1ned with 
KCL- or ET-l-induced vascular tone potentiates responses to 5-CT in 
rat PRAs in a synergistic fashion and mimics the effects of chroniC 
hypoxic exposure. This synergism may therefore become 
pathophysiologic ally important in PHT which is characterised by 
elevated pulmonary vascular tone. increased Gq-coupled receptor 
activation and membrane depolarisation. 
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